



# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 156274

**TO: Janet Epps-Ford**  
**Art Unit: 1653**  
**Location: REM-2C05&2C18**  
**Serial Number: 09/915543**

**Friday, June 10, 2005**

**From: Beverly Shears**  
**Location: Biotech-Chem Library**  
**REM 1A54**  
**Phone: 571-272-2528**  
**beverly.shears@uspto.gov**

### Search Notes

#### Protein Sequence Searches – February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (uniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.



**This Page Blank (uspto)**

155274

From: Epps-Ford, Janet  
Sent: Thursday, June 02, 2005 3:48 PM  
To: STIC-Biotech/ChemLib  
Subject: Amino acid sequence search

Application No. 09/915,543

Isolated polypeptides comprising:

a) a peptide consisting of amino acids 177 to 204 of SEQ ID NO: 15;

or

b) a peptide consisting of amino acids 349 to 384 of SEQ ID NO: 15;

wherein said isolated polypeptide does not comprise both of (a) and (b).

Please search all pending and commercial amino acid databases.

Thanks,  
Janet L. Epps-Ford, Ph.D.  
Art Unit 1635  
Mailbox: Remsen 2C18  
Office: Remsen 2C05  
Phone: 571-272-0757  
Fax: 571-273-0757

11

CRFE

ME

\*\*\*\*\*

## STAFF USE ONLY

Searcher: \_\_\_\_\_  
Searcher Phone: 2-\_\_\_\_\_  
Date Searcher Picked up: \_\_\_\_\_  
Date Completed: \_\_\_\_\_  
Searcher Prep/Rev. Time: \_\_\_\_\_  
Online Time: \_\_\_\_\_

\*\*\*\*\*

## Type of Search

NA#: \_\_\_\_\_ AA#: \_\_\_\_\_  
Interference: \_\_\_\_\_ SPDI: \_\_\_\_\_  
S/L: \_\_\_\_\_ Oligomer: \_\_\_\_\_  
Encode/Transl: \_\_\_\_\_  
Structure#: \_\_\_\_\_ Text: \_\_\_\_\_  
Inventor: \_\_\_\_\_ Litigation: \_\_\_\_\_

\*\*\*\*\*

## Vendors and cost where applicable

STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
QUESTEL/ORBIT: \_\_\_\_\_  
LEXIS/NEXIS: \_\_\_\_\_  
SEQUENCE SYSTEM: \_\_\_\_\_  
WWW/Internet: \_\_\_\_\_  
Other(Specify): \_\_\_\_\_

Date completed: \_\_\_\_\_

Searcher: Bejarin e 2528

Terminal time: \_\_\_\_\_

Elapsed time: \_\_\_\_\_

CPU time: \_\_\_\_\_

Total time: \_\_\_\_\_

Number of Searches: \_\_\_\_\_

Number of Databases: \_\_\_\_\_

## Search Site

\_\_\_\_\_ STIC

\_\_\_\_\_ CM-1

\_\_\_\_\_ Pre-S

## Type of Search

\_\_\_\_\_ N.A. Sequence

\_\_\_\_\_ A.A. Sequence

\_\_\_\_\_ Structure

\_\_\_\_\_ Bibliographic

## Vendors

\_\_\_\_\_ IG

\_\_\_\_\_ STN

\_\_\_\_\_ Dialog

\_\_\_\_\_ APS

\_\_\_\_\_ Geninfo

\_\_\_\_\_ SDC

\_\_\_\_\_ DARC/Questel

✓ \_\_\_\_\_ Other CGN

***This Page Blank (uspto)***



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 8, 2005, 03:09:59 ; Search time 27.5625 Seconds  
(without alignments)  
125.671 Million cell updates/sec

Title: US-09-915-543-15\_COPY\_349\_384

Perfect score: 183  
Sequence: 1 DGLSQQLHHRERSLQTLRDIQMLPDPKEFTGAQ 36

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 79:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	57	31.1	1034	2 AB0551	exonuclease Sbcc I
2	56	30.6	584	2 S51882	topoisomerase I-re
3	56	30.6	859	2 T46372	hypothetical prote
4	55	30.1	287	2 AE2895	transcription regu
5	55	30.1	295	2 H97670	hex regulon repres
6	55	30.1	643	2 B59436	Rho GTPase activat
7	54.5	29.8	1171	2 S14065	phytochrome B - ri
8	53.5	29.2	266	2 AE1124	1-pyrroline-5-carb
9	53.5	29.2	4957	2 T03455	ALR protein - huma
10	53.5	29.2	5262	2 T03454	ALR protein - huma
11	53	29.0	227	2 B70438	hypothetical prote
12	53	29.0	376	1 E69957	gamma-D-glutamyl-L
13	53	29.0	818	2 S62790	mismatch DNA recog
14	52.5	28.7	242	2 B70366	hypothetical prote
15	52.5	28.7	705	2 T24343	hypothetical prote
16	52.5	28.7	1039	2 T14802	phytochrome B - so
17	52	28.4	332	2 B47017	probable transcrip
18	52	28.4	332	2 AD2541	transcription init
19	52	28.4	572	2 D82984	pyruvate dehydroge
20	52	28.4	1009	2 S61174	hypothetical prote
21	51	27.9	102	2 AH0216	conserved hypothet
22	51	27.9	237	2 A85901	probable alpha hel
23	51	27.9	237	2 A49940	probable alpha hel
24	51	27.9	237	2 E91056	probable alpha hel
25	51	27.9	329	2 D96834	hypothetical prote
26	51	27.9	477	2 T18801	hypothetical prote
27	51	27.9	518	2 G86454	CDS protein F9L11.
28	51	27.9	899	1 GNMVMM	pol polyprotein -
29	51	27.9	1047	2 C85535	ATP-dependent dsDN

30	51	27.9	1047	2 G90684	ATP-dependent dsDN
31	51	27.9	1161	2 G81186	conserved hypothet
32	51	27.9	1161	2 G81915	hypothetical prote
33	51	27.9	1464	2 S58984	development protei
34	50.5	27.6	835	2 AD2441	endopeptidase Clp
35	50	27.3	273	2 H69337	conserved hypothet
36	50	27.3	275	2 H69843	hypothetical prote
37	50	27.3	319	2 S49771	hypothetical prote
38	50	27.3	788	2 S67595	hypothetical prote
39	50	27.3	1162	2 D83454	conserved hypothet
40	50	27.3	1236	2 B36329	hypothetical prote
41	49.5	27.0	302	1 TPCHTC	tropomyosin T, cardia
42	49.5	27.0	336	2 S72858	hypothetical prote
43	49.5	27.0	830	2 T18860	hypothetical prote
44	49.5	27.0	2101	2 A42184	nuclear mitotic ap
45	49	26.8	310	2 A84142	L-lactate dehydrog

ALIGNMENTS

RESULT 1

AB0551

exonuclease Sbcc [imported] - Salmonella enterica subsp. enterica serovar Typhi (strain

C;Species: Salmonella enterica subsp. enterica serovar Typhi

A;Note: this species has also been called Salmonella typhi

C;Date: 09-Nov-2001 #sequence\_revision 09-Nov-2001 #text\_change 18-Nov-2002

C;Accession: AB0551

R;Parkhill, J.; Dougan, G.; James, K.D.; Thomson, N.R.; Pickard, D.; Wain, J.; Churcher,  
th, T.; Connor, P.; Cronin, A.; Davis, P.; Davies, R.M.; Dowd, L.; White, N.; Farrar,  
, S.; Moule, S.; O'Gaora, P.  
Nature 413, 848-852, 2001

A;Authors: Parry, C.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.;

A;Title: Complete genome sequence of a multiple drug resistant Salmonella enterica serov

A;Reference number: AB0502; MUID:21534947; PMID:11677608

A;Accession: AB0551

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-1034 <PAR>

A;Cross-references: GB:AL513382; PIDN:CAD08850.1; PID:g16501663; GSPDB:GN00176

C;Genetics:

A;Gene: STY0429

C;Superfamily: sbcc protein

Query Match 31.1%; Score 57; DB 2; Length 1034;  
Best Local Similarity 42.9%; Pred. No. 30;  
Matches 12; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 3 LSQQLHHRERSLQTLRDIQMLPDPDEK 30

Db 213 LADQLQLQLASLQALTDEKRLADQQ 240

RESULT 2

S51882

topoisomerase I-related protein TRF4 - yeast (Saccharomyces cerevisiae)

N;Alternate names: protein HRC584; protein O0716; protein YOL115w

C;Species: Saccharomyces cerevisiae

C;Date: 05-May-1995 #sequence\_revision 03-Aug-1995 #text\_change 09-Jul-2004

C;Accession: S51882; S59158; S58774; S66811

R;Vandenbol, M.; Durand, P.; Portetelle, D.; Hilger, F.

submitted to the EMBL Data Library, January 1995

A;Description: Sequence analysis of a 44kb DNA fragment of yeast chromosome XV including

and a Delta.

A;Reference number: S51848

A;Accession: S51882

A;Molecule type: DNA

A;Residues: 1-584 <VAN>

A;Cross-references: UNIPROT:P53632; EMBL:Z48149; NID:g663234; PID:g663237

R;Vandenbol, M.; Durand, P.; Portetelle, D.; Hilger, F.

Yeast 11, 1069-1075, 1995

A;Title: Sequence analysis of a 44 kb DNA fragment of yeast chromosome XV including the  
a delta element.

```

A/Reference number: S59156; MUID:96076631; PMID:7502582
A/Accession: S59158
A/Status: nucleic acid sequence not shown; translation not shown
A/Molecule type: DNA
A/Residues: 1-584 <VAM>
A/Cross-references: EMBL:Z48149; NID:g663234; PIDN:CAA88145.1; PID:g663237
A/Note: the nucleotide sequence was submitted to the EMBL Data Library, January 1995
R/Sadoff, B.U.; Heath-Pagliuso, S.; Castano, I.B.; Zhu, Y.; Kieff, F.S.; Christman, M.F.
Genetics 141, 465-479, 1995
A/Title: Isolation of mutants of Saccharomyces cerevisiae requiring DNA topoisomerase I.
A/Reference number: S58774; MUID:96109595; PMID:8647385
A/Accession: S58774
A/Molecule type: DNA
A/Residues: 1-584 <SAD>
A/Cross-references: EMBL:U31355; NID:g950225; PIDN:AAC49091.1; PID:g950226
R/Durand, P.; Hilger, F.; Portetelle, D.; Vandenbol, M.
submitted to the Protein Sequence Database, July 1996
A/Reference number: S66791
A/Accession: S66811
A/Molecule type: DNA
A/Residues: 1-584 <DUR>
A/Cross-references: EMBL:Z74857; NID:g1419986; PID:e251905; PID:g1419987; MIPS:YOL115W
A/Experimental source: strain S288C
C/Genetics:
A/Gene: SGD:TRF4
A/Cross-references: SGD:S0005475; MIPS:YOL115W
A/Map position: 15L
C/Keywords: nucleus

Query Match          30.6%; Score 56; DB 2; Length 584;
Best Local Similarity 36.0%; Pred. No. 22;
Matches 9; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

OY 4 SEQLEHRRERSLQTLRDIQMLFPD 28
      ||:||| ||::|||: ||:|||
Db 193 SREEIERNQTIISTIREAVKQLWPD 217

RESULT 3
T46372
hypothetical protein DKFZp434P1818.1 - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 04-Feb-2000 #sequence_revision 04-Feb-2000 #text_change 09-Jul-2004
C/Accession: T46372
R/Ottenweider, B.; Obermaier, B.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
submitted to the Protein Sequence Database, January 2000
A/Reference number: Z23031
A/Accession: T46372
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-859 <AAA>
A/Cross-references: UNIPROT:Q9NT51; EMBL:AL137528
A/Experimental source: adult testis; clone DKFZp434P1818
C/Genetics:
A/Note: DKFZp434P1818.1

Query Match          30.6%; Score 56; DB 2; Length 859;
Best Local Similarity 33.3%; Pred. No. 33;
Matches 10; Conservative 8; Mismatches 12; Indels 0; Gaps 0;

OY 5 QEQLEHRRERSLQTLRDIQMLFPDEKEFTG 34
      ||:||| ||::|||: ||:|||
Db 317 ENQRSHQELISQLQSYMKLLLPDDEKPHG 346

RESULT 4
AE2895
transcription regulator, Rpir family Atu2598 [imported] - Agrobacterium tumefaciens (str
C/Species: Agrobacterium tumefaciens
C/Date: 11-Jan-2002 #sequence_revision 11-Jan-2002 #text_change 09-Jul-2004
C/Accession: AE2895
R/Wood, D.W.; Setubal, J.C.; Kaul, R.; Monks, D.; Chen, L.; Wood, G.E.; Chen, Y.; Woo, L
erage, G.; Gillet, W.; Grant, C.; Guenther, D.; Kutayavin, T.; Levy, R.; Li, M.; Mclellan

```

```

; Karp, P.; Romero, P.; Zhang, S.
Science 294, 2317-2323, 2001
A:/Authors: Yoo, H.; Tao, Y.; Biddle, P.; Jung, M.; Krespan, W.; Perry, M.; Gordon-Kamm, J.
ster, E.W.
A;/Title: The Genome of the Natural Genetic Engineer Agrobacterium tumefaciens C58.
A;/Reference number: AB2577; MUID:21608550; PMID:11743193
A;/Accession: AE2895
A;/Status: preliminary
A;/Molecule type: DNA
A;/Residues: 1-287 <KUR>
A;/Cross-references: UNIPROT:Q8UCA0; GB:AE008688; PIDN:AAL43579.1; PID:g17741095; GSPDB:GT
A;/Experimental source: strain C58 (Dupont)
C;/Genetics:
A;/Gene: Atu2598
A;/Map position: circular chromosome
C;/Superfamily: hypothetical protein ybbH

Query Match      30.1%; Score 55; DB 2; Length 287;
Best Local Similarity 40.0%; Pred. No. 13;
Matches 12; Conservative 7; Mismatches 7; Indels 4; Gaps 1;

OY      9 EHRERSLQTLRDIQRLF----PDEKEFTG 34
       :|::||:||||:|::|::|::|
Db      257 QQRGRSMVTLRHIIKQLVEHRDPPDKQLLG 286

RESULT 5
H97670
hex regulon repressor [imported] - Agrobacterium tumefaciens (strain C58, Cereon)
C;/Species: Agrobacterium tumefaciens
C;/Date: 30-Sep-2001 #sequence_revision 30-Sep-2001 #text_change 09-Jul-2004
C;/Accession: H97670
R;/Gooder, B.; Hinkle, G.; Gattung, S.; Miller, N.; Blanchard, M.; Qurollo, B.; Goldman,
A.; Liu, F.; Wollam, C.; Allinger, M.; Doughty, D.; Scott, C.; Lappas, C.; Markelz, B.;
Science 294, 2323-2328, 2001
A;/Title: Genome Sequence of the Plant Pathogen and Biotechnology Agent Agrobacterium tume
A;/Reference number: A97359; MUID:21608551; PMID:11743194
A;/Accession: H97670
A;/Status: preliminary
A;/Molecule type: DNA
A;/Residues: 1-295 <KUR>
A;/Cross-references: UNIPROT:Q8UCA0; GB:AE007869; PIDN:AAK88321.1; PID:g15157797; GSPDB:GN
C;/Genetics:
A;/Gene: AGR_C_4707
A;/Map position: circular chromosome
C;/Superfamily: hypothetical protein ybbH

Query Match      30.1%; Score 55; DB 2; Length 295;
Best Local Similarity 40.0%; Pred. No. 14;
Matches 12; Conservative 7; Mismatches 7; Indels 4; Gaps 1;

OY      9 EHRERSLQTLRDIQRLF----PDEKEFTG 34
       :|::||:||||:|::|::|::|
Db      265 QQRGRSMVTLRHIIKQLVEHRDPPDKQLLG 294

RESULT 6
B59436
Rho GTPase activating protein RhogAP8 - human
C;/Species: Homo sapiens (man)
C;/Date: 03-Jun-2002 #sequence_revision 03-Jun-2002 #text_change 09-Jul-2004
C;/Accession: B59436
R;/Goward, M.E.; Huckie, E.J.
submitted to GenBank, April 2000
A;/Reference number: B59436
A;/Accession: B59436
A;/Status: preliminary
A;/Molecule type: mRNA
A;/Residues: 1-643 <GOW>
A;/Cross-references: UNIPROT:Q9NSG0; GB:CAB90248; PID:g7711011; PIDN:CAB90248.1

Query Match      30.1%; Score 55; DB 2; Length 643;
Best Local Similarity 52.2%; Pred. No. 32;
```





RESULT 16  
T14802  
phytochrome B - sorghum (fragment)  
C/Species: Sorghum bicolor (sorghum)  
C/Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 05-May-2000  
C/Accession: T14802  
R/Childs, K.L.; Miller, F.R.; Cordonnier-Pratt, M.M.; Pratt, L.H.; Morgan, P.W.; Mullet,  
submitted to the EMBL Data Library, April 1996  
A/Description: The Sorghum bicolor photoperiod sensitivity gene, Ma3, encodes a phytochr  
A/Reference number: Z18185  
A/Accession: T14802  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 1-1039 <CHI>  
A/Cross-references: EMBL:U56730; NID:g1800216; PID:g1800217  
A/Experimental source: cultivar 58M  
C/Genetics:  
A/Gene: PHYB  
A/Note: Intron positions not resolved (incomplete sequence)  
C/Superfamily: phytochrome; phytochrome homology  
C/Keywords: chromoprotein; photoreceptor; phytochromobilin  
F/233/Binding site: phytochromobilin (Cys) (covalent) #status predicted

Query Match 28.4%; Score 52; DB 2; Length 1039;  
Best Local Similarity 51.9%; Pred. No. 1.2e+02;  
Matches 14; Conservative 2; Mismatches 6; Indels 5; Gaps 1;

QY 3 LSGEQLEHRSLSQTLRDIQRLFPDE 29  
DB 887 VSQAMLLRERDLQLIRDI-----PDE 908

RESULT 17  
B47017  
probable transcription initiation factor sigma SigB - Anabaena sp.  
C/Species: Anabaena sp.  
C/Date: 21-Sep-1993 #sequence\_revision 18-Nov-1994 #text\_change 18-Jun-1999  
C/Accession: B47017  
R/Brahamsha, B.; Haseikorn, R.  
J. Bacteriol. 174, 7273-7282, 1992  
A/Title: Identification of multiple RNA polymerase sigma factor homologs in the cyanobac  
A/Reference number: A47017; MUID:93054341; PMID:1385387  
A/Accession: B47017  
A/Status: preliminary  
A/Molecule type: nucleic acid  
A/Residues: 1-332 <BRA>  
A/Cross-references: GB:M95760; NID:g142111; PIDN:AAA22046.1; PID:g142112  
A/Experimental source: PCC 7120  
A/Note: sequence extracted from NCBI backbone (NCBIN:118034, NCBI:P:118036)  
C/Superfamily: transcription initiation factor sigma katF; transcription initiation fact  
C/Keywords: DNA binding; sigma factor; transcription initiation  
F/103-328/Domain: transcription initiation factor sigma katF homology <KTF>

Query Match 28.4%; Score 52; DB 2; Length 332;  
Best Local Similarity 35.5%; Pred. No. 39;  
Matches 11; Conservative 6; Mismatches 14; Indels 0; Gaps 0;

QY 1 DGLSGEQLEHRSLSQTLRDIQRLFPDEKE 31  
DB 248 DGMSPERYAERELLYQDIHNLAKLTPQKE 278

RESULT 18  
AD2541  
transcription initiation factor sigma sigB [imported] - Nostoc sp. (strain PCC 7120) pla  
C/Species: Nostoc sp. PCC 7120  
A/Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120  
C/Date: 14-Dec-2001 #sequence\_revision 14-Dec-2001 #text\_change 09-Jul-2004  
C/Accession: AD2541  
R/Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi  
Nakazaki, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S  
DNA Res. 8, 205-213, 2001  
A/Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Ana

A/Reference number: AB1807; MUID:21595285; PMID:11759840  
A/Accession: AD2541  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-332 <KUR>  
A/Cross-references: UNIPROT:Q03065; GB:AP003602; PIDN:BAB77258.1; PID:g17134700; GSPDB:G  
A/Experimental source: strain PCC 7120  
C/Genetics:  
A/Gene: sigB  
A/Genome: plasmid  
C/Superfamily: transcription initiation factor sigma katF; transcription initiation fact  
C/Keywords: transcription initiation

Query Match 28.4%; Score 52; DB 2; Length 332;  
Best Local Similarity 35.5%; Pred. No. 39;  
Matches 11; Conservative 6; Mismatches 14; Indels 0; Gaps 0;

QY 1 DGLSGEQLEHRSLSQTLRDIQRLFPDEKE 31  
DB 248 DGMSPERYAERELLYQDIHNLAKLTPQKE 278

RESULT 19  
D82984  
pyruvate dehydrogenase (cytochrome) PA5297 [imported] - Pseudomonas aeruginosa (strain P  
C/Species: Pseudomonas aeruginosa  
C/Date: 15-Sep-2000 #sequence\_revision 15-Sep-2000 #text\_change 16-Aug-2004  
C/Accession: D82984  
R/Stover, C.K.; Pham, X.O.; Erwin, A.L.; Mizoguchi, S.D.; Warren, P.; Hickey, M.J.; Br  
adman, S.; Yuan, Y.; Brody, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Larbig, K.; Lim,  
.; Lory, S.; Olson, M.V.  
Nature 406, 959-964, 2000  
A/Title: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic patho  
A/Reference number: A82950; MUID:20437337; PMID:10984043  
A/Accession: D82984  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-572 <STO>  
A/Cross-references: UNIPROT:Q9HTQ7; GB:AE004942; GB:AE004091; NID:g9951607; PIDN:AA0868  
A/Experimental source: strain PA01  
C/Genetics:  
A/Gene: poxB; PA5297  
C/Superfamily: Acetolactate synthase, large subunit/pyruvate oxidase; thiamin pyrophosph

Query Match 28.4%; Score 52; DB 2; Length 572;  
Best Local Similarity 84.6%; Pred. No. 70;  
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 6 EQLEHRSLSQTL 18  
DB 333 ECLEHRSLSRTL 345

RESULT 20  
S61174  
hypothetical protein YDR379w - yeast (Saccharomyces cerevisiae)  
N/Alternate names: hypothetical protein D9481.4  
C/Species: Saccharomyces cerevisiae  
C/Date: 23-Feb-1996 #sequence\_revision 01-Mar-1996 #text\_change 15-Mar-2004  
C/Accession: S61174  
R/Ding, H.  
submitted to the EMBL Data Library, June 1995  
A/Description: The sequence of S. cerevisiae cosmid 9481.  
A/Reference number: S61159  
A/Accession: S61174  
A/Molecule type: DNA  
A/Residues: 1-1009 <DIN>  
A/Cross-references: EMBL:U28373; NID:g849184; PIDN:AAB64815.1; PID:g849200; MIPS:YDR379w  
A/Experimental source: strain S288C (AB972)  
C/Genetics:  
A/Gene: SGD:RGA2  
A/Cross-references: SGD:S0002787; MIPS:YDR379w  
A/Map position: 4R



F,13-66/Domain: LIM metal-binding repeat homology <LIM2>

Query Match 28.4%; Score 52; DB 2; Length 1009;  
Best Local Similarity 34.1%; Pred. No. 1.3e+02;  
Matches 15; Conservative 2; Mismatches 13; Indels 14; Gaps 1;

QY 3 LSQQLHRRSLQTLRDIQRLPDP-----EKEF 32  
DB 575 LSSESARRSSSLQTSRSTNALLEDSTKVDATDESATSLKDF 618

RESULT 21  
AH0216

conserved hypothetical protein YP01778 [imported] - Yersinia pestis (strain CO92)

C:Species: Yersinia pestis  
C:Date: 02-Nov-2001 #sequence\_revision 02-Nov-2001 #text\_change 09-Jul-2004

C:Accession: AH0216  
R:Parkhill, J.; Wren, B.W.; Thomson, N.R.; Titball, R.W.; Holden, M.T.G.; Prentice, M.B.; deno-Tarraga, A.M.; Chillingworth, T.; Cronin, A.; Davies, R.M.; Davis, P.; Dougan, G.; il, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.; Whitehead, S.; Barrell, Nature 413, 523-527, 2001

A:Title: Genome sequence of Yersinia pestis, the causative agent of plague.

A:Reference number: AB0001; MUID:21470413; PMID:11586360

A:Accession: AH0216

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-102 <KUR>

A:Cross-references: UNIPROT:Q8ZFD6; GB:AL590842; PIDN:CAC90596.1; PID:g15979803; GSPDB:G

C:Genetics:

A:Gene: YP01778

C:Superfamily: uncharacterized conserved protein

Query Match 27.9%; Score 51; DB 2; Length 102;  
Best Local Similarity 31.2%; Pred. No. 14;  
Matches 10; Conservative 6; Mismatches 16; Indels 0; Gaps 0;

QY 1 DGLSQQLHRRSLQTLRDIQRLFPDEKEF 32  
DB 63 DGLSRHAEQENMSLDLKKVIAIYPGLDRF 94

RESULT 22

A85901

probable alpha helix protein yfhg [imported] - Escherichia coli (strain O157:H7, substra

C:Species: Escherichia coli

C:Date: 16-Feb-2001 #sequence\_revision 16-Feb-2001 #text\_change 14-Sep-2001

C:Accession: A85901

R:Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew

iller, L.; Grotbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca, Nature 409, 529-533, 2001

A:Title: Genome sequence of enterohemorrhagic Escherichia coli O157:H7.

A:Reference number: A85480; MUID:21074935; PMID:11206551

A:Accession: A85901

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-237 <STO>

A:Cross-references: GB:AE005174; NID:g12516965; PIDN:AAG57669.1; GSPDB:GN00145; UWGP:Z38

A:Experimental source: strain O157:H7, substrain EDL933

C:Genetics:

A:Gene: yfhg

Query Match 27.9%; Score 51; DB 2; Length 237;  
Best Local Similarity 52.4%; Pred. No. 36;  
Matches 11; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 5 QEQLEHRRSLQTLRDIQRL 25  
DB 185 QOQLELTTRKLENTDIERQL 205

RESULT 23

A49940

probable alpha helix protein [imported] - Escherichia coli (strain K-12)

C:Species: Escherichia coli

C:Date: 13-Sep-1994 #sequence\_revision 18-Nov-1994 #text\_change 09-Jul-2004

C:Accession: A49940; B65033

R:Lin, J.; Magasanik, B.

J. Bacteriol. 175, 7441-7449, 1993

A:Title: The glbB region of the Escherichia coli chromosome.

A:Reference number: A49940; MUID:94042920; PMID:8226691

A:Accession: A49940

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-237 <LIU>

A:Cross-references: UNIPROT:P37328; GB:S67014; NID:g455660; PIDN:AAB28777.1; PID:g455661

A>Note: sequence extracted from NCBI backbone (NCBIN:139878, NCBI:P139880)

R:Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.; Riley, M.; Coj

.A.; Rose, D.J.; Mau, B.; Shao, Y.

Science 277, 1453-1462, 1997

A:Title: The complete genome sequence of Escherichia coli K-12.

A:Reference number: A64720; MUID:97426617; PMID:9278503

A:Accession: B65033

A:Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-237 <BLAT>

A:Cross-references: GB:AE000341; GB:U00096; NID:g1788899; PIDN:AACT5608.1; PID:g1788906;

A:Experimental source: strain K-12, substrain MG1655

C:Genetics:

A:Gene: yfhg

Query Match 27.9%; Score 51; DB 2; Length 237;  
Best Local Similarity 52.4%; Pred. No. 36;  
Matches 11; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 5 QEQLEHRRSLQTLRDIQRL 25  
DB 185 QOQLELTTRKLENTDIERQL 205

RESULT 24

E91056

probable alpha helix protein [imported] - Escherichia coli (strain O157:H7, substrain R10

C:Species: Escherichia coli

C:Date: 18-Jul-2001 #sequence\_revision 18-Jul-2001 #text\_change 09-Jul-2004

C:Accession: E91056

R:Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.,

gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.

DNA Res. 8, 11-22, 2001

A:Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genom

A:Reference number: A99629; MUID:21156231; PMID:11258796

A:Accession: E91056

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-237 <HAY>

A:Cross-references: UNIPROT:P37328; GB:BA000007; PIDN:BA036844.1; PID:g13362892; GSPDB:GN

A:Experimental source: strain O157:H7, substrain R1MD 0509952

C:Genetics:

A:Gene: ECs3421

Query Match 27.9%; Score 51; DB 2; Length 237;  
Best Local Similarity 52.4%; Pred. No. 36;  
Matches 11; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 5 QEQLEHRRSLQTLRDIQRL 25  
DB 185 QOQLELTTRKLENTDIERQL 205

RESULT 25

D96834

hypothetical protein F516.4 [imported] - Arabidopsis thaliana

C:Species: Arabidopsis thaliana (mouse-ear cress)

C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 09-Jul-2004

C:Accession: D96834

R:Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,

Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;

ansen, N.F.; Hughes, B.; Huizar, L.  
Nature 408, 816-820, 2000  
A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.  
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Lueros, J.S.; Maiti, R.; Marziani,  
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
A;Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,  
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
A;Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.  
A;Reference number: A86141; MUID:21016719; PMID:11130712  
A;Accession: D96834  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-329 <STO>  
A;Cross-references: UNIPROT:Q9C975; GB:AE005173; NID:g6751704; PIDN:AAF27686.1; GSPDB:GN  
C;Genetics:  
A;Gene: F516.4  
A;Map position: 1

Query Match 27.9%; Score 51; DB 2; Length 329;  
Best Local Similarity 37.5%; Pred. No. 51;  
Matches 9; Conservative 7; Mismatches 8; Indels 0; Gaps 0;

Qy 2 GLSQEQLEHRRSLQTLRDIGRM 25  
Db 272 GLSSRRVHRKRGNCIREFHRVM 295

RESULT 26  
T18801  
hypothetical protein ZK131.11 - Caenorhabditis elegans  
C;Species: Caenorhabditis elegans  
C;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004  
C;Accession: T18801; T27746  
R;Percy, C.  
Submitted to the EMBL Data Library, March 1997  
A;Reference number: Z19024  
A;Accession: T18801  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-477 <WIL>  
A;Cross-references: UNIPROT:O62022; EMBL:Z93373; PIDN:CAB07552.1; GSPDB:GN00020; CESP:ZK  
A;Experimental source: clone C01B9  
R;Steward, C.  
Submitted to the EMBL Data Library, December 1996  
A;Reference number: Z20413  
A;Accession: T27746  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-477 <W12>  
A;Cross-references: EMBL:Z83245; PIDN:CAB05840.1; GSPDB:GN00020; CESP:ZK131.11  
A;Experimental source: clone ZK131  
C;Genetics:  
A;Gene: CESP:ZK131.11  
A;Map position: 2  
A;Introns: 20/2; 49/2; 113/1; 169/1; 260/2; 375/3; 432/3  
C;Superfamily: Caenorhabditis elegans hypothetical protein ZK131.11

Query Match 27.9%; Score 51; DB 2; Length 477;  
Best Local Similarity 50.0%; Pred. No. 77;  
Matches 11; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 3 LSQEQLEHRRSLQTLRDIGRM 24  
Db 428 LKREMKEMERDAQILSDLQRV 449

RESULT 27  
G86454  
CDS protein F9L11.17 [imported] - Arabidopsis thaliana  
C;Species: Arabidopsis thaliana (mouse-ear cress)  
C;Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 09-Jul-2004  
C;Accession: G86454  
R;Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,

Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;  
ansen, N.F.; Hughes, B.; Huizar, L.  
Nature 408, 816-820, 2000  
A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.  
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Lueros, J.S.; Maiti, R.; Marziani,  
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
A;Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, I  
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
A;Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.  
A;Reference number: A86141; MUID:21016719; PMID:11130712  
A;Accession: G86454  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-518 <STO>  
A;Cross-references: UNIPROT:Q9MAP1; GB:AE005172; NID:g6910585; PIDN:AAF31290.1; GSPDB:GN  
C;Genetics:  
A;Gene: F9L11.17  
A;Map position: 1  
C;Superfamily: Arabidopsis thaliana hypothetical protein At2g23160

Query Match 27.9%; Score 51; DB 2; Length 518;  
Best Local Similarity 34.1%; Pred. No. 84;  
Matches 14; Conservative 9; Mismatches 10; Indels 8; Gaps 3;

Qy 1 DGLSQEQLEHRRSLQTLRDI-----QRMLFPDEKEFTGAQ 36  
Db 442 DG-DDPTVAHQQRDHTFKSISKFAQRLL--DDDEFTGVK 479

RESULT 28  
GNMVM  
pol polyprotein - mouse mammary tumor virus  
C;Species: mouse mammary tumor virus, MMTV  
C;Date: 31-Mar-1989 #sequence\_revision 31-Mar-1989 #text\_change 09-Jul-2004  
C;Accession: C26795  
R;Moore, R.; Dixon, M.; Smith, R.; Peters, G.; Dickson, C.  
J. Virol. 61, 480-490, 1987  
A;Title: Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: t  
A;Reference number: A93030; MUID:87112944; PMID:3027377  
A;Accession: C26795  
A;Molecule type: DNA  
A;Residues: 1-899 <MOO>  
A;Cross-references: UNIPROT:P03365; EMBL:M15122  
C;Genetics:  
A;Gene: pol  
C;Superfamily: pol polyprotein  
C;Keywords: polyprotein; reverse transcriptase

Query Match 27.9%; Score 51; DB 1; Length 899;  
Best Local Similarity 40.0%; Pred. No. 1.5e+02;  
Matches 10; Conservative 7; Mismatches 8; Indels 0; Gaps 0;

Qy 1 DGLSQEQLEHRRSLQTLRDIGRM 25  
Db 240 DSVSYQKQIRTDKRLTNDFOKLL 264

RESULT 29  
C85535  
ATP-dependent dsDNA exonuclease [imported] - Escherichia coli (strain O157:H7, substrain  
C;Species: Escherichia coli  
C;Date: 16-Feb-2001 #sequence\_revision 16-Feb-2001 #text\_change 09-Jul-2004  
C;Accession: C85535  
R;Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew  
iller, L.; Grotbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca,  
Nature 409, 529-533, 2001  
A;Title: Genome sequence of enterohemorrhagic Escherichia coli O157:H7.  
A;Reference number: A85480; MUID:21074935; PMID:11206551  
A;Accession: C85535  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-1047 <STO>  
A;Cross-references: UNIPROT:Q8XEU6; GB:AE005174; NID:g12513240; PIDN:AAG54743.1; GSPDB:G





C;Accession: AD2441  
R;Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi, Nakazaki, N.; Shimpō, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S DNA Res. 8, 205-213, 2001  
A;Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Anabaena Reference number: AB1807; MUID:21595285; PMID:11759840  
A;Accession: AD2441  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-835 <KUR>  
A;Cross-references: UNIPROT:Q8YM56; GB:BA000019; PIDN:BAH76783.1; PID:g17134222; GSPDB:G A;Experimental source: strain PCC 7120  
C;Genetics:  
A;Gene: clpB  
C;Superfamily: endopeptidase Clp ATP-binding chain

Query Match 27.6%; Score 50.5; DB 2; Length 835;  
Best Local Similarity 38.2%; Pred. No. 1.6e+02;  
Matches 13; Conservative 7; Mismatches 11; Indels 3; Gaps 1;

Qy 1 DGLSQQLHRRSLQTLRDIQRLPDEKE 31  
Db 399 DAASRERLERLEKELADLKEEQRTLTNTQWQSEKD 432

RESULT 35  
H69337  
conserved hypothetical protein AF0704 - Archaeoglobus fulgidus  
C;Species: Archaeoglobus fulgidus  
C;Date: 05-Dec-1997 #sequence\_revision 05-Dec-1997 #text\_change 09-Jul-2004  
C;Accession: H69337  
R;Klenk, H.P.; Clayton, R.A.; Tomb, J.F.; White, O.; Nelson, K.E.; Ketchum, K.A.; Dodson, J.; Fleischmann, R.D.; Quackenbush, J.; Lee, N.H.; Sutton, G.G.; Gill, S.; Kirkness, E.F.; Glodek, A.; Zhou, L.; Overbeek, R.; Gocayne, J.D.; Weidman, J.F.; McDonald, L.  
Nature 390, 364-370, 1997  
A;Authors: Uitterback, T.; Cotton, M.D.; Spriggs, T.; Artlisch, P.; Kaine, B.P.; Sykes, S.; Smith, H.O.; Woese, C.R.; Venter, J.C.  
A;Title: The complete genome sequence of the hyperthermophilic, sulfate-reducing archaeon Pyrococcus furiosus Reference number: A69250; MUID:98049343; PMID:9389475  
A;Accession: H69337  
A;Status: preliminary; nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA  
A;Residues: 1-273 <KLE>  
A;Cross-references: UNIPROT:O29554; GB:AE001056; GB:AE000782; NID:g2689379; PIDN:AAB9053 C;Superfamily: Methanococcus jannaschii conserved hypothetical protein MJ1557

Query Match 27.3%; Score 50; DB 2; Length 273;  
Best Local Similarity 37.9%; Pred. No. 56;  
Matches 11; Conservative 7; Mismatches 11; Indels 0; Gaps 0;

Qy 1 DGLSQQLHRRSLQTLRDIQRLPDEKE 29  
Db 9 DRLSEELKLVRRSFEIIGDVIIIEIPDE 37

RESULT 36  
H69843  
hypothetical protein yjdh - Bacillus subtilis  
C;Species: Bacillus subtilis  
C;Date: 05-Dec-1997 #sequence\_revision 05-Dec-1997 #text\_change 09-Jul-2004  
C;Accession: H69843  
R;Kunst, F.; Ogasawara, N.; Moszer, I.; Albertini, A.M.; Alloni, G.; Azevedo, V.; Bertero, C.; Bron, S.; Brouillet, S.; Bruschi, C.V.; Caldwell, B.; Capuano, V.; Carter, N.M.; Choc A.; Ehrlich, S.D.; Emmerson, P.T.; Entian, K.D.; Errington, J.; Fabret, C.; Ferrarri, E.  
Nature 390, 249-256, 1997  
A;Authors: Foulger, D.; Fritzt, C.; Fujita, M.; Fujita, Y.; Fuma, S.; Galizzi, A.; Gallier, J.; Harwood, C.R.; Henaut, A.; Hilbert, H.; Holsappel, S.; Hosono, S.; Hullo, M.F.; Koetter, P.; Koningsstein, G.; Krogh, S.; Kumano, M.; Kurita, K.; Lapidus, A.; Lardinois, A.; Authors: lauber, J.; Lazarevic, V.; Lee, S.M.; Levine, A.; Liu, H.; Masuda, S.; Maueel Y., M.; Ogawa, K.; Ogiwara, A.; Oudega, B.; Park, S.H.; Parro, V.; Pohl, T.M.; Portetelle Rieger, M.; Rivolta, C.; Rocha, E.; Roche, B.; Rose, M.; Sadale, Y.; Sato, T.; Scanlon, A;Authors: Schleich, S.; Schroeter, R.; Scoffone, F.; Sekiguchi, J.; Sekowska, A.; Serot akeuchi, M.; Tamakoshi, A.; Tanaka, T.; Terpstra, P.; Tognoni, A.; Tosato, V.; Uchiyama,

T.; Winters, P.; Wipat, A.; Yamamoto, H.; Yamane, K.; Yasumoto, K.; Yata, K.; Yoshida, K A;Authors: Yoshikawa, H.F.; Zumstein, E.; Yoshikawa, H.; Danchin, A.  
A;Title: The complete genome sequence of the Gram-positive bacterium Bacillus subtilis. A;Reference number: A69580; MUID:98044033; PMID:9384377  
A;Accession: H69843  
A;Status: preliminary; nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA  
A;Residues: 1-275 <KUN>  
A;Cross-references: UNIPROT:O31606; GB:Z99110; GB:AL009126; NID:g2633472; PIDN:CAB13012. A;Experimental source: strain 168  
C;Genetics:  
A;Gene: yjdh

Query Match 27.3%; Score 50; DB 2; Length 275;  
Best Local Similarity 37.0%; Pred. No. 57;  
Matches 10; Conservative 7; Mismatches 10; Indels 0; Gaps 0;

Qy 7 QLEHRRSLQTLRDIQRLPDEKEPT 33  
Db 91 ELQGRKAGMQFLRMQESLFFVSKNIT 117

RESULT 37  
S49771  
hypothetical protein YDR175c - yeast (Saccharomyces cerevisiae)  
N;Alternate names: hypothetical protein YD9395.08c  
C;Species: Saccharomyces cerevisiae  
C;Date: 13-Jan-1995 #sequence\_revision 10-Feb-1995 #text\_change 09-Jul-2004  
C;Accession: S49771  
R;Murphy, L.; Harris, D.E.  
submitted to the EMBL Data Library, November 1994  
A;Reference number: S49764  
A;Accession: S49771  
A;Molecule type: DNA  
A;Residues: 1-319 <MUR>  
A;Cross-references: UNIPROT:Q03976; EMBL:Z46727; NID:g1289283; PID:e223724; PID:g1289290 C;Genetics:  
A;Gene: SGD:RSM24; MIPS:YDR175c  
A;Cross-references: SGD:S0002582  
A;Map position: 4R

Query Match 27.3%; Score 50; DB 2; Length 319;  
Best Local Similarity 29.0%; Pred. No. 67;  
Matches 9; Conservative 9; Mismatches 13; Indels 0; Gaps 0;

Qy 3 LLSQQLHRRSLQTLRDIQRLPDEKEPT 33  
Db 236 MSSDKFEHASQNAHYLHDILQRLAESKDLT 266

RESULT 38  
S67595  
hypothetical protein YDL060w - yeast (Saccharomyces cerevisiae)  
N;Alternate names: hypothetical protein D2544  
C;Species: Saccharomyces cerevisiae  
C;Date: 12-Jul-1996 #sequence\_revision 12-Jul-1996 #text\_change 09-Jul-2004  
C;Accession: S67595  
R;Bloeker, H.; Brandt, P.  
submitted to the Protein Sequence Database, July 1996  
A;Reference number: S67587  
A;Accession: S67595  
A;Molecule type: DNA  
A;Residues: 1-788 <BLO>  
A;Cross-references: UNIPROT:Q07381; EMBL:Z74108; NID:g1431062; PID:g1431063; GSPDB:GN000 A;Experimental source: strain S288C  
C;Genetics:  
A;Gene: SGD:TSR1; MIPS:YDL060w  
A;Cross-references: SGD:S0002218  
A;Map position: 4L

Query Match 27.3%; Score 50; DB 2; Length 788;  
Best Local Similarity 36.4%; Pred. No. 1.8e+02;  
Matches 12; Conservative 6; Mismatches 13; Indels 2; Gaps 1;

```

Qy      1 DGLSQOLEHRERSLQTLRDQR--MLFPDEKE 31
      : | : | | : | | : | | | |
Db      455 EGFEELSPSEERQLREFRDMEKEDREFPDEIE 487

```

### RESULT 39

D833454  
conserved hypothetical protein PA1527 [imported] - *Pseudomonas aeruginosa* (strain PA01)  
C/Species: *Pseudomonas aeruginosa*  
C/Date: 15-Sep-2000 #sequence\_revision 15-Sep-2000 #text\_change 09-Jul-2004  
C/Accession: D833454  
R/Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warrenner, P.; Hickey, M.J.; Bradman, S.; Yuan, Y.; Brody, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Lardig, K.; Lim, .; Loay, S.; Olson, M.V.  
Nature 406, 959-964, 2000  
A/Title: Complete genome sequence of *Pseudomonas aeruginosa* PA01, an opportunistic pathogen  
A/Reference number: AB2950; MUID:20437337; PMID:10984043  
A/Accession: D833454  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-1162 <STO>  
A/Cross-references: UNIPROT:Q91316; GB:AE004581; GB:AE004091; NID:G9947482; PIDN:AA0491  
A/Experimental source: strain PA01  
C/Genetics:  
A/Gene: PA1527

Query Match	27.3%	Score 50;	DB 2;	Length 1162;
Best Local Similarity	39.1%;	Pred. No. 2.7e+02;		
Matches 9;	Conservative 8;	Mismatches 6;	Indels 0;	Gaps 0;

```
QY      3 LSOEQLEHREERSLQTLRDIQRM L 25
      : | : : | | : | : | : | : |
Db      400 VQOSRIQHLQSLERLQDRERRL 422
```

## RESULT 40

B36329  
hypothetical protein 2 - cabbage looper transposon TED (fragment)  
C;Species: Trichoplusia ni (cabbage looper)  
C;Date: 01-Feb-1991 #sequence\_revision 01-Feb-1991 #text\_change 30-Sep-1993  
C;Accession: B36329  
R;Friesen, P.D.; Nissen, M.S.  
Mol. Cell. Biol. 10, 3067-3077, 1990  
A;Title: Gene organization and transcription of TED, a lepidopteran retrotransposon inte  
A;Reference number: A36329; MUID:90258898; PMID:1692964  
A;Accession: B36329  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-1236 <FRI>  
A;Cross-references: GB:M32662

Query Match	27.3%	Score 50;	DB 2;	Length 1236;
Best Local Similarity	42.9%;	Pred. No. 2.9e+02;		
Matches 12;	Conservative 4;	Mismatches 12;	Indels 0;	Gaps 0;

```

0y      5 QEQLHRRSLQTLRDIQRMLFPDEKEF 32
      ||||: ||||: ||: ||
Db      459 QEHLNLRVYQRLRESNFKIQMDSEF 486

```

Search completed: June 8, 2005, 03:23:55  
Job time : 29.5625 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 8, 2005, 03:09:59 ; Search time 21.4375 Seconds  
(without alignments)  
125.671 Million cell updates/sec

Title: US-09-915-543-15\_COPY\_177\_204  
Perfect score: 136  
Sequence: 1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR\_79:.\*  
1: pir1:.\*  
2: pir2:.\*  
3: pir3:.\*  
4: pir4:.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	60	44.1	205	2 I40812	porphobilinogen sy
2	55	40.4	634	2 T27465	hypothetical prote
3	51	37.5	243	2 G97070	zn-dependent hydro
4	49	36.0	210	2 D86398	protein F17J21.2 f
5	49	36.0	458	2 F71315	probable response
6	49	36.0	586	2 D82484	Sgat protein VCA02
7	48.5	35.7	311	2 C81380	probable D-2-hydro
8	48	35.3	330	2 E84074	dihydroxyacetone k
9	47	34.6	319	2 T01822	hypothetical prote
10	47	34.6	352	2 F90179	prolidase (Xaa-Pro
11	47	34.6	662	2 AD0623	probable bacteriop
12	46.5	34.2	586	2 T29695	hypothetical prote
13	46	33.8	330	2 S08500	QUTG protein - Eme
14	46	33.8	363	2 C69962	branched-chain fat
15	46	33.8	461	2 E95887	probable aminotran
16	46	33.8	1289	2 F72308	hypothetical prote
17	46	33.8	2123	2 S55089	probable acetyl-Co
18	45.5	33.5	256	2 S04363	class II histocomp
19	45.5	33.5	268	2 A99261	glutacolate CoA-tr
20	45.5	33.5	504	2 S54744	cellulase (EC 3.2.
21	45.5	33.5	505	2 S39962	endoglucanase - Er
22	45	33.1	131	2 H72478	hypothetical prote
23	45	33.1	451	2 B96495	hypothetical prote
24	45	33.1	555	2 H96762	hypothetical prote
25	44.5	32.7	48	2 D90907	hypothetical prote
26	44.5	32.7	50	2 F85710	unknown protein en
27	44	32.4	126	2 T43131	hypothetical prote
28	44	32.4	265	2 T14645	hypothetical prote
29	44	32.4	318	2 C64445	conserved hypothet

30	44	32.4	340	2 T19105	phosphate carrier
31	44	32.4	350	2 A85056	probable transposo
32	44	32.4	395	2 AH3455	acriiflavin resista
33	44	32.4	437	2 A72498	probable DNA/panto
34	44	32.4	476	2 AG1051	probable transport
35	44	32.4	484	2 D65230	hypothetical 52.9
36	44	32.4	484	2 A98275	hypothetical prote
37	44	32.4	484	2 A86116	hypothetical prote
38	44	32.4	533	2 T05092	probable 1,2-diacy
39	44	32.4	609	2 JC5756	vibriolysin (EC 3.
40	44	32.4	619	2 G72709	probable DNA ligas
41	44	32.4	980	2 T33630	valine-tRNA ligase
42	44	32.4	4427	2 PN0637	polyketide synthas
43	43	31.6	119	2 T18644	hypothetical prote
44	43	31.6	159	2 T40440	6,7-dimethyl-8-rib
45	43	31.6	234	2 H98154	amino acid ABC tra

ALIGNMENTS

RESULT 1

I40812 porphobilinogen synthase (EC 4.2.1.24) - Clostridium josui (fragment)  
N/Alternate names: delta-aminolevulinic acid dehydratase  
C/Species: Clostridium josui  
C/Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 09-Jul-2004  
C/Accession: I40812  
R/Fujino, E.; Fujino, T.; Karita, S.; Sakka, K.; Ohmura, K.  
J. Bacteriol. 177, 5169-5175, 1995  
A/Title: Cloning and sequencing of some genes responsible for porphyrin biosynthesis fro  
A/Reference number: A57344; MUID:95394829; PMID:765501  
A/Accession: I40812  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 1-205 <RES>  
A/Cross-references: UNIPROT:Q59295; GB:D28503; NID:G536874; PIDN:BAA05863.1; PID:G556484  
C/Genetics:  
A/Gene: hemB  
C/Superfamily: porphobilinogen synthase  
C/Keywords: carbon-oxygen lyase; hydro-lyase

Query Match 44.1%; Score 60; DB 2; Length 205;  
Best Local Similarity 46.2%; Pred. No. 0.24;  
Matches 12; Conservative 5; Mismatches 9; Indels 0; Gaps 0;  
QY 2 VYVFSTEMANKAAEAVLKQGVETIVSF 27  
Db 51 YHFSPPDWGKAIEAALKADVKSVLLF 76

RESULT 2

T27465 hypothetical protein Y87G2A.m - Caenorhabditis elegans  
C/Species: Caenorhabditis elegans  
C/Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999  
C/Accession: T27465  
R/White, S.  
submitted to the EMBL Data Library, September 1999  
A/Reference number: Z20371  
A/Accession: T27465  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 1-634 <WIL>  
A/Cross-references: EMBL:AL110500; NID:e1542314; PIDN:CAB54487.1; CESP:Y87G2A.m  
A/Experimental source: clone Y87G2A  
C/Genetics:  
A/Gene: CESP:Y87G2A.m  
A/Introns: 74/1; 270/1

Query Match 40.4%; Score 55; DB 2; Length 634;  
Best Local Similarity 44.4%; Pred. No. 4.4;  
Matches 12; Conservative 2; Mismatches 13; Indels 0; Gaps 0;

```

Qy      2 YVFSTEMANKAAEAVLKGVETIVSFH 28
          || || || || || || || ||
Db      461 YVCAHMAEKAAVAANGDLQIIPEFH 487

```

### RESULT 3

G97070  
Zn-dependent hydrolases, glyoxylase family [imported] - Clostridium acetobutylicum  
C/Species: Clostridium acetobutylicum  
C/Date: 14-Sep-2001 #sequence\_revision 14-Sep-2001 #text\_change 09-Jul-2004  
C/Accession: G97070  
R/Nolling, J.; Breton, G.; Omelchenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee, J.; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.  
J. Bacteriol. 183, 4823-4838, 2001  
A/Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium Clostridium acetobutylicum  
A/Reference number: A96900; MUID:21359325; PMID:21359325  
A/Accession: G97070  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-243 <KUR>  
A/Cross-references: UNIPROT:Q97JJA0; GB:AE001437; PIDN:AAK79354.1; PID:g15024323; GSPDB:GSP000000001  
A/Experimental source: Clostridium acetobutylicum ATCC824  
C/Genetics:  
A/Gene: CAC1386

Query Match	37.5%	Score 51;	DB 2;	Length 243;
Best Local Similarity	25.0%	Pred. No. 6.2;		
Matches	7;	Conservative 11;	Mismatches 10;	Indels 0;
			Gaps	0;

```
Qy      1 VYVFESTEMANKAAEAVLKGQVETIVSFH 28
        ::|:::|::|::|::|::|::|::|
Db      199 LFDFDSNISKSKLEKLTKYDIETIVICFH 226
```

## RESULT 4

protein F17L21.2 [imported] - Arabidopsis thaliana  
C:Species: Arabidopsis thaliana (mouse-ear cress)  
C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 09-Jul-2004  
C:Accession: D86398  
R:Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,  
Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewart, K.;  
ansen, N.F.; Hughes, B.; Huizart, L.  
Nature 408, 816-820, 2000  
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.  
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marzali,  
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,  
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.  
A:Reference number: A86141; MUID:21016719; PMID:11130712  
A:Accession: D86398  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-210 <STO>  
A:Cross-references: UNIPROT:Q9FZLL; GB:AE005172; NID:g9802520; PIDN:AAF99722.1; GSPDB:GN  
C:Genetics:  
A:Gene: F17L21.2  
A:Map position: 1

Query Match	36.0%	Score 49;	DB 2;	Length 210;
Best Local Similarity	41.7%;	Pred. No. 11;		
Matches 10; Conservative	6;	Mismatches 8;	Indels 0;	Gaps 0;

```
QY      4  FSTEMANKAAEAVLKQGVETIVSF  27
      :| ||| : ||| : ||| : |||
Db      181 WSFIRSTNKAADRLAKGELENNVTF  204
```

## RESULT 5

**F71315** probable response regulatory protein (atoc) - syphilis spirochete

C/Species: *Treponema pallidum* subsp. *pallidum* (syphilis spirochete)  
C/Date: 24-Jul-1998 #sequence\_revision 24-Jul-1998 #text\_change 02-Jun-2003  
C/Accession: F71315  
R/Frazer, C.M.; Norris, S.J.; Weinstock, G.M.; White, O.; Sutton, G.G.; Dodson, R.; Gwin  
rson, J.; Khalak, H.; Richardson, D.; Howell, J.K.; Chidambaram, M.; Utterback, T.; McDo  
rthy, L.; Weidman, J.; Smith, H.O.; Venter, J.C.

A;Title: Complete genome sequence of *Treponema pallidum*, the syphilis spirochete.  
A;Reference number: A71250; MUID:98332770; PMID:9665876

A;Status: preliminary; nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA

A; Cross-references: GB:AE001227; GB:AE000520; NID:g3322797; PIDN:AAC65507.1; PID:g3322811  
A; Experimental source: strain Nichols

A:Gene: TP0519  
C:Superfamily: response regulator, NtrC type; response regulator homology; RNA polymerase

F:143-365/Domain: RNA polymerase sigma factor interaction domain homology <SFI>  
C:aejw0003: pncsnp00020  
F:5-114/Domain: response regulator homology <RRH>

F;53/Binding site: phosphate (Asp)	(covalent)	#status predicted
F;74/Binding site: phosphate (Asp)	(covalent)	#status predicted

Query Match	36.0%;	Score 49;	DB 2;	Length 458;
Best Local Similarity	37.5%;	Pred. NO. 24;		
Matches	9;	Conservative	5;	Mismatches 10;
				Indels 0;
				Gaps 0;

```
QY      3 VFSTEMANKAAEAVLKQVETIVS 26
      ||:| | | |||::|:
Db      29 VFTEADGNTGVEIALKGDIDLIT 52
```

## RESULT 6

Sgat protein VCA0246 [imported] - *Vibrio cholerae* (strain N16961 serogroup O1)  
C:Species: *Vibrio cholerae*  
C:Date: 18-Aug-2000 #sequence\_revision 20-Aug-2000 #text\_change 09-Jul-2004  
C:Accession: D82484  
R:Heidelberg, J.F.; Eisen, J.A.; Nelson, W.C.; Clayton, R.A.; Gwinn, M.L.; Dodson, R.J.;  
chardson, D.; Ermolaeva, M.D.; Vamathevan, J.; Bass, S.; Qin, H.; Dragoi, I.; Sellers, P.  
1, R.R.; Mekalanos, J.J.; Venter, J.C.; Fraser, C.M.  
Nature 406, 477-483, 2000  
A:Title: DNA Sequence of both chromosomes of the cholera pathogen *Vibrio cholerae*.  
A:Reference number: A82035; MUID:20406833; PMID:10952301  
A:Accession: D82484  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-586 <HEI>  
A:Cross-references: UNIPROT:Q9KMS4; GB:AE004364; GB:AE003853; NID:G9657630; PIDN:AAF96157  
A:Experimental source: serogroup O1, strain N16961, biotype El Tor  
C:Genetics:  
A:Gene: VCA0246  
A:Map position: 2

Query Match	36.0%;	Score 49;	DB 2;	Length 586;
Best Local Similarity	25.0%;	Pred. No. 31;		
Matches	11;	Conservative	8;	Mismatches 7;
				Indels 18;
				Gaps 1;

```
QY      2 YVFSTEMANKA-----AEAVLKQGVETIVSF 27
      ||:|::: ||      |::||:||||| |
DB      9 YIFYSQVMTKAPLLGLVTLIGWLLRRDATYIIKGSIKTIIVGF 52
```

## RESULT 7

probable D-2-hydroxyacid dehydrogenase Cj0373 [imported] - Campylobacter jejuni (strain R  
CjSpecies: Campylobacter jejuni  
CjDate: 31-Mar-2000 #sequence\_revision 31-Mar-2000 #text\_change 09-Jul-2004  
CjAccession: C81380  
RjParkhill, J.; Wren, B.W.; Mungall, K.; Ketley, J.M.; Churcher, C.; Basham, D.; Chilling  
C.W.; Quail, M.; Rajandream, M.A.; Rutherford, K.M.; VanVliet, A.; Whitehead, S.; Barrell  
Nature 403, 665-668, 2000

```

A/Title: The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hyp
A/Reference number: A81250; MUID:20150912; PMID:10688204
A/Accession: C81380
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-311 <PAR>
A/Cross-references: UNIPROT:Q9PIC9; GB:AL139075; GB:AL111168; NID:g6967817; PIDN:CA87420
A/Experimental source: serotype O2, strain NCTC 11168
C/Genetics:
A/Gene: Cj0373
C/Superfamily: phosphoglycerate dehydrogenase

Query Match          35.7%; Score 48.5; DB 2; Length 311;
Best Local Similarity 42.4%; Pred. No. 19;
Matches 14; Conservative 6; Mismatches 8; Indels 5; Gaps 2;

OY      1 YVVFSTEMANKAAEA---LKQVET--IVSFH 28
          :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db      171 IYYTSGANKNADFVHLELKDLLKTCDIISIH 203

RESULT 8
E84074
dihydroxyacetone kinase BH3397 [imported] - Bacillus halodurans (strain C-125)
C/Species: Bacillus halodurans
C/Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 09-Jul-2004
C/Accession: E84074
R/Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; Hira
Nucleic Acids Res. 28, 4317-4331, 2000
A/Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and
A/Reference number: A83650; MUID:20512582; PMID:11058132
A/Accession: E84074
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-330 <STO>
A/Cross-references: UNIPROT:Q9K7G4; GB:AP001518; GB:BA000004; NID:G10175792; PIDN:BA8071
A/Experimental source: strain C-125
C/Genetics:
A/Gene: BH3397

Query Match          35.3%; Score 48; DB 2; Length 330;
Best Local Similarity 42.3%; Pred. No. 24;
Matches 11; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

OY      2 YVVFSTEMANKAAEA---LKQVETIVSF 27
          |||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db      270 YVFMDVANKLTEEGLNIQFKVGSF 295

RESULT 9
T01822
hypothetical protein T27D20.16 - Arabidopsis thaliana
C/Species: Arabidopsis thaliana (mouse-ear cress)
C/Date: 26-Feb-1999 #sequence_revision 26-Feb-1999 #text_change 09-Jul-2004
C/Accession: T01822
R/Edwards, J.; Wollam, C.; Dubbelde, C.
submitted to the EMBL Data Library, August 1998
A/Description: The sequence of A. thaliana T27D20.
A/Reference number: Z14441
A/Accession: T01822
A/Status: translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-319 <EDW>
A/Cross-references: UNIPROT:O81460; EMBL:AF076274; NID:g3293583; PID:g3377852
A/Experimental source: cultivar Columbia
C/Genetics:
A/Map position: 4
A/Introns: 49/3; 151/3; 210/3; 269/2
A/Note: T27D20.16
C/Superfamily: Arabidopsis hypothetical protein F7N22.18

Query Match          34.6%; Score 47; DB 2; Length 319;
Best Local Similarity 48.0%; Pred. No. 33;

```

```

Matches      12;      Conservative      4;      Mismatches      7;      Indels      2;      Gaps      1;

OY      5      STEMANK--AAEAVLKGQVETIVSF      27
      .      |      |      |      |      |      |      |      |      |
Db      243      SIELSQKLAEEALIANQAEKITSF      267

RESULT 10
F90179
prolidase (Xaa-Pro dipeptidase) (pepQ) [imported] - Sulfolobus solfataricus
C;Species: Sulfolobus solfataricus
C;Date: 24-May-2001 #sequence_revision 24-May-2001 #text_change 09-Jul-2004
C;Accession: F90179
R;She, Q.; Singh, R.K.; Confalonieri, F.; Zivanovic, Y.; Allard, G.; Awayez, M.J.; Chan-
Jong, I.; Jeffries, A.C.; Kozera, C.J.; Medina, N.; Peng, X.; Thi-Ngoc, H.P.; Redder, P
arrett, R.A.; Ragan, M.A.; Sensen, C.W.; Van der Oost, J.
submitted to GenBank, April 2001
A;Description: Sulfolobus solfataricus complete genome.
A;Reference number: A99139
A;Accession: F90179
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-352 <KUR>
A;Cross-references: UNIPROT:Q980E9; GB:AE006641; NID:G13813507; PIDN:AAK40693.1; GSPDB:G
C;Genetics:
A;Gene: pepQ
C;Superfamily: X-Pro aminopeptidase

Query Match      34.6%;      Score 47;      DB 2;      Length 352;
Best Local Similarity 43.5%;      Pred. No. 36;
Matches      10;      Conservative      3;      Mismatches      10;      Indels      0;      Gaps      0;

OY      2      VFSTEMANKAAEAVLKGQVETI      24
      :      |      |      |      |      |      |      |      |      |
Db      232      FVFKNSEAKKYEVVLEAQMEAI      254

RESULT 11
AD0623
probable bacteriophage protein STY1061 [imported] - Salmonella enterica subsp. enterica :
C;Species: Salmonella enterica subsp. enterica serovar Typh
A;Note: this species has also been called Salmonella typhi
C;Date: 09-Nov-2001 #sequence_revision 09-Nov-2001 #text_change 18-Nov-2002
C;Accession: AD0623
R;Parkhill, J.; Dougan, G.; James, K.D.; Thomson, N.R.; Pickard, D.; Wain, J.; Churcher,
S., T.; Connerton, P.; Cronin, A.; Davis, P.; Davies, R.M.; Dowd, L.; White, N.; Farrar,
, S.; Moule, S.; O'Gaora, P.
Nature 413, 848-852, 2001
A;Authors: Parry, C.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.;
A;Title: Complete genome sequence of a multiple drug resistant Salmonella enterica serov
A;Reference number: AB0502; MUID:21534947; PMID:11677608
A;Accession: AD0623
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-662 <PAR>
A;Cross-references: GB:AL513382; PIDN:CAD05454.1; PID:g16502215; GSPDB:GN00176
C;Genetics:
A;Gene: STY1061

Query Match      34.6%;      Score 47;      DB 2;      Length 662;
Best Local Similarity 40.9%;      Pred. No. 71;
Matches      9;      Conservative      6;      Mismatches      7;      Indels      0;      Gaps      0;

OY      3      VFSTEMANKAAEAVLKGQVETI      24
      :      |      |      |      |      |      |      |      |      |
Db      600      IYSRELINKAAVAAGISGKTEV      621

RESULT 12
T29695
hypothetical protein T18H9.1 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004

```





C.M.  
Nature 399, 323-329, 1999  
A/Title: Evidence for lateral gene transfer between Archaea and Bacteria from genome seq  
A/Reference number: A72200; MUID:99287316; PMID:10360571  
A/Accession: F72308  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-1289 <ARN>  
A/Cross-references: UNIPROT:Q9X087; GB:AE001761; GB:AE000512; NID:g4981529; PIDN:AAD3607  
A/Experimental source: strain MSB8  
C/Genetics:  
A/Gene: TM0992

Query Match 33.8%; Score 46; DB 2; Length 1289;  
Best Local Similarity 52.9%; Pred. No. 2e+02;  
Matches 9; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 7 EMANKAAEAVLKQVET 23  
| | | | | : | | | | : | |  
Db 264 ETAKKSAESILKNIET 280

RESULT 17

S55089  
probable acetyl-CoA carboxylase (EC 6.4.1.2) HPA1 - Yeast (Saccharomyces cerevisiae)  
N/Alternate names: protein YM8261.01c; protein YM8325.08c; protein YMR207c  
C/Species: Saccharomyces cerevisiae  
C/Date: 08-Jul-1995 #sequence\_revision 05-Dec-1997 #text\_change 09-Jul-2004  
C/Accession: S55089; S41802; S59447  
R/Dedman, K.; Brown, D.; Bowman, S.  
Submitted to the EMBL Data Library, June 1995  
A/Reference number: S55089  
A/Accession: S55089

A/Molecule type: DNA  
A/Residues: 1-833 <DED>  
A/Cross-references: UNIPROT:P32874; EMBL:Z49809; MIPS:YMR207c; NID:g854459; PIDN:CAA8992  
A/Experimental source: strain AB972  
A/Note: the published sequence extends beyond the amino end  
R/Kearsey, S.E.  
Submitted to the EMBL Data Library, April 1993  
A/Description: Identification of an Saccharomyces cerevisiae gene closely related to FAS  
A/Reference number: S41802

A/Accession: S41802  
A/Molecule type: DNA  
A/Residues: 1-510, 'L', 512-799 <KEA>  
A/Cross-references: EMBL:Z22558; NID:g396212; PIDN:CAA80280.1; PID:g388250  
A/Note: the published sequence extends beyond the amino end  
R/Odell, C.; Bowman, S.  
Submitted to the EMBL Data Library, March 1995  
A/Reference number: S59441  
A/Accession: S59447

A/Molecule type: DNA  
A/Residues: 812-2123 <CODE>  
A/Cross-references: EMBL:Z48755; MIPS:YMR207c; NID:g736296; PIDN:CAA88647.1; PID:g763183  
A/Experimental source: strain AB972  
C/Genetics:  
A/Gene: SGD:HPA1

A/Cross-references: MIPS:YMR207c; SGD:S0004820  
A/Map position: 13R  
C/Superfamily: human acetyl-CoA carboxylase; biotin carboxylase homology; lipoyl/biotin-  
C/Keywords: biotin binding; ligase  
F/1-487/Domain: biotin carboxylase homology <BCH>  
F/615-687/Domain: lipoyl/biotin-binding homology <LPB>  
F/654/Binding site: biotin (Lys) (covalent) #status predicted

Query Match 33.8%; Score 46; DB 2; Length 2123;  
Best Local Similarity 45.0%; Pred. No. 3.4e+02;  
Matches 9; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

Qy 2 YVFSTEMANKAAEAVLKQV 21  
| | | | | : | | | | : | |  
Db 509 YVFTEKVRNKYLELLRRGV 528

RESULT 18  
S04363  
class II histocompatibility antigen RT1-B alpha chain precursor - rat  
C/Species: Rattus norvegicus (Norway rat)  
C/Date: 28-Feb-1990 #sequence\_revision 28-Feb-1990 #text\_change 09-Jul-2004  
C/Accession: S04363  
R/Syha, J.; Henkes, W.; Reske, K.  
Nucleic Acids Res. 17, 3985, 1989

A/Title: Complete cDNA sequence coding for the MHC class II RT1.B alpha chain of the LEW  
A/Reference number: S04363; MUID:89282410; PMID:2499874  
A/Accession: S04363  
A/Molecule type: mRNA  
A/Residues: 1-256 <SYH>  
A/Cross-references: UNIPROT:Q95572; EMBL:X14879; NID:g57154; PIDN:CAA33020.1; PID:g57155  
C/Superfamily: class II histocompatibility antigen; immunoglobulin homology  
F/1-23/Domain: signal sequence #status predicted <SIG>  
F/24-256/Product: class II histocompatibility antigen, RT1-B alpha chain #status predict  
F/127-192/Domain: immunoglobulin homology <IMM>

Query Match 33.5%; Score 45.5; DB 2; Length 256;  
Best Local Similarity 40.0%; Pred. No. 43;  
Matches 12; Conservative 3; Mismatches 8; Indels 7; Gaps 1;

Qy 5 STEMANKAAEA-----VLKQVETIVSF 27  
| | | | | : | | | | : | |  
Db 106 STQAVNKVPEATVFSKSPVLGQPNLTLCF 135

RESULT 19

A99261  
glutamate CoA-transferase, subunit A (gcta) [imported] - Sulfolobus solfataricus  
C/Species: Sulfolobus solfataricus  
C/Date: 24-May-2001 #sequence\_revision 24-May-2001 #text\_change 09-Jul-2004  
C/Accession: A99261  
R/She, Q.; Singh, R.K.; Confalonieri, F.; Zivanovic, Y.; Allard, G.; Awayez, M.J.; Chan-  
Jong, I.; Jeffries, A.C.; Kozera, C.J.; Medina, N.; Peng, X.; Thi-Ngoc, H.P.; Redder, P  
arrett, R.A.; Ragan, M.A.; Sensen, C.W.; Van der Oost, J.  
Submitted to GenBank, April 2001  
A/Description: Sulfolobus solfataricus complete genome.  
A/Reference number: A99139  
A/Accession: A99261

A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-268 <KUR>  
A/Cross-references: UNIPROT:Q97252; GB:AE006641; NID:g13814274; PIDN:AAK41344.1; GSPDB:G  
C/Genetics:  
A/Gene: gcta

Query Match 33.5%; Score 45.5; DB 2; Length 268;  
Best Local Similarity 33.3%; Pred. No. 45;  
Matches 13; Conservative 5; Mismatches 10; Indels 11; Gaps 2;

Qy 1 YVFPSTEMAN-----KAAEAVLKQVETI--VSFH 28  
: | | | | | : | | | | | : | | | | |  
Db 6 IYIFPVEIIMESKLSLEBAVEVVKGDSTVTSISIH 44

RESULT 20

S54744  
cellulase (EC 3.2.1.4) CelV1 precursor - Erwinia carotovora (SCC 3193)  
N/Alternate names: endo-1,4-beta-glucanase

C/Species: Erwinia carotovora  
A/Variety: SCC 3193  
C/Date: 27-Oct-1995 #sequence\_revision 03-Nov-1995 #text\_change 09-Jul-2004  
C/Accession: S54744; S44996  
R/Mae, A.; Heikinheimo, R.; Palva, E.T.  
Mol. Gen. Genet. 247, 17-26, 1995  
A/Title: Structure and regulation of the Erwinia carotovora subspecies carotovora SCC319  
A/Reference number: S54744; MUID:95231512; PMID:7715600  
A/Accession: S54744  
A/Molecule type: DNA  
A/Residues: 1-504 <MAE>





D90907  
hypothetical protein ECs2228 [imported] - Escherichia coli (strain O157:H7, substrain R1  
C/Species: Escherichia coli  
C/Date: 18-Jul-2001 #sequence\_revision 18-Jul-2001 #text\_change 09-Jul-2004  
C/Accession: D90907  
R;Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.  
gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.  
DNA Res. 8, 11-22, 2001  
A/Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and geno  
A/Reference number: A99629; MUID:21156231; PMID:11258796  
A/Accession: D90907  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-48 <HAY>  
A/Cross-references: UNIPROT:Q8XC69; GB:BA000007; PIDN:BAB35651.1; PID:gl3361694; GSPDB:G  
A/Experimental source: strain O157:H7, substrain R1MD 0509952  
C/Genetic8:  
A/Gene: ECs2228

Query Match	32.7%;	Score 44.5;	DB 2;	Length 48;
Best Local Similarity	43.5%;	Pred. No. 10;		
Matches	10;	Conservative 5;	Mismatches 5;	Indels 3;
				Gaps 1;
QY	2	YVFSTEMANKAAB---	AVLKGOV	21
	: :	: :	: :	
Db	7	YISSTSFANEMAEMRQQVMEGQI		29

RESULT 26  
F85710

unknown protein encoded by prophage CP-9330 [imported] - *Escherichia coli* (strain O157:H7)  
C/Species: *Escherichia coli*  
C/Date: 16-Feb-2001 #sequence\_revision 16-Feb-2001 #text\_change 09-Jul-2004  
C/Accession: F85710  
R/Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew  
Miller, L.; Grobbeck, B.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca,  
Nature 409, 529-533, 2001  
A/Title: Genome sequence of enterohemorrhagic *Escherichia coli* O157:H7.  
A/Reference number: A85480, MUID:21074935, PMID:11206551  
A/Accession: F85710  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-50 <STO>  
A/Cross-references: UNIPROT:Q8XC69; GB:AE005174; NID:g12515022; PIDN:AA656146.1; GSPDB:G  
A/Experimental source: strain O157:H7, substrain EDU933  
C/Genetics:  
A/Gene: Z2076

Query Match	32.7%;	Score 44.5;	DB 2;	Length 50;
Best Local Similarity	43.5%;	Pred. No. 11;		
Matches	10;	Conservative	5;	Mismatches 5; Indels 3; Gaps 1;
QY	2	YVFSTEMANKAAE--AVLKGOV	21	
		: : : : : : : : : :		
Db	9	YISSTSFANEMAEMRQVMGQI	31	

## RESULT 27

hypothetical protein - *Lactococcus lactis* plasmid pMRC01  
C/Species: *Lactococcus lactis*  
C/Date: 02-Jun-2000 #sequence\_revision 02-Jun-2000 #text\_change 09-Jul-2004  
C/Accession: T43131  
R/Dougherty, B.A.; Hill, C.; Weidman, J.F.; Richardson, D.R.; Venter, J.C.; Ross, R.P.  
Mol. Microbiol. 29, 1029-1038, 1998  
A/Title: Sequence and analysis of the 60 kb conjugative, bacteriocin-producing plasmid F  
A/Reference number: Z22314  
A/Accession: T43131  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 1-126 <DOU>  
A/Cross-references: UNIPROT:O32777; EMBL:AE001272; PIDN:AAC56049.1  
A/Experimental source: strain DPC3147

C;Genetics:  
A;Genome: plasmid pMRC01  
A;Note: ORF00060

Query Match	32.4%	Score 44;	DB 2;	Length 126;
Best Local Similarity	33.3%;	Pred. No. 34;		
Matches	7; Conservative	8; Mismatches	6; Indels	0; Gaps
				0;

QY 8 MANKAAEAVLKGQVETIVSFH 28  
: : : | | | : : : : |  
Db 67 IASRIAETVTKGSLVSLIGYH 87

## RESULT 28

hypothetical protein 265 - Sorghum mitochondrion  
C;Species: mitochondrion Sorghum bicolor (sorghum)  
C;Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
C;Accession: T14645  
R;Tang, H.V.; Pring, D.R.; Muza, F.R.; Yan, B.  
Curr. Genet. 29, 265-274, 1996  
A;Title: Sorghum mitochondrial orf25 and a related chimeric configuration of a male-ster  
A;Reference number: S65767; MUID:96163056; PMID:8595673  
A;Accession: T14645  
A;Status: preliminary; translated from GB/EMBL/DBDJ  
A;Molecule type: DNA  
A;Residues: 1-265 <VAN>  
A;Cross-references: UNIPROT:Q35783; EMBL:U22068; NID:g733079; PIDN:AAA97555.1; PID:g7330  
A;Experimental source: strain IS112C; coleoptile  
C;Genetics:  
A;Genome: mitochondrion  
C;Keywords: mitochondrion

	Query Match	Best Local	Similarity	Score	DB	Length	Matches	Conservative	Mismatches	Indels	Gaps
QY	1	VYVFSTEMANKAAEAVALKGOVETI	24	:	:	:	:	:	:	:	:
Db	22	VWVFSRKSLSGKTFFKETLDGRIESTI	45								

## RESULT 29

C64445  
conserved hypothetical protein MJ1164 - *Methanococcus jannaschii*  
C/Species: *Methanococcus jannaschii*  
C/Date: 13-Sep-1996 #sequence\_revision 13-Sep-1996 #text\_change 09-Jul-2004  
C/Accession: C64445  
R/Bult, C.J.; White, O.; Olsen, G.J.; Zhou, L.; Fleischmann, R.D.; Sutton, G.G.; Blake, R.; Reich, C.I.; Overbeek, R.; Kirkness, E.F.; Weinstock, K.G.; Merrick, J.M.; Glodek, A.; Rison, J.D.; Sadow, P.W.; Hanna, M.C.; Cotton, M.D.; Roberts, K.M.; Hurst, M.A. Science 273, 1058-1073, 1996  
A/Authors: Kaine, B.P.; Borodovsky, M.; Klenk, H.P.; Fraser, C.M.; Smith, H.O.; Woese, C.A./Title: Complete genome sequence of the methanogenic archaeon, *Methanococcus jannaschii* A./Reference number: A64300; MUID:96337999; PMID:8688087

A;Molecul

A/Cross-references: UNIPROT:Q58564; GB:U67558; GB:L77117; NID:g1591786; PIDN:AAB99166.1;  
A/Genetics:  
A/Map position: REV1106050-1105094  
A/Start codon: GTG  
C/Superfamily: Methanococcus jannaschii conserved hypothetical protein MJ1164

	Query Match	Best Local Similarity	Score 44;	DB 2;	Length 318;
Matches	7;	Conservative	38.9%;	Pred. No. 90;	Mismatches 5;
				Indels 6;	Gaps 0;

Oy 1 VYVSTEMANKAEAVLK 18  
::|::|||::|  
Db 156 IYKYEOTOMANPVDVALK 173

```

RESULT 30
T19105
phosphate carrier protein - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text_change 09-Jul-2004
C;Accession: T19105; S44093; T20489
R;Harris, B.
submitted to the EMBL Data Library, May 1996
A;Reference number: Z19073
A;Accession: T19105
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-340 <WIL>
A;Cross-references: UNIPROT:P40614; EMBL:Z73103; PIDN:CAA97430.1; GSPDB:GN00022; CESP:FO1G4.6
R;Runswick, M.J.; Philippides, A.; Lauria, G.; Walker, J.E.
submitted to the EMBL Data Library, November 1993
A;Description: Extension of the mitochondrial transport superfamily: sequences of five p
A;Reference number: S44090
A;Accession: S44093
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-340 <RUN>
A;Cross-references: EMBL:X76113; NID:g472905; PID:g472906
R;Harris, B.
submitted to the EMBL Data Library, January 1996
A;Reference number: Z19281
A;Accession: T20489
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-340 <WI2>
A;Cross-references: EMBL:Z68341; PIDN:CAA92769.1; GSPDB:GN00022; CESP:FO1G4.6
A;Experimental source: clone FO1G4
C;Genetics:
A;Gene: CESP.FO1G4.6
A;Map position: 4
A;Introns: 32/1; 72/3; 315/3
C;Superfamily: ADP,ATP carrier protein; ADP,ATP carrier protein repeat homology
C;Keywords: mitochondrion; transmembrane protein
F;137-223/Domain: ADP,ATP carrier protein repeat homology <ACR>

Query Match      32.4%; Score 44; DB 2; Length 340;
Best Local Similarity 33.3%; Pred. No. 97;
Matches      8; Conservative    7; Mismatches     9; Indels     0; Gaps     0;

QY      4 FSTEMANKAAEAVLKGVETIVSF 27
          |||::|||::|
Db      85 FRTTIAEGARALVKGWAPTLGY 108

RESULT 31
A85056
probable transposon protein [imported] - Arabidopsis thaliana
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 09-Jul-2004
C;Accession: A85056
R;anonymous, The European Union Arabidopsis Genome Sequencing Consortium, The Cold Spring
Nature 402, 769-777, 1999
A;Title: Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana.
A;Reference number: A85001; MUID:20083488; PMID:10617198
A;Accession: A85056
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-350 <STO>
A;Cross-references: UNIPROT:Q9XEC1; GB:NC_001268; NID:g7267200; PIDN:CAB77911.1; GSPDB:G
C;Genetics:
A;Gene: AT4g04430
A;Map position: 4
C;Superfamily: Arabidopsis hypothetical protein F7N22.18

Query Match      32.4%; Score 44; DB 2; Length 350;
Best Local Similarity 44.0%; Pred. No. 1e+02;

```

```

Matches      11; Conservative      6; Mismatches      6; Indels      2; Gaps      1;

QY      3 VESTEMANKAAEAVLKQVETIVSF 27
      :|::| |||| ::| |||
Db      260 IFTEKLA--AAEACTIQSQAERINSF 282

RESULT 32
AH3455
acriflavin resistance protein A precursor [imported] - Brucella melitensis (strain 16M)
C/Species: Brucella melitensis
C/Date: 01-Feb-2002 #sequence_revision 01-Feb-2002 #text_change 09-Jul-2004
C/Accession: AH3455
R/DelVecchio, V.G.; Kapatal, V.; Redkar, R.J.; Patra, G.; Mujer, C.; Los, T.; Ivanova, N.
.; Mazur, M.; Goldsman, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Letessac
Proc. Natl. Acad. Sci. U.S.A. 99, 443-448, 2002
A/Title: The genome sequence of the facultative intracellular pathogen Brucella melitensis
A/Reference number: AD3252; PMID:1175668
A/Accession: AH3455
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-395 <KUR>
A/Cross-references: UNIPROT:Q8YF92; GB:AE008917; PIDN:AL52811.1; PID:gl7983649; GSPDB:GN
A/Experimental source: strain 16M
C/Genetics:
A/Gene: BME11630
A/Map position: 1

Query Match      32.4%; Score 44; DB 2; Length 395;
Best Local Similarity 50.0%; Pred. No. 1.1e+02;
Matches      10; Conservative      2; Mismatches      8; Indels      0; Gaps      0;

QY      4 FSTEMANKAAEAVLKQVET 23
      |:| |||| | | | :|
Db      144 FATRDLNKAAVAAAKAQLRT 163

RESULT 33
A72498
probable DNA/pantothenate metabolism flavoprotein APE1959 - Aeropyrum pernix (strain K1)
C/Species: Aeropyrum pernix
C/Date: 20-Aug-1999 #sequence_revision 20-Aug-1999 #text_change 09-Jul-2004
C/Accession: A72498
R/Kawarabayashi, Y.; Hino, Y.; Horikawa, H.; Yamazaki, S.; Haikawa, Y.; Jin-no, K.; Takahae
awa, H.; Takamiya, M.; Masuda, S.; Funahashi, T.; Tanaka, T.; Kudoh, Y.; Yamazaki, J.; Ku
DNA Res. 6, 83-101, 1999
A/Title: Complete genome sequence of an aerobic hyper-thermophilic Crenarchaeon, Aeropyru
A/Reference number: A72450; MUID:99310339; PMID:10382966
A/Accession: A72498
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-437 <KAW>
A/Cross-references: UNIPROT:Q9YAI0; DDBJ:AP000063; NID:g5105654; PIDN:BAAB0969.1; PID:g510
A/Experimental source: strain K1
C/Genetics:
A/Gene: APE1959
C/Superfamily: pantothenate metabolism flavoprotein dfp

Query Match      32.4%; Score 44; DB 2; Length 437;
Best Local Similarity 52.4%; Pred. No. 1.3e+02;
Matches      11; Conservative      2; Mismatches      2; Indels      6; Gaps      1;

QY      8 MANKAAEAVLKQVETIVSFH 28
      |:| |||| | | | |||
Db      405 MLDKSGEAVLKG-----SFH 419

RESULT 34
AG1051
probable transport protein Sgat sgat [imported] - Salmonella enterica subsp. enterica ser
C/Species: Salmonella enterica subsp. enterica serovar Typhi
A/Note: this species has also been called Salmonella typhi
C/Date: 09-Nov-2001 #sequence revision 09-Nov-2001 #text change 18-Nov-2002

```

C/Accession: AG1051  
R;Pathkill, J.; Dougan, G.; James, K.D.; Thomson, N.R.; Pickard, D.; Wain, J.; Churcher, T.; Connerton, P.; Cronin, A.; Davis, P.; Davies, R.M.; Dowd, L.; White, N.; Farrar, S.; Moule, S.; O'Garra, P.  
Nature 413, 848-852, 2001  
A;Authors: Parry, C.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.; A;Title: Complete genome sequence of a multiple drug resistant *Salmonella enterica* serov A;Reference number: AB0502; MUID:21534947; PMID:11677608  
A/Accession: AG1051  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-476 <PAR>  
A/Cross-references: GB:AL513382; PIDN:CAD06860.1; PID:gl6505508; GSPDB:GN00176  
C;Genetics:  
A;Gene: sgat

Query Match 32.4%; Score 44; DB 2; Length 476;  
Best Local Similarity 30.0%; Pred. No. 1.4e+02;  
Matches 6; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Oy 8 MANKAAEAVLKQVETIVSF 27  
: | : : | : | : | : | : |  
Db 44 LLRKSVSVIIKGTIKTIIGF 63

RESULT 35  
D65230  
hypothetical 52.9 kD protein in aidB-rpsF intergenic region - *Escherichia coli* (strain K N;Alternate names: hypothetical protein o488  
C;Species: *Escherichia coli*  
C;Date: 12-Sep-1997 #sequence\_revision 17-Sep-1997 #text\_change 09-Jul-2004  
A/Accession: D65230; S56418  
R;Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.; Riley, M.; C. A.; Rose, D.J.; Mau, B.; Shao, Y.  
Science 277, 1453-1462, 1997  
A;Title: The complete genome sequence of *Escherichia coli* K-12.  
A;Reference number: A64720; MUID:97426617; PMID:9278503  
A/Accession: D65230  
A;Status: nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA  
A;Residues: 1-484 <BLAT>  
A/Cross-references: UNIPROT:P39301; GB:AE000491; GB:U00096; NID:g2367357; PIDN:AACT77150. A;Experimental source: strain K-12, substrain MG1655  
R;Burland, V.; Plunkett III, G.; Sofia, H.J.; Daniels, D.L.; Blattner, F.R.  
Nucleic Acids Res. 23, 2105-2119, 1995  
A;Title: Analysis of the *Escherichia coli* genome VI: DNA sequence of the region from 92. A;Reference number: S56314; MUID:9534362; PMID:7610040  
A/Accession: S56418  
A;Status: nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA  
A;Residues: 1-469, 'AQQKMQXNNWQNSLINKP' <BUR>  
A/Cross-references: EMBL:U14003; NID:gl263172; PIDN:AAA97089.1; PID:g537034  
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1994  
C;Genetics:  
A;Gene: YJf5  
A;Start codon: GTG

Query Match 32.4%; Score 44; DB 2; Length 484;  
Best Local Similarity 30.0%; Pred. No. 1.4e+02;  
Matches 6; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Oy 8 MANKAAEAVLKQVETIVSF 27  
: | : : | : | : | : | : |  
Db 52 LLRKSVSVIIKGTIKTIIGF 71

RESULT 36  
A98275  
hypothetical protein EC55169 [imported] - *Escherichia coli* (strain O157:H7, substrain R1 C;Species: *Escherichia coli*  
C;Date: 18-Jul-2001 #sequence\_revision 18-Jul-2001 #text\_change 09-Jul-2004  
C/Accession: A98275  
R;Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.

gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.  
DNA Res. 8, 11-22, 2001  
A;Title: Complete genome sequence of enterohemorrhagic *Escherichia coli* O157:H7 and geno A;Reference number: A99629; MUID:21156231; PMID:11258796  
A/Accession: A98275  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-484 <HAY>  
A/Cross-references: UNIPROT:Q8XDJ5; GB:BA000007; PIDN:BAB38592.1; PID:gl3364646; GSPDB:G A;Experimental source: strain O157:H7, substrain R1MD 0509952  
C;Genetics:  
A;Gene: EC55169

Query Match 32.4%; Score 44; DB 2; Length 484;  
Best Local Similarity 30.0%; Pred. No. 1.4e+02;  
Matches 6; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Oy 8 MANKAAEAVLKQVETIVSF 27  
: | : : | : | : | : | : |  
Db 52 LLRKSVSVIIKGTIKTIIGF 71

RESULT 37  
A86116  
hypothetical protein sgat [imported] - *Escherichia coli* (strain O157:H7, substrain EDL93 C;Species: *Escherichia coli*  
C;Date: 16-Feb-2001 #sequence\_revision 16-Feb-2001 #text\_change 09-Jul-2004  
A/Accession: A86116  
R;Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew iller, L.; Grothbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca, Nature 409, 529-533, 2001  
A;Title: Genome sequence of enterohemorrhagic *Escherichia coli* O157:H7.  
A;Reference number: A85480; MUID:21074935; PMID:11206551  
A/Accession: A86116  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-484 <STO>  
A/Cross-references: UNIPROT:Q8XDJ5; GB:AE005174; NID:gl2519184; PIDN:AAG59389.1; GSPDB:G A;Experimental source: strain O157:H7, substrain EDL933  
C;Genetics:  
A;Gene: sgat

Query Match 32.4%; Score 44; DB 2; Length 484;  
Best Local Similarity 30.0%; Pred. No. 1.4e+02;  
Matches 6; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Oy 8 MANKAAEAVLKQVETIVSF 27  
: | : : | : | : | : | : |  
Db 52 LLRKSVSVIIKGTIKTIIGF 71

RESULT 38  
T05092  
probable 1,2-diacylglycerol 3-beta-galactosyltransferase (BC 2.4.1.46) - *Arabidopsis tha C;Species: Arabidopsis thaliana* (mouse-ear cress)  
C;Date: 23-Apr-1999 #sequence\_revision 23-Apr-1999 #text\_change 09-Jul-2004  
A/Accession: T05092  
R;Bevan, M.; Rieger, M.; Mueller-Auer, S.; Zipp, M.; Schaefer, M.; Hohnsels, J.; Mewes, submitted to the Protein Sequence Database, November 1998  
A;Reference number: Z15398  
A/Accession: T05092  
A;Molecule type: DNA  
A;Residues: 1-533 <BEV>  
A/Cross-references: UNIPROT:Q9MU68; UNIPROT:O81770; EMBL:AL031004  
A;Experimental source: cultivar Columbia; BAC clone F28M20  
C;Genetics:  
A;Map position: 4  
A;Intons: 175/3; 233/2; 287/2; 334/3; 409/3; 430/3; 455/3  
A;Note: F28M20.30  
C;Keywords: glycosyltransferase; hexosyltransferase

Query Match 32.4%; Score 44; DB 2; Length 533;



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 8, 2005, 03:00:28 ; Search time 127.75 Seconds  
(without alignments)  
112.237 Million cell updates/sec

Title: US-09-915-543-15\_COPY\_177\_204  
Perfect score: 136  
Sequence: 1 VYVFSTEMANKAAEAVALKGQVETIVSFH 28

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Uniprot 03: \*  
1: uniprot\_sprot: \*  
2: uniprot\_trembl: \*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	136	100.0	1425	2 Q67FX9	Q67fx9 mus musculu
2	136	100.0	1426	1 BCL9_HUMAN	Q00512 homo sapien
3	122	89.7	796	2 Q6NRE2	Q6nre2 xenopus lae
4	102	75.0	1474	2 Q67FY0	Q67fy0 brachydanio
5	98	72.1	1469	1 BCL9_DROME	Q961d9 drosophila
6	94	69.1	1457	2 Q641L9	Q641l9 mus musculu
7	94	69.1	1494	2 Q67FY2	Q67fy2 mus musculu
8	94	69.1	1494	2 Q617B5	Q617b5 mus musculu
9	91	66.9	1494	2 Q67FY1	Q67fy1 homo sapien
10	91	66.9	1499	2 Q86UT0	Q86u00 homo sapien
11	84	61.8	1530	2 Q67FY3	Q67fy3 brachydanio
12	60	44.1	205	1 HEM2_CLOJO	Q59295 clostridium
13	55	40.4	1050	2 Q9U1Q4	Q9u1q4 caenorhabdi
14	55	40.4	1062	2 Q767M3	Q767m3 sus scrofa
15	54	39.7	193	2 Q6HQ86	Q6hq86 bacillus an
16	54	39.7	523	2 Q630I9	Q630i9 bacillus ce
17	54	39.7	523	2 Q72X37	Q72x37 bacillus ce
18	54	39.7	523	2 Q6HAM4	Q6ham4 bacillus th
19	53	39.0	516	2 Q71SH3	Q71sh3 oryza sativ
20	53	39.0	516	2 Q7XN11	Q7xn11 oryza sativ
21	52	38.2	1059	2 Q6ZQL7	Q6zql7 mus musculu
22	52	38.2	1065	2 Q6MG21	Q6mg21 rattus norv
23	52	38.2	1086	2 Q69Z78	Q69z78 mus musculu
24	51	37.5	523	2 Q97JAO	Q97ja0 clostridium
25	51	37.5	520	2 Q84P52	Q84p52 lycopersico
26	51	37.5	1049	2 Q960E6	Q960e6 drosophila
27	51	37.5	1049	2 Q9V6L1	Q9v6l1 drosophila
28	51	37.5	1217	1 SYV_FUGRU	P49696 fugu rubrip
29	50	36.8	338	2 Q89JQ9	Q89jq9 bradyrhizob
30	50	36.8	459	2 Q82521	Q82521 capicum ch
31	50	36.8	523	2 Q814L6	Q814l6 bacillus ce

32	50	36.8	642	2 Q9H6R2	Q9h6r2 homo sapien
33	50	36.8	657	2 Q6DKJ5	Q6dkj5 homo sapien
34	50	36.8	733	2 Q96GN2	Q96gn2 homo sapien
35	50	36.8	1098	2 Q96Q02	Q96q02 homo sapien
36	49.5	36.4	350	2 Q8GG19	Q8gg19 lactobacill
37	49	36.0	141	2 Q9LFW7	Q9lfw7 arabidopsis
38	49	36.0	143	2 Q976C9	Q976c9 sulfolobus
39	49	36.0	187	2 Q8G3S3	Q8g3s3 bifidobacte
40	49	36.0	210	2 Q9FZL1	Q9fzl1 arabidopsis
41	49	36.0	233	2 Q96YA9	Q96ya9 sulfolobus
42	49	36.0	237	2 Q96X55	Q96x55 sulfolobus
43	49	36.0	268	2 Q8DFX2	Q8dfx2 vibrio vuln
44	49	36.0	446	2 Q6C2I5	Q6c2i5 yarrowia li
45	49	36.0	458	2 Q83532	Q83532 treponema p

ALIGNMENTS

RESULT 1

ID	Q67FX9	PRELIMINARY;	PRT;	1425 AA.
AC	Q67FX9;			
DT	25-OCT-2004 (TREMBLrel. 28, Created)			
DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)			
DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)			
DE	BCL9.			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			
OX	NCBI_TaxID=10090;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=C57BL/6;			
RA	Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S.,			
RA	Hammerschmidt M., Birchmeier W.;			
RT	"Essential role of BCL9-2 in the switch between [beta]-catenin's			
RT	adhesive and transcriptional functions.";			
RL	Genes Dev. 18:0-0(2004).			
DR	EMBL; AY296061; AAQ62699.1; -			
SQ	SEQUENCE 1425 AA; 148970 MW; 77347CF56FC4A815 CRC64;			

Query Match 100.0%; Score 136; DB 2; Length 1425;  
Best Local Similarity 100.0%; Pred. No. 4.2e-11;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1 VYVFSTEMANKAAEAVALKGQVETIVSFH 28
Db	177 VYVFSTEMANKAAEAVALKGQVETIVSFH 204

RESULT 2

ID	BCL9_HUMAN	STANDARD;	PRT;	1426 AA.
AC	Q00512;			
DT	28-FEB-2003 (Rel. 41, Created)			
DT	28-FEB-2003 (Rel. 41, Last sequence update)			
DT	05-JUL-2004 (Rel. 44, Last annotation update)			
DE	B-cell lymphoma 9 protein (Bcl-9) (legless homolog).			
GN	Name=BCL9;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Euthera; Primates; Catarrhini; Homidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Fetal brain;			
RC	MEDLINE=98158621; PubMed=9490669;			
RA	Willis T.G., Zalberg I.R., Coignet L.J.A., Wlodarska I., Stul M.,			
RA	Jadav D.M., Baard C., Treleven J.G., Catovsky D., Silva M.L.M.,			
RA	Dyer M.J.S.;			
RT	"Molecular cloning of translocation t(1;14)(q21;q32) defines a novel			
RT	gene (BCL9) at chromosome 1q21.";			

```
RL Blood 91:1873-1881(1998) .
RN [2]
RP FUNCTION.
RX MEDLINE=21952490; PubMed=11955446; DOI=10.1016/S0092-8674(02)00679-7;
RA Kramps T., Peter O., Brunner E., Nellen D., Froesch B., Chatterjee S.,
RA Murone M., Zuelzig S., Basler K.;
RT "Wnt/wingless signaling requires BCL9/legless-mediated recruitment of
RT pygopus to the nuclear beta-catenin-TCF complex.";
RL Cell 109:47-60(2002) .
CC -1- FUNCTION: Involved in signal transduction through the Wnt pathway.
CC -1- SUBUNIT: Binds to beta-catenin (CTNNB1), PYGO1 and PYGO2.
CC -1- SUBCELLULAR LOCATION: Nuclear (Probable).
CC -1- TISSUE SPECIFICITY: Detected at low levels in thymus, prostate,
CC testis, ovary and small intestine, and at lower levels in spleen,
CC colon and blood.
CC -1- DISEASE: Involved in a t(1;14)(q21;q32) chromosomal translocation
CC found in a patient with precursor B-cell acute lymphoblastic
CC leukemia (ALL). This translocation leaves the coding region
CC intact, but may have pathogenic effects due to alterations in the
CC expression level of BCL9. Several cases of translocations within
CC the 3' untranslated region of BCL9 have been found in B-cell
CC malignancies.
CC -1- CAUTION: It is uncertain whether Met-1 or Met-27 is the initiator.
CC -1- CAUTION: Ref.1 sequence differs from that shown due to a
CC frameshift in position 1391.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
-----
DR EMBL; Y13620; CAA73942.1; ALT_FRAME.
DR Genew; HGNC:1008; BCL9.
DR MIM; 602597; -.
KW Chromosomal translocation; Nuclear protein; Proto-oncogene;
KW Wnt signaling pathway.
FT DOMAIN 231 1378 Pro-rich.
FT DOMAIN 347 377 CTNNB1-binding.
FT DOMAIN 331 335 Poly-Pro.
FT DOMAIN 514 517 Poly-Pro.
FT DOMAIN 900 903 Poly-Ala.
FT DOMAIN 970 973 Poly-Pro.
SQ SEQUENCE 1426 AA; 149314 MW; A240A487716B7F1B CRC64;

Query Match 100.0%; Score 136; DB 1; Length 1426;
Best Local Similarity 100.0%; Pred. No. 4.2e-11;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28
Db 177 VYVFSTEMANKAAEAVLKQGVETIVSFH 204

RESULT 3
Q6NRE2 PRELIMINARY; PRT; 796 AA.
AC Q6NRE2;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE MGC8388 protein.
GN Name=MGC8388;
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
```

```
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McGwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Buterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002) .
RN [2]
RN SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
RX MEDLINE=22341132; PubMed=12454917; DOI=10.1002/dvdy.10174;
RA Klein S.L., Strausberg R.L., Wagner L., Pontius J., Clifton S.W.,
RA Richardson P.;
RT "Genetic and genomic tools for Xenopus research: The NIH Xenopus
RT initiative.";
RL Dev. Dyn. 225:384-391(2002) .
RN [3]
RN SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
RA Klein S., Strausberg R.;
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC070813; AAH70813.1; -.
SQ SEQUENCE 796 AA; 86048 MW; 9A282C1DCA316678 CRC64;

Query Match 89.7%; Score 122; DB 2; Length 796;
Best Local Similarity 89.3%; Pred. No. 2.9e-09;
Matches 25; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28
Db 173 VYVFSTEMANKAAEAVLKQAEIVLFFH 200

RESULT 4
Q67FY0 PRELIMINARY; PRT; 1474 AA.
AC Q67FY0;
DT 25-OCT-2004 (TREMBlrel. 28, Created)
DT 25-OCT-2004 (TREMBlrel. 28, Last sequence update)
DT 25-OCT-2004 (TREMBlrel. 28, Last annotation update)
DE Bcl9.
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RN SEQUENCE FROM N.A.
RP Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S.,
RA Hammerschmidt M., Birchmeier W.;
RT "Essential role of BCL9-2 in the switch between [beta]-catenin's
RT adhesive and transcriptional functions.";
RL Genes Dev. 18:0-0(2004) .
DR EMBL; AY296060; AAQ62698.1; -.
SQ SEQUENCE 1474 AA; 154339 MW; 4B2C3E8092BE3532 CRC64;

Query Match 75.0%; Score 102; DB 2; Length 1474;
Best Local Similarity 64.3%; Pred. No. 5.3e-06;
Matches 18; Conservative 7; Mismatches 3; Indels 0; Gaps 0;
```



BCL9\_DROME STANDARD; PRT; 1469 AA.

ID BCL9\_DROME

AC Q96ID9; Q9VAD2;

DT 28-FEB-2003 (Rel. 41, Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DT 25-JAN-2005 (Rel. 46, Last annotation update)

DE Bcl-9 homolog (Legless protein).

GN Name=lg9; Synonyms=BCL9; ORFNames=CG2041;

OS Drosophila melanogaster (Fruit fly).

OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
Ephydroidea; Drosophilidae; Drosophila.

OX NCBI\_TaxID=7227;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=Berkeley;

RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;

RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
Amanatides P.G., Scherer S.E., U l P.W., Hoskins R.A., Galle R.F.,  
George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
Sutton G.G., Wortman J.R., Yandell M.D., Zhang O., Chen L.X.,  
Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,  
Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,  
Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,  
Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
Beeson K.Y., Benos P.V., Bernan B.P., Bhandari D., Bolshakov S.,  
Botkova D., Botchan M.R., Bouck J., Brokstern P., Bottier P.,  
Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
Cherry J.M., Cawley S., Dahlke C., Davenkoport L.B., Davies P.,  
de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
Dodson K., Doup L.E., Downes W., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,  
Foster C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,  
Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,  
Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwan C.,  
Jamali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,  
Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
Mount S.M., Moy M., Murphy B., Murphy L., Munzy D.M., Nelson D.L.,  
Nelson D.R., Nelson K.A., Nixon K., Nusseren D.R., Pacleb J.M.,  
Palazzo M., Pittman G.S., Pan S., Pollard J., Put V., Reese M.G.,  
Reiner K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,  
Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
Spiet E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
Swirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
Wang Z.-Y., Wasserman D.A., Weinstock G.M., Weissbach J.,  
Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,  
Ye J., Yen R.-P., Zavert J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
[2]  
The genome sequence of Drosophila melanogaster." ;  
Science 287:2185-2195(2000).  
GENOME REANNOTATION.  
MEDLINE=22426069; PubMed=12537572;  
Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochick S.E.,  
Smith C.D., Tuhy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
Betencourt B.R., Celniker S.E., de Grey A.D.N.U., Drysdale R.A.,  
Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
Lewis S.E. ;  
Annotation of the Drosophila melanogaster euchromatic genome: a

```

RT systematic review." ;
RL Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002) .
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Berkeley; TISSUE=Embryo;
RX MEDLINE=22426066; PubMed=12537569;
RA Stapleton M., Carlson J.W., Brokstein P., Yu C., Champe M.,
RA George R.A., Guarin H., Krommiller B., Pacleb J.M., Park S., Wan K.H.,
RA Rubin G.M., Celniker S.E.;
RT "A Drosophila full-length cDNA resource." ;
RL Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002) .
RN [4]
RP SEQUENCE OF 6-1469 FROM N.A., AND MUTAGENESIS OF GLY-514; LEU-534 AND
RP ILE-537.
RX MEDLINE=21952490; PubMed=11955446; DOI=10.1016/S0092-8674(02)00679-7;
RA Kramps T., Peter O., Brunner E., Nellen D., Froesch B., Chatterjee S.,
RA Murone M., Zuellich S., Basler K.;
RT "Wnt/wingless signaling requires BCL9/legless-mediated recruitment of
RT pygopus to the nuclear beta-catenin-TCF complex." ;
RL Cell 109:47-60(2002) .
CC -1- FUNCTION: Involved in signal transduction through the Wnt pathway.
CC -1- SUBUNIT: Binds to ARM and PYGO.
CC -1- SUBCELLULAR LOCATION: Nuclear.
CC -1- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically
CC throughout development.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch) .
CC -----
DR EMBL; AE003844; AAF59345.2; -.
DR EMBL; AY051651; AAK93075.1; -.
DR EMBL; AF457205; AAL91368.1; -.
DR FlyBase; FBgn0039907; lgs.
DR GO; GO:0005634; C:nucleus; IDA.
DR GO; GO:0030528; F:transcription regulator activity; IPI.
DR GO; GO:0030177; P:positive regulation of Wnt receptor signal. . . ; IPI.
DR GO; GO:0007367; P:segment polarity determination; IMP.
KW Developmental protein; Nuclear protein; Segmentation polarity protein;
KW Wnt signaling pathway.
KW DOMAIN 511 555 ARM-binding.
FT DOMAIN 1134 1173 Asn-rich.
FT DOMAIN 1340 1449 Gln-rich.
FT DOMAIN 1162 1169 POLY-Asn.
FT MUTAGEN 514 514 G->E: In allele lgs-21L.
FT MUTAGEN 534 534 L->F: In allele lgs-17E; segment polarity
FT phenotype.
FT MUTAGEN 537 537 I->K: In allele lgs-17P.
FT SEQUENCE 1469 AA; 153759 MW; 5672E01B720ED08 CRC64;
QY Query Match 72.1%; Score 98; DB 1; Length 1469;
QY Best Local Similarity 57.1%; Pred. No. 2.1e-05;
DB Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;
DB 323 IFVFSTQLANKGAESVLSGQFQTIIAYH 350
1 VYVFSTEMANKAAEAVALKGQVETIVSFH 28
:::|||||:|||||:|||||:|||||:
RESULT 6
ID Q641L9 PRELIMINARY; PRT; 1457 AA.
AC Q641L9;
DT 25-OCT-2004 (TREMBlrel. 28, Created)
DT 25-OCT-2004 (TREMBlrel. 28, Last sequence update)
DT 25-OCT-2004 (TREMBlrel. 28, Last annotation update)
DE Bcl9l protein.
GN Name=Bcl9l;
OS Mus musculus (Mouse) .

```





```
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euteria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Kubo T., Arai Y., Ohira M., Gamou T., Maeno G., Sakiyama T.,
RA Toyoda A., Hattori M., Sakaki Y., Nakagawara A., Ohki M.;
RL Submitted (OCT-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AB094091; BAC76045.1; -.
SQ SEQUENCE 1499 AA; 157129 MW; 8415C2EDB7AA9C0C CRC64;

Query Match
Best Local Similarity 66.9%; Score 91; DB 2; Length 1499;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 1 VYFSTEMANKAAEAVLKQGVETIVSF 28
DB 240 VYFPTTLANTAAEAVLQGRADSIAYH 267

RESULT 11
Q67FY3 PRELIMINARY; PRT; 1530 AA.
AC Q67FY3;
DT 25-OCT-2004 (TReMBLrel. 28, Created)
DT 25-OCT-2004 (TReMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TReMBLrel. 28, Last annotation update)
DE Bc19-2.
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RA Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S.,
RA Hammerschmidt M., Bircheimer W.;
RT "Essential role of BCL9-2 in the switch between [beta]-catenin's
RT adhesive and transcriptional functions.";
RL Genes Dev. 18:0-0(2004).
DR EMBL: AY296057; AAQ62695.1; -.
SQ SEQUENCE 1530 AA; 159872 MW; C29FEC9433ED28C0 CRC64;

Query Match
Best Local Similarity 61.8%; Score 84; DB 2; Length 1530;
Matches 15; Conservative 7; Mismatches 6; Indels 0; Gaps 0;

QY 1 VYFSTEMANKAAEAVLKQGVETIVSF 28
DB 195 VYFPTTLANSAAEAVMHGHTDSILYH 222

RESULT 12
HEM2_CLOJO STANDARD; PRT; 205 AA.
ID HEM2_CLOJO
AC 059295;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Delta-aminolevulinic acid dehydratase (EC 4.2.1.24) (Porphobilinogen
DE synthase) (ALAD) (ALADH) (Fragment).
GN Name=hemb;
OS Clostridium josui.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=1499;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=FERM P-9684;
RX MEDLINE=95394829; PubMed=7665501;
RA Fujino E., Fujino T., Karita S., Sakka K., Ohmiya K.;
RT "Cloning and sequencing of some genes responsible for porphyrin
```

```
RT biosynthesis from the anaerobic bacterium Clostridium josui.";
RL J. Bacteriol. 177:5169-5175(1995).
CC -1- CATALYTIC ACTIVITY: 2 5-aminolevulinate = porphobilinogen + 2
CC H(2)O.
CC -1- COFACTOR: Zinc (By similarity).
CC -1- PATHWAY: Siroheme biosynthesis.
CC -1- SUBUNIT: Homooctamer (By similarity).
CC -1- SIMILARITY: Belongs to the ALADH family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: D28503; BAA05863.1; -.
DR PIR: I40812; I40812.
DR HSSP: P15002; 1L6S.
DR InterPro: IPR001731; Alad_dehydratase.
DR Pfam: PF00490; ALAD; 1.
DR PRINTS: PR00144; DALDHYDRTASE.
DR ProDom: PD002304; Alad_dehydratase; 1.
DR PROSITE: PS00169; D_ALA_DEHYDRATASE; PARTIAL.
KW Lyase; Porphyrin biosynthesis; Zinc.
FT DOMAIN 114 132 Zinc-binding (By similarity).
FT NON_TER 205 205
SQ SEQUENCE 205 AA; 23172 MW; 886F9DAEFDB1144E CRC64;

Query Match
Best Local Similarity 44.1%; Score 60; DB 1; Length 205;
Matches 12; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 2 VYFSTEMANKAAEAVLKQGVETIVSF 27
DB 51 YHFSPPDWGKAIEALKADVKSULLF 76

RESULT 13
Q9U1Q4 PRELIMINARY; PRT; 1050 AA.
ID Q9U1Q4
AC Q9U1Q4;
DT 01-MAY-2000 (TReMBLrel. 13, Created)
DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Hypothetical protein Y87G2A.5.
GN Name=vrs-2; ORFNames=Y87G2A.5;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Pelodierinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RA none;
RT "Genome sequence of the nematode C.elegans: A platform for
RT investigating biology.";
RL Science 282:2012-2018(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA White S.;
RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL: AL110500; CAB60428.1; -.
DR HSSP: P96142; 1IVS.
DR WormBase; WBGene00006936; vrs-2.
DR WormPeP; Y87G2A.5; CE24685.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.
DR InterPro; IPR002300; tRNA-synt_1a.
```

DR InterPro; IPR001412; tRNA-synt\_1.  
DR InterPro; IPR002303; tRNA-synt\_val.  
DR InterPro; IPR009080; tRNA-syn\_1a\_bind.  
DR InterPro; IPR010978; tRNA\_binding\_arm.  
DR InterPro; IPR009008; ValRS\_1Iers\_edit.  
DR Pfam; PF00133; tRNA-synt\_1; 1.  
DR PRINTS; PR00986; TRNASYNTHVAL.  
DR TIGRFAMs; TIGR00422; vals; 1.  
DR PROSITE; PS00178; AA\_TRNA\_LIGASE\_I; 1.  
KW Hypothetical protein.  
SQ SEQUENCE 1050 AA; 118920 MW; F33DB53587EAC057 CRC64;

Query Match 40.4%; Score 55; DB 2; Length 1050;  
Best Local Similarity 44.4%; Pred. No. 40;  
Matches 12; Conservative 2; Mismatches 13; Indels 0; Gaps 0;

QY 2 YVFSTEMANKAAEAVLKQGVETIVSFH 28  
DB 461 YVCAHMAERKAAVAVANGDLQIPEFH 487

## RESULT 14

Q767M3 PRELIMINARY; PRT; 1062 AA.  
AC Q767M3;  
DT 05-JUL-2004 (TReMBLrel. 27, Created)  
DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)  
DE Hypothetical protein KIAA1885.  
GN Name=KIAA1885;  
OS Sus scrofa (Pig).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
OX NCBI\_TaxID=9823;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=larg white, and large white;  
RA Shigenari A., Ando A., Renard C., Chardon P., Shina T., Kulski J.K.,  
RA yasue H., Inoko H.;  
RT "Nucleotide sequencing analysis of the swine 433-kb genomic segment  
RT located between the non-classical and classical SLA class I gene  
RT clusters."  
RL Immunogenetics 55:695-705(2004).  
DR EMBL; AB113355; BAD08425.1; -.  
DR EMBL; AB113354; BAD08423.1; -.  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.  
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.  
DR InterPro; IPR002110; ANK.  
DR InterPro; IPR002300; tRNA-synt\_1a.  
DR InterPro; IPR001412; tRNA-synt\_1.  
DR InterPro; IPR002303; tRNA-synt\_val.  
DR InterPro; IPR009080; tRNA-syn\_1a\_bind.  
DR InterPro; IPR009008; ValRS\_1Iers\_edit.  
DR Pfam; PF00133; tRNA-synt\_1; 1.  
DR PRINTS; PR01415; ANKYRIN\_1.  
DR PRINTS; PR00986; TRNASYNTHVAL.  
DR TIGRFAMs; TIGR00422; vals; 1.  
DR PROSITE; PS00178; AA\_TRNA\_LIGASE\_I; 1.  
SQ SEQUENCE 1062 AA; 118287 MW; 619F230CC078BEC7 CRC64;

Query Match 40.4%; Score 55; DB 2; Length 1062;  
Best Local Similarity 44.4%; Pred. No. 40;  
Matches 12; Conservative 5; Mismatches 10; Indels 0; Gaps 0;

QY 2 YVFSTEMANKAAEAVLKQGVETIVSFH 28  
DB 481 FVRCQEMGEQAQAVVSGALFLSPSFH 507

RESULT 15  
Q6HQ86 PRELIMINARY; PRT; 193 AA.

AC Q6HQ86;  
DT 05-JUL-2004 (TReMBLrel. 27, Created)  
DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)  
DE Two-component sensor protein, C-terminus.  
GN OrderedLocuNames=BAS5264;  
OS Bacillus anthracis.  
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.  
OX NCBI\_TaxID=1392;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Sterne;  
RA Brettin T.S., Bruce D., Challacombe J.F., Gilna P., Han C., Hill K.,  
RA Hitchcock P., Jackson P., Keim P., Longmire J., Lucas S., Okinaka R.,  
RA Richardson P., Rubin E., Tice H.;  
RL Submitted (JAN-2004) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AE017225; AAT57552.1; -.  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR InterPro; IPR003594; ATPbind\_ATPase.  
DR Pfam; PF02518; HATPase\_c; 1.  
SQ SEQUENCE 193 AA; 21865 MW; DE1F60ACD9C3BDD0 CRC64;

Query Match 39.7%; Score 54; DB 2; Length 193;  
Best Local Similarity 54.5%; Pred. No. 9.9;  
Matches 12; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

QY 3 VPFSTEMANKAAEAVLKQGVETI 24  
DB 19 LFSLTFTKGAFAVLKQGNKV 40

## RESULT 16

Q630I9 PRELIMINARY; PRT; 523 AA.  
AC Q630I9;  
DT 25-OCT-2004 (TReMBLrel. 28, Created)  
DT 25-OCT-2004 (TReMBLrel. 28, Last sequence update)  
DT 25-OCT-2004 (TReMBLrel. 28, Last annotation update)  
DE Sensor histidine kinase (EC 2.7.3.-).  
GN ORFNames=BTZK5109;  
OS Bacillus cereus ZK.  
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.  
OX NCBI\_TaxID=288681;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=ZK;  
RA Brettin T.S., Bruce D., Challacombe J.F., Gilna P., Han C., Hill K.,  
RA Hitchcock P., Jackson P., Keim P., Longmire J., Lucas S., Okinaka R.,  
RA Richardson P., Rubin E., Tice H.;  
RT "Complete genome sequence of Bacillus cereus ZK."  
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.  
DR EMBL; CP000001; AAU20240.1; -.  
KW kinase; Transferase.  
SQ SEQUENCE 523 AA; 59703 MW; 85B6AE9BB8CC2A3B CRC64;

Query Match 39.7%; Score 54; DB 2; Length 523;  
Best Local Similarity 54.5%; Pred. No. 28;  
Matches 12; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

QY 3 VPFSTEMANKAAEAVLKQGVETI 24  
DB 349 LFSLTFTKGAFAVLKQGNKV 370

RESULT 17  
Q72X37 PRELIMINARY; PRT; 523 AA.  
AC Q72X37;  
DT 05-JUL-2004 (TReMBLrel. 27, Created)  
DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)  
DE Sensor histidine kinase, putative (EC 2.7.3.-).  
GN OrderedLocuNames=BCE5541;

```

OS Bacillus cereus (strain ATCC 10987).
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=222523;
[1]
RP SEQUENCE FROM N.A.
RX PubMed=14960714; DOI=10.1093/nar/gkh258;
RA Rasko D.A., Ravel J., Oekstad O.A., Helgason E., Cer R.Z., Jiang L.,
RA Shores K.A., Fouts D.E., Tounasse N.J., Angiuoli S.V., Kolonay J.F.,
RA Nelson W.C., Kolstoe A.-B., Fraser C.M., Read T.D.;
RT "The genome sequence of Bacillus cereus ATCC 10987 reveals metabolic
RT adaptations and a large plasmid related to Bacillus anthracis pXO1."
RL Nucleic Acids Res. 32:977-988(2004).
DR EMBL; AE017281; AAS44441.1; -.
DR TIGR; BCE5541; -.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0016301; F:kinase activity; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR InterPro; IPR003594; ATPbind_ATPase.
DR InterPro; IPR003018; GAF.
DR Pfam; PF01590; GAF; 2.
DR Pfam; PF02518; HATPase_c; 1.
DR SMART; SM00065; GAF; 2.
KW Complete proteome; Kinase; Transferase.
SQ SEQUENCE 523 AA; 59731 MW; 4F105468CA527ABF CRC64;

QY Query Match 39.7%; Score 54; DB 2; Length 523;
Best Local Similarity 54.5%; Pred. No. 28;
Matches 12; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

Db 3 VFSTEMANKAAEAVLKQVETI 24
: || | ||||| ||| :
349 LFSLTFTMTKGAEAVLKQNEKV 370

RESULT 18
Q6HAM4 PRELIMINARY; PRT; 523 AA.
ID Q6HAM4;
AC Q6HAM4;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
DE Two-component sensor protein.
GN OrderedLocusNames=BT9727_5092;
OS Bacillus thuringiensis (subsp. konkukian).
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=180856;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=97-27;
RA Brettin T.S., Bruce D., Challacombe J.F., Gilna P., Han C., Hill K.,
RA Hitchcock P., Jackson P., Keim P., Longmire J., Lucas S., Okinaka R.,
RA Richardson P., Rubin E., Tice H.;
RT "Complete genome sequence of Bacillus thuringiensis 97-27."
RT Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AE017355; AAT61192.1; -.
DR GO; GO:0005524; F:ATP binding; IEA.
DR InterPro; IPR003594; ATPbind_ATPase.
DR InterPro; IPR003018; GAF.
DR Pfam; PF01590; GAF; 2.
DR Pfam; PF02518; HATPase_c; 1.
DR SMART; SM00065; GAF; 2.
KW Complete proteome.
SQ SEQUENCE 523 AA; 59795 MW; 2C87843AEA3C3AA7 CRC64;

QY Query Match 39.7%; Score 54; DB 2; Length 523;
Best Local Similarity 54.5%; Pred. No. 28;
Matches 12; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

Db 3 VFSTEMANKAAEAVLKQVETI 24
: || | ||||| ||| :
349 LFSLTFTMTKGAEAVLKQNEKV 370

```

```

RESULT 19
Q71SH3
ID Q71SH3 PRELIMINARY; PRT; 516 AA.
AC Q71SH3;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, last sequence update)
DE 05-JUL-2004 (TREMBLrel. 27, last annotation update)
PT Putative aminotransferase.
OS Oryza sativa (Rice).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoideae; Oryzeae; Oryza.
OX NCBI_TaxID=4530;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Senescent leaf;
RA Ansari M.I., Lee R.H., Chen S.C.G.;
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: Belongs to the class-III pyridoxal-phosphate-dependent
CC aminotransferase family.
CC EMBL; AF297651; AAQ14479.1; -.
DR GO; GO:0030170; F:pyridoxal phosphate binding; IEA.
DR GO; GO:0008483; F:transaminase activity; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR InterPro; IPR005814; AminoTran_3.
DR Pfam; PF00202; AminoTran_3; 1.
KW Aminotransferase; Pyridoxal phosphate; Transferase.
SQ SEQUENCE 516 AA; 56474 MW; DCC7AC57563C403B CRC64;

```

Query Match	39.0%;	Score 53;	DB 2;	Length 516;
Best Local Similarity	45.8%;	Pred. No. 38;		
Matches 11;	Conservative 4;	Mismatches 9;	Indels 0;	Gaps 0;

Qy 4 FSTEMANKAAEAVLKQVETTVSF 27  
| : : | | : | : | : |  
Db 252 PATRLANNLEELILKEGPETIAAF 275

```

RESULT 20
Q7XN11
ID Q7XN11 PRELIMINARY; PRT; 516 AA.
AC Q7XN11;
DT 01-OCT-2003 (TREMBlrel. 25, Created)
DT 01-MAR-2004 (TREMBlrel. 26, last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, last annotation update)
DE OSUNBA0008M17.4 protein.
GN Name=OSUNBA0008M17.4;
OS Oryza sativa (japonica cultivar-group).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoideae; Oryzeae; Oryza.
OX NCBI_TaxID=39947;
RN [1]
RP SEQUENCE FROM N.A.
RX PubMed=12447439; DOI=10.1038/nature01183;
RA Feng Q., Zhang Y., Hao P., Wang S., Fu G., Huang Y., Li Y., Zhu J.,
RA Liu Y., Hu X., Jia P., Zhang Y., Zhao Q., Ying K., Yu S., Tang Y.,
RA Weng Q., Zhang L., Lu Y., Mu J., Lu Y., Zhang L.S., Yu Z., Fan D.,
RA Liu X., Lu T., Li C., Wu Y., Sun T., Lei H., Li T., Hu H., Guan J.,
RA Wu M., Zhang R., Zhou B., Chen Z., Chen L., Jin Z., Wang R., Yin H.,
RA Cai Z., Ren S., Lv G., Gu W., Zhu G., Tu Y., Jia J., Zhang Y.,
RA Chen J., Kang H., Chen X., Shao C., Sun Y., Hu Q., Zhang X., Zhang W.,
RA Wang L., Ding C., Sheng H., Gu J., Chen S., Ni L., Zhu F., Chen W.,
RA Lan L., Lai Y., Cheng Z., Gu M., Jiang J., Li J., Hong G., Xue Y.,
RA Han B.;
RT "Sequence and analysis of rice chromosome 4.";
RL Nature 420:316-320(2002).
CC -!- SIMILARITY: Belongs to the class-III pyridoxal-phosphate-dependent
CC aminotransferase family.
DR EMBL; AL662950; CAE04333.2; -.
DR HSSP; P16932; IDKA.
DR Gramene; Q7XN11; -.
DR GO; GO:0030170; F:pyridoxal phosphate binding; IEA.

```



```
DR GO; GO:0005524; F:ATP-binding; IEA.
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.
DR InterPro; IPR002300; tRNA-synt_1a.
DR InterPro; IPR001412; tRNA-synt_1.
DR InterPro; IPR002303; tRNA-synt_val.
DR InterPro; IPR009080; tRNAsyn_1a_bind.
DR Pfam; PF00133; tRNA-synt_1; 1.
DR PRINTS; PR00986; TRNASYNTHVAL.
DR TIGRFAMs; TIGR00422; vals; 1.
DR PROSITE; PS00178; AA_TRNA_LIGASE_I; 1.
FT NON_TER 1
SQ SEQUENCE 1086 AA; 120787 MW; DD957F2882106A62 CRC64;

Query Match
Best Local Similarity 38.2%; Score 52; DB 2; Length 1086;
Matches 12; Conservative 5; Mismatches 10; Indels 0; Gaps 0;

QY 2 YVFSTEMANKAAEAVLKQVETIVSF 28
DB 504 FVRCQEMGDRAAKAVESGALWPSFH 530

RESULT 24
Q97JAO PRELIMINARY; PRT; 243 AA.
AC Q97JAO;
DT 01-OCT-2001 (TReMBLrel. 18, Created)
DT 01-OCT-2001 (TReMBLrel. 18, Last sequence update)
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)
DE Zn-dependent hydrolases, glyoxylase family.
GN OrderedLocustNames=CAC1386;
OS Clostridium acetobutylicum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=1488;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 824 / DSM 792 / VKM B-1787;
RX MEDLINE=21359325; PubMed=11466286;
RX DOI=10.1128/JB.183.16.4823-4838.2001;
RA Noelling J., Breton G., Omelchenko M.V., Makarova K.S., Zeng Q.,
RA Gibson R., Lee H.M., Dubois J., Qiu D., Hitti J., Wolf Y.I.,
RA Tatusov R.L., Sabathe F., Doucette-Stamm L.A., Soucaille P.,
RA Daly M.J., Bennett G.N., Koonin E.V., Smith D.R.;
RT "Genome sequence and comparative analysis of the solvent-producing
RT bacterium Clostridium acetobutylicum.";
RL J. Bacteriol. 183:4823-4838(2001).
DR EMBL; AE007650; AAK79354.1; -.
DR PIR; G97070; G97070.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR InterPro; IPR001279; Blactamase-like.
DR Pfam; PF00753; Lactamase B; 1.
KW Complete proteome; Hydrolase.
SQ SEQUENCE 243 AA; 26880 MW; 0F9F6A3EADBC0D CRC64;

Query Match
Best Local Similarity 37.5%; Score 51; DB 2; Length 243;
Matches 7; Conservative 11; Mismatches 10; Indels 0; Gaps 0;

QY 1 YVFSTEMANKAAEAVLKQVETIVSF 28
DB 199 LFDFDSNLSKKSLEKLTXYDIETVICYH 226

RESULT 25
Q84P52 PRELIMINARY; PRT; 520 AA.
AC Q84P52;
DT 01-JUN-2003 (TReMBLrel. 24, Created)
DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Gamma-aminobutyrate transaminase subunit isozyme 3 (EC 2.6.1.19).
```

```
OS Lycopersicon esculentum (Tomato).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;
OC Lamids; Solanales; Solanaceae; Solanum.
OX NCBI_TaxID=4081;
RN [1]
RP SEQUENCE FROM N.A.
RA Clark S.M., Shelp B.J.;
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: Belongs to the class-III pyridoxal-phosphate-dependent
CC aminotransferase family.
DR EMBL; AY240231; AAO92257.1; -.
DR HGSP; P12995; 1QY3.
DR GO; GO:0003867; F:4-aminobutyrate transaminase activity; IEA.
DR GO; GO:0030170; F:pyridoxal phosphate binding; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR InterPro; IPR005814; Aminotrans_3.
DR Pfam; PF00202; Aminotran_3; 1.
DR PROSITE; PS00600; AA_TRANSFER_CLASS_3; 1.
KW Aminotransferase; Pyridoxal phosphate; Transferase.
SQ SEQUENCE 520 AA; 57239 MW; E4FCD1E922BD28F9 CRC64;

Query Match
Best Local Similarity 37.5%; Score 51; DB 2; Length 520;
Matches 11; Conservative 3; Mismatches 10; Indels 0; Gaps 0;

QY 4 FSTEMANKAAEAVLKQVETIVSF 27
DB 253 FSTRLANLENLILKEGPETIAF 276

RESULT 26
Q960E6 PRELIMINARY; PRT; 1049 AA.
AC Q960E6;
DT 01-DEC-2001 (TReMBLrel. 19, Created)
DT 01-DEC-2001 (TReMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE SD04748P.
GN Name=Aats-val;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RA Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA Champe M., Chavez C., Dorsett V., Farfan D., Frise E., George R.,
RA Gonzalez M., Guarin H., Li P., Liao G., Miranda A., Mungall C.J.,
RA Nunoo J., Pacleb J., Paragas V., Park S., Phouanavong S., Wan K.,
RA Yu C., Lewis S.E., Rubin G.M., Celniker S.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY052099; AAK93523.1; -.
DR HGSP; P96142; 1IVS.
DR FlyBase; FBgn0027079; Aats-val.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.
DR InterPro; IPR002300; tRNA-synt_1a.
DR InterPro; IPR001412; tRNA-synt_1.
DR InterPro; IPR002303; tRNA-synt_val.
DR InterPro; IPR009080; tRNAsyn_1a_bind.
DR InterPro; IPR010978; tRNA binding arm.
DR InterPro; IPR009008; ValRS_1IERS_edit.
DR Pfam; PF00133; tRNA-synt_1; 1.
DR PRINTS; PR00986; TRNASYNTHVAL.
DR TIGRFAMs; TIGR00422; vals; 1.
DR PROSITE; PS00178; AA_TRNA_LIGASE_I; 1.
SQ SEQUENCE 1049 AA; 118331 MW; 56F322C7414BEAC4 CRC64;

Query Match
Best Local Similarity 37.5%; Score 51; DB 2; Length 1049;
Matches 40.7%; Pred. No. 1.6e+02;
```



```
Matches 11; Conservative 5; Mismatches 11; Indels 0; Gaps 0;
QY 2 YVFSTEMANKAAEAVLKGOVETIVSFH 28
DB 471 YVSCSDMAASATEAVRSGELKRIPEHH 497
RESULT 27
Q9V6L1 PRELIMINARY; PRT; 1049 AA.
AC Q9V6L1;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE CG4062-PA (Cg4062-pb).
GN Name=Aats-val; ORFNames=CG4062;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,
RA Ballew R.M., Baau A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotlier P.,
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.B., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA Foslter C., Gabrieliian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwan C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., Mcleod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacleb J.M.,
RA Palazolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.Y., Wasserman D.A., Weinstein G.M., Weissbach J.,
RA Williams S.M., WoodageT, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426065; PubMed=12537568;
RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Laverly T., Muzny D.M., Nelson C.R.,
RA Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila
melanogaster euchromatic genome sequence.";
```

```
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426070; PubMed=12537573;
RA Kaminker J.S., Bergman C.M., Krommiller B., Carlson J., Svirskas R.,
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA Ashburner M., Celniker S.E.;
RT "The transposable elements of the Drosophila melanogaster euchromatin:
a genomics perspective.";
RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426069; PubMed=12537572;
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.B.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
systematic review.";
RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).
RN [5]
RP SEQUENCE FROM N.A.
RG FlyBase;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
RN [6]
RP SEQUENCE FROM N.A.
RG FlyBase;
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AE003819; AAM68598.1; -.
DR HSSP; P96142; 1IIVS.
DR IntAct; Q9V6L1; -.
DR FlyBase; FBgn0027079; Aats-val.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.
DR InterPro; IPR002300; tRNA-synt 1a.
DR InterPro; IPR001412; tRNA-synt 1.
DR InterPro; IPR002303; tRNA-synt val.
DR InterPro; IPR009080; tRNA-synt 1a_bind.
DR InterPro; IPR010978; tRNA binding arm.
DR InterPro; IPR009008; ValRS_1IERS_edit.
DR Pfam; PF00133; tRNA-synt 1; 1.
DR PRINTS; PR00986; TRNASYNT1VAL.
DR TIGRFAMs; TIGR00422; vals; 1.
DR PROSITE; PS00178; AA TRNA LIGASE I; 1.
SQ SEQUENCE 1049 AA; 118253 MW; 13A513ABF69E8EBB CRC64;
Query Match 37.5%; Score 51; DB 2; Length 1049;
Best Local Similarity 40.7%; Pred. No. 1.6e+02;
Matches 11; Conservative 5; Mismatches 11; Indels 0; Gaps 0;
QY 2 YVFSTEMANKAAEAVLKGOVETIVSFH 28
DB 471 YVSCSDMAASATEAVRSGELKRIPEHH 497
RESULT 28
SYV_FUGRU
ID_SYV_FUGRU STANDARD; PRT; 1217 AA.
AC P49696;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Valyl-tRNA synthetase (EC 6.1.1.9) (Valine--tRNA ligase) (ValRS).
GN Name=VARSL;
OS Fugu rubripes (Japanese pufferfish) (Takifugu rubripes).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
OC Tetraodontidae; Tetraodontidae; Takifugu.
```

```
OX NCB1_TaxID=31033;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97396021; PubMed=9254008;
RA Lim E.H., Corrochano L.M., Elgar G., Brenner S.;
RT "Genomic structure and sequence analysis of the valyl-tRNA synthetase
RL gene of the Japanese pufferfish, Fugu rubripes.";
RU DNA Seq. 7:141-151(1997).
CC -1- CATALYTIC ACTIVITY: ATP + L-valine + tRNA(Val) = AMP + diphosphate
CC + L-valyl-tRNA(Val).
CC -1- SIMILARITY: Belongs to the class-I aminoacyl-tRNA synthetase
CC family.
CC -1- SIMILARITY: Contains 1 GST-like domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X91856; CAA62967.1; -.
DR HSSP; P96142; 11VS.
DR InterPro; IPR010987; GST_C_like.
DR InterPro; IPR004046; GST_Cterm.
DR InterPro; IPR002300; tRNA-synt_1a.
DR InterPro; IPR001412; tRNA-synt_I.
DR InterPro; IPR002303; tRNA-synt_val.
DR InterPro; IPR010978; tRNA binding arm.
DR InterPro; IPR009080; tRNA_syn_1a_bind.
DR InterPro; IPR009008; ValRS_1Iers_edit.
DR Pfam; PF00043; GST_C; 1.
DR Pfam; PF00133; tRNA-synt_1; 1.
DR PRINTS; PR00986; TRNASYNTHVAL.
DR TIGRFAMs; TIGR00422; vals; 1.
DR PROSITE; PS00178; AA_TRNA_LIGASE_I; 1.
KW Aminoacyl-tRNA synthetase; ATP-binding; ligase; Protein biosynthesis.
FT DOMAIN 1 ? GST.
FT SITE 293 303 "HIGH" region.
FT SITE 809 813 "KMSKS" region.
FT BINDING 812 812 ATP (By similarity).
SQ SEQUENCE 1217 AA; 138218 MW; 5E08AF24B5C8A7A1 CRC64;

Query Match 37.5%; Score 51; DB 1; Length 1217;
Best Local Similarity 37.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 8; Mismatches 9; Indels 0; Gaps 0;

CY 2 YVFSTEMANKAAEAVLKQVETIVSFH 28
||:|:|:|:|:|:|:|:|:|
Db 626 YVCSMDMGKQADAVREGRLKTIPIPHH 652

RESULT 29
Q89JQ9 PRELIMINARY; PRT; 338 AA.
AC Q89JQ9;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE B1r5213 protein.
GN OrderedLocustNames=b1r5213;
OS Bradyrhizobium japonicum.
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Bradyrhizobiaceae; Bradyrhizobium.
OX NCB1_TaxID=375;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=USDA110;
RX MEDLINE=22484998; PubMed=12597275;
RA Kaneko T., Nakamura Y., Sato S., Minamisawa K., Uchiyumi T.,
RA Sasamoto S., Watanabe A., Idesawa K., Iriguchi M., Kawashima K.,
RA Kohara M., Matsumoto M., Shimpo S., Tsuruoka H., Wada T., Yamada M.,
```

```
RA Tabata S.;
RT "Complete genomic sequence of nitrogen-fixing symbiotic bacterium
RT Bradyrhizobium japonicum USDA110.";
RU DNA Res. 9:189-197(2002).
DR EMBL; AP005954; BAC50478.1; -.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0003910; F:DNA ligase (ATP) activity; IEA.
DR GO; GO:0006310; P:DNA recombination; IEA.
DR GO; GO:0006281; P:DNA repair; IEA.
DR GO; GO:0006260; P:DNA replication; IEA.
DR InterPro; IPR000977; DNA_ligase.
DR Pfam; PF04679; DNA_ligase_A_C; 1.
DR Pfam; PF01068; DNA_ligase_A_M; 1.
KW Complete proteome.
SQ SEQUENCE 338 AA; 37922 MW; 8E27957946E4E1D9 CRC64;

Query Match 36.8%; Score 50; DB 2; Length 338;
Best Local Similarity 48.1%; Pred. No. 70;
Matches 13; Conservative 3; Mismatches 11; Indels 0; Gaps 0;

CY 2 YVFSTEMANKAAEAVLKQVETIVSFH 28
:|:|:|:|:|:|:|:|:|
Db 232 HVGFTSGIKSAKAAALTDTLETIVSDH 258

RESULT 30
ID 082521 PRELIMINARY; PRT; 459 AA.
AC 082521;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Putative aminotransferase.
OS Capsicum chinense (Scotch bonnet) (Bonnet pepper).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;
OC Lamids; Solanales; Solanaceae; Capsicum.
OX NCB1_TaxID=80379;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=habanero;
RA Aluru M., Curry J., O'Connell M.;
RT "Nucleotide Sequence of a Probable Aminotransferase Gene (Accession
RT No. AF085149) from Habanero Chile. (PGR98-182).";
RL Plant Physiol. 118:1102-1102(1998).
CC -1- SIMILARITY: Belongs to the class-III pyridoxal-phosphate-dependent
CC aminotransferase family.
CC EMBL; AF085149; AAC78480.1; -.
DR HSSP; P04181; 2OAT.
DR GO; GO:0030170; F:pyridoxal phosphate binding; IEA.
DR GO; GO:0008483; F:transaminase activity; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR InterPro; IPR005814; Aminotran_3.
DR Pfam; PF00202; Aminotran_3; 1.
DR PROSITE; PS00600; AA_TRANSFER_CLASS_3; 1.
KW Aminotransferase; Pyridoxal phosphate; Transferase.
SQ SEQUENCE 459 AA; 50729 MW; 02ABB4D728B524E4 CRC64;

Query Match 36.8%; Score 50; DB 2; Length 459;
Best Local Similarity 41.7%; Pred. No. 95;
Matches 10; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

CY 4 FSTEMANKAAEAVLKQVETIVSF 27
||:|:|:|:|:|:|:|:|:|
Db 196 FSTRLANNESLILKEGPETVAAF 219

RESULT 31
Q814L6 PRELIMINARY; PRT; 523 AA.
ID Q814L6;
AC Q814L6;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
```

DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)  
DE Two-component sensor protein yhcY (EC 2.7.3.-).  
GN OrderedLocusNames=BC5412;  
OS Bacillus cereus (strain ATCC 14579 / DSM 31).  
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.  
OX NCBI\_TaxID=226900;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22608415; PubMed=12721630; DOI=10.1038/nature01582;  
RA Ivanova N., Sorokin A., Anderson I., Galleron N., Candelon B.,  
RA Kapatral V., Bhattacharya A., Reznik G., Mikhailova N., Lapidus A.,  
RA Chu L., Mazur M., Goltzman E., Larsen N., D'Souza M., Walunas T.,  
RA Grechkin Y., Pusch G., Haselkorn R., Fonstein M., Ehrlich S.D.,  
RA Overbeek R., Kyrpides N.C.;  
RT "Genome sequence of Bacillus cereus and comparative analysis with  
RT Bacillus anthracis";  
RL Nature 423:87-91(2003).  
DR EMBL; AE017015; AAP12274.1; -  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0016740; F:transferase activity; IEA.  
DR InterPro; IPR003594; ATPbind\_ATPase.  
DR InterPro; IPR003018; GAF.  
DR Pfam; PF01590; GAF; 2.  
DR Pfam; PF02518; HATPase\_c; 1.  
DR SMART; SM00065; GAF; 2.  
DR SMART; SM00387; HATPase\_c; 1.  
KW Complete proteome; Transferase.  
SQ SEQUENCE 523 AA; 59607 MW; CAA8B8C8D0CE3E7D CRC64;  
  
Query Match 36.8%; Score 50; DB 2; Length 523;  
Best Local Similarity 50.0%; Pred. No. 1.1e+02;  
Matches 11; Conservative 3; Mismatches 8; Indels 0; Gaps 0;  
  
QY 3 VFSTEMANKAAEAVLKQGVETI 24  
Db 349 LFSLTFTKGAEAVALKGNKEV 370  
  
RESULT 32  
Q9H6R2 PRELIMINARY; PRT; 642 AA.  
AC Q9H6R2;  
DT 01-MAR-2001 (TReMBLrel. 16, Created)  
DT 01-MAR-2001 (TReMBLrel. 16, Last sequence update)  
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)  
DE Hypothetical protein FLJ21965.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Kawabata A., Hikiiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,  
RA Okitani R., Ota T., Suzuki Y., Odayashi M., Nishi T., Shibahara T.,  
RA Tanaka T., Nakamura Y., Isogai T., Sugano S.;  
RL Submitted (Aug-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AK025618; BAB15191.1; -  
DR HSSP; P96142; IIVS.  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.  
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.  
DR InterPro; IPR002300; tRNA-synt\_1a.  
DR InterPro; IPR002303; tRNA-synt\_val.  
DR InterPro; IPR009080; tRNA-synt\_1a\_bind.  
DR InterPro; IPR009080; VALRS\_1IERS\_edit.  
DR Pfam; PF00133; tRNA-synt\_1; 1.  
DR PRINTS; PR00986; TRNASYNTHVAL.  
SQ SEQUENCE 642 AA; 71578 MW; C9E37EE1D742B7F1 CRC64;  
  
Query Match 36.8%; Score 50; DB 2; Length 642;  
Best Local Similarity 44.4%; Pred. No. 1.3e+02;  
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

QY 2 VFSTEMANKAAEAVLKQGVETIVSFH 28  
Db 60 FVRCQEMGARAARAKAVESGALFELSPSFH 86  
  
RESULT 33  
Q6DKJ5 PRELIMINARY; PRT; 657 AA.  
AC Q6DKJ5;  
DT 25-OCT-2004 (TReMBLrel. 28, Created)  
DT 25-OCT-2004 (TReMBLrel. 28, Last sequence update)  
DT 25-OCT-2004 (TReMBLrel. 28, Last annotation update)  
DE VARS2L protein (Fragment).  
GN Name=VARS2L;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Brain;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.B.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Mullahy S.J.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
RA Krzywinski M.I., Skalska U., Smalins D.E., Schnerch A., Schein J.E.,  
RA Jones S.J., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Brain;  
RA Director MGC Project;  
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC073838; AAH73838.1; -  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.  
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.  
DR InterPro; IPR002300; tRNA-synt\_1a.  
DR InterPro; IPR002303; tRNA-synt\_val.  
DR InterPro; IPR009080; tRNA-synt\_1a\_bind.  
DR InterPro; IPR009080; VALRS\_1IERS\_edit.  
DR Pfam; PF00133; tRNA-synt\_1; 1.  
DR PRINTS; PR00986; TRNASYNTHVAL.  
FT NON TER 1  
SQ SEQUENCE 657 AA; 73196 MW; BC34A3735FFA400A CRC64;  
  
Query Match 36.8%; Score 50; DB 2; Length 657;  
Best Local Similarity 44.4%; Pred. No. 1.4e+02;  
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;  
  
QY 2 VFSTEMANKAAEAVLKQGVETIVSFH 28  
Db 75 FVRCQEMGARAARAKAVESGALFELSPSFH 101  
  
RESULT 34  
Q96GN2 PRELIMINARY; PRT; 733 AA.  
AC Q96GN2;



```
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-MAR-2004 (Tremblrel. 26, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE VARS2L protein (Fragment).
GN Name=VARS2L;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uedlin T.B., Toshlyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smalhus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RA Strausberg R.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC009355; AA09355.2; -.
DR HSSP; P96142; 11VS.
DR GO; GO:0005524; P:ATP binding; IEA.
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.
DR InterPro; IPR002110; ANK.
DR InterPro; IPR002300; tRNA-synt_1a.
DR InterPro; IPR002303; tRNA-synt_val.
DR InterPro; IPR009080; tRNA-syn_1a_bind.
DR InterPro; IPR009008; VALRS_1IERS_edit.
DR Pfam; PF00133; tRNA-synt_1; 1.
DR PRINTS; PR01415; ANKYRIN.
DR PRINTS; PR00986; TRNASYNTHVAL.
FT NON TER 1
SQ SEQUENCE 733 AA; 81230 MW; B0433DC47AAB6721 CRC64;

Query Match 36.8%; Score 50; DB 2; Length 733;
Best Local Similarity 44.4%; Pred. No. 1.5e+02;
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

QY 2 YVFSTEMANKAAEAVLKQVETIVSFH 28
Db 151 FVRCQEMGARAARAKAVESGALSLSPSFH 177

RESULT 35
Q96Q02 PRELIMINARY; PRT; 1098 AA.
AC Q96Q02;
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE KIAA1885 protein (Fragment).
GN Name=KIAA1885;
OS Homo sapiens (Human).
```

```
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=21456161; PubMed=11572484;
RA Nagase T., Kikuno R., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. XXI.
RT The complete sequences of 60 new cDNA clones from brain which code for
RT large proteins."
RL DNA Res. 8:179-187(2001).
DR EMBL; AB067472; BAB67778.1; -.
DR HSSP; P96142; 11VS.
DR Genew; HGNC:21642; VARS2L.
DR GO; GO:0005524; P:ATP binding; IEA.
DR GO; GO:0004832; F:valine-tRNA ligase activity; IEA.
DR GO; GO:0006438; P:valyl-tRNA aminoacylation; IEA.
DR InterPro; IPR002300; tRNA-synt_1a.
DR InterPro; IPR001412; tRNA-synt_1.
DR InterPro; IPR002303; tRNA-synt_val.
DR InterPro; IPR009080; tRNA-syn_1a_bind.
DR InterPro; IPR009008; VALRS_1IERS_edit.
DR Pfam; PF00133; tRNA-synt_1; 1.
DR PRINTS; PR00986; TRNASYNTHVAL.
DR TIGRFAMs; TIGR00422; VALS; 1.
DR PROSITE; PS00178; AA_TRNA_LIGASE_I; 1.
FT NON TER 1
SQ SEQUENCE 1098 AA; 122469 MW; E01DCA8C8E42BC4D CRC64;

Query Match 36.8%; Score 50; DB 2; Length 1098;
Best Local Similarity 44.4%; Pred. No. 2.3e+02;
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

QY 2 YVFSTEMANKAAEAVLKQVETIVSFH 28
Db 516 FVRCQEMGARAARAKAVESGALSLSPSFH 542

RESULT 36
Q8GG19 PRELIMINARY; PRT; 350 AA.
AC Q8GG19;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Abc1.
GN Name=abc1;
OS Lactobacillus plantarum.
OC Bacteria; Firmicutes; Lactobacillales; Lactobacillaceae;
OC Lactobacillus.
OX NCBI_TaxID=1590;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CCM3626;
RA Bringel F., Hubert J.-C.;
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF514870; AA015990.1; -.
SQ SEQUENCE 350 AA; 38178 MW; 64D1986ED73C8AAA CRC64;

Query Match 36.4%; Score 49.5; DB 2; Length 350;
Best Local Similarity 54.5%; Pred. No. 86;
Matches 12; Conservative 4; Mismatches 3; Indels 3; Gaps 1;

QY 3 VPFSTEMANKAAEAVLKQVETI 24
Db 176 VYSTDLAKAAE---KGVDAT 194

RESULT 37
Q9LFW7 PRELIMINARY; PRT; 141 AA.
AC Q9LFW7;
```

```

DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE T7N9.31.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosid II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Khan S., Brooks S., Buehler E., Chao Q., Johnson-Hopson C., Kim C.,
RA Shinn P., Altafi H., Bei Q., Chin C., Chiou J., Choi E., Conn L.,
RA Conway A., Gonzales A., Hansen N., Howng B., Koo T., Lam B., Lee J.,
RA Lenz C., Li J., Liu A., Liu K., Liu S., Mukharsky N., Nguyen M.,
RA Palm C., Pham P., Sakano H., Schwartz J., Southwick A., Thaveri A.,
RA Toriumi M., Vaysberg M., Yu G., Federspiel N.A., Theologis A.,
RA Ecker J.R.;
RL Submitted (MAY-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Cheuk R., Shinn P., Brooks S., Buehler E., Chao Q., Johnson-Hopson C.,
RA Khan S., Kim C., Altafi H., Bei B., Chin C., Chiou J., Choi E.,
RA Conn L., Conway A., Gonzalez A., Hansen N., Howing B., Koo T., Lam B.,
RA Lee J., Lenz C., Li J., Liu A., Liu J., Liu S., Mukharsky N.,
RA Nguyen M., Palm C., Pham P., Sakano H., Schwartz J., Southwick A.,
RA Thaveri A., Toriumi M., Vaysberg M., Yu G., Davis R., Federspiel N.,
RA Theologis A., Ecker J.;
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RA Cheuk R., Shinn P., Brooks S., Buehler E., Chao Q., Johnson-Hopson C.,
RA Khan S., Kim C., Altafi H., Bei B., Chin C., Chiou J., Choi E.,
RA Conn L., Conway A., Gonzalez A., Hansen N., Howing B., Koo T., Lam B.,
RA Lee J., Lenz C., Li J., Liu A., Liu J., Liu S., Mukharsky N.,
RA Nguyen M., Palm C., Pham P., Sakano H., Schwartz J., Southwick A.,
RA Thaveri A., Toriumi M., Vaysberg M., Yu G., Davis R., Federspiel N.,
RA Theologis A., Ecker J.;
RL Submitted (SEP-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL: AC000348; AAF79866.1; -
SQ SEQUENCE 141 AA; 16649 MW; 6FEC48B07326B313 CRC64;

Query Match          36.0%; Score 49; DB 2; Length 141;
Best Local Similarity 41.7%; Pred. No. 40;
Matches 10; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

QY      4 FSTEMANKAAEAVLKGVETIVSF 27
Db       :|||:::||:|:|
        112 WSFRSTNKADRLAKGELENNVTF 135

RESULT 38
O976C9 PRELIMINARY; PRT; 143 AA.
AC O976C9;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Hypothetical protein ST0252.
GS OrderedLocustNames=ST0252;
SN Sulfolobus tokodaii.
OC Archaea; Crenarchaeota; Thermoprotei; Sulfolobales; Sulfolobaceae;
OC Sulfolobus.
OX NCBI_TaxID=111955;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=JCM 10545 / ?;
RX MEDLINE=21456156; PubMed=11572479;
RA Kawarabayashi Y., Hino Y., Horikawa H., Jin-no K., Takahashi M.,
RA Sekine M., Baba S.-I., Ankaei A., Kosugi H., Hosoyama A., Fukui S.,
RA Nagai Y., Nishijima K., Otsuka R., Nakazawa H., Takamiya M., Kato Y.,
RA Yoshizawa T., Tanaka T., Kudoh Y., Yamazaki J., Kushida N., Oguchi A.,
RA Aoki K.-I., Masuda S., Yanagii M., Nishimura M., Yamagishi A.,
```

```

RA Oshima T., Kikuchi H.;
RT "Complete genome sequence of an aerobic thermoacidophilic
RL Crenarchaeon, Sulfolobus tokodaii strain7.";
RU DNA Res. 8:123-140(2001).
DR EMBL; AP000982; BAB65218.1; -.
KW Complete proteome; Hypothetical protein.
SQ SEQUENCE 143 AA; 16822 MW; D1AFCC5157298CA2 CRC64;

Query Match 36.0%; Score 49; DB 2; Length 143;
Best Local Similarity 43.3%; Pred. No. 41;
Matches 13; Conservative 4; Mismatches 11; Indels 2; Gaps 1;

QY 1 VYVFSTEMAN--KAAEAVLKQVETIVSFH 28
| | | | | | | | | | | | | | | | | |
Db 26 VLVVLTNMKNVEKEAEKVLKTRIDKVVYIH 55

RESULT 39
Q8G3S3 PRELIMINARY; PRT; 187 AA.
ID Q8G3S3
AC Q8G3S3;
DT 01-MAR-2003 (TREMBLrel. 23, Created)
DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE Hypoxanthine-guanine phosphoribosyltransferase.
GN Name-hprt; OrderedlocusNames=Bl1681;
OS Bifidobacterium longum.
OC Bacteria; Actinobacteria; Actinobacteridae; Bifidobacteriales;
OC Bifidobacteriaceae; Bifidobacterium.
OX NCBI_TaxID=216816;
RX MEDLINE=22294977; PubMed=12381787; DOI=10.1073/pnas.212527599;
RA Schell M.A., Karmirantzou M., Snel B., Vilanova D., Berger B.,
RA Pessi G., Zwahlen M.-C., Desiere F., Bork P., Delley M.,
RA Pridmore R.D., Arigoni F.;
RT "The genome sequence of Bifidobacterium longum reflects its adaptation
RT to the human gastrointestinal tract.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:14422-14427(2002).
CC -1- SIMILARITY: Belongs to the purine/pyrimidine
CC phosphoribosyltransferase family.
DR EMBL; AB014802; AAN25468.1; -.
DR HSSP; O33799; 1J7J.
DR GO; GO:0005737; C:cytoplasm; IEA.
DR GO; GO:0004422; F:hypoxanthine phosphoribosyltransferase acti. . .; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR GO; GO:0009116; P:nucleoside metabolism; IEA.
DR GO; GO:0006166; P:purine ribonucleoside salvage; IEA.
DR InterPro; IPR002110; ANK.
DR InterPro; IPR005904; Hxn_phospho_trans.
DR InterPro; IPR002375; Pr/py_rp_transf.
DR InterPro; IPR000836; Pctransferase.
DR Pfam; PF00156; Pribosyltran; 1.
DR PRINTS; PR01415; ANKYRIN.
DR TIGRFAMs; TIGR01203; HGPRTase; 1.
DR PROSITE; PS01013; PUR_PYR_PR_TRANSFER; 1.
KW Complete proteome; Glycosyltransferase; Transferase.
SQ SEQUENCE 187 AA; 20617 MW; E697C3C127277DB1 CRC64;

Query Match 36.0%; Score 49; DB 2; Length 187;
Best Local Similarity 45.2%; Pred. No. 54;
Matches 14; Conservative 3; Mismatches 4; Indels 10; Gaps 1;

QY 7 EMANKAAE-----AVLKQVETIVSF 27
| | | | | | | | | | | | | | | | | |
Db 26 EMAALASEDYRDKNPPLVAVLKGAVENTVAF 56

RESULT 40
Q9FZL1 PRELIMINARY; PRT; 210 AA.
ID Q9FZL1
AC Q9FZL1;

```

DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE F17L21.2.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
 OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
 OC NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Johnson-Hopson C., Brooks S., Buehler E., Chao Q., Khan S., Kim C.,  
 RA Shinn P., Altafi H., Bei Q., Chin C., Chio J., Choi E., Conn L.,  
 RA Conway A., Gonzales A., Hansen N., Howing B., Koo T., Lam B., Lee J.,  
 RA Lenz C., Li J., Liu A., Liu K., Liu S., Mukharsky N., Nguyen M.,  
 RA Palm C., Pham P., Sakano H., Schwartz J., Southwick A., Thaveri A.,  
 RA Toriumi M., Vaysberg M., Yu G., Federspiel N.A., Theologis A.,  
 RA Ecker J.R.;  
 RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA Cheuk R., Shinn P., Brooks S., Buehler E., Chao Q., Johnson-Hopson C.,  
 RA Khan S., Kim C., Altafi H., Bei B., Chin C., Chio J., Choi E.,  
 RA Conn L., Conway A., Gonzales A., Hansen N., Howing B., Koo T., Lam B.,  
 RA Lee J., Lenz C., Li J., Liu A., Liu J., Liu S., Mukharsky N.,  
 RA Nguyen M., Palm C., Pham P., Sakano H., Schwartz J., Southwick A.,  
 RA Thaveri A., Toriumi M., Vaysberg M., Yu G., Davis R., Federspiel N.,  
 RA Theologis A., Ecker J.;  
 RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AC004557; AAF99722.1; --  
 DR PIR; D86398; D86398.  
 DR GO; GO:0005634; C:nucleus; IEA.  
 DR GO; GO:0004089; F:carbonate dehydratase activity; IEA.  
 DR GO; GO:0008270; F:zinc ion binding; IEA.  
 DR GO; GO:0015976; P:carbon utilization; IEA.  
 DR GO; GO:0006355; P:regulation of transcription, DNA-dependent; IEA.  
 DR InterPro; IPR003822; PAH.  
 DR InterPro; IPR001765; Prok\_plnt\_coahnd.  
 DR Pfam; PF02671; PAH; 1.  
 SQ SEQUENCE 210 AA; 24697 MW; FCD8130CD75700A0 CRC64;

Query Match 36.0%; Score 49; DB 2; Length 210;  
 Best local Similarity 41.7%; Pred. No. 60;  
 Matches 10; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

Oy 4 FSTEMANKAAEAVLKQGVETIVSF 27  
 :|:::|::|::|  
 Db 181 WSFRSTNKADRLAKGELNNVTF 204

Search completed: June 8, 2005, 03:22:56  
 Job time : 136.25 secs

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 8, 2005, 03:00:28 ; Search time 164.25 Seconds  
(without alignments)  
112.237 Million cell updates/sec

Title: US-09-915-543-15\_COPY\_349\_384  
Perfect score: 163  
Sequence: 1 DGIHQEQLHRRSLQTLRDIQMLFPDEKEFTGAQ 36

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Uniprot 03: \*  
1: uniprot\_sprot: \*  
2: uniprot\_trembl: \*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	183	100.0	1426	1 BCL9_HUMAN	O00512 homo sapien
2	173	94.5	1425	2 Q67FX9	Q67fx9 mus. musculu
3	163	89.1	796	2 Q6NRE2	Q6nre2 xenopus lae
4	147	80.3	1474	2 Q67FY0	Q67fy0 brachydanio
5	113	61.7	1530	2 Q67FY3	Q67fy3 brachydanio
6	109	59.6	1457	2 Q641L9	Q641l9 mus musculu
7	109	59.6	1494	2 Q67FY1	Q67fy1 homo sapien
8	109	59.6	1494	2 Q67FY2	Q67fy2 mus musculu
9	109	59.6	1494	2 Q617B5	Q617b5 mus musculu
10	109	59.6	1499	2 Q86U00	Q86u00 homo sapien
11	66	36.1	1469	1 BCL9_DROME	Q961d9 drosophila
12	62	33.9	192	2 Q7RLG2	Q7rlg2 plasmodium
13	61	33.3	833	2 Q89YQ1	Q89yq1 bacteroides
14	58	31.7	102	2 Q7VNS5	Q7vns5 haemophilus
15	57	31.1	1034	2 Q8Z8Y6	Q8z8y6 salmonella
16	57	31.1	1036	2 Q83SZ9	Q83sz9 salmonella
17	57	31.1	1046	2 Q8ZRE3	Q8zre3 salmonella
18	56.5	30.9	476	2 Q7Q3P6	Q7q3p6 anopheles g
19	56	30.6	584	1 TRF4_YEAST	P53632 saccharomyc
20	56	30.6	818	2 Q8TGZ1	Q8tgz1 methanopyru
21	56	30.6	859	2 Q9NT51	Q9nt51 homo sapien
22	56	30.6	1150	2 Q9Y2H2	Q9y2h2 homo sapien
23	56	30.6	1208	2 Q9VXU1	Q9vxu1 drosophila
24	56	30.6	1398	2 Q9VXU2	Q9vxu2 drosophila
25	55.5	30.3	767	2 Q81U73	Q81u73 bacillus an
26	55.5	30.3	974	2 Q63EZ1	Q63ez1 bacillus ce
27	55	30.1	287	2 Q8UCA0	Q8uca0 agrobacteri
28	55	30.1	295	2 Q7CWN9	Q7cwn9 agrobacteri
29	55	30.1	335	2 Q6PCC7	Q6pcc7 homo sapien
30	55	30.1	337	2 Q6NVX9	Q6nvx9 homo sapien
31	55	30.1	426	1 HEMI_SYNEL	Q8d153 synechococc

32	55	30.1	428	2 Q6PUW1	Q6puw1 homo sapien
33	55	30.1	433	2 Q81ZM6	Q81zm6 homo sapien
34	55	30.1	464	2 Q86XV6	Q86xv6 homo sapien
35	55	30.1	718	1 RHG8_HUMAN	Q9nsg0 homo sapien
36	54.5	29.8	174	1 ASC3_MOUSE	Q9jjr7 mus musculu
37	54.5	29.8	1171	1 PHYB_ORYSA	P25764 oryza sativ
38	54.5	29.8	1171	2 Q84LN8	Q84ln8 oryza sativ
39	54	29.5	326	2 Q6D1R6	Q6d1r6 erwinia car
40	54	29.5	554	2 Q7R1P0	Q7r1p0 giardia lam
41	54	29.5	832	2 Q64WV9	Q64wv9 bacteroides
42	53.5	29.2	155	2 Q8VD56	Q8vds6 rattus norv
43	53.5	29.2	208	2 Q6PZ60	Q6pzb0 mycobacteri
44	53.5	29.2	266	2 Q8Y9X2	Q8y9x2 listeria mo
45	53.5	29.2	974	2 Q73CF5	Q73cf5 bacillus ce

## ALIGNMENTS

RESULT 1  
BCL9\_HUMAN STANDARD; PRT; 1426 AA.  
ID BCL9\_HUMAN  
AC 000512;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE B-cell lymphoma 9 protein (Bcl-9) (Legless homolog).  
GN Name=BCL9;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Fetal brain;  
RX MEDLINE=98158621; PubMed=9490669;  
RA Willis T.G., Zalberg I.R., Coignet L.J.A., Wlodarska I., Stul M.,  
RA Jadayel D.M., Bastard C., Treleaven J.G., Catovsky D., Silva M.L.M.,  
RA Dyer M.J.S.;  
RT "Molecular cloning of translocation t(1;14)(q21;q32) defines a novel  
RL gene (BCL9) at chromosome 1q21.";  
RL Blood 91:1873-1881(1998).  
RN [2]  
RP FUNCTION.  
RX MEDLINE=21952490; PubMed=11955446; DOI=10.1016/S0092-8674(02)00679-7;  
RA Kramps T., Peter O., Brunner E., Nellen D., Froesch B., Chatterjee S.,  
RA Muirone M., Zueligg S., Basler K.;  
RT "Wnt/wingless signaling requires BCL9/Legless-mediated recruitment of  
RL pygopus to the nuclear beta-catenin-TCF complex.";  
RL Cell 109:47-60(2002).  
CC -1- FUNCTION: Involved in signal transduction through the Wnt pathway.  
CC -1- SUBUNIT: Binds to beta-catenin (CTNBN1), PYGO1 and PYGO2.  
CC -1- SUBCELLULAR LOCATION: Nuclear (Probable).  
CC -1- TISSUE SPECIFICITY: Detected at low levels in thymus, prostate,  
CC testis, ovary and small intestine, and at lower levels in spleen,  
CC colon and blood.  
CC -1- DISEASE: Involved in a t(1;14)(q21;q32) chromosomal translocation  
CC found in a patient with precursor B-cell acute lymphoblastic  
CC leukemia (ALL). This translocation leaves the coding region  
CC intact, but may have pathogenic effects due to alterations in the  
CC expression level of BCL9. Several cases of translocations within  
CC the 3' untranslated region of BCL9 have been found in B-cell  
CC malignancies.  
CC -1- CAUTION: It is uncertain whether Met-1 or Met-27 is the initiator.  
CC -1- CAUTION: Ref.1 sequence differs from that shown due to a  
CC frameshift in position 1391.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

```
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; Y13620; CAA73942.1; ALT_FRAME.
DR Genew; HGNC:1008; BCL9.
DR MIM; 602597; -.
KM Chromosomal translocation; Nuclear protein; Proto-oncogene;
KW Wnt signaling pathway.
FT DOMAIN 231 1378 Pro-rich.
FT DOMAIN 347 377 CTNMB1-binding.
FT DOMAIN 331 335 Poly-Pro.
FT DOMAIN 514 517 Poly-Pro.
FT DOMAIN 900 903 Poly-Ala.
FT DOMAIN 970 973 Poly-Pro.
SQ SEQUENCE 1426 AA; 149314 MW; A240A487716B7F1B CRC64;

Query Match
Best Local Similarity 100.0%; Score 183; DB 1; Length 1426;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DGLSQEQLEHRSLSQTLRDIQRLFPDEKEFTGAQ 36
Db 349 DGLSQEQLEHRSLSQTLRDIQRLFPDEKEFTGAQ 384

RESULT 2
Q67FX9 PRELIMINARY; PRT; 1425 AA.
AC Q67FX9;
DT 25-OCT-2004 (TREMBLrel. 28, Created)
DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)
DE BCL9.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S.,
RA Hammerschmidt M., Birchmeier W.;
RT "Essential role of BCL9-2 in the switch between [beta]-catenin's
RT adhesive and transcriptional functions.";
RL Genes Dev. 18:0-0(2004).
DR EMBL; AY296061; AAQ62699.1; -.
SQ SEQUENCE 1425 AA; 148970 MW; 77347CF56FC4A815 CRC64;

Query Match
Best Local Similarity 94.5%; Score 173; DB 2; Length 1425;
Matches 34; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DGLSQEQLEHRSLSQTLRDIQRLFPDEKEFTGAQ 36
Db 349 DGLSQEQLEHRSLSQTLRDIQRLFPDEKEFTGAQ 384

RESULT 3
Q6NRE2 PRELIMINARY; PRT; 796 AA.
AC Q6NRE2;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
DE MGC83888 protein.
GN Name=MGC83888;
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
```

```
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Caavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
RX MEDLINE=22341132; PubMed=12454917; DOI=10.1002/dvdy.10174;
RA Klein S.L., Strausberg R.L., Wagner L., Pontius J., Clifton S.W.,
RA Richardson P.;
RT "Genetic and genomic tools for Xenopus research: The NIH Xenopus
RT initiative.";
RL Dev. Dyn. 225:384-391(2002).
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
RA Klein S., Strausberg R.;
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC070813; AAH70813.1; -.
SQ SEQUENCE 796 AA; 86048 MW; 9A282C1DCA316678 CRC64;

Query Match
Best Local Similarity 89.1%; Score 163; DB 2; Length 796;
Matches 32; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DGLSQEQLEHRSLSQTLRDIQRLFPDEKEF 32
Db 343 DGLSQEQLEHRSLSQTLRDIQRLFPDEKEF 374

RESULT 4
Q67FY0 PRELIMINARY; PRT; 1474 AA.
AC Q67FY0;
DT 25-OCT-2004 (TREMBLrel. 28, Created)
DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)
DE Bcl9.
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RA Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S.,
RA Hammerschmidt M., Birchmeier W.;
RT "Essential role of BCL9-2 in the switch between [beta]-catenin's
RT adhesive and transcriptional functions.";
RL Genes Dev. 18:0-0(2004).
DR EMBL; AY296060; AAQ62698.1; -.
SQ SEQUENCE 1474 AA; 154339 MW; 4B2C3E8092BE3532 CRC64;

Query Match
Best Local Similarity 80.3%; Score 147; DB 2; Length 1474;
Matches 28; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```



```

Oy      1 DGSQEQLEHRRSLQTLRDIQRMLEPDEKE 31
         :|||||:|||||:|||||:|||||:|:
Db      403 EGISQEQLEHRRSLQTLRDIQRMLEPDDKD 433

```

## RESULT 5

ID	Q67FY3	PRELIMINARY;	PRT;	1530 AA.
AC	Q67FY3;			
DT	25-OCT-2004	(TREMBLrel. 28, Created)		
DT	25-OCT-2004	(TREMBLrel. 28, Last sequence update)		
DT	25-OCT-2004	(TREMBLrel. 28, Last annotation update)		
DE	Bc19-2.			
OS	Brachydanio rerio (Zebrafish)	(Danio rerio).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;			
OC	Cyprinidae; Danio.			
OX	NCBI_TaxID=7955;			

RP SEQUENCE FROM N.A.  
RA Brembeck F.H., Schwarz-Romond T., Bakkera J., Wilhelm S.,  
RA Hamerschmidt M., Bircheimer W.;  
RT "Essential role of BCL9-2 in the switch between [beta]-catenin's  
RT adhesive and transcriptional functions."; Genes Dev. 18:0-0(2004).  
RL EMBL: AY296057; AA062695.1; -.  
DR GENE: AY296057; AA062695.1; -.  
SQ SEQUENCE 1530 AA; 159872 MW; C29FEC9433ED28C0 CRC64;

Query Match	61.7%;	Score 113;	DB 2;	Length 1530;
Best Local Similarity	88.0%;	Pred. No. 2.4e-05;		
Matches 22;	Conservative 3;	Mismatches 0;	Indels 0;	Gaps 0;

```

Oy      1 DGLSQÖLEHREKRSLOTRDIÖRML 25
         |||:|||||:|:|
Db      371 DGLSKÖLEHREKRSLOTRDIÖRML 395

```

## RESULT 6

ID	Q641L9	PRELIMINARY;	PRT; 1457 AA.
AC	Q641L9;		
DT	25-OCT-2004	(TREMBLrel. 28, Created)	
DT	25-OCT-2004	(TREMBLrel. 28, Last sequence update)	
DT	25-OCT-2004	(TREMBLrel. 28, Last annotation update)	
DE	Bcl191 protein.		
GN	Name=Bcl191;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
OX	NCBI_TaxID=10090;		

RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6; TISSUE=Brain;  
RX PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,  
RA Jones S.J., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human

RT and mouse cDNA sequences." /  
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002) .  
RL

RN [2]  
 RP SEQUENCE FROM N.A.  
 RA STRAIN=C57BL/6; TISSUE=Brain;  
 RC Director MGC Project;  
 RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.

DR EMBL; BC082304; AAH82304.1; -.  
SEQUENCE 1457 AA; 152636 MW; 4FD2B47ADDE92A33 CRC64; SQ

Query Match	59.6%;	Score 109;	DB 2;	Length 1457;
Best Local Similarity	84.0%;	Pred. No. 7.3e-05;		
Matches 21; Conservative	4;	Mismatches 0;	Indels 0;	Gaps 0;

```

OY      1 DGLSOEQLERERSLOTLRDIQRM 25
        :||:|||||:|||||:|:|
Db      357 EGLSKEQLERERSLOTLRDIERLL 381

```

## RESULT 7

ID	Q67FY1	PRELIMINARY;	PRT;	1494	AA.
AC	Q67FY1;				
DT	25-OCT-2004	(TREMBLrel. 28,	Created)		
DT	25-OCT-2004	(TREMBLrel. 28,	Last sequence update)		
DT	25-OCT-2004	(TREMBLrel. 28,	Last annotation update)		
DE	BCL9-2.				
OS	Homo sapiens (Human).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.				
OX	NCBI_TaxID=9606;				

RP SEQUENCE FROM N.A.  
RA Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S.,  
RA Hammerschmidt M., Bircheimer W.;  
RT "Essential role of BCL9-2 in the switch between [beta]-catenin's  
RT adhesive and transcriptional functions.";

DR	EMBL; AY296059; AAQ62697.1; -.	2D591F45FF3AEE36	CRC64;
SQ	SEQUENCE 1494 AA; 156528 MW;		

Query Match	59.6%	Score 109;	DB 2;	Length 1494;
Best Local Similarity	84.0%	Pred. No. 7.5e-05;		
Matches 21; Conservative	4;	Mismatches 0;	Indels 0;	Gaps 0;

```
QY      1 DGLSQEQLERERSLQTRDIQRML 25
        :|||:|||||:|||||:|||||:
Db      392 EGLSKQELEHERERSLQTRDIERLL 416
```

## RESULT 8

ID	Q67FY2	PRELIMINARY;	PRT;	1494 AA.
AC	O67FY2;			
DT	25-OCT-2004	(TREMBLrel.	28,	Created)
DT	25-OCT-2004	(TREMBLrel.	28,	Last sequence update)
DT	25-OCT-2004	(TREMBLrel.	28,	Last annotation update)
DE	BCL9-2.			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa;	Chordata;	Cranialata;	Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria;	Rodentia;	Sciurognathi;	Muridae; Murinae; Mus

RA Hamerschmidt M., Birchemier W.;  
 RA "Essential role of BCL9-2 in the switch between [beta]-catenin's  
 RT adhesive and transcriptional functions."  
 RL Genes Dev. 18:0-0(2004).  
 DR EMBL; AY296058; AAQ62696.1; -.  
 SQ SEQUENCE 1494 AA; 156679 MW; 31A9904C5923581C CRC64;



```

RL Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002).
RN [4]
RP SEQUENCE OF 6-1469 FROM N.A., AND MUTAGENESIS OF GLY-514; LEU-534 AND
RP ILE-537.
RX MEDLINE=21952490; PubMed=11955446; DOI=10.1016/S0092-8674(02)00679-7;
RA Kramps T., Peter O., Brunner E., Neilen D., Froesch B., Chatterjee S.,
RA Murone M., Zuelzig S., Basler K.;
RT "Wnt/wingless signaling requires BCL9/legless-mediated recruitment of
RT pygopus to the nuclear beta-catenin-TCF complex.";
RL Cell 109:47-60(2002).
CC -1- FUNCTION: Involved in signal transduction through the Wnt pathway.
CC -1- SUBUNIT: Binds to ARM and PYGO.
CC -1- SUBCELLULAR LOCATION: Nuclear.
CC -1- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically
CC throughout development.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
-----
DR EMBL; AE003844; AAF59345.2; -.
DR EMBL; AY051651; AAK93075.1; -.
DR EMBL; AF457205; AAL91368.1; -.
DR FLYBase; FBgn0039907; lgs.
DR GO; GO:0005634; C:nucleus; IDA.
DR GO; GO:0030528; F:transcription regulator activity; IPI.
DR GO; GO:0030177; P:positive regulation of Wnt receptor signal. . .; IPI.
DR GO; GO:0007367; P:segment polarity determination; IMP.
KW Developmental protein; Nuclear protein; Segmentation polarity protein;
KW Wnt signaling pathway.
FT DOMAIN 511 555 ARM-binding.
FT DOMAIN 1134 1173 Arm-rich.
FT DOMAIN 1340 1449 Gln-rich.
FT DOMAIN 1162 1169 Poly-Asn.
FT MUTAGEN 514 514 G->E: in allele lgs-21L.
FT MUTAGEN 534 534 L->F: in allele lgs-17E; segment polarity
FT phenotype.
FT MUTAGEN 537 537 I->K: in allele lgs-17P.
SQ SEQUENCE 1469 AA; 153759 MW; 5672E01B7200ED08 CRC64;
Query Match 36.1%; Score 66; DB 1; Length 1469;
Best Local Similarity 31.4%; Pred. No. 22;
Matches 11; Conservative 10; Mismatches 14; Indels 0; Gaps 0;
OY 1 DGLSQQLHRRSLQTLRDIOQMLFPDEKEFTGA 35
DB 520 ENLTPQQRHREQLAKIKKNQFLPENNSVGA 554
RESULT 12
O7RLG2 PRELIMINARY; PRT; 192 AA.
AC O7RLG2;
DT 01-MAR-2004 (Tremblrel. 26, Created)
DT 01-MAR-2004 (Tremblrel. 26, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Hypothetical protein.
GN Name=PY02582;
OS Plasmodium yoelii yoelii.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=73239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=17XNL;
RX PubMed=12368865; DOI=10.1038/nature01099;
RA Carlton J.M., Angiuoli S.V., Suh B.B., Koof J.T.W., Pertea M.,
RA Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,
RA Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,
RA Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,

```

```

RA Cho J.K., Quackenbush J., Sedegah M., Shoaibi A., Cummings L.M.,
RA Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,
RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,
RA van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,
RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,
RA Carucci D.J.;
RT "Genome sequence and comparative analysis of the model rodent malaria
RT parasite Plasmodium yoelii yoelii.";
RL Nature 419:512-519(2002).
CC -1- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AABL01000710; EAA22049.1; -.
KW Hypothetical protein.
SQ SEQUENCE 192 AA; 22971 MW; 40C958BFC68C6754 CRC64;
Query Match 33.9%; Score 62; DB 2; Length 192;
Best Local Similarity 35.5%; Pred. No. 7.4;
Matches 11; Conservative 10; Mismatches 10; Indels 0; Gaps 0;
OY 1 DGLSQQLHRRSLQTLRDIOQMLFPDEKE 31
DB 41 EALSQKLEKEKVSDDIYLYLVFASEKE 71
RESULT 13
O89YQ1 PRELIMINARY; PRT; 833 AA.
AC O89YQ1;
DT 01-JUN-2003 (Tremblrel. 24, Created)
DT 01-JUN-2003 (Tremblrel. 24, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE DNA mismatch repair protein Muts.
GN OrderedLocustNames=BT4680;
OS Bacteroides thetaiotaomicron.
OC Bacterioides; Bacteroidetes; Bacteroidales;
OC Bacteroidaceae; Bacterioides.
OX NCBI_TaxID=818;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=VPI-5482 / ATCC 29148;
RX MEDLINE=22550858; PubMed=12663928; DOI=10.1126/science.1080029;
RA Xu J., Bjursell M.K., Himrod J., Deng S., Carmichael L.K.,
RA Chiang H.C., Hooper L.V., Gordon J.I.;
RT "A genomic view of the human-Bacteroides thetaiotaomicron symbiosis.";
RL Science 299:2074-2076(2003).
CC -1- SIMILARITY: Belongs to the DNA mismatch repair muts family.
DR EMBL; AE016946; AAO79785.1; -.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0003684; F:damaged DNA binding; IEA.
DR GO; GO:0006259; P:DNA metabolism; IEA.
DR GO; GO:0006298; P:mismatch repair; IEA.
DR InterPro; IPR000432; Muts_C.
DR InterPro; IPR007696; Muts_TII.
DR InterPro; IPR002625; Smr/Muts2_C.
DR Pfam; PF00488; Muts_V; 1.
DR Pfam; PF01713; Smr; 1.
DR ProDom; PD001263; Muts_C; 1.
DR SMART; SM00534; Mutsac; 1.
DR SMART; SM00533; Mutsd; 1.
KW Complete proteome; DNA-binding.
SQ SEQUENCE 833 AA; 94722 MW; 3B40B0168D6E7076 CRC64;
Query Match 33.3%; Score 61; DB 2; Length 833;
Best Local Similarity 44.8%; Pred. No. 51;
Matches 13; Conservative 7; Mismatches 9; Indels 0; Gaps 0;
OY 3 LSQQLHRRSLQTLRDIOQMLFPDEKE 31
DB 87 LDEQLFLRLRSLETIRDIVRFLHNEEE 115
RESULT 14

```

```
Q7VNS5
ID Q7VNS5 PRELIMINARY; PRT; 102 AA.
AC Q7VNS5;
DT 01-OCT-2003 (TReMBLrel. 25, Created)
DT 01-OCT-2003 (TReMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Hypothetical protein.
GN OrderedLocusNames=HD0412;
OS Haemophilus ducreyi.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
OC Pasteurellaceae; Haemophilus.
OX NCBI_TaxID=730;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3500HP / ATCC 700724;
RA Munson R.S. Jr., Ray W.C., Mahairas G., Sabo P., Mungur R.,
RA Johnson L., Nguyen D., Wang J., Forest C., Hood L.;
RT "The complete genome sequence of Haemophilus ducreyi.";
RL Submitted (JUN-2003) to the EMBL/Genbank/DBJ databases.
DR EMBL; AB017152; AAP95377.1; -
DR InterPro; IPR008314; UCP029143.
DR ProDom; PD030073; UCP029143; 1.
KW Complete proteome; Hypothetical protein.
SQ SEQUENCE 102 AA; 12071 MW; 6E2DECFCB5B14256 CRC64;

Query Match
Best Local Similarity 31.7%; Score 58; DB 2; Length 102;
Matches 10; Conservative 10; Mismatches 12; Indels 0; Gaps 0;

OY 1 DGLSQEQLHRRSLQTLRDIGRLFPDEKEF 32
|::: |||||:::|
DB 62 DDLNEQHAQENMSLAELRQVIREIYFNEQKF 93

RESULT 15
O8Z8Y6 PRELIMINARY; PRT; 1034 AA.
AC O8Z8Y6;
DT 01-MAR-2002 (TReMBLrel. 20, Created)
DT 01-MAR-2002 (TReMBLrel. 20, Last sequence update)
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
DE Exonuclease Sbcc.
GN Name=sbcc; OrderedLocusNames=STY0429;
OS Salmonella typhi.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Salmonella.
OX NCBI_TaxID=601;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CT18;
RX MEDLINE=21534947; PubMed=11677608; DOI=10.1038/35101607;
RA Parkhill J., Dougan G., James K.D., Thomson N.R., Pickard D., Main J.,
RA Churcher C.M., Mungall K.L., Bentley S.D., Holden M.T.G., Sebatina M.,
RA Baker S., Basham D., Brooks K., Chillingworth T., Connerton P.,
RA Cronin A., Davis P., Davies R.M., Dowd L., White N., Farrar J.,
RA Feltwell T., Hamlin N., Haque A., Hien T.T., Holroyd S., Jagels K.,
RA Krogh A., Larsen T.S., Leather S., Moule S., O'Gaora P., Parry C.,
RA Quail M.A., Rutherford K.M., Simmonds M., Skelton J., Stevens K.,
RA Whitehead S., Barrall B.G.;
RT "Complete genome sequence of a multiple drug resistant Salmonella
RT enterica serovar Typhi CT18.";
RL Nature 413:848-852(2001).
DR EMBL; AL627266; CAD08850.1; -
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005634; C:nucleus; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0042626; F:ATPase activity; coupled to transmembrane m. . .; IEA.
DR GO; GO:0004527; F:exonuclease activity; IEA.
DR GO; GO:0007059; P:chromosome segregation; IEA.
DR GO; GO:0006259; P:DNA metabolism; IEA.
DR GO; GO:0006810; P:transport; IEA.
DR Pfam; PF02463; SMC_N; 1.
DR TIGRFAMs; TIGR00618; sbcc; 1.
```

```
KW Complete proteome; Exonuclease.
SQ SEQUENCE 1034 AA; 116759 MW; 2513B7573626960A CRC64;

Query Match
Best Local Similarity 31.1%; Score 57; DB 2; Length 1034;
Matches 12; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

OY 3 LSEQQLHRRSLQTLRDIGRLFPDEK 30
|::: |||||:::|
DB 213 LADEQLQLEASLQALTDEKRLADQ 240

RESULT 16
O83SZ9 PRELIMINARY; PRT; 1036 AA.
ID O83SZ9;
AC O83SZ9;
DT 01-JUN-2003 (TReMBLrel. 24, Created)
DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
DE Exonuclease Sbcc.
GN Name=sbcc; OrderedLocusNames=t2469;
OS Salmonella typhi.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Salmonella.
OX NCBI_TaxID=601;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Ty2 / ATCC 700931;
RX MEDLINE=22531367; PubMed=12644504;
RX DOI=10.1128/JB.185.7.2330-2337.2003;
RA Deng W., Liou S.-R., Plunkett G. III, Mayhew G.F., Rose D.J.,
RA Burland V., Kodoyianni V., Schwartz D.C., Blattner F.R.;
RT "Comparative genomics of Salmonella enterica serovar Typhi strains Ty2
RT and CT18.";
RL J. Bacteriol. 185:2330-2337(2003).
DR EMBL; AB016842; AA070059.1; -
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005634; C:nucleus; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0042626; F:ATPase activity; coupled to transmembrane m. . .; IEA.
DR GO; GO:0004527; F:exonuclease activity; IEA.
DR GO; GO:0007059; P:chromosome segregation; IEA.
DR GO; GO:0006259; P:DNA metabolism; IEA.
DR GO; GO:0006810; P:transport; IEA.
DR InterPro; IPR003439; ABC_transporter.
DR InterPro; IPR004592; Sbcc.
DR InterPro; IPR003395; SMC_N.
DR Pfam; PF02463; SMC_N; 1.
DR TIGRFAMs; TIGR00618; sbcc; 1.
KW Exonuclease.
SQ SEQUENCE 1036 AA; 116943 MW; 31EE32204ADBA905 CRC64;

Query Match
Best Local Similarity 31.1%; Score 57; DB 2; Length 1036;
Matches 12; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

OY 3 LSEQQLHRRSLQTLRDIGRLFPDEK 30
|::: |||||:::|
DB 213 LADEQLQLEASLQALTDEKRLADQ 240

RESULT 17
O8ZRE3 PRELIMINARY; PRT; 1046 AA.
ID O8ZRE3;
AC O8ZRE3;
DT 01-MAR-2002 (TReMBLrel. 20, Created)
DT 01-MAR-2002 (TReMBLrel. 20, Last sequence update)
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
DE ATP-dependent dsDNA exonuclease.
GN Name=sbcc; OrderedLocusNames=STM0395;
OS Salmonella typhimurium.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Salmonella.
```

```
OX NCBI_TaxID=602;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=LT2;
RX MEDLINE=21534948; PubMed=11677609; DOI=10.1038/35101614;
RA McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P.,
RA Courtney L., Porwollik S., Ali J., Dante M., Du F., Hou S., Layman D.,
RA Leonard S., Nguyen C., Scott K., Holmes A., Grewal N., Mulvaney E.,
RA Ryan E., Sun H., Florea L., Miller W., Stoneking T., Nhan M.,
RA Waterston R., Wilson R.K.;
RT "Complete genome sequence of Salmonella enterica serovar Typhimurium
LT2.";
RL Nature 413:852-856(2001).
DR EMBL; AE008713; AAL19349.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005634; C:nucleus; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0042626; F:ATPase activity; coupled to transmembrane m. . .; IEA.
DR GO; GO:0004527; F:exonuclease activity; IEA.
DR GO; GO:0007059; P:chromosome segregation; IEA.
DR GO; GO:0006259; P:DNA metabolism; IEA.
DR GO; GO:0006810; P:transport; IEA.
DR Pfam; PF02463; SMC N; 1.
DR TIGRFAMs; TIGR00618; sbcc; 1.
KW Complete proteome; Exonuclease.
SQ SEQUENCE 1046 AA; 117823 MW; BA565CA3BDAD0C82 CRC64;

Query Match 31.1%; Score 57; DB 2; Length 1046;
Best Local Similarity 42.9%; Pred. No. 2.1e+02;
Matches 12; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 3 LSOEQLHRRSLQTLRDIQRMFPDEK 30
DB 213 LADEQLQLEASLQALTDEKRLADQ 240

RESULT 18
Q7Q3P6 PRELIMINARY; PRT; 476 AA.
AC Q7Q3P6;
DT 01-MAR-2004 (TRENBLrel. 26, Created)
DT 01-MAR-2004 (TRENBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DE AGCP10924 (Fragment).
GN Name=agCG50252; ORFNames=ENSANGG00000009382;
OS Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae; Anopheles.
OX NCBI_TaxID=180454;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PEST;
RA Anopheles Genome Sequencing Consortium;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAB01008964; EAA12408.1; -.
DR InterPro; IPR009060; UBA_1like.
DR InterPro; IPR001012; UBX.
DR PROSITE; PS50033; UBX; 1.
FT NON_TER 1
SQ SEQUENCE 476 AA; 54397 MW; 5A7EC8C1E8C30576 CRC64;

Query Match 30.9%; Score 56.5; DB 2; Length 476;
Best Local Similarity 43.8%; Pred. No. 1e+02;
Matches 14; Conservative 3; Mismatches 10; Indels 5; Gaps 1;
```

```
RESULT 19
TRF4_YEAST STANDARD; PRT; 584 AA.
ID TRF4_YEAST
AC P53632.1
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Topoisomerase 1-related protein TRF4.
GN Name=TRF4; OrderedLocustNames=YOL115W; ORFNames=O0716, HRC584;
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96109595; PubMed=8647385;
RA Sadoff B.U., Heath-Pagliuso S., Castano I.B., Zhu Y., Kieff F.S.,
RA Christman M.F.;
RT "Isolation of mutants of Saccharomyces cerevisiae requiring DNA
RT topoisomerase I.";
RL Genetics 141:465-479(1995).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=96076631; PubMed=7502582;
RA Vandenbol M., Durand P., Portetelle D., Hilger F.;
RT "Sequence analysis of a 44 kb DNA fragment of yeast chromosome XV
RT including the Tyl-H3 retrotransposon, the sufi(+) frameshift
RT suppressor gene for tRNA-Gly, the yeast transfer RNA-Thr-1a and a
RT delta element.";
RL Yeast 11:1069-1075(1995).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=S288c;
RA Marsischky G., Rolfs A., Richardson A., Kane M., Baqui M., Taycher E.,
RA Hu Y., Vamberg F., Weger J., Kramer J., Moreira D., Kelley F.,
RA Zuo D., Raphael J., Hogle C., Jepson D., Williamson J., Camargo A.,
RA Gonzaga L., Vasconcelos A.T., Simpson A., Kolodner R., Harlow E.,
RA Labaer J.;
RT "Creation of the YFLEX clone resource: cloning of Saccharomyces
RT cerevisiae ORFs in the Gateway recombinational cloning system.";
RL Submitted (AUG-2004) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Essential protein required for proper nuclear division
CC in mitosis. May mediate mitotic chromosome condensation.
CC -!- SIMILARITY: Belongs to the Cid1/TRF4/TRF5 family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; U31355; AAC49091.1; -.
DR EMBL; Z48149; CAA88145.1; -.
DR EMBL; Z74857; CAA99134.1; -.
DR EMBL; AY723865; AAU09782.1; -.
DR PIR; S51882; S51882.
DR GerMOnline; 143537; -.
DR SGD; S000005475; TRF4.
DR GO; GO:0005634; C:nucleus; IEA.
DR GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA.
DR GO; GO:0006265; P:DNA topological change; IGI.
DR GO; GO:0007076; P:mitotic chromosome condensation; IMP.
DR InterPro; IPR002934; NTP_transf.
DR InterPro; IPR001201; PAP_25A_core.
DR InterPro; IPR002058; PAP_assoc.
DR Pfam; PF01909; NTP_transf_2; 1.
DR Pfam; PF03828; PAP_assoc; 1.
DR MitoSys.
KW SEQUENCE 584 AA; 66030 MW; 8A58B29E4BFD022 CRC64;

Query Match 30.6%; Score 56; DB 1; Length 584;
```







OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; Drosophila.  
OX NCBI\_TaxID=7227;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;  
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,  
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
RA Brandon R.C., Rogers Y.H., Blazey R.G., Champe M., Pfeiffer B.D.,  
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,  
RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,  
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,  
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferrier S., Fleischmann W.,  
RA Fostler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,  
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,  
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwan C.,  
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,  
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacle J.M.,  
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,  
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun B.,  
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
RA Wang Z.Y., Wassarman D.A., Weinstein G.M., Weissbach J.,  
RA Williams S.M., Woodgett, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,  
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
RT "The genome sequence of Drosophila melanogaster.";  
RL Science 287:2185-2195(2000).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22426065; PubMed=12537568;  
RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,  
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,  
RA George R.A., Hoskins R.A., Laverly T., Muzny D.M., Nelson C.R.,  
RA Pacle J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,  
RA Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,  
RA Weinstein G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;  
RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila  
RT melanogaster euchromatic genome sequence.";  
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).  
RN [3]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22426070; PubMed=12537573;  
RA Kaminker J.S., Bergman C.M., Krommiller B., Carlson J., Svirskas R.,  
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,  
RA Ashburner M., Celniker S.E.;  
RT "The transposable elements of the Drosophila melanogaster euchromatin:  
RT a genomic perspective.";  
RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).  
RN [4]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22426069; PubMed=12537572;  
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,  
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
RA Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,

RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
RA Lewis S.E.;  
RT "Annotation of the Drosophila melanogaster euchromatic genome: a  
RT systematic review.";  
RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).  
RN [5]  
RP SEQUENCE FROM N.A.  
RG FlyBase;  
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.  
RN [6]  
RP SEQUENCE FROM N.A.  
RG FlyBase;  
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AE003499; AAF48467.2; -  
DR FlyBase; FBgn0027287; 1(1)G0168.  
DR InterPro; IPR000237; GRIP.  
DR PROSITE; PSS0913; GRIP; 1.  
SQ SEQUENCE 1208 AA; 137773 MW; 131F2EB663826A92 CRC64;  
Query Match 30.6%; Score 56; DB 2; Length 1208;  
Best Local Similarity 45.5%; Pred. No. 3.3e+02;  
Matches 10; Conservative 6; Mismatches 6; Indels 0; Gaps 0;  
QY 3 LSOEQLHERSLQTRDQRM 24  
DB 811 LQQQQAESQEQASTLRDLRL 832  
RESULT 24  
ID Q9VXU2 PRELIMINARY; PRT; 1398 AA.  
AC Q9VXU2; Q960D0;  
DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)  
DE CG33206-PA (SD07366P).  
GN Name=CG33206; ORFNames=CG33206;  
OS Drosophila melanogaster (Fruit fly).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; Drosophila.  
OX NCBI\_TaxID=7227;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;  
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,  
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
RA Brandon R.C., Rogers Y.H., Blazey R.G., Champe M., Pfeiffer B.D.,  
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,  
RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,  
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,  
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferrier S., Fleischmann W.,  
RA Fostler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,  
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,  
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwan C.,  
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,  
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacle J.M.,  
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,

RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,  
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
RA Wang Z.Y., Wasserman D.A., Weinstein G.M., Weissenbach J.,  
RA Williams S.M., Woodgett, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,  
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
RT "The genome sequence of *Drosophila melanogaster*,"  
RL Science 287:2185-2195(2000).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22426065; PubMed=12537568;  
RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,  
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,  
RA George R.A., Hoskins R.A., Lavery T., Muzny D.M., Nelson C.R.,  
RA Pacle J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,  
RA Svirskas R., Taber P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,  
RA Weinstein G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;  
RT "Finishing a whole-genome shotgun: Release 3 of the *Drosophila*  
RT *melanogaster* euchromatic genome sequence."  
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).  
RN [3]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22426070; PubMed=12537573;  
RA Kaminker J.S., Bergman C.M., Krommiller B., Carlson J., Svirskas R.,  
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,  
RA Ashburner M., Celniker S.E.;  
RT "The transposable elements of the *Drosophila melanogaster* euchromatin:  
RT a genomics perspective."  
RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).  
RN [4]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22426069; PubMed=12537572;  
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochuk S.E.,  
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
RA Belencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,  
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
RA Lewis S.E.;  
RT "Annotation of the *Drosophila melanogaster* euchromatic genome: a  
RT systematic review."  
RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).  
RN [5]  
RP SEQUENCE FROM N.A.  
RG FlyBase;  
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.  
RN [6]  
RP SEQUENCE FROM N.A.  
RG FlyBase;  
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.  
RN [7]  
RP SEQUENCE FROM N.A.  
RA Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,  
RA Champe M., Chavez C., Dorsett V., Dresnek D., Farfan D., Frise E.,  
RA George R., Gonzalez M., Guarin H., Krommiller B., Li P., Liao G.,  
RA Miranda A., Mungall C.J., Nunco J., Pacle J., Paragas V., Park S.,  
RA Patel S., Phouanavong S., Wan K., Yu C., Lewis S.E., Rubin G.M.,  
RA Celniker S.;  
RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AE003499; AAF48466.2; -  
DR EMBL; AY052121; AAK93545.1; -  
DR FlyBase; FBgn0027287; 1(1)G0168.  
DR InterPro; IPR000237; GRIP.  
DR PROSITE; PSS0913; GRIP; 1.  
SQ SEQUENCE 1398 AA; 158483 MW; 8BA1C2FB3E9F555D CRC64;

Query Match 30.6%; Score 56; DB 2; Length 1398;  
Best Local Similarity 45.5%; Pred. No. 3.9e+02;  
Matches 10; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

Qy 3 LSGQLEHRRSLQTLRDIQRM 24  
Db 1001 LQCCQAESEQCASTRDLRL 1022  
RESULT 25  
ID Q81U73 PRELIMINARY; PRT; 767 AA.  
AC Q81U73; Q612G0; Q6KM87;  
DT 01-JUN-2003 (TREMBLrel. 24, Created)  
DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)  
DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)  
DE Hypothetical protein.  
GN OrderedLocustNames=BA1011, BAS0946, GBAA1011;  
OS *Bacillus anthracis*.  
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; *Bacillus*.  
OX NCBI\_TaxID=1392;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Ames / isolate Porton;  
RX MEDLINE=22608414; PubMed=12721629; DOI=10.1038/nature01586;  
RA Read T.D., Peterson S.N., Tourasse N.J., Baillie L.W., Paulsen I.T.,  
RA Nelson K.E., Tettelin H., Fouts D.E., Eisen J.A., Gill S.R.,  
RA Holtzapple E.K., Okstad O.A., Helgason E., Ristone J., Wu M.,  
RA Kolonay J.F., Beanan M.J., Dodson R.J., Brinkac L.M., Gwinn M.L.,  
RA DeBoy R.T., Madpu R., Daugherty S.C., Durkin A.S., Haft D.H.,  
RA Nelson W.C., Peterson J.D., Pop M., Khouri H.M., Radune D.,  
RA Benton J.L., Mahamoud Y., Jiang L., Hance I.R., Weidman J.F.,  
RA Berry K.J., Plaut R.D., Wolf A.M., Watkins K.L., Nierman W.C.,  
RA Hazen A., Cline R.T., Redmond C., Thwaite J.E., White O.,  
RA Salzberg S.L., Thomson B., Friedlander A.M., Koehler T.M.,  
RA Hanna P.C., Kolstoe A.-B., Fraser C.M.;  
RT "The genome sequence of *Bacillus anthracis* Ames and comparison to  
RT closely related bacteria."  
RL Nature 423:81-86(2003).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Ames / isolate 0581;  
RA Ravel J., Rasko D.A., Shumway M.F., Jiang L., Cer R.Z., Federova N.B.,  
RA Wilson M., Stanley S., Decker S., Read T.D., Salzberg S.L.,  
RA Fraser C.M.;  
RT "Bacillus anthracis comparative genomics."  
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Stearne;  
RA Brettin T.S., Bruce D., Challacombe J.F., Gilna P., Han C., Hill K.,  
RA Hitchcock P., Jackson P., Keim P., Longmire J., Lucas S., Okinaka R.,  
RA Richardson P., Rubin E., Tice H.;  
RL Submitted (JAN-2004) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AE017027; AAP24998.1; -  
DR EMBL; AE017334; AAT30114.2; -  
DR EMBL; AE017225; AAT53271.1; -  
DR TIGR; BA1011; -  
DR TIGR; GBAA1011; -  
KW Complete proteome; Hypothetical protein.  
SQ SEQUENCE 767 AA; 90630 MW; 37E501351906E9E4 CRC64;

Query Match 30.3%; Score 55.5; DB 2; Length 767;  
Best Local Similarity 38.7%; Pred. No. 2.3e+02;  
Matches 12; Conservative 8; Mismatches 8; Indels 3; Gaps 1;  
Qy 3 LSGQLEHRRSLQTLRDIQRM LFPDEKEFT 33  
Db 190 VAQEQLEEQE--ENIRQIQKQMLADEERNT 217  
RESULT 26  
ID Q63E21 PRELIMINARY; PRT; 974 AA.  
AC Q63E21;  
DT 25-OCT-2004 (TREMBLrel. 28, Created)  
DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)

```

DE 25-OCT-2004 (TrEMBLrel. 28, last annotation update)
DE Hypothetical protein yhan.
OS Name=yhan, ORFNames=BTZK0919;
OS Bacillus cereus ZK.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=288681;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ZK;
RA Brettin T.S., Bruce D., Challacombe J.F., Gilna P., Han C., Hill K.,
RA Hitchcock P., Jackson P., Keim P., Longmire J., Lucas S., Okinaka R.,
RA Richardson P., Rubin E., Tice H.;
RT "Complete genome sequence of Bacillus cereus ZK.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; CP000001; AAU19326.1; -.
KW Hypothetical protein.
SQ SEQUENCE 974 AA; 114224 MW; 66DA2EE4B43CE41A CRC64;

Query Match 30.3%; Score 55.5; DB 2; Length 974;
Best Local Similarity 38.7%; Pred. No. 3e+02;
Matches 12; Conservative 8; Mismatches 8; Indels 3; Gaps 1;

OY 3 LSEQQLHRRSLQTLRDIQMLFPDEKEFT 33
Db 397 VAQEQLEEQE--ENIRQIQKQMLADEERNT 424

RESULT 27
Q8UCA0 PRELIMINARY; PRT; 287 AA.
AC Q8UCA0;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Transcriptional regulator, RpiR family.
GN OrderedLocustNames=Atu2598;
OS Agrobacterium tumefaciens (strain C58 / ATCC 33970).
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Rhizobiaceae; Rhizobium/Agrobacterium group; Agrobacterium.
OX NCBI_TaxID=176299;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Dupont;
RX MEDLINE=21608550; PubMed=11743193; DOI=10.1126/science.1066804;
RA Wood D.W., Setubal J.C., Kaul R., Monks D.E., Kitajima J.P.,
RA Okura V.K., Zhou Y., Chen L., Wood G.E., Almeida N.F. Jr., Woo L.,
RA Chen Y., Paulsen I.T., Eisen J.A., Karp P.D., Bovee D. Sr.,
RA Chapman P., Clendenning J., Deatherage G., Gillet W., Grant C.,
RA Kutayavin T., Levy R., Li M.-J., McClelland E., Palmieri A.,
RA Raymond C., Rouse G., Saenphimmachak C., Wu Z., Romero P., Gordon D.,
RA Zhang S., Yoo H., Tao Y., Biddle P., Jung M., Krespan W., Perry M.,
RA Gordon-Kamm B., Liao L., Kim S., Hendrick C., Zhao Z.-Y., Dolan M.,
RA Chumley F., Tingey S.V., Tomb J.-F., Gordon M.P., Olson M.V.,
RA Nester E.W.;
RT "The genome of the natural genetic engineer Agrobacterium tumefaciens
RT C58.";
RL Science 294:2317-2323 (2001).
DR EMBL; AE009206; AAL43579.1; -.
DR PIR; AE2895; AE2895.
DR PIR; H97670; H97670.
DR GO; GO:0005529; F:sugar binding; IEA.
DR GO; GO:0003700; F:transcription factor activity; IEA.
DR GO; GO:0005975; P:carbohydrate metabolism; IEA.
DR GO; GO:0006355; P:regulation of transcription, DNA-dependent; IEA.
DR Pfam; PF01380; SIS; 1.
DR PROSITE; PS00356; HTH_LACI_1; UNKNOWN_1.
KW Complete proteome.
SQ SEQUENCE 287 AA; 31331 MW; 2877CC6B531A0D4A CRC64;

Query Match 30.1%; Score 55; DB 2; Length 287;
Best Local Similarity 40.0%; Pred. No. 90;
Matches 12; Conservative 7; Mismatches 7; Indels 4; Gaps 1;

```

```

QY      9 EHRERSLQTLRDIOQMLF----PDEKEFTG 34
       :|:||:||||||:|:|:|
Db      257 QQRQRSMVTLRHIKQLVEHRDPDDKQLLG 286

RESULT 28
Q7CWN9 ID PRELIMINARY; PRT; 295 AA.
AC Q7CWN9;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, last annotation update)
DE AGR_C_4707P.
OS OrderedLocustNames=AGR_C_4707;
ON Agrobacterium tumefaciens (strain C58 / ATCC 33970).
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Rhizobiaceae; Rhizobium/Agrobacterium group; Agrobacterium.
OX NCBI_TaxID=176299;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=Cereon;
RX MEDLINE=21608551; Pubmed=11743194; DOI=10.1126/science.1066803;
RA Goodner B., Hinkle G., Gattung S., Miller N., Blanchard M.,
RA Qurollo B., Goldman B.S., Cao Y., Askenazi M., Halling C., Mullin L.,
RA Houmlet K., Gordon J., Vaudin M., Iartchouk O., Epp A., Liu F.,
RA Wollam C., Allinger M., Doughty D., Scott C., Lappas C., Markelz B.,
RA Flanagan C., Crowell C., Gurson J., Lomo C., Sear C., Strub G.,
RA Cielo C., Slater S.;
RT "Genome sequence of the plant pathogen and biotechnology agent
RT Agrobacterium tumefaciens C58.";
RL Science 294:2323-2328(2001).
DR EMBL; AE008173; AAK88321.1; -.
DR GO; GO:0005529; F:sugar binding; IEA.
DR GO; GO:0003700; F:transcription factor activity; IEA.
DR GO; GO:0005975; P:carbohydrate metabolism; IEA.
DR GO; GO:0006355; P:regulation of transcription, DNA-dependent; IEA.
DR InterPro; IPR000843; HTH_LacI.
DR InterPro; IPR001347; SIS.
DR InterPro; IPR009058; Wing_hlx_DNA_bnd.
DR Pfam; PF01380; SIS; 1.
DR PROSITE; PS00356; HTH_LACI_1; UNKNOWN 1.
SQ SEQUENCE 295 AA; 32258 MW; 3B50926B3CB72456 CRC64;

Query Match 30.1%; Score 55; DB 2; Length 295;
Best Local Similarity 40.0%; Pred. No. 92;
Matches 12; Conservative 7; Mismatches 7; Indels 4; Gaps 1;

QY      9 EHRERSLQTLRDIOQMLF----PDEKEFTG 34
       :|:||:||||||:|:|:|
Db      265 QQRQRSMVTLRHIKQLVEHRDPDDKQLLG 294

RESULT 29
Q6PC7 ID PRELIMINARY; PRT; 335 AA.
AC Q6PC7;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, last annotation update)
DE Hypothetical protein (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
[1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RX MEDLINE=22388257; Pubmed=12477932; DOI=10.1073/pnas.242603899;
RA Straube R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

```

```
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bogak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodrigues A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RA Strausberg R.;
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC059382; AAH59382.1; -.
DR HSSP; Q07960; IAM4.
DR InterPro; IPR001251; CRAL_TRIO_C.
DR InterPro; IPR000198; RhOGAP.
DR InterPro; IPR008936; Rho_GAP.
DR Pfam; PF00620; RhOGAP; 1.
DR SMART; SM00324; RhOGAP; 1.
DR SMART; SM00516; SEC14; 1.
DR PROSITE; PS50191; CRAL_TRIO; 1.
DR PROSITE; PS50238; RhOGAP; 1.
DR PROSITE; PS50238; RhOGAP; 1.
KW Hypothetical protein.
FT NON_TER 1
SQ SEQUENCE 335 AA; 38646 MW; 7B1B179BD5873F9A CRC64;

Query Match 30.1%; Score 55; DB 2; Length 335;
Best Local Similarity 52.2%; Pred. No. 1.le+02;
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 2 GLSQEQLEHREKSLQTLRDIOQM 24
DB 265 GLRTEGLFRRSASVQTVREIQRL 287

RESULT 30
Q6NVX9 PRELIMINARY; PRT; 337 AA.
AC Q6NVX9;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE ARHGAP8 protein (Fragment).
GN Name=ARHGAP8;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shermen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
```

```
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodrigues A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RA Strausberg R.;
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC067824; AAH67824.1; -.
DR HSSP; Q07960; IAM4.
DR InterPro; IPR001251; CRAL_TRIO_C.
DR InterPro; IPR000198; RhOGAP.
DR InterPro; IPR008936; Rho_GAP.
DR SMART; SM00324; RhOGAP; 1.
DR SMART; SM00516; SEC14; 1.
DR PROSITE; PS50191; CRAL_TRIO; 1.
DR PROSITE; PS50238; RhOGAP; 1.
FT NON_TER 1
SQ SEQUENCE 337 AA; 38956 MW; DB3921FA61C78C92 CRC64;

Query Match 30.1%; Score 55; DB 2; Length 337;
Best Local Similarity 52.2%; Pred. No. 1.le+02;
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 2 GLSQEQLEHREKSLQTLRDIOQM 24
DB 256 GLRTEGLFRRSASVQTVREIQRL 278

RESULT 31
HEMI SYNEBL
ID HEMI SYNEBL STANDARD; PRT; 426 AA.
AC Q8DI53;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Glutamyl-tRNA reductase (EC 1.2.1.-) (GluTR).
GN Name=hema; OrderedLocustNames=tl11738;
OS Synechococcus elongatus (Thermosynechococcus elongatus).
OC Bacteria; Cyanobacteria; Chroococcales; Synechococcus.
OX NCBI_TaxID=32046;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BP-1;
RX MEDLINE=22225144; PubMed=12240834;
RA Nakamura Y., Kaneko T., Sato S., Ikeuchi M., Katoh H., Sasamoto S.,
RA Watanabe A., Iriguchi M., Kawashima K., Kimura T., Kishida Y.,
RA Kiyokawa C., Kohara M., Matsumoto M., Matsuno A., Nakazaki N.,
RA Shimo S., Sugimoto M., Takeuchi C., Yamada M., Tabata S.;
RT "Complete genome structure of the thermophilic cyanobacterium
RT Thermosynechococcus elongatus BP-1.";
RL DNA Res. 9:123-130(2002).
CC -1- CATALYTIC ACTIVITY: Glutamyl-tRNA(Glu) + NADPH = glutamate-1-
CC semialdehyde + NADP(+) + tRNA(Glu).
CC -1- PATHWAY: Porphyrin biosynthesis by the C5 pathway; first step.
CC Involved in chlorophyll biosynthesis.
CC -1- SIMILARITY: Belongs to the glutamyl-tRNA reductase family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AP005375; BAC09290.1; -.
DR HSSP; Q9UXR8; 1GPI.
DR HAMAP; MF_00087; -, 1.
```

DR InterPro; IPR000343; GlutR.  
DR InterPro; IPR000594; Thif domain.  
DR Pfam; PF00745; GlutR\_dimer; 1.  
DR Pfam; PF05201; GlutR\_N; 1.  
DR Pfam; PF05200; GlutR\_NAD\_bind; 1.  
DR TIGRFAMs; TIGR01035; hema; 1.  
DR PROSITE; PS00747; GLUTR; FALSE NEG.  
KW Chlorophyll biosynthesis; Complete proteome; NADP; Oxidoreductase;  
KW Porphyrin biosynthesis.  
FT ACT\_SITE 50 50 Nucleophile (By similarity).  
FT ACT\_SITE 99 99 Proton acceptor (By similarity).  
SQ SEQUENCE 426 AA; 47596 MW; D84CE5A1D2AA777E CRC64;

Query Match 30.1%; Score 55; DB 1; Length 426;  
Best Local Similarity 55.6%; Pred. No. 1.4e+02;  
Matches 10; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 4 SGOQLHRSLSQTLRDI 21  
Db 401 SQRDLESROAMQTLQDL 418

RESULT 32  
Q6PJW1 PRELIMINARY; PRT; 428 AA.  
AC Q6PJW1;  
DT 05-JUL-2004 (TReMBLrel. 27, Created)  
DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)  
DE Hypothetical protein (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Placenta;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marsina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
RA Krzywinski M.I., Skalska U., Smailus D.B., Schnerch A., Schein J.E.,  
RA Jones S.J., Maira M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Placenta;  
RA Strausberg R.;  
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.  
DR HSSP; Q07960; 1AM4.  
DR InterPro; IPR001251; CRAL\_TRIO\_C.  
DR InterPro; IPR000198; RhOGAP.  
DR InterPro; IPR008936; Rho\_GAP.  
DR Pfam; PF00620; RhOGAP; 1.  
DR SMART; SM00324; RhOGAP; 1.  
DR SMART; SM00516; SEC14; 1.  
DR PROSITE; PS50191; CRAL\_TRIO; 1.  
DR PROSITE; PS50238; RhOGAP; 1.

KW Hypothetical protein.  
FT NON TER 1  
SQ SEQUENCE 428 AA; 48607 MW; 5DE5828FF2043024 CRC64;  
Query Match 30.1%; Score 55; DB 2; Length 428;  
Best Local Similarity 52.2%; Pred. No. 1.4e+02;  
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 2 GLSGOQLHRSLSQTLRDIQRM 24  
Db 219 GLRTEGLFRRSASVQTVREIQRL 241

RESULT 33  
Q8IZM6 PRELIMINARY; PRT; 433 AA.  
AC Q8IZM6;  
DT 01-MAR-2003 (TReMBLrel. 23, Created)  
DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)  
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)  
DE BCH domain-containing Cdc42GAP-like protein.  
GN Name=BPGAP1;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22970011; PubMed=12944407; DOI=10.1074/jbc.M304514200;  
RA Shang X., Zhou Y.T., Low B.C.;  
RT "Concerted regulation of cell dynamics by BNP-2 and Cdc42GAP  
RT homology/Sec14p-like, proline-rich, and GTPase-activating protein  
RT domains of a novel Rho GTPase-activating protein, BPGAP1.";  
RT J. Biol. Chem. 278:45903-45914(2003).  
RL EMBL; AF544240; AAN40769.1; -.  
DR HSSP; Q07960; 1RGP.  
DR InterPro; IPR001251; CRAL\_TRIO\_C.  
DR InterPro; IPR000198; RhOGAP.  
DR InterPro; IPR008936; Rho\_GAP.  
DR Pfam; PF00620; RhOGAP; 1.  
DR SMART; SM00324; RhOGAP; 1.  
DR SMART; SM00516; SEC14; 1.  
DR PROSITE; PS50191; CRAL\_TRIO; 1.  
DR PROSITE; PS50238; RhOGAP; 1.  
SQ SEQUENCE 433 AA; 49691 MW; 0AE4B42A404AE1D3 CRC64;

Query Match 30.1%; Score 55; DB 2; Length 433;  
Best Local Similarity 52.2%; Pred. No. 1.4e+02;  
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 2 GLSGOQLHRSLSQTLRDIQRM 24  
Db 224 GLRTEGLFRRSASVQTVREIQRL 246

RESULT 34  
Q86XV6 PRELIMINARY; PRT; 464 AA.  
AC Q86XV6;  
DT 01-JUN-2003 (TReMBLrel. 24, Created)  
DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)  
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)  
DE ARHGAP8 protein (Fragment).  
GN Name=ARHGAP8;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Colon;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,



RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marsina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulys S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
RA Krzywinski M.I., Skalska U., Smalusz D.E., Schermer A., Schein J.E.,  
RA Jones S.J., Maira M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences.";  
RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Colon;  
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC048280; AAH48280.1; -.  
DR HSSP; Q07960; 1RGP.  
DR InterPro; IPR001251; CRAL\_TRIO\_C.  
DR InterPro; IPR000198; RhogAP.  
DR InterPro; IPR008936; Rho\_GAP.  
DR Pfam; PF00620; RhogAP; 1.  
DR SMART; SM00324; RhogAP; 1.  
DR SMART; SM00516; SEC14; 1.  
DR PROSITE; PS50191; CRAL\_TRIO; 1.  
DR PROSITE; PS50238; RhogAP; 1.  
PT NON TER 1  
SQ SEQUENCE 464 AA; 53142 MW; 82F68ACD8AD219C7 CRC64;  
  
Query Match 30.1%; Score 55; DB 2; Length 464;  
Best Local Similarity 52.2%; Pred. NO. 1.5e+02;  
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;  
  
QY 2 GLSQQLEHRSLSQTLRDIQRM 24  
DB 255 GLRTGGLFRRSASVQTVREIQRL 277  
  
RESULT 35  
RHG8\_HUMAN STANDARD; PRT; 718 AA.  
AC Q9NSG0; Q75983; Q95695; Q96RW1; Q96RW2; Q9HA49; Q9HC46; Q9NVX8;  
AC Q9NXL1; Q9UH20;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Rho-GTPase-activating protein 8 (PP610).  
GN Name=ARHGAP8;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A. (ISOFORM 4).  
RA Gu J.R., Wan D.F., Zhao X.T., Zhou X.M., Jiang H.Q., Zhang P.P.,  
RA Qin W.X., Huang Y., Qiu X.K., Qian L.F., He L.P., Li H.N., Yu Y.,  
RA Yu J., Han L.H.;  
RT "Novel human cDNA clones with function of inhibiting cancer cell  
RT growth.";  
RN Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).  
RA McDermid H.E., Hu S., Grundy P., Trichet V.;  
RT "ARHGAP8: a putative tumor-suppressor gene on chromosome 22q13.3";  
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.

RN [3]  
RP SEQUENCE FROM N.A. (ISOFORMS 5; 6 AND 7).  
RC TISSUE=Colon mucosa, and Mammary gland;  
RX PubMed=14702039; DOI=10.1038/ng1285;  
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,  
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,  
RA Sekine M., Oobayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,  
RA Yamamoto J.-I., Saito K., Kawai Y., Isono Y., Nakamura Y.,  
RA Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuna M.,  
RA Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H.,  
RA Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E.,  
RA Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M.,  
RA Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K.,  
RA Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoaka S., Chiba Y.,  
RA Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T.,  
RA Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O.,  
RA Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,  
RA Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,  
RA Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,  
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,  
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,  
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,  
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,  
RA Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,  
RA Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,  
RA Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,  
RA Ohtani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,  
RA Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,  
RA Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,  
RA Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,  
RA Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,  
RA Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;  
RT "Complete sequencing and characterization of 21,243 full-length human  
RT cDNAs.";  
RL Nat. Genet. 36:40-45(2004).  
RN [4]  
RP SEQUENCE FROM N.A. (ISOFORM 3).  
RA Goward M.E., Huckle E.J.;  
RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.  
RN [5]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=20057165; PubMed=10591208; DOI=10.1038/990031;  
RA Dunham I., Hunt A.R., Collins J.E., Bruskiewicz R., Beare D.M.,  
RA Ciamp M., Smink L.J., Alnscough R., Almeida J.P., Babbage A.K.,  
RA Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,  
RA Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,  
RA Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,  
RA Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,  
RA Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,  
RA Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,  
RA Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,  
RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,  
RA Hall R.E., Hall-Tamlyn G., Heathcote R.W., Ho S., Holmes S.,  
RA Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,  
RA Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,  
RA Martyn I.D., Mashreghi-Mohammadi A., Matthews L.H., Mccann O.T.,  
RA Mcclay J., McLaren S., McMurray A.A., Milne S.A., Mortimore B.J.,  
RA Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,  
RA Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,  
RA Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,  
RA Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,  
RA Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,  
RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,  
RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,  
RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,  
RA Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,  
RA Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,  
RA Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,  
RA Lewis J., Lewis S., Lin S.-P., Loh P., Malaf B., Nguyen T., Pan H.,  
RA Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,  
RA Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,  
RA Zhan M., Zhang G., Chisoe S., Murray J., Miller N., Minx P.,  
RA Fulton R., Johnson D., Bents G., Bentley D., Bradshaw H., Bourne S.,



RA Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,  
RA Hinds K., Kemp K., Latreille P., Layman D., Ozeraky P., Rohlfing T.,  
RA Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,  
RA Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,  
RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saita S.,  
RA Budarf M.L., McDermaid H.E., Johnson A., Wong A.C.C., Morrow B.E.,  
RA Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanaki J.P.,  
RA Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,  
RA O'Brien K.P., Wilkinson P., Bodeneich A., Hartman K., Hu X.,  
RA Khan A.S., Lane L., Tilahun Y., Wright H.;  
RT "The DNA sequence of human chromosome 22.";  
RL Nature 402:489-495(1999).  
CC -1- FUNCTION: GTPase activator for the Rho-type GTPases by converting  
CC them to an inactive GDP-bound state (By similarity).  
CC -1- ALTERNATIVE PRODUCTS:  
CC Event=Alternative splicing; Named isoforms=8;  
CC Comment=Additional isoforms seem to exist. Full isoforms so far  
CC detected are isoforms 1 to 7. Experimental confirmation may be  
CC lacking for some isoforms;  
CC Name=8;  
CC IsoId=Q9NSGO-1; Sequence=Displayed;  
CC Name=1;  
CC IsoId=Q9NSGO-2; Sequence=VSP\_001645, VSP\_001649, VSP\_001652;  
CC Name=2;  
CC IsoId=Q9NSGO-3; Sequence=VSP\_001645, VSP\_001649, VSP\_001653,  
CC VSP\_001655;  
CC Name=3;  
CC IsoId=Q9NSGO-4; Sequence=VSP\_001651;  
CC Name=4;  
CC IsoId=Q9NSGO-5; Sequence=VSP\_001650, VSP\_001654;  
CC Name=5;  
CC IsoId=Q9NSGO-6; Sequence=VSP\_001647;  
CC Name=6;  
CC IsoId=Q9NSGO-7; Sequence=VSP\_001647, VSP\_001652, VSP\_001656,  
CC VSP\_001657;  
CC Name=7;  
CC IsoId=Q9NSGO-8; Sequence=VSP\_001646, VSP\_001648, VSP\_001650,  
CC VSP\_001654;  
CC -1- SIMILARITY: Contains 1 CRAL-TRIO domain.  
CC -1- SIMILARITY: Contains 1 Rho-GAP domain.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; AF177331; AAG17975.1; -;  
DR EMBL; AF195968; AAK58136.1; -;  
DR EMBL; AF195969; AAK58137.1; -;  
DR EMBL; AK000192; BAA90999.1; -;  
DR EMBL; AK001306; BAA91614.1; -;  
DR EMBL; AK022305; BAB14008.1; -;  
DR EMBL; AL355192; CAB90248.1; -;  
DR EMBL; Z98743; CAB11416.1; ALT\_INIT.  
DR EMBL; Z93244; -; NOT\_ANNOTATED\_CDS.  
DR EMBL; Z83838; CAB62953.1; ALT\_INIT.  
DR PIR; B59436; B59436.  
DR HSSP; Q07960; IRGP.  
DR Genew; HGNC:677; ARHGAP8.  
DR InterPro; IPR001251; CRAL\_TRIO\_C.  
DR InterPro; IPR008936; Rho\_GAP.  
DR InterPro; IPR000198; RhoGAP.  
DR Pfam; PF00620; RhoGAP; 1.  
DR PROSITE; PS50191; CRAL\_TRIO; 1.  
DR PROSITE; PS50238; RHO\_GAP; 1.  
KW Alternative splicing; GTPase activation.  
FT DOMAIN 267 453 CRAL-TRIO.  
FT DOMAIN 480 666 Rho-GAP.  
FT VARSPPLIC 1 95 Missing (in isoform 1 and isoform 2).  
/FTId=VSP\_001645.

FT VARSPPLIC 1 101 Missing (in isoform 7).  
FT FT /FTId=VSP\_001646.  
FT VARSPPLIC 1 254 Missing (in isoform 5 and isoform 6).  
FT FT /FTId=VSP\_001647.  
FT VARSPPLIC 102 107 KIRFYB -> MAPMPT (in isoform 7).  
FT FT /FTId=VSP\_001648.  
FT VARSPPLIC 108 230 Missing (in isoform 1 and isoform 2).  
FT FT /FTId=VSP\_001649.  
FT VARSPPLIC 232 388 LQDKAAAAAVLGAVKRPSVPMAGODPALSTHPEFYDVA  
FT FT RHGILQVAGDDRFGRVVTFSCCRMPPSHLDHQRLLLEYLK  
FT FT YTLQYVENDYITIVFYGLNSRNKPSLGWLQSAYPEDRK  
FT FT DGDLTWMPRLVNSKLRSSHLSPKYWDYRYKK -> KRL  
FT FT LRRSRGDLAKNPVRSKSYNTPLINPVOEHAEAGAAAGG  
FT FT TSIRRHVSSEMTSCPEQGFSDPPGQPTGTFRSSPAPHS  
FT FT PCPSRLYPTQPEQGLPTRSSLPSSPENLVQILLESVD  
FT FT SDSEGIFIDFGRGRGSGMSDLESGGRQSVV (in  
FT FT isoform 4 and isoform 7).  
FT FT /FTId=VSP\_001650.  
FT VARSPPLIC 311 385 Missing (in isoform 3).  
FT FT /FTId=VSP\_001651.  
FT VARSPPLIC 355 385 Missing (in isoform 1 and isoform 6).  
FT FT /FTId=VSP\_001652.  
FT VARSPPLIC 386 451 YKDKALALVYVHPTSFIVLNLKPLISHKFGKVIYFNY  
FT FT LSELHEHLKYDQVIVPEVLRVDEK -> QEPGQANTLVL  
FT FT KGPDSQHSFAGLLYCNSAGLCSSTLWTLKCEHFVIFT  
FT FT CHEIFFCFFSTT (in isoform 2).  
FT FT /FTId=VSP\_001653.  
FT VARSPPLIC 389 718 Missing (in isoform 4 and isoform 7).  
FT FT /FTId=VSP\_001654.

Query Match 30.1%; Score 55; DB 1; Length 718;  
Best Local Similarity 52.2%; Pred. No. 2.5e+02;  
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

OY 2 GLSQQLERHRSLSLTLDIQRM 24  
Db 509 GLRTEGLFRRSASVQTVREIQRL 531

RESULT 36  
ASCS\_MOUSE STANDARD; PRT; 174 AA.  
AC Q9JJR7;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Achaete-scute homolog 3 (bHLH transcriptional regulator Sgn-1) (Mash-  
DE 3).  
OS Name=Ascl3; Synonyms=Mash3, Sgn1;  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RN SEQUENCE FROM N.A.  
RA Kemp P.R., Cooper W.N., Metcalfe J.C.;  
RT "MASH3 a novel basic helix-loop-helix protein that inhibits myogenesis  
RT in C2C12 cells."  
RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RN SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6;  
RX MEDLINE=21643927; PubMed=11784080; DOI=10.1006/dbio.2001.0473;  
RA Yoshida S., Ohbo K., Takakura A., Takebayashi H., Okada T., Abe K.,  
RA Nabeshima Y.;  
RT "Sgn1, a basic helix-loop-helix transcription factor delineates the  
RT salivary gland duct cell lineage in mice."  
RL Dev. Biol. 240:517-530(2001).  
RN [3]  
RN SEQUENCE FROM N.A.  
RX MEDLINE=21418998; PubMed=11528127;  
RA Amid C., Bahr A., Mujica A., Sampson N., Bikar S.E., Winterpacht A.,  
RA Zabel B., Hankein T., Schmidt E.R.;

```
RT "Comparative genomic sequencing reveals a strikingly similar
RT architecture of a conserved syntenic region on human chromosome
RT 11p15.3 (including gene ST5) and mouse chromosome 7.";
RL Cytogenet. Cell Genet. 93:284-290(2001).
CC -1- FUNCTION: Transcriptional repressor. Inhibits myogenesis.
CC -1- SUBUNIT: Efficient DNA binding requires dimerization with another
CC BHLH protein.
CC -1- SUBCELLULAR LOCATION: Nuclear.
CC -1- TISSUE SPECIFICITY: Specifically expressed in the salivary duct
CC cells.
CC -1- SIMILARITY: Contains 1 basic helix-loop-helix (bHLH) domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AJ277605; CAC37689.1; -.
DR EMBL; AB046448; BAB83911.1; -.
DR EMBL; AJ400878; CAB92296.1; -.
DR MGD; MGI:1928820; Aac13.
DR GO; GO:0005634; C:nucleus; IDA.
DR GO; GO:0005667; C:transcription factor complex; IPI.
DR GO; GO:0003677; F:DNA binding; IDA.
DR GO; GO:0005515; F:protein binding; IPI.
DR GO; GO:0030528; F:transcription regulator activity; IDA.
DR GO; GO:0006357; P:regulation of transcription from Pol II pro. . ; IDA.
DR InterPro; IPR001092; HLH_basic.
DR Pfam; PF00010; HLH; 1.
DR SMART; SM00353; HLH; 1.
DR PROSITE; PS50888; HLH; 1.
DR DNA-binding; Nuclear protein; Repressor; Transcription regulation.
FT DNA BIND 95 105 Basic motif.
FT DOMAIN 106 145 Helix-loop-helix motif.
SQ SEQUENCE 174 AA; 20245 MW; D89E56C8A9D3440B CRC64;

Query Match 29.8%; Score 54.5; DB 1; Length 174;
Best Local Similarity 36.1%; Pred. No. 59;
Matches 13; Conservative 7; Mismatches 9; Indels 7; Gaps 1;

QY 3 LSEQLEHRRSLQTLRD-----IQMLFPDEKE 31
Db 119 LPEDYLEKRLSKVETLRAAIKYISYLQSLYPDESE 154

RESULT 37
PHYB_ORYSA STANDARD; PRT; 1171 AA.
AC P25764;
DT 01-MAY-1992 (Rel. 22, Created)
DT 01-MAY-1992 (Rel. 22, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Phytochrome B.
GN Name=PHYB; Synonyms=PHYB1;
OS Oryza sativa (Rice).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoideae; Oryzaceae; Oryza.
OX NCBI_TaxID=4530;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Indica / IR36; TISSUE=Seedling shoot;
RX MEDLINE=91172131; PubMed=2005872;
RA Dehesh K., Tepperman J., Christensen A.H., Quail P.H.;
RT "phyB is evolutionarily conserved and constitutively expressed in rice
RT seedling shoots.";
RL Mol. Gen. Genet. 225:305-313(1991).
CC -1- FUNCTION: Regulatory photoreceptor which exists in two forms that
CC are reversibly interconvertible by light: the Pr form that absorbs
CC maximally in the red region of the spectrum and the Pfr form that
```

```
CC absorbs maximally in the far-red region. Photoconversion of Pr in
CC Pfr induces an array of morphogenic responses, whereas
CC reconversion of Pfr to Pr cancels the induction of those
CC responses. Pfr controls the expression of a number of nuclear
CC genes including those encoding the small subunit of ribulose-
CC biphosphate carboxylase, chlorophyll A/B binding protein,
CC protochlorophyllide reductase, rRNA, etc. It also controls the
CC expression of its own gene(s) in a negative feedback fashion.
CC -1- SUBUNIT: Homodimer.
CC -1- PTM: Contains one covalently linked tetrapyrrole chromophore.
CC -1- SIMILARITY: Belongs to the phytochrome family.
CC -1- SIMILARITY: Contains 1 histidine kinase domain.
CC -1- SIMILARITY: Contains 2 PAS (PBR-ARNT-SIM) dimerization domains.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X57563; CAA40795.2; -.
DR PIR; S14065; S14065.
DR Gramene; P25764; -.
DR InterPro; IPR003594; ATPbind_ATPase.
DR InterPro; IPR003018; GAF.
DR InterPro; IPR005467; His_kinase.
DR InterPro; IPR003661; His_kina_N.
DR InterPro; IPR00014; PAS.
DR InterPro; IPR001294; Phytochrome.
DR Pfam; PF01590; GAF; 1.
DR Pfam; PF02518; HATPase_c; 1.
DR Pfam; PF00512; HisKA; 1.
DR Pfam; PF00989; PAS; 2.
DR Pfam; PF00360; Phytochrome; 1.
DR PRINTS; PR01033; PHYTOCHROME.
DR SMART; SM00065; GAF; 1.
DR SMART; SM00387; HATPase_c; 1.
DR SMART; SM00388; HisKA; 1.
DR SMART; SM00091; PAS; 2.
DR TIGRFAMs; TIGR00229; sensory_box; 2.
DR PROSITE; PS50109; HIS_KIN; 1.
DR PROSITE; PS50112; PAS; 2.
DR PROSITE; PS00245; PHYTOCHROME_1; 1.
DR PROSITE; PS50046; PHYTOCHROME_2; 1.
KW Chromophore; Multigene family; Photoreceptor; Phytochrome; Repeat;
KW Transcription regulation.
FT DOMAIN 661 732 PAS 1.
FT DOMAIN 795 866 PAS 2.
FT DOMAIN 943 1161 Histidine kinase.
FT DOMAIN 39 51 Poly-Gly.
FT BINDING 364 364 Chromophore (By similarity).
SQ SEQUENCE 1171 AA; 128384 MW; E8292E88B769BF16 CRC64;

Query Match 29.8%; Score 54.5; DB 1; Length 1171;
Best Local Similarity 48.1%; Pred. No. 5e+02;
Matches 13; Conservative 4; Mismatches 5; Indels 5; Gaps 1;

QY 3 LSEQLEHRRSLQTLRDIQMLFPDE 29
Db 1019 VSQVMIQLRERDLQLRDI-----PDE 1040

RESULT 38
O84LN8 PRELIMINARY; PRT; 1171 AA.
ID O84LN8;
AC O84LN8;
DT 01-JUN-2003 (TREMBLrel. 24, Created)
DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE Phytochrome B.
GN Name=PHYB;
```

Oryza sativa (japonica cultivar-group).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
OC Ehrhartoideae; Oryzeae; Oryza.  
OX NCBI\_TaxID=39947;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Tahir M., Kanegae H., Takano M.;  
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.  
CC -1- SIMILARITY: Contains 1 histidine kinase domain.  
DR EMBL; AB109892; BAC76432.1; -.  
DR Gramene; Q84LN8; -.  
DR GO; GO:0016020; C:membrane; IEA.  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0008020; F:G-protein coupled photoreceptor activity; IEA.  
DR GO; GO:0016301; F:kinase activity; IEA.  
DR GO; GO:0000155; F:two-component sensor molecule activity; IEA.  
DR GO; GO:0018298; P:protein-chromophore linkage; IEA.  
DR GO; GO:0009585; P:red, far-red light phototransduction; IEA.  
DR GO; GO:0006355; P:regulation of transcription, DNA-dependent; IEA.  
DR GO; GO:0007165; P:signal transduction; IEA.  
DR GO; GO:0007601; P:visual perception; IEA.  
DR InterPro; IPR003594; Atphind ATPase.  
DR InterPro; IPR000977; DNA\_ligase.  
DR InterPro; IPR003018; GAF.  
DR InterPro; IPR005467; His\_kinase.  
DR InterPro; IPR003661; His\_kin\_N.  
DR InterPro; IPR000014; PAS.  
DR InterPro; IPR001294; Phytochrome.  
DR InterPro; IPR001680; WD40.  
DR Pfam; PF01590; GAF; 1.  
DR Pfam; PF02518; HATPase\_c; 1.  
DR Pfam; PF00512; HiskA; 1.  
DR Pfam; PF00989; PAS; 2.  
DR Pfam; PF00360; Phytochrome; 1.  
DR PRINTS; PR01033; PHYTOCHROME.  
DR SMART; SM00065; GAF; 1.  
DR SMART; SM00387; HATPase\_c; 1.  
DR SMART; SM00388; HiskA; 1.  
DR SMART; SM00091; PAS; 2.  
DR TIGRFAMs; TIGR00229; sensory box; 1.  
DR PROSITE; PS00697; DNA\_LIGASE\_A1; UNKNOWN\_1.  
DR PROSITE; PS50109; HIS\_KIN; 1.  
DR PROSITE; PS50112; PAS; 2.  
DR PROSITE; PS00245; PHYTOCHROME\_1; 1.  
DR PROSITE; PS50046; PHYTOCHROME\_2; 1.  
DR PROSITE; PS00678; WD\_REPEATS\_1; UNKNOWN\_1.  
KW Chromophore; Photoreceptor; Phytochrome.  
SQ SEQUENCE 1171 AA; 128492 MW; DEB981FC89D46FDC CRC64;  
  
Query Match 29.8%; Score 54.5; DB 2; Length 1171;  
Best Local Similarity 48.1%; Pred. No. 5e+02;  
Matches 13; Conservative 4; Mismatches 5; Indels 5; Gaps 1;  
  
Qy 3 LSOQLHRRSLQTLRDIQRLFPDE 29  
Db 1019 VSQVMQLRRDLQLIRDI-----PDE 1040  
  
RESULT 39  
Q6D1R6 PRELIMINARY; PRT; 326 AA.  
AC Q6D1R6; 25-OCT-2004 (TREMBlrel. 28, Created)  
DT 25-OCT-2004 (TREMBlrel. 28, Last sequence update)  
DE Pyoverdine biosynthesis protein.  
GN Name=PVCA; OrderedLocustNames=ECA3381;  
OS Erwinia carotovora (subsp. atroseptica) (Pectobacterium atrosepticum).  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
OC Enterobacteriaceae; Pectobacterium.  
OX NCBI\_TaxID=29471;  
RN [1]

RP SEQUENCE FROM N.A.  
RC STRAIN=SCRI 1043 / ATCC BAA-672;  
RX PubMed=15263089; DOI=10.1073/pnas.0402424101;  
RA Bell K.S., Sebahia M., Pritchard L., Holden M.T.G., Hyman L.J.,  
RA Holeva M.C., Thomson N.R., Bentley S.D., Churcher L.J.C., Mungall K.,  
RA Ackin R., Bason N., Brooks K., Chillingworth T., Clark K., Doggett J.,  
RA Fraser A., Hance Z., Hauser H., Jagels K., Moule S., Norbertczak H.,  
RA Ormond D., Price C., Quail M.A., Sanders M., Walker D., Whitehead S.,  
RA Salmond G.P.C., Birch P.R.J., Parkhill J., Toth I.K.;  
RT "Genome sequence of the enterobacterial phytopathogen Erwinia  
RT carotovora subsp. atroseptica and characterization of virulence  
RT factors."  
RL Proc. Natl. Acad. Sci. U.S.A. 101:11105-11110(2004).  
DR EMBL; BX950851; CAG76279.1; -.  
DR InterPro; IPR007817; DIT1\_PVCA.  
DR Pfam; PF05141; DIT1\_PVCA; 1.  
KW Complete proteome.  
SQ SEQUENCE 326 AA; 37006 MW; FAE727C53CC6B78B CRC64;  
  
Query Match 29.5%; Score 54; DB 2; Length 326;  
Best Local Similarity 39.4%; Pred. No. 1.4e+02;  
Matches 13; Conservative 5; Mismatches 13; Indels 2; Gaps 1;  
  
Qy 5 QEOLEHRRSLQTLRDIQRLFPD--EKEFTGA 35  
Db 187 KEQLMQSEGLQLYRSITRFLYEDSLRPDYTG 219  
  
RESULT 40  
Q7R1P0 PRELIMINARY; PRT; 554 AA.  
AC Q7R1P0; 01-MAR-2004 (TREMBlrel. 26, Created)  
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)  
DE 01-MAR-2004 (TREMBlrel. 26, Last annotation update)  
DE GLP 28 36755 35091.  
OS Giardia lamblia ATCC 50803.  
OC Eukaryota; Diplomonadida; Hexamitidae; Giardinae; Giardia.  
OX NCBI\_TaxID=184922;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=WB C6;  
RA Morrison H.G., McArthur A.G., Adam R.D., Aley S.B., Gillin F.D.,  
RA Olsen G.J., Sogin M.L.;  
RT "Draft sequence of the Giardia lamblia genome."  
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.  
CC -1- SIMILARITY: Belongs to the Ser/Thr protein kinase family.  
CC -1- CAUTION: The sequence shown here is derived from an  
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
CC preliminary data.  
DR EMBL; AACB01000026; EAA41219.1; -.  
DR HSSP; P24941; IEIX.  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.  
DR GO; GO:0016740; F:transferase activity; IEA.  
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.  
DR InterPro; IPR011009; Kinase like.  
DR InterPro; IPR000719; Prot\_kinase.  
DR InterPro; IPR008271; Ser\_thr\_pkin\_AS.  
DR ProDom; PD000001; Prot\_kinase; 1.  
DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; UNKNOWN\_1.  
DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
KW ATP-binding; Kinase; Serine/threonine-protein kinase; Transferase.  
SQ SEQUENCE 554 AA; 62825 MW; 0A159E9518D36EF0 CRC64;  
  
Query Match 29.5%; Score 54; DB 2; Length 554;  
Best Local Similarity 43.3%; Pred. No. 2.5e+02;  
Matches 13; Conservative 4; Mismatches 11; Indels 2; Gaps 1;  
  
Qy 1 DGLSQEOLEHRRSLQTLRDIQRLFPDEK 30  
Db 265 EALGYPSLEERQGLSQ--NDIYRVIFPDEK 292

Search completed: June 8, 2005, 03:22:59  
Job time : 167.75 secs

---

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 8, 2005, 02:59:37 ; Search time 133.875 Seconds  
(without alignments)  
104.003 Million cell updates/sec

Title: US-09-915-543-15\_COPY\_349\_384

Perfect score: 183  
Sequence: 1 DGIHQEQLEHRRSLQTLRDIQMLFPDEKEFTGAQ 36

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_16Dec04:\*

1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	183	100.0	1394	ADQ18945	Adq18945 Human sof
2	183	100.0	1426	AAB71229	Aab71229 Human leg
3	183	100.0	1426	ABW01534	Abw01534 Human lgs
4	183	100.0	1426	ADJ70152	Adj70152 Human hea
5	183	100.0	1426	ADJ71903	Adj71903 Human lgs
6	183	100.0	1435	ABB11808	Abb11808 Human BCL
7	178	97.3	35	ADJ71893	Adj71893 Human lgs
8	109	59.6	320	AAU78461	Aau78461 Mouse bet
9	109	59.6	1494	AAU78460	Aau78460 Mouse bet
10	107	58.5	738	AAU78463	Aau78463 Human bet
11	107	58.5	1115	AAAB71230	Aab71230 Human leg
12	107	58.5	1115	ABW01535	Abw01535 Human lgs
13	107	58.5	1115	ADJ71905	Adj71905 Human lgs
14	66	36.1	35	ABW01529	Abw01529 Drosophil
15	66	36.1	35	ADJ71892	Adj71892 Drosophil
16	66	36.1	1429	ABB58779	Abb58779 Drosophil
17	66	36.1	1464	AAB71228	Aab71228 D. melano
18	66	36.1	1464	ABW01527	Abw01527 Drosophil
19	66	36.1	1464	ADJ71911	Adj71911 Fruit fly
20	61.5	33.6	1014	ABP98879	Abp98879 Human mol
21	57.5	31.4	603	ABJ25853	Abj25853 Aspergill
22	57.5	31.4	618	ABJ26453	Abj26453 Aspergill
23	57	31.1	411	ABU44941	Abu44941 Protein e
24	57	31.1	1034	ABU47461	Abu47461 Protein e
25	56	30.6	425	ADP04653	Adp04653 Sea squir

26	56	30.6	584	6	ABR53351	AbR53351 Protein s
27	56	30.6	584	7	ADK63408	AdK63408 Disease t
28	56	30.6	584	8	ADN19362	Adn19362 Bacterial
29	56	30.6	818	7	ADM26229	Adm26229 Hyperther
30	56	30.6	1132	8	ADL83239	Adl83239 Human PRO
31	56	30.6	1132	8	ADQ17519	Adq17519 Human sof
32	56	30.6	1294	4	ABB63502	Abb63502 Drosophil
33	55.5	30.3	757	6	ABU17570	Abu17570 Protein e
34	55	30.1	237	8	ADP56607	Adp56607 Human bre
35	55	30.1	248	8	ADP56608	Adp56608 Human bre
36	55	30.1	294	4	AAB95073	Aab95073 Human pro
37	55	30.1	294	6	ABR82444	AbR82444 Human ARP
38	55	30.1	294	8	ADQ74859	Adq74859 Human and
39	55	30.1	333	7	ADM83551	Adm83551 Human Rho
40	55	30.1	337	8	ADP56606	Adp56606 Human bre
41	55	30.1	357	8	ADP56605	Adp56605 Human bre
42	55	30.1	390	5	ABG96285	Abg96285 Human ova
43	55	30.1	433	4	AAB68522	Aab68522 Human GTP
44	55	30.1	433	4	AAG63851	Aag63851 Amino aci
45	55	30.1	433	4	AAG63852	Aag63852 Amino aci

ALIGNMENTS

RESULT 1  
ADQ18945  
ID ADQ18945 standard; protein; 1394 AA.  
XX  
AC ADQ18945;  
XX  
DT 26-AUG-2004 (first entry)  
XX  
DE Human soft tissue sarcoma-upregulated protein - SEQ ID 1764.  
XX  
KM soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2004048938-A2.  
XX  
PD 10-JUN-2004.  
XX  
PF 26-NOV-2003; 2003WO-US038193.  
XX  
PR 26-NOV-2002; 2002US-0429739P.  
XX  
PA (PROT-) PROTEIN DESIGN LABS INC.  
XX  
PI Aziz N, Ginsburg WM, Zlotnik A;  
XX  
DR WPI; 2004-441208/41.  
XX  
PT Early detection of soft tissue sarcoma comprises determining expression  
PT of a gene in a first soft tissue sample and a normal soft tissue sample  
PT and comparing the gene expression, also useful in treating soft tissue  
PT sarcoma.  
XX  
PS Example 2; SEQ ID NO 1764; 210pp; English.  
XX  
The invention relates to a novel method for detecting soft tissue sarcoma  
CC which comprises obtaining a first soft tissue sample from an individual  
CC and a normal soft tissue sample from the same or different individual,  
CC determining the expression of a gene in both samples and comparing the  
CC expression of the gene in both soft tissue samples, where a higher level  
CC of protein expression in the first soft tissue sample indicates the  
CC presence of soft tissue sarcoma. The method of the invention has  
CC cyostatic applications and may be useful for detecting soft tissue  
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic  
CC acid sequences may be useful in diagnostic and screening applications.  
CC The current sequence is that of a human soft tissue sarcoma-upregulated  
CC protein of the invention. The current sequence is not shown within the  
CC specification per se but was submitted in CD format by the inventor.

XX Sequence 1394 AA;  
SQ  
Query Match 100.0%; Score 183; DB 8; Length 1394;  
Best Local Similarity 100.0%; Pred. No. 5.9e-16;  
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DGLSQEQLEHRRSLQTLRDIQRLFPDEKEFTGAQ 36  
|||||  
DB 349 DGLSQEQLEHRRSLQTLRDIQRLFPDEKEFTGAQ 384

RESULT 2  
AAB71229 standard; protein; 1426 AA.  
XX AAB71229;  
AC AAB71229;  
XX 18-NOV-2002 (first entry)  
DT  
XX Human legless homologue lgs/bcl9 protein.  
DE  
XX Legless; human; lgs; Wnt/Wingless signaling pathway; Wnt; Wg;  
KW tissue proliferation; tumour; cytosatic; cellular disorder; colon;  
KW blood disorder; cancer; breast; head and neck cancer; brain; thyroid;  
KW medulloblastoma; skin cancer; tissue regeneration; tissue repair.  
XX  
OS Homo sapiens.  
XX  
PN US2002086986-A1.  
XX  
PD 04-JUL-2002.  
XX  
PF 27-JUL-2001; 2001US-00915543.  
XX  
PR 28-JUL-2000; 2000US-0221502P.  
XX  
XX (BASL/) BASLER K.  
PA (BRUN/) BRUNNER E.  
PA (FROE/) FROESCH B.  
PA (KRAM/) KRAMPS T.  
PA (PETE/) PETER O.  
XX  
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
XX  
DR WPI; 2002-635689/68.  
DR N-PSDB; AAF88467.  
XX  
PT Novel polypeptide useful in therapeutic method for treating disorders of  
PT cell fate such as cell differentiation or cell proliferation.  
XX  
XX Example II; Fig 8B; 41pp; English.  
XX  
CC This invention describes a novel polypeptide sharing one or more  
CC homologous amino acid domains with the legless (lgs) protein, a  
CC downstream component of the Wnt/Wingless (Wnt/Wg) signaling pathway  
CC involved in the formation and maintenance of spatial arrangements and  
CC proliferation of tissues during development, and in the formation and  
CC growth of many human tumours. The products of the invention have  
CC cytosatic activity and can be used to treat cellular disorders, blood  
CC disorders and cancers caused by over-stimulation of the Wnt pathway,  
CC where the cancerous condition is colon, breast, head and neck, brain,  
CC thyroid, medulloblastoma or skin cancer. The product could also be used  
CC to promote tissue regeneration and repair. This sequence represents the  
CC human legless (lgs) protein homologue lgs/bcl9 described in the  
CC disclosure of the invention  
XX  
SQ Sequence 1426 AA;

Query Match 100.0%; Score 183; DB 5; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 6e-16;  
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX

QY 1 DGLSQEQLEHRRSLQTLRDIQRLFPDEKEFTGAQ 36  
|||||  
DB 349 DGLSQEQLEHRRSLQTLRDIQRLFPDEKEFTGAQ 384

RESULT 3  
ABW01534 standard; protein; 1426 AA.  
XX ABW01534;  
AC ABW01534;  
XX 15-JAN-2004 (first entry)  
DT  
XX Human lgs/bcl9 protein.  
DE  
XX Legless protein; lgs; cell fate disorder; blood disease; gene therapy;  
KW cancer; tissue regeneration; tissue repair; cytosatic.  
XX  
OS Homo sapiens.  
XX  
PN US2003114413-A1.  
XX  
PD 19-JUN-2003.  
XX  
PF 19-DEC-2002; 2002US-00322579.  
XX  
PR 28-JUL-2000; 2000US-0221502P.  
PR 27-JUL-2001; 2001US-00915543.  
XX  
PA (UYZU-) UNIV ZURICH.  
XX  
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
XX  
DR WPI; 2003-829432/77.  
DR N-PSDB; AAD62642.  
XX  
PT Novel lgs polypeptide useful for isolation of lgs-binding proteins,  
PT diagnosing disorders of cell fate, treating diseases such as cancer.  
XX  
PS Example 2; Fig 8B; 0pp; English.  
XX  
CC The invention relates to novel legless (lgs) proteins and polynucleotides  
CC encoding such proteins. Lgs sequences are useful for the treatment of  
CC disorders of cell fate such as differentiation or proliferation. The  
CC invention is used to treat blood disease or a cancerous condition  
CC characterised by over-stimulation of the Wnt pathway such as colon,  
CC breast, head and neck, brain, thyroid, medulloblastoma or skin cancer and  
CC is administered to prevent progression from a pre-neoplastic or non-  
CC malignant condition to a neoplastic or malignant state. It is  
CC administered to promote tissue regeneration and repair. The invention is  
CC also useful in the therapy of diseases cost by an over-activation of Wg  
CC pathway. It is useful for reducing lgs gene expression in an invertebrate  
CC or vertebrate organism or an invertebrate or vertebrate cell line. The  
CC invention is also useful in gene therapy. The present sequence is human  
CC lgs/bcl9 protein used in the invention  
XX  
SQ Sequence 1426 AA;

Query Match 100.0%; Score 183; DB 7; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 6e-16;  
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DGLSQEQLEHRRSLQTLRDIQRLFPDEKEFTGAQ 36  
|||||  
DB 349 DGLSQEQLEHRRSLQTLRDIQRLFPDEKEFTGAQ 384

RESULT 4  
ADJ70152 standard; protein; 1426 AA.  
XX ADJ70152;  
AC ADJ70152;  
XX



DT 06-MAY-2004 (first entry)  
XX  
DE Human heat mitochondrial protein as a therapeutic target SegID1958.  
XX  
KW mitochondrial; human; screening assay; diabetes mellitus;  
KW Huntington's disease; osteoarthritis;  
KW Leber's hereditary optic neuropathy; LHON;  
KW mitochondrial encephalopathy lactic acidosis and stroke; MELAS;  
KW myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;  
KW neuroprotective; nootropic; antidiabetic; anticonvulsant; antiarthritic;  
KW osteopathic; ophthalmological; cyostatic.  
XX  
OS Homo sapiens.  
XX  
PN WO2003087768-A2.  
XX  
PD 23-OCT-2003.  
XX  
PF 04-APR-2003; 2003WO-US010870.  
XX  
PR 12-APR-2002; 2002US-0372843P.  
PR 17-JUN-2002; 2002US-0389987P.  
PR 20-SEP-2002; 2002US-0412418P.  
XX  
PA (MITO-) MITOKOR.  
PA (BUCK-) BUCK INST AGE RES.  
XX  
PI Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;  
PI Warnock DE;  
XX  
DR WPI; 2003-845369/78.  
XX  
PT Identifying a mitochondrial target for drug screening assays and for  
PT treating diseases associated with altered mitochondrial function.  
PT comprises detecting a modified polypeptide in a sample and correlating  
PT with the disease.  
XX  
PS Claim 1; SEQ ID NO 1958; 180pp; English.  
XX  
CC This invention relates to novel mitochondrial targets that can be used  
CC for therapeutic intervention in treating a disease associated with  
CC altered mitochondrial function. Specifically, it refers to a method for  
CC identifying proteins of the human heart mitochondrial proteome that are  
CC useful for drug screening assays, as well as therapeutic targets. The  
CC present invention describes a method for identifying such proteins that  
CC can be used in the treatment of various diseases associated with altered  
CC mitochondrial function including diabetes mellitus, Huntington's disease,  
CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial  
CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy  
CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these  
CC compositions have neuroprotective, nootropic, antidiabetic,  
CC anticonvulsant, antiarthritic, osteopathic, ophthalmological and  
CC cyostatic activities. This polypeptide sequence is a human heart  
CC mitochondrial protein of the invention.  
XX  
SQ Sequence 1426 AA;  
Query Match 100.0%; Score 183; DB 7; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 6e-16;  
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DGLSQEQLHRRERSLQTLRDIQMLFPDEKEFTGAQ 36  
DB 349 DGLSQEQLHRRERSLQTLRDIQMLFPDEKEFTGAQ 384  
RESULT 5  
ADJ71903  
ID ADJ71903 standard; protein; 1426 AA.  
XX  
AC ADJ71903;  
XX  
DT 20-MAY-2004 (first entry)

XX  
DE Human Lgs/Bcl9 polypeptide.  
XX  
KW Human; legless; lgs; cell differentiation disorder;  
KW cell proliferation disorder; cancer; Wnt pathway; medulloblastoma; colon;  
KW breast; head; neck; brain; thyroid; skin; blood disease;  
KW tissue regeneration; tissue repair; cyostatic; lgs/Bcl9.  
XX  
OS Homo sapiens.  
XX  
PN US2004038901-A1.  
XX  
PD 26-FEB-2004.  
XX  
PF 22-SEP-2003; 2003US-00664859.  
XX  
PR 28-JUL-2000; 2000US-0221502P.  
PR 27-JUL-2001; 2001US-00915543.  
XX  
PA (UYZU-) UNIV ZURICH.  
XX  
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
XX  
DR WPI; 2004-203288/19.  
DR N-PSDB; ADJ71902.  
XX  
PT Novel polypeptide sharing one or more homologue amino acid domains with  
PT legless protein being functional homologue of legless, useful for  
PT diagnosing disorders of cell fate.  
XX  
PS Example 2; SEQ ID NO 15; 62pp; English.  
XX  
CC The invention relates to a polypeptide sharing one or more homologous  
CC amino acid domains with a legless (lgs) protein and is therefore a  
CC functional homologue of lgs. The invention also relates to a nucleotide  
CC sequence encoding a protein present in invertebrate and/or vertebrate  
CC organisms, the nucleotide sequence encoding a protein comprising a  
CC positive function in a regulatory pathway and the use of the polypeptide  
CC for the isolation of lgs-binding proteins by carrying out an assay chosen  
CC from an in vitro binding assay with such a peptide or a co-  
CC immunoprecipitation from vertebrate or invertebrate cell lysates or a  
CC mammalian or yeast two hybrid assay. The polypeptide and polynucleotide  
CC are useful for treating disorders of cell fate, which involves  
CC administering therapeutic compounds chosen from invertebrate and  
CC vertebrate lgs protein homologues or fragments, antibodies, antibody  
CC fragments, lgs antisense DNA, lgs antisense RNA, lgs double-stranded RNA,  
CC small peptides or chemical and natural compounds being capable of  
CC interfering with lgs function, synthesis and degradation. The disorders  
CC are related to cell differentiation or cell proliferation. The compound  
CC is administered to treat a cancerous condition by preventing progression  
CC from a pre-neoplastic or non-malignant condition to a neoplastic or  
CC malignant state. The cancerous condition is characterised by over-  
CC stimulation of the Wnt pathway and is medulloblastoma or cancer of the  
CC colon, breast, head and neck, brain, thyroid or skin. The therapeutic  
CC compound may also be administered to a blood disease to promote tissue  
CC regeneration and repair. This sequence represents the human lgs/Bcl9  
CC polypeptide of the invention.  
XX  
SQ Sequence 1426 AA;  
Query Match 100.0%; Score 183; DB 8; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 6e-16;  
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DGLSQEQLHRRERSLQTLRDIQMLFPDEKEFTGAQ 36  
DB 349 DGLSQEQLHRRERSLQTLRDIQMLFPDEKEFTGAQ 384  
RESULT 6  
ABB11808  
ID ABB11808 standard; peptide; 1435 AA.  
XX

AC ABB11808;  
XX  
DT 11-JAN-2002 (first entry)  
XX  
DE Human BCL9 homologue, SEQ ID NO:2178.  
XX  
KW Human; cytokine; cell proliferation; cell differentiation; growth factor;  
KW haematopoiesis regulation; tissue growth; immunomodulator; activin;  
KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;  
KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;  
KW chronic inflammatory condition; proliferative retinopathy;  
KW atherosclerosis; coronary heart disease; arterial ischaemia;  
KW bone disorder; osteoporosis; vascular growth disorder;  
KW tissue regeneration; wound healing; infection; immune disorder;  
KW cell culture; drug screening; gene therapy; antiinflammatory;  
KW antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;  
KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
KW antifungal; vulnery; antitlcer.  
XX  
OS Homo sapiens.  
XX  
PN WO200157188-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 05-FEB-2001; 2001WO-US003800.  
XX  
PR 03-FEB-2000; 2000US-00496914.  
PR 27-APR-2000; 2000US-00560875.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Drmanac RT;  
XX  
DR WPI; 2001-457740/49.  
DR N-PSDB; ABA09052.  
XX  
PT Human proteins and DNA encoding sequences useful for preventing, treating  
PT or ameliorating a medical condition in a mammalian subject e.g. arthritis  
PT and cancer.  
XX  
PS Claim 20; Page 256-257; 1963pp; English.

XX  
CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
CC invention also relates to vectors and recombinant host cells comprising a  
CC nucleotide of the invention, methods of producing the novel polypeptides,  
CC antibodies against the polypeptides, methods of detecting the nucleotides  
CC or polypeptides in a sample, and methods of identifying compounds which  
CC bind to polypeptides of the invention. Although novel, many of the  
CC polypeptides of the invention have homology to known proteins, thereby  
CC giving an insight into their probable biological activities, and hence  
CC potential therapeutic applications. The polypeptides of the invention may  
CC have various activities, including cytokine, cell proliferation or cell  
CC differentiation activities; stem cell growth factor activity;  
CC haematopoiesis regulatory activity; tissue growth activity;  
CC immunomodulatory activity; activin- or inhibin-related activities;  
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or  
CC thrombolytic activities; receptor or ligand activities; or may be  
CC involved in oncogenesis, cancer cell proliferation or metastasis.  
CC Depending on their biological activities, polypeptides and nucleotides of  
CC the invention are useful for preventing, treating or ameliorating medical  
CC conditions, e.g., by protein or gene therapy. Such conditions include  
CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),  
CC proliferative retinopathy, atherosclerosis, coronary heart disease,  
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
CC vascular growth. Polypeptides involved with tissue regeneration and  
CC repair (or nucleic acids encoding them) may be used to promote wound  
CC healing (e.g., of burns, incisions and ulcers), while those with  
CC immunomodulatory activities may be used in the treatment of viral,  
CC bacterial and fungal infections in addition to immune disorders.

CC Polypeptides with growth factor activity may be used in cell cultures to  
CC promote cell growth. For example, such polypeptides may be used to  
CC manipulate stem cells in culture to give rise to neuroepithelial cells  
CC that can be used to augment or replace cells damaged by illness,  
CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
CC may also be used in the diagnosis of the above conditions, and in drug  
CC screening techniques. The present sequence represents a novel human  
CC polypeptide of the invention  
XX  
SQ Sequence 1435 AA;  
XX  
Query Match 100.0%; Score 183; DB 4; Length 1435;  
Best Local Similarity 100.0%; Pred. No. 6e-16;  
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DGLSGEQLHRRSLQTLADIQMLFPDEKEFTGAQ 36  
Db 389 DGLSGEQLHRRSLQTLADIQMLFPDEKEFTGAQ 424

RESULT 7  
ADJ71893  
ID ADJ71893 standard; peptide; 35 AA.  
XX  
AC ADJ71893;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human Lgs/Bcl9 peptide fragment #2.  
XX

KW Human; legless; lgs; cell differentiation disorder;  
KW cell proliferation disorder; cancer; wnt pathway; medulloblastoma; colon;  
KW breast; head; neck; brain; thyroid; skin; blood disease;  
KW tissue regeneration; tissue repair; cytostatic; Lgs/Bcl9.  
XX  
OS Homo sapiens.  
XX  
PN US2004038901-A1.  
XX  
PD 26-FEB-2004.  
XX  
PF 22-SEP-2003; 2003US-00664859.  
XX  
PR 28-JUL-2000; 2000US-0221502P.  
PR 27-JUL-2001; 2001US-00915543.  
XX  
PA (UYZU-) UNIV ZURICH.  
XX  
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
XX  
DR WPI; 2004-203288/19.  
XX

PT Novel polypeptide sharing one or more homologue amino acid domains with  
PT legless protein being functional homologue of legless, useful for  
PT diagnosing disorders of cell fate.  
XX  
PS Disclosure; SEQ ID NO 5; 62pp; English.  
XX

CC The invention relates to a polypeptide sharing one or more homologous  
CC amino acid domains with a legless (Lgs) protein and is therefore a  
CC functional homologue of Lgs. The invention also relates to a nucleotide  
CC sequence encoding a protein present in invertebrate and/or vertebrate  
CC organisms, the nucleotide sequence encoding a protein comprising a  
CC positive function in a regulatory pathway and the use of the polypeptide  
CC for the isolation of Lgs-binding proteins by carrying out an assay chosen  
CC from an in vitro binding assay with such a peptide or a co-  
CC immunoprecipitation from vertebrate or invertebrate cell lysates or a  
CC mammalian or yeast two hybrid assay. The polypeptide and polynucleotide  
CC are useful for treating disorders of cell fate, which involves  
CC administering therapeutic compounds chosen from invertebrate and  
CC vertebrate Lgs protein homologues or fragments, antibodies, antibody  
CC fragments, lgs antisense DNA, lgs antisense RNA, lgs double-stranded RNA,  
CC small peptides or chemical and natural compounds being capable of

CC interfering with lgs function, synthesis and degradation. The disorders  
CC are related to cell differentiation or cell proliferation. The compound  
CC is administered to treat a cancerous condition by preventing progression  
CC from a pre-neoplastic or non-malignant condition to a neoplastic or  
CC malignant state. The cancerous condition is characterised by over-  
CC stimulation of the Wnt pathway and is medulloblastoma or cancer of the  
CC colon, breast, head and neck, brain, thyroid or skin. The therapeutic  
CC compound may also be administered to a blood disease to promote tissue  
CC regeneration and repair. This sequence represents a human lgs/Bcl19  
CC peptide fragment of the invention.  
XX  
SQ Sequence 35 AA;

Query Match 97.3%; Score 178; DB 8; Length 35;  
Best Local Similarity 100.0%; Pred. No. 5e-17;  
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 DGLSQEQLHRRSLQTLRDIQRMFPDEKEFTGA 35  
|||  
Db 1 DGLSQEQLHRRSLQTLRDIQRMFPDEKEFTGA 35

RESULT 8  
AAU78461  
ID AAU78461 standard; protein; 320 AA.

XX AC AAU78461;

XX DT 02-JUL-2002 (first entry)

XX DE Mouse beta-catenin nuclear localised protein #2.

XX KW Mouse; beta-catenin nuclear localised protein; cancer; gene therapy; EST;

XX KM expressed sequence tag.

XX OS Mus musculus.

XX PN WO200224738-A1.

XX PD 28-MAR-2002.

XX PF 19-SEP-2001; 2001WO-JP008140.

XX PR 22-SEP-2000; 2000JP-00287876.

XX PA (KYOW ) KYOWA HAKKO KOGYO KK.

XX PI Akiyama T, Adachi S;

XX DR WPI; 2002-330014/36.

XX DR N-PSDB; ABK47632.

XX PT New beta-catenin nuclear localized protein for diagnosis and treatment of  
XX PT diseases associated with nuclear localization of beta-catenin e.g.  
XX PT cancer.

XX PS Claim 2; Page 91-92; 113pp; Japanese.

XX XX The invention relates to a beta-catenin nuclear localised protein and DNA

XX CC encoding the protein. The protein and encoding DNA are applicable in

XX CC diagnosis and treatment of diseases associated with nuclear localisation

XX CC of beta-catenin e.g. cancer, including gene therapy. The present sequence

XX CC represents the amino acid sequence of mouse beta-catenin nuclear

XX CC localised protein #2

XX SQ Sequence 320 AA;

Query Match 59.6%; Score 109; DB 5; Length 320;  
Best Local Similarity 84.0%; Pred. No. 1.7e-06;  
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 1 DGLSQEQLHRRSLQTLRDIQRM 25  
:||||:|||||

Db 150 EGLSQEQLHRRSLQTLRDIERLL 174

RESULT 9

AAU78460  
ID AAU78460 standard; protein; 1494 AA.

XX AC AAU78460;

XX DT 02-JUL-2002 (first entry)

XX DE Mouse beta-catenin nuclear localised protein.

XX KW Mouse; beta-catenin nuclear localised protein; cancer; gene therapy; EST;

XX KM expressed sequence tag.

XX OS Mus musculus.

XX PN WO200224738-A1.

XX PD 28-MAR-2002.

XX PF 19-SEP-2001; 2001WO-JP008140.

XX PR 22-SEP-2000; 2000JP-00287876.

XX PA (KYOW ) KYOWA HAKKO KOGYO KK.

XX PI Akiyama T, Adachi S;

XX DR WPI; 2002-330014/36.

XX DR N-PSDB; ABK47631.

XX PT New beta-catenin nuclear localized protein for diagnosis and treatment of  
XX PT diseases associated with nuclear localization of beta-catenin e.g.

XX PT cancer.

XX PS Claim 1; Page 81-88; 113pp; Japanese.

XX CC The invention relates to a beta-catenin nuclear localised protein and DNA

XX CC encoding the protein. The protein and encoding DNA are applicable in

XX CC diagnosis and treatment of diseases associated with nuclear localisation

XX CC of beta-catenin e.g. cancer, including gene therapy. The present sequence

XX CC represents the amino acid sequence of mouse beta-catenin nuclear

XX CC localised protein

XX SQ Sequence 1494 AA;

Query Match 59.6%; Score 109; DB 5; Length 1494;  
Best Local Similarity 84.0%; Pred. No. 9.3e-06;  
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 1 DGLSQEQLHRRSLQTLRDIQRM 25  
:||||:|||||

Db 394 EGLSQEQLHRRSLQTLRDIERLL 418

RESULT 10

AAU78463  
ID AAU78463 standard; protein; 738 AA.

XX AC AAU78463;

XX DT 02-JUL-2002 (first entry)

XX DE Human beta-catenin nuclear localised protein #2.

XX KW Mouse; beta-catenin nuclear localised protein; cancer; gene therapy; EST;

XX KM expressed sequence tag.

XX OS Homo sapiens.

XX PN WO200224738-A1.

```
XX 28-MAR-2002.
PD
XX
XX 19-SEP-2001; 2001WO-JP008140.
PF
XX 22-SEP-2000; 2000JP-00287876.
PR
XX (KYOW ) KYOWA HAKKO KOGYO KK.
PA
XX Akiyama T, Adachi S;
PI
XX WPI; 2002-330014/36.
DR
DR N-PSDB; ABK47638.
XX
PT New beta-catenin nuclear localized protein for diagnosis and treatment of
PT diseases associated with nuclear localization of beta-catenin e.g.
PT cancer.
XX
XX Claim 8; Page 102-105; 113pp; Japanese.
XX
CC The invention relates to a beta-catenin nuclear localised protein and DNA
CC encoding the protein. The protein and encoding DNA are applicable in
CC diagnosis and treatment of diseases associated with nuclear localisation
CC of beta-catenin e.g. cancer, including gene therapy. The present sequence
CC represents the amino acid sequence of human beta-catenin nuclear
CC localised protein #2
XX
SQ Sequence 738 AA;

Query Match          58.5%; Score 107; DB 5; Length 738;
Best Local Similarity 87.5%; Pred. No. 8e-06;
Matches 21; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 GLSQEQLEHRRERSLQTLRDIQRL 25
   |||:|||||:|||||:|:|
Db 1 GLSKQLEHRRERSLQTLRDIERLL 24

RESULT 11
AAB71230
ID AAB71230 standard; protein; 1115 AA.
XX
AC AAB71230;
XX
DT 18-NOV-2002 (first entry)
XX
DE Human legless homologue hlgs-1 partial protein.
XX
KW legless; human; lgs; Wnt/Wingless signaling pathway; Wnt; Wg;
KW tissue proliferation; tumour; cytosstatic; cellular disorder; colon;
KW blood disorder; cancer; breast; head and neck cancer; brain; thyroid;
KW medulloblastoma; skin cancer; tissue regeneration; tissue repair.
XX
OS Homo sapiens.
XX
PN US2002086986-A1.
XX
PD 04-JUL-2002.
XX
PF 27-JUL-2001; 2001US-00915543.
XX
PR 28-JUL-2000; 2000US-0221502P.
XX
PA (BASL/) BASLER K.
PA (BRUN/) BRUNNER E.
PA (FROE/) FROESCH B.
PA (GRAM/) KRAMPS T.
PA (PETE/) PETER O.
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;
XX
DR WPI; 2002-635689/68.
DR N-PSDB; AAF88468.
CC
```

```
XX
PT Novel polypeptide useful in therapeutic method for treating disorders of
PT cell fate such as cell differentiation or cell proliferation.
XX
XX Example II; Fig 10B; 41pp; English.
XX
CC This invention describes a novel polypeptide sharing one or more
CC homologous amino acid domains with the legless (lgs) protein, a
CC downstream component of the Wnt/Wingless (Wnt/Wg) signaling pathway
CC involved in the formation and maintenance of spatial arrangements and
CC proliferation of tissues during development, and in the formation and
CC growth of many human tumours. The products of the invention have
CC cytosstatic activity and can be used to treat cellular disorders, blood
CC disorders and cancers caused by over-stimulation of the Wnt pathway,
CC where the cancerous condition is colon, breast, head and neck, brain,
CC thyroid, medulloblastoma or skin cancer. The product could also be used
CC to promote tissue regeneration and repair. This sequence represents the
CC human legless (lgs) protein homologue hlgs-1 described in the disclosure
CC of the invention
XX
SQ Sequence 1115 AA;

Query Match          58.5%; Score 107; DB 5; Length 1115;
Best Local Similarity 87.5%; Pred. No. 1.3e-05;
Matches 21; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 GLSQEQLEHRRERSLQTLRDIQRL 25
   |||:|||||:|||||:|:|
Db 76 GLSKQLEHRRERSLQTLRDIERLL 99

RESULT 12
ABW01535
ID ABW01535 standard; protein; 1115 AA.
XX
AC ABW01535;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human lgs-1 protein.
XX
KW legless protein; lgs; cell fate disorder; blood disease; gene therapy;
KW cancer; tissue regeneration; tissue repair; cytosstatic.
XX
OS Homo sapiens.
XX
PN US2003114413-A1.
XX
PD 19-JUN-2003.
XX
PF 19-DEC-2002; 2002US-00322579.
XX
PR 28-JUL-2000; 2000US-0221502P.
PR 27-JUL-2001; 2001US-00915543.
XX
PA (UYZU-) UNIV ZURICH.
XX
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;
XX
DR WPI; 2003-839432/77.
DR N-PSDB; AAD62643.
XX
PT Novel lgs polypeptide useful for isolation of lgs-binding proteins,
PT diagnosing disorders of cell fate, treating diseases such as cancer.
XX
XX Claim 7; Fig 10B; opp; English.
XX
CC The invention relates to novel legless (lgs) proteins and polynucleotides
CC encoding such proteins. lgs sequences are useful for the treatment of
CC disorders of cell fate such as differentiation or proliferation. The
CC invention is used to treat blood disease or a cancerous condition
CC characterised by over-stimulation of the Wnt pathway such as colon,
CC breast, head and neck, brain, thyroid, medulloblastoma or skin cancer and
```

CC is administered to prevent progression from a pre-neoplastic or non-  
 CC malignant condition to a neoplastic or malignant state. It is  
 CC administered to promote tissue regeneration and repair. The invention is  
 CC also useful in the therapy of diseases cost by an over-activation of Wg  
 CC pathway. It is useful for reducing lgs gene expression in an invertebrate  
 CC or vertebrate organism or an invertebrate or vertebrate cell line. The  
 CC invention is also useful in gene therapy. The present sequence is human  
 CC lgs-1 protein used in the invention  
 XX  
 SQ Sequence 1115 AA;  
 Query Match 58.5%; Score 107; DB 7; Length 1115;  
 Best Local Similarity 87.5%; Pred. No. 1.3e-05;  
 Matches 21; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 OY 2 GLSQEQLEHRRERSLQTLRDIDRML 25  
 |||:|||||||:|||||||:|  
 DB 76 GLSQEQLEHRRERSLQTLRDIERLL 99  
 RESULT 13  
 ADJ71905  
 ID ADJ71905 standard; protein; 1115 AA.  
 XX  
 AC ADJ71905;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human Lgs/Bcl9 partial polypeptide.  
 XX  
 KM Human; legless; lgs; cell differentiation disorder;  
 KM cell proliferation disorder; cancer; Wnt pathway; medulloblastoma; colon;  
 KM breast; head; neck; brain; thyroid; skin; blood disease;  
 KM tissue regeneration; tissue repair; cytostatic; lgs/Bcl9.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004038901-A1.  
 XX  
 PD 26-FEB-2004.  
 XX  
 PF 22-SEP-2003; 2003US-00664859.  
 XX  
 PR 28-JUL-2000; 2000US-0221502P.  
 PR 27-JUL-2001; 2001US-00915543.  
 XX  
 PA (UYZU-) UNIV ZURICH.  
 XX  
 PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
 XX  
 DR WPI; 2004-203288/19.  
 DR N-PSDB; ADJ71904.  
 XX  
 PT Novel polypeptide sharing one or more homologue amino acid domains with  
 PT legless protein being functional homologue of Legless, useful for  
 PT diagnosing disorders of cell fate.  
 XX  
 PS Example 2; SEQ ID NO 17; 62pp; English.  
 XX  
 CC The invention relates to a polypeptide sharing one or more homologous  
 CC amino acid domains with a Legless (lgs) protein and is therefore a  
 CC functional homologue of lgs. The invention also relates to a nucleotide  
 CC sequence encoding a protein present in invertebrate and/or vertebrate  
 CC organisms, the nucleotide sequence encoding a protein comprising a  
 CC positive function in a regulatory pathway and the use of the polypeptide  
 CC for the isolation of lgs-binding proteins by carrying out an assay chosen  
 CC from an in vitro binding assay with such a peptide or a co-  
 CC immunoprecipitation from vertebrate or invertebrate cell lysates or a  
 CC mammalian or yeast two hybrid assay. The polypeptide and polynucleotide  
 CC are useful for treating disorders of cell fate, which involves  
 CC administering therapeutic compounds chosen from invertebrate and  
 CC vertebrate lgs protein homologues or fragments, antibodies, antibody  
 CC fragments, lgs antisense DNA, lgs antisense RNA, lgs double-stranded RNA,

CC small peptides or chemical and natural compounds being capable of  
 CC interfering with lgs function, synthesis and degradation. The disorders  
 CC are related to cell differentiation or cell proliferation. The compound  
 CC is administered to treat a cancerous condition by preventing progression  
 CC from a pre-neoplastic or non-malignant condition to a neoplastic or  
 CC malignant state. The cancerous condition is characterised by over-  
 CC stimulation of the Wnt pathway and is medulloblastoma or cancer of the  
 CC colon, breast, head and neck, brain, thyroid or skin. The therapeutic  
 CC compound may also be administered to a blood disease to promote tissue  
 CC regeneration and repair. This sequence represents a human Lgs/Bcl9  
 CC partial polypeptide of the invention.  
 XX  
 SQ Sequence 1115 AA;  
 Query Match 58.5%; Score 107; DB 8; Length 1115;  
 Best Local Similarity 87.5%; Pred. No. 1.3e-05;  
 Matches 21; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 OY 2 GLSQEQLEHRRERSLQTLRDIDRML 25  
 |||:|||||||:|||||||:|  
 DB 76 GLSQEQLEHRRERSLQTLRDIERLL 99  
 RESULT 14  
 ABW01529  
 ID ABW01529 standard; peptide; 35 AA.  
 XX  
 AC ABW01529;  
 XX  
 DT 15-JAN-2004 (first entry)  
 XX  
 DE Drosophila species legless (lgs) peptide #2.  
 XX  
 KM Legless protein; lgs; cell fate disorder; blood disease; gene therapy;  
 KM cancer; tissue regeneration; tissue repair; cytostatic.  
 XX  
 OS Drosophila sp.  
 XX  
 PN US2003114413-A1.  
 XX  
 PD 19-JUN-2003.  
 XX  
 PF 19-DEC-2002; 2002US-00322579.  
 XX  
 PR 28-JUL-2000; 2000US-0221502P.  
 PR 27-JUL-2001; 2001US-00915543.  
 XX  
 PA (UYZU-) UNIV ZURICH.  
 XX  
 PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
 XX  
 DR WPI; 2003-829432/77.  
 XX  
 PT Novel lgs polypeptide useful for isolation of lgs-binding proteins,  
 PT diagnosing disorders of cell fate, treating diseases such as cancer.  
 XX  
 PS Claim 28; Fig 7B; 0pp; English.  
 XX  
 CC The invention relates to novel legless (lgs) proteins and polynucleotides  
 CC encoding such proteins. Lgs sequences are useful for the treatment of  
 CC disorders of cell fate such as differentiation or proliferation. The  
 CC invention is used to treat blood disease or a cancerous condition  
 CC characterised by over-stimulation of the Wnt pathway such as colon,  
 CC breast, head and neck, brain, thyroid, medulloblastoma or skin cancer and  
 CC is administered to prevent progression from a pre-neoplastic or non-  
 CC malignant condition to a neoplastic or malignant state. It is  
 CC administered to promote tissue regeneration and repair. The invention is  
 CC also useful in the therapy of diseases cost by an over-activation of Wg  
 CC pathway. It is useful for reducing lgs gene expression in an invertebrate  
 CC or vertebrate organism or an invertebrate or vertebrate cell line. The  
 CC invention is also useful in gene therapy. The present sequence is  
 CC Drosophila species legless (lgs) peptide





ID	AAB71228	standard; protein; 1464 AA.
XX		
AC	AAB71228;	
XX		
DT	18-NOV-2002	(first entry)
XX		
DE	D. melanogaster lgs protein.	
KW	Legless; fruitfly; lgs; Wnt/Wingless signaling pathway; Wnt; Wg;	
KM	tissue proliferation; tumour; cyostatic; cellular disorder; colon;	
KW	blood disorder; cancer; breast; head and neck cancer; brain; thyroid;	
KM	medulloblastoma; skin cancer; tissue regeneration; tissue repair.	
XX		
OS	Drosophila melanogaster.	
XX		
PN	US2002086986-A1.	
PD		
XX	04-JUL-2002.	
PF	27-JUL-2001; 2001US-00915543.	
XX		
PR	28-JUL-2000; 2000US-0221502P.	
XX		
PA	(BASL/) BASLER K.	
PA	(BRUN/) BRUNNER E.	
PA	(FROE/) FROESCH B.	
PA	(KRAM/) KRAMPS T.	
PA	(PETE/) PETER O.	
PI	Basler K, Brunner E, Froesch B, Kramps T, Peter O,	
XX		
DR	WPI; 2002-635689/68.	
DR	N-PSDB; AAF88466.	
XX		
PT	Novel polypeptide useful in therapeutic method for treating disorders of	
cell fate such as cell differentiation or cell proliferation.		
Example II; Fig 2; 4lpp; English.		
XX		
CC	This invention describes a novel polypeptide sharing one or more	
CC	homologous amino acid domains with the legless (lgs) protein, a	
CC	downstream component of the Wnt/Wingless (Wnt/Wg) signaling pathway	
CC	involved in the formation and maintenance of spatial arrangements and	
CC	proliferation of tissues during development, and in the formation and	
CC	growth of many human tumours. The products of the invention have	
CC	cytostatic activity and can be used to treat cellular disorders, blood	
CC	disorders and cancers caused by over-stimulation of the Wnt pathway,	
CC	where the cancerous condition is colon, breast, head and neck, brain,	
CC	thyroid, medulloblastoma or skin cancer. The product could also be used	
CC	to promote tissue regeneration and repair. This sequence represents the	
CC	Drosophila melanogaster (fruitfly) legless (lgs) protein described in the	
CC	disclosure of the invention	
XX		
SQ	Sequence 1464 AA;	
Query Match	36.1%; Score 66; DB 5; Length 1464;	
Best Local Similarity	31.4%; Pred. No. 7.3;	
Matches 11; Conservative 10; Mismatches 14; Indels 0; Gaps 0;		
OY	1 DGLSQEQLEHRRSLQTLRDIDQMFPDEKEFTGA 35	
:	: ::     :::  :	
Db	515 ENLTPOQRQHREQLAKIKMNQFLPPENNSVGA 549	
RESULT 18		
ID	ABW01527 standard; protein; 1464 AA.	
AC	ABW01527;	
XX		
DT	15-JAN-2004 (first entry)	
XX		

DE	Drosophila species legless (lgs) protein.
KW	legless protein; lgs; cell fate disorder; blood disease; gene therapy;
KM	cancer; tissue regeneration; tissue repair; cytostatic.
OS	Drosophila sp.
PN	US2003114413-A1.
PD	19-JUN-2003.
XX	
PF	19-DEC-2002; 2002US-00322579.
XX	
PR	28-JUL-2000; 2000US-0221502P.
PR	27-JUL-2001; 2001US-00915543.
XX	
PA	(UYZU-) UNIV ZURICH.
XX	
PI	Basler K, Brunner E, Froesch B, Kramps T, Peter O;
XX	
DR	WPI; 2003-829432/77.
DR	N-PSDB; AAD62641.
XX	
PT	Novel Lgs polypeptide useful for isolation of lgs-binding proteins,
PT	diagnosing disorders of cell fate, treating diseases such as cancer.
XX	
PS	Claim 5; Fig 2; Opp; English.
XX	
CC	The invention relates to novel legless (lgs) proteins and polymucleotides
CC	encoding such proteins. Lgs sequences are useful for the treatment of
CC	disorders of cell fate such as differentiation or proliferation. The
CC	invention is used to treat blood disease or a cancerous condition
CC	characterised by over-stimulation of the Wnt pathway such as colon,
CC	breast, head and neck, brain, thyroid, medulloblastoma or skin cancer and
CC	is administered to prevent progression from a pre-neoplastic or non-
CC	malignant condition to a neoplastic or malignant state. It is
CC	administered to promote tissue regeneration and repair. The invention is
CC	also useful in the therapy of diseases cost by an over-activation of Wg
CC	pathway. It is useful for reducing lgs gene expression in an invertebrate
CC	or vertebrate organism or an invertebrate or vertebrate cell line. The
CC	invention is also useful in gene therapy. The present sequence is
CC	Drosophila species legless (lgs) protein
XX	
SQ	Sequence 1464 AA;
Query Match	36.1%; Score 66; DB 7; Length 1464;
Best Local Similarity	31.4%; Pred. No. 7.3;
Matches	11; Conservative 10; Mismatches 14; Indels 0; Gaps 0;
OY	1 DGLSQEQLHRRSLQTLRDIOQMFLPPDEKEFTGA 35 ::   ::   ::   ::   ::
Db	515 ENLTPQQRQHREEQLAKIKKMNQFLFPENENSVGA 549
RESULT 19	
ID	ADJ71911 standard; protein; 1464 AA.
XX	
AC	ADJ71911;
XX	
DT	20-MAY-2004 (first entry)
XX	
DE	Fruit fly legless (lgs) polypeptide.
XX	
KW	Fruit fly; legless; lgs; cell differentiation disorder;
KW	cell proliferation disorder; cancer; Wnt pathway; medulloblastoma; colon;
KW	breast; head; neck; brain; thyroid; skin; blood disease;
KW	tissue regeneration; tissue repair; cytosstatic.
XX	
OS	Drosophila melanogaster.
XX	
PN	US2004038901-A1.
XX	

PD 26-FEB-2004.  
XX  
XX 22-SEP-2003; 2003US-00664859.  
PF  
XX 28-JUL-2000; 2000US-0221502P.  
PR 27-JUL-2001; 2001US-00915543.  
XX  
XX (UYZU-) UNIV ZURICH.  
PA  
XX  
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
XX  
XX WPI; 2004-203288/19.  
DR  
DR N-PSDB; ADJ71889.  
XX  
XX Novel polypeptide sharing one or more homologue amino acid domains with  
PT Legless protein being functional homologue of Legless, useful for  
PT diagnosing disorders of cell fate.  
XX  
XX Example 2; SEQ ID NO 1; 62pp; English.  
PS  
XX The invention relates to a polypeptide sharing one or more homologous  
CC amino acid domains with a Legless (lgs) protein and is therefore a  
CC functional homologue of lgs. The invention also relates to a nucleotide  
CC sequence encoding a protein present in invertebrate and/or vertebrate  
CC organisms, the nucleotide sequence encoding a protein comprising a  
CC positive function in a regulatory pathway and the use of the polypeptide  
CC for the isolation of lgs-binding proteins by carrying out an assay chosen  
CC from an in vitro binding assay with such a peptide or a co-  
CC immunoprecipitation from vertebrate or invertebrate cell lysates or a  
CC mammalian or yeast two hybrid assay. The polypeptide and polynucleotide  
CC are useful for treating disorders of cell fate, which involves  
CC administering therapeutic compounds chosen from invertebrate and  
CC vertebrate lgs protein homologues or fragments, antibodies, antibody  
CC fragments, lgs antisense DNA, lgs antisense RNA, lgs double-stranded RNA,  
CC small peptides or chemical and natural compounds being capable of  
CC interfering with lgs function, synthesis and degradation. The disorders  
CC are related to cell differentiation or cell proliferation. The compound  
CC is administered to treat a cancerous condition by preventing progression  
CC from a pre-neoplastic or non-malignant condition to a neoplastic or  
CC malignant state. The cancerous condition is characterised by over-  
CC stimulation of the wnt pathway and is medulloblastoma or cancer of the  
CC colon, breast, head and neck, brain, thyroid or skin. The therapeutic  
CC compound may also be administered to a blood disease to promote tissue  
CC regeneration and repair. This sequence represents the Drosophila lgs  
CC polypeptide of the invention.  
XX  
XX  
SQ Sequence 1464 AA;  
Query Match 36.1%; Score 66; DB 8; Length 1464;  
Best Local Similarity 31.4%; Pred. No. 7.3;  
Matches 11; Conservative 10; Mismatches 14; Indels 0; Gaps 0;  
QY 1 DGLSQEQLHRRSLQTLRDIDQMLFPDEKEFTGA 35  
Db 515 ENLTPQQRHREEQIAKIKKMNQFLPENNSVGA 549  
RESULT 20  
ID ABP98879 standard; protein; 1014 AA.  
XX  
AC ABP98879;  
XX  
DT 24-JUL-2003 (first entry)  
XX  
XX Human molecule for disease detection and treatment MDDT-7.  
DE  
XX Cytostatic; antiarteriosclerotic; anti-HIV; antiallergic; nephrotropic;  
KW antithyroid; cerebroprotective; antiparkinsonian; anticonvulsant; MDDT;  
KW nootropic; neuroprotective; antidiabetic; gene therapy; atherosclerosis;  
KW molecule for disease detection and treatment; cancer; AIDS; allergy;  
KW diabetes; glomerulonephritis; autoimmune thyroiditis; Cushing's syndrome;  
KW stroke; Parkinson's disease; epilepsy.

XX  
OS Homo sapiens.  
XX  
PN WO2003031595-A2.  
XX  
PD 17-APR-2003.  
XX  
PF 10-OCT-2002; 2002WO-US032852.  
XX  
PR 12-OCT-2001; 2001US-0328944P.  
PR 26-OCT-2001; 2001US-0345384P.  
PR 02-NOV-2001; 2001US-0343880P.  
PR 09-NOV-2001; 2001US-0345143P.  
PR 16-NOV-2001; 2001US-0332430P.  
XX  
PA (INCY-) INCYTE GENOMICS INC.  
XX  
PI Tang YT, Forsythe IJ, Emerling BM, Hafalia AJA, Yue H, Xu Y;  
PI Gietzen KJ, Chawla NK, Baughn MR, Marguis JP, Becha SD, Kabie AE;  
PI Lal PG, Richardson TW, Lee SY, Lee EA, Tran B, Warren BA, Lu DAM;  
PI Gururajan R, Sprague WW, Blake JJ, Thangavelu K, Swarnakar A;  
PI Gorvad AE, Griffin JA, Lindquist EA, Elliott VS, Ison CH;  
PI Ramkumar J;  
XX  
XX WPI; 2003-421277/39.  
DR  
DR N-PSDB; ACC44394.  
XX  
PT Isolated peptide molecules for disease detection and treatment, useful  
PT for diagnosing, treating or preventing disorders, e.g. cancer, AIDS,  
PT atherosclerosis, diabetes or stroke.  
XX  
XX Claim 1; Page 151-153; 234pp; English.  
PS  
XX The invention relates to the isolation of a number of "molecules for  
CC disease detection and treatment" (MDDT) and genes encoding them. The  
CC invention also includes molecule which are at least 90% identical to the  
CC protein and nucleotide sequences. This sequence represents a protein of  
CC the invention. Disorders associated with aberrant expression of MDDT, are  
CC cell proliferative disorders (e.g. cancer or atherosclerosis),  
CC autoimmune/inflammatory disorders (e.g. AIDS, allergies, diabetes,  
CC glomerulonephritis or autoimmune thyroiditis), developmental disorders  
CC (e.g. Cushing's syndrome) or neurological disorders (e.g. stroke,  
CC Parkinson's disease or epilepsy)  
XX  
XX  
SQ Sequence 1014 AA;  
Query Match 33.6%; Score 61.5; DB 6; Length 1014;  
Best Local Similarity 44.8%; Pred. No. 20;  
Matches 13; Conservative 10; Mismatches 5; Indels 1; Gaps 1;  
QY 8 LEHRRSLQTLRDIDQMLFPDEKEFTGAQ 36  
Db 51 VGHKDRTM-NLQDIRYILKNDLKDFTTGAQ 78  
RESULT 21  
ID ABJ25853 standard; protein; 603 AA.  
XX  
AC ABJ25853;  
XX  
DT 16-APR-2003 (first entry)  
XX  
XX Aspergillus fumigatus essential gene protein #511.  
DE  
XX Fungicide; cytostatic; essential gene; Aspergillus fumigatus; infection;  
KW cancer; contamination; biofilm; antibody; immune response.  
XX  
OS Aspergillus fumigatus.  
XX  
PN WO200286090-A2.  
XX  
PD 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013142.  
XX  
XX 23-APR-2001; 2001US-0285697P.  
PR 27-APR-2001; 2001US-0287066P.  
PR 05-JUN-2001; 2001US-0295890P.  
PR 09-JUL-2001; 2001US-0303899P.  
PR 31-AUG-2001; 2001US-0316362P.  
XX  
PA (ELIT-) ELITRA PHARM INC.  
XX  
PI Jiang B, Tishkoff D, Zamudio C, Eroshkin AM, Hu W, Lemieux SM;  
XX  
DR WPI; 2003-093124/08.  
XX  
PT New purified or isolated nucleic acids of essential genes of Aspergillus  
PT fumigatus, useful for treating or preventing infections by A. fumigatus,  
PT or for treating a non-infectious disease in a subject e.g. cancer.  
XX  
XX  
PS Disclosure; Page; 175pp; English.  
CC The invention relates to novel purified or isolated nucleic acids of  
CC essential genes of Aspergillus fumigatus. The isolated nucleic acids of  
CC the invention are used to treat or prevent infections by a pathogenic  
CC organism such as A. fumigatus, to treat a non-infectious disease in a  
CC subject (e.g. cancer), to prevent or contain contamination of an object  
CC by A. fumigatus, or to prevent or inhibit formation on a surface of a  
CC biofilm comprising A. fumigatus. The polynucleotides are useful for  
CC expressing recombinant protein for characterisation, screening or  
CC therapeutic use, as markers for host tissues in which the pathogenic  
CC organisms invade or reside, for comparing with the DNA sequence of A.  
CC fumigatus to identify duplicated genes or paralogues having the same or  
CC similar biochemical activity and/or function, for comparing with DNA  
CC sequences of other related or distant pathogenic organisms to identify  
CC potential orthologous essential or virulence genes, for selecting and  
CC making oligomers for attachment to a nucleic acid array for examination  
CC of expression patterns, for raising anti-protein antibodies, as an  
CC antigen to raise anti-DNA antibodies or to elicit another immune  
CC response, and for identifying polynucleotides encoding the other protein  
CC with which binding occurs or to identify inhibitors of the binding  
CC interaction. The polypeptides may be used to raise antibodies or to  
CC elicit immune response, as a reagent in assays designed to quantitatively  
CC determine levels of the protein in biological fluids, as a marker for  
CC host tissues in which pathogenic organism invade or reside, and to  
CC isolate correlative receptors or ligands in the case of virulence  
CC factors. This sequence represents a protein of one of the essential genes  
CC of Aspergillus fumigatus of the invention  
XX  
SQ Sequence 603 AA;  
QY  
Query Match 31.4%; Score 57.5; DB 6; Length 603;  
Best Local Similarity 31.4%; Pred. No. 41;  
Matches 11; Conservative 11; Mismatches 10; Indels 3; Gaps 1;  
Db 1 DGLSQEQLHRRERSLQTLRDIQRLFPDEKEFTGA 35  
45 DGVETEKIREKD--EVEKKLERMLFGDDGEGFVGA 76  
RESULT 22  
ABU26453  
ID ABU26453 standard; protein; 618 AA.  
XX  
AC ABU26453;  
XX  
DT 16-APR-2003 (first entry)  
XX  
DE Aspergillus fumigatus essential gene protein #1111.  
XX  
KW Fungicide; cytostatic; essential gene; Aspergillus fumigatus; infection;  
XX cancer; contamination; biofilm; antibody; immune response.  
OS Aspergillus fumigatus.

XX  
PN WO200286090-A2.  
XX  
XX 31-OCT-2002.  
XX  
XX 23-APR-2002; 2002WO-US013142.  
XX  
XX 23-APR-2001; 2001US-0285697P.  
PR 27-APR-2001; 2001US-0287066P.  
PR 05-JUN-2001; 2001US-0295890P.  
PR 09-JUL-2001; 2001US-0303899P.  
PR 31-AUG-2001; 2001US-0316362P.  
XX  
PA (ELIT-) ELITRA PHARM INC.  
XX  
PI Jiang B, Tishkoff D, Zamudio C, Eroshkin AM, Hu W, Lemieux SM;  
XX  
DR WPI; 2003-093124/08.  
XX  
PT New purified or isolated nucleic acids of essential genes of Aspergillus  
PT fumigatus, useful for treating or preventing infections by A. fumigatus,  
PT or for treating a non-infectious disease in a subject e.g. cancer.  
XX  
XX  
PS Disclosure; Page; 175pp; English.  
CC The invention relates to novel purified or isolated nucleic acids of  
CC essential genes of Aspergillus fumigatus. The isolated nucleic acids of  
CC the invention are used to treat or prevent infections by a pathogenic  
CC organism such as A. fumigatus, to treat a non-infectious disease in a  
CC subject (e.g. cancer), to prevent or contain contamination of an object  
CC by A. fumigatus, or to prevent or inhibit formation on a surface of a  
CC biofilm comprising A. fumigatus. The polynucleotides are useful for  
CC expressing recombinant protein for characterisation, screening or  
CC therapeutic use, as markers for host tissues in which the pathogenic  
CC organisms invade or reside, for comparing with the DNA sequence of A.  
CC fumigatus to identify duplicated genes or paralogues having the same or  
CC similar biochemical activity and/or function, for comparing with DNA  
CC sequences of other related or distant pathogenic organisms to identify  
CC potential orthologous essential or virulence genes, for selecting and  
CC making oligomers for attachment to a nucleic acid array for examination  
CC of expression patterns, for raising anti-protein antibodies, as an  
CC antigen to raise anti-DNA antibodies or to elicit another immune  
CC response, and for identifying polynucleotides encoding the other protein  
CC with which binding occurs or to identify inhibitors of the binding  
CC interaction. The polypeptides may be used to raise antibodies or to  
CC elicit immune response, as a reagent in assays designed to quantitatively  
CC determine levels of the protein in biological fluids, as a marker for  
CC host tissues in which pathogenic organism invade or reside, and to  
CC isolate correlative receptors or ligands in the case of virulence  
CC factors. This sequence represents a protein of one of the essential genes  
CC of Aspergillus fumigatus of the invention  
XX  
SQ Sequence 618 AA;  
QY  
Query Match 31.4%; Score 57.5; DB 6; Length 618;  
Best Local Similarity 31.4%; Pred. No. 42;  
Matches 11; Conservative 11; Mismatches 10; Indels 3; Gaps 1;  
Db 1 DGLSQEQLHRRERSLQTLRDIQRLFPDEKEFTGA 35  
45 DGVETEKIREKD--EVEKKLERMLFGDDGEGFVGA 76  
RESULT 23  
ABU44941  
ID ABU44941 standard; protein; 411 AA.  
XX  
AC ABU44941;  
XX  
DT 19-JUN-2003 (first entry)  
XX  
DE Protein encoded by Prokaryotic essential gene #30468.  
XX

**KW** Antisense; prokaryotic essential gene; cell proliferation; drug design..

OS *Salmonella paratyphi*.

PN WO200277183-A2.

PD 03-OCT-2002.

PF 21-MAR-2002; 2002WO-US009107.

PR 21-MAR-2001; 2001US-00815242.

PR 25-OCT-2001; 2001US-0342923P.

PR 06-MAR-2002; 2002US-0362699P.

PA (ELIT-) ELITRA PHARM INC.

PI Wang L, Zamudio C, Malone C

XX

DR N-PSDB; ACA48811.

PT New antisense nucleic acids,

PT isolate candidate molecules f

PS Claim 25; SEQ ID NO 72865; 17

CC The invention relates to an i

CC of the nucleic acid inhibits

Sequence 411 AA;

Query Match	31.18;
-------------	--------

Matches 12; Conservative 6

QY 3 LSQEQLEHRESLQTLRDIQ

## RESULT 24

ABU4 / 461  
ID ABU4

AC ABU47461;

DT 19-JUN-2003 (first entry)

DE Protein encoded by Prokaryotic essential gene #32988.

**KW** Antisense; prokaryotic essential gene; cell proliferation; drug design.

05 Salmomella typhi.

PN WO200277183-A2.

03-OCT-2002.

21-MAR-2002; 2002WO-US009107.

21-MAR-2001; 2001US-00815242.

PR 25-OCT-2001; 2001US-0342923P.

PR 06-MAR-2002; 2002US-0362699P.

PA (ELIT-) ELITRA PHARM INC.

PI Wang L, Zamudio C, Malone C

xx

DR N-PSDB; ACA51331.

PT New antisense nucleic acids,

PT isolate candidate molecules

PS Claim 25; SEQ ID NO 75385; 1766pp; English.

CC The invention relates to an isolated nucleic

CC of the nucleic acid inhibits

Sequence 1034 AA;  
SQ

<b>Query Match</b>	<b>31.1%;</b>	<b>Score 57;</b>	<b>DB 6;</b>	<b>Length 1034;</b>
<b>Best Local Similarity</b>	<b>42.9%;</b>	<b>Pred. NO. 86;</b>		
<b>Matches 12; Conservative</b>	<b>6;</b>	<b>Mismatches 10;</b>	<b>Indels 0;</b>	<b>Gaps 0;</b>

  

<b>QY</b>	<b>3</b>	<b>LSQEQLHRRERSLQTLRDIOQMFLPDEK</b>	<b>30</b>
	:     :	:	: :
<b>Db</b>	<b>213</b>	<b>LADQQLQLEASLQALTDEEKRLIADQQ</b>	<b>240</b>

RESULT 25  
ADP04653  
ID ADP04653 standard; protein; 425 AA.

AC	ADP04653;
XX	
DT	29-JUL-2004 (first entry)
XX	
DE	Sea squirt protein with tissue specific expression in development Seq248.

KW sea squirt; regeneration medicine; gene therapy; cell proliferation;  
KW differentiation; reproduction; environmental measurement; water survey.  
XX  
OS *Ciona intestinalis*.

PN JP2004057129-A.

PD 26-FEB-2004.

PF 31-JUL-2002; 2002JP-00222593.

PR 31-JUL-2002; 2002JP-00222593.

PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

DR WPI; 2004-287079/27.

DR N-PSDB; ADP04652.

PT Novel gene cluster which is specifically expressed in tissue or organ during developmental phase of sea squirt, useful for elucidation of mechanism of development of tissue or organ of sea squirt.

PS Claim 1; SEQ ID NO 248; 1846bp; Japanese.

This invention relates to novel genes and the encoded proteins thereof that are derived from the sea squirt *Ciona intestinalis*. Specifically, it refers to those genes that are expressed in the tissues or organs of the sea squirt during its developmental phase. The present invention describes the identification of these genes as useful for elucidation of the mechanism of development and hence for developing regeneration medicines and gene therapy techniques. Accordingly, they can be used in the research of various genetic diseases, as well as the analysis of cell proliferation, differentiation and reproduction. Furthermore, such compositions can be useful for environmental measurements and water surveys, particularly for sea water surveys, and also for the preparation of transformed sea squirt for improving edibility of sea squirt such as *Halocynthia roretzi*. This polypeptide sequence is a sea squirt protein sequence that has tissue specific expression during development, given in an exemplification of the invention.

**SQ** Sequence 425 AA;

```

Query Match      30.6%; Score 56; DB 8; Length 425;
Best Local Similarity 36.4%; Pred. No. 44;
Matches 12; Conservative 9; Mismatches 8; Indels 4; Gaps 1;

QY      3 LSOEQLHRRERSLQTLR----DIQRLMFPDEKE 31
      ::||:::|||::|::|::|::|::|::|::|
Db      391 MAQEEILRKERELQAROKLAQIRRMRYKDDSE 423

```

RESULT 26  
ABR53351

ID ABR53351 standard; protein; 584 AA.

AC ABR53351;

DT 20-JUN-2003 (first entry)

DE Protein sequence #SEQ ID 1567.

KW Multiprotein complex; eukaryote; drug target; diagnosis.

OS *Saccharomyces cerevisiae*.

PN EP1258494-A1

PD 20-NOV-2002.

PF 20-DEC-2001; 2001EP-00130253.

PR 15-MAY-2001; 2001EP-00111774.

PA (CELL-) CELLZONE AG.

PI Bauer A, Grandi P, Krause R, Kruse UD, Kuester BD;

PI Marzioch M, Schultz JD, Superti-Furga GD; 1

DR WPI; 2003-250078/25.

XX

disorder, or as a target for an active agent of a pharmaceutical,

PT disorder.

PS Disclosure; SEQ ID NO 1567; 17pp + Sequence Listing; English.

The invention relates to multiprotein complexes from eukaryotes. Proteins of the invention and DNA sequences encoding them are given in records ABR52568-ABR53903 and ACC60610-ACC61944 respectively. The complexes are obtainable by using a protein as a bait and isolating the set of proteins which is attached thereto from cells. Such protein complexes may comprise up to 30 distinct proteins. Protein complexes of the invention are useful for diagnosing a disease or disorder, or as a target for an active agent of a pharmaceutical, preferably a drug target in the treatment or prevention of a disease or disorder. Note: The sequence data for this patent is not represented in the printed specification, but is based on sequence information supplied by the European Patent Office. The complete document is available on CD-ROM

**SQ Sequence 584 AA;**

Query Match	30.6%;	Score 56;	DB 6;	Length 584;
Best Local Similarity	36.0%;	Pred. No. 63;		
Matches	9;	Conservative 10;	Mismatches 6;	Indels 0;
			Gaps 0;	
QY	4	SOEQLHRRERSLQTLRDIQRMLFPD	28	
	: : : : : : : : : :			
Db	193	SREIEIIRNQITISTIREAVKOLMPD	217	

ADK63408

XX

AC ADK63408;

DT 06-MAY-2004 (first entry)

DE Disease treating protein complex-derived protein #949.

KW protein complex; drug target; diagnosis.

OS Unidentified.



PN EP1338608-A2.  
XX  
XX 27-AUG-2003.  
XX  
XX 20-DEC-2002; 2002EP-00102902.  
XX  
XX 20-DEC-2001; 2001EP-00130253.  
XX  
XX (CELL-) CELLZOME AG.  
XX  
PI Bauer A, Gavin A, Superti-Furga G, Kuester B, Schultz J;  
PI Marzioch M, Grandi P, Krause R, Kruse U, Merino A, Bauch A;  
PI Michon A, Leutwein C, Rick J;  
XX  
XX WPI; 2003-638460/61.  
DR N-PSDB; ADK63409.  
XX  
PT New proteins and protein complexes from eukaryotes, useful as targets in  
PT drug screening, or in diagnosing or screening for the presence of a  
PT disease or disorder, or a predisposition for developing a disease or  
PT disorder in a subject.  
XX  
XX  
PS Disclosure; SEQ ID NO 1897; 13pp; English.  
XX  
XX The invention relates to novel protein complexes comprising a first and a  
XX second protein, or its derivative, fragment, homologue or variant. The  
XX proteins are selected from given protein complexes, which are not defined  
XX in the specification. The variants are encoded by nucleic acids that  
XX hybridize to the nucleic acids encoding the proteins under low stringency  
XX conditions. The protein complexes are useful as targets for an active  
XX agent of a pharmaceutical. These protein complexes are particularly  
XX useful as drugs targets for the treatment or preventing of a disease or  
XX disorder. The complexes and methods above are useful in diagnosing or  
XX screening for the presence of a disease or disorder in a predisposition  
XX for developing a disease or disorder in a subject. These are also useful  
XX in screening for a drug for treatment or prevention of a disease or  
XX disorder. The molecule that modulates the amount, activity or protein  
XX components of the complex is useful for the manufacture of a medicament  
XX for the treatment or prevention of a disease or disorder. This sequence  
XX corresponds to a protein of the invention. (Note: the sequence data for  
XX this patent did not form part of the printed specification but was  
XX obtained from the EPO in electronic format).  
SQ Sequence 584 AA;  
QY  
Query Match 30.6%; Score 56; DB 7; Length 584;  
Best Local Similarity 36.0%; Pred. No. 63;  
Matches 9; Conservative 10; Mismatches 6; Indels 0; Gaps 0;  
DB 4 SEQLEHRSLSQTLRDIGRLFPD 28  
193 SREEIERNQISTIREAVKQLMPD 217  
RESULT 28  
ADN19362  
ID ADN19362 standard; protein; 584 AA.  
XX  
XX ADN19362;  
AC  
XX  
XX 02-DEC-2004 (first entry)  
DT  
XX  
XX Bacterial polypeptide #2015.  
DE  
XX  
XX Recombinant DNA construct; transformed plant; improved plant property;  
KW cold tolerance; heat tolerance; drought tolerance; herbicide; osmosis;  
KW pathogen tolerance; pest tolerance; plant disease resistance;  
KW cell cycle pathway modification; plant growth regulator;  
KW homologous recombination; seed oil yield; protein yield; carbohydrate;  
KW nitrogen; phosphorus; photosynthesis; lignin; galactomannan;  
KW bacterial polypeptide.  
XX  
XX Bacteria.  
OS

XX  
XX US2003233675-A1.  
PN  
XX  
XX 18-DEC-2003.  
PD  
XX  
XX 20-FEB-2003; 2003US-00369493.  
PF  
XX  
XX 21-FEB-2002; 2002US-0360039P.  
PR  
XX  
XX (CAOY/) CAO Y.  
PA (HINK/) HINKLE G J.  
PA (SLAT/) SLATER S C.  
PA (CHEN/) CHEN X.  
PA (GOLD/) GOLDMAN B S.  
XX  
XX Cao Y, Hinkle GJ, Slater SC, Chen X, Goldman BS;  
PI  
XX  
XX WPI; 2004-061375/06.  
DR  
XX  
XX  
PT New recombinant DNA construct comprising a promoter positioned to provide  
PT for expression of a polynucleotide encoding a polypeptide from a  
PT microbial source, useful for producing plants with improved properties.  
XX  
XX  
PS Claim 1; SEQ ID NO 2015; 122pp; English.  
XX  
XX The invention relates to a recombinant DNA construct comprising a  
XX promoter functional in a plant cell, where the promoter is positioned to  
XX provide for expression of a polynucleotide encoding a polypeptide from a  
XX microbial source. The invention also relates to a transformed plant  
XX comprising the recombinant DNA construct and a method of producing a  
XX transformed plant having an improved property. The plant is a crop plant  
XX such as maize or soybean. The method of producing a transformed plant  
XX having an improved property comprises transforming a plant with the  
XX recombinant DNA construct and growing the transformed plant, where the  
XX polynucleotide or polypeptide is useful for improving plant properties.  
XX The recombinant DNA construct is useful for producing plants with  
XX improved plant properties, e.g. improved cold, heat or drought tolerance,  
XX tolerance to herbicides, extreme osmotic conditions, pathogens or pests,  
XX increased resistance to plant disease, better growth rate by modification  
XX of the cell cycle pathway with plant growth regulators, increased rate of  
XX homologous recombination, modified seed oil or protein yield and/or  
XX content, improved yield by modification of carbohydrate, nitrogen or  
XX phosphorus use and/or uptake, by modification of photosynthesis or by  
XX providing improved plant growth and development under at least one stress  
XX condition, improved lignin production or improved galactomannan  
XX production. This sequence represents a bacterial polypeptide used in the  
XX scope of the invention. Note: The sequence data for this patent did not  
XX form part of the printed specification but was obtained in electronic  
XX format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
SQ Sequence 584 AA;  
QY  
Query Match 30.6%; Score 56; DB 8; Length 584;  
Best Local Similarity 36.0%; Pred. No. 63;  
Matches 9; Conservative 10; Mismatches 6; Indels 0; Gaps 0;  
DB 4 SEQLEHRSLSQTLRDIGRLFPD 28  
193 SREEIERNQISTIREAVKQLMPD 217  
RESULT 29  
ADM26229  
ID ADM26229 standard; protein; 818 AA.  
XX  
XX ADM26229;  
AC  
XX  
XX 20-MAY-2004 (first entry)  
DT  
XX  
XX Hyperthermophile Methanopyrus kandleri protein #835.  
DE  
XX  
XX hyperthermophile; protein stability enhancement;  
KW protein activity enhancement.  
KW



XX OS Methanopyrus kandleri.  
XX PN WO2003076575-A2.  
XX PD 18-SEP-2003.  
XX PF 04-MAR-2003; 2003WO-US006664.  
XX PR 04-MAR-2002; 2002US-0361742P.  
XX PR 14-MAY-2002; 2002US-0380423P.  
XX PR 16-SEP-2002; 2002US-0410974P.  
XX PA (FIDE-) FIDELITY SYSTEMS INC.  
XX PA (MALY/) MALYKH A.  
XX PI Slesarev AI, Pavlov A, Pavlova N, Koz'yavkin S;  
XX DR WPI, 2003-748383/70.  
XX DR N-PSDB; ADM27081.  
XX PT New isolated nucleic acids encoding any of about 1700 Methanopyrus  
XX PT kandleri proteins, and the encoded proteins, useful as a medicaments or  
XX PT as diagnostic agents.  
XX PS Claim 31; SEQ ID NO 835; 1023pp; English.  
XX CC The invention comprises the amino acid sequence of proteins from the  
XX CC hyperthermophile Methanopyrus kandleri, the invention also comprises the  
XX CC complete genome from Methanopyrus kandleri. The Methanopyrus kandleri  
XX CC proteins of the invention are useful for enhancing the stability and/or  
XX CC activity of other proteins. The Methanopyrus kandleri genome is useful in  
XX CC a variety of diagnostic and analytical methods. The present amino acid  
XX CC sequence represents a Methanopyrus kandleri protein of the invention.  
XX SQ Sequence 818 AA;  
QY Query Match 30.6%; Score 56; DB 7; Length 818;  
Best Local Similarity 42.9%; Pred. No. 91;  
Matches 15; Conservative 4; Mismatches 16; Indels 0; Gaps 0;  
Db 2 GLSQQLHRRSLQTLRDIQRLFPDEKEFTGAQ 36  
134 GFSQTLLEKLERLLHELRLDIDRVEMVDPAPDPAE 168  
RESULT 30  
ADL83239  
ID ADL83239 standard; protein; 1132 AA.  
XX AC ADL83239;  
XX DT 17-JUN-2004 (first entry)  
XX DE Human PRO84721, SEQ ID 441.  
XX KW Immunosuppressive; Cytostatic; Antiarthritic; Antirheumatic; Antianemic;  
KW Antiallergic; Muscular; Neuroprotective; Nephrotropic; Antiinflammatory;  
KW Gene Therapy; PRO; B cell related disorder; cancer;  
KW Immune-mediated inflammatory disease; human.  
XX OS Homo sapiens.  
XX PN WO2004024097-A2.  
XX PD 25-MAR-2004.  
XX PF 15-SEP-2003; 2003WO-US029097.  
XX PR 16-SEP-2002; 2002US-0411392P.  
XX PA (GETH ) GENENTECH INC.  
XX

PI Chiu H, Clark H, Dennis K, Fong S, Schoenfeld JR, Wood WI;  
PI Wu TD;  
XX DR WPI; 2004-329389/30.  
XX DR N-PSDB; ADL83238.  
XX PT New PRO polypeptide, useful for diagnosing and treating a B cell related  
XX PT disorder, e.g. Burkitt's lymphoma, rheumatoid arthritis, autoimmune  
XX PT mediated hemolytic anemia, myasthenia gravis or ankylosing spondylitis.  
XX PS Claim 10; Fig 441; 695pp; English.  
XX CC The present invention relates to PRO proteins and their coding sequences.  
XX CC The PRO proteins are useful for diagnosing and treating a B cell related  
XX CC disorder, e.g. X-linked infantile hypogammaglobulinemia, polysaccharide  
XX CC antigen unresponsiveness, selective IGA deficiency, selective IGM  
XX CC deficiency, selective deficiency of IgG subclasses, immunodeficiency with  
XX CC hyper IGM, transient hypogammaglobulinemia of infancy, Burkitt's  
XX CC lymphoma, intermediate lymphoma, follicular lymphoma, type II  
XX CC hypersensitivity, rheumatoid arthritis, autoimmune mediated haemolytic  
XX CC anaemia, myasthenia gravis, hypoadrenocorticism, glomerulonephritis, or  
XX CC ankylosing spondylitis. The PRO proteins are also useful for preparing a  
XX CC medicament for treating a condition that is responsive to the PRO  
XX CC protein, e.g. cancer or immune-mediated inflammatory diseases. The PRO  
XX CC coding sequences are useful as hybridization probes in chromosome and  
XX CC gene mapping, in preparing PRO proteins, or in generating transgenic  
XX CC animals or knockout animals, which in turn are useful in the development  
XX CC and screening of therapeutically useful reagents.  
XX SQ Sequence 1132 AA;  
QY Query Match 30.6%; Score 56; DB 8; Length 1132;  
Best Local Similarity 33.3%; Pred. No. 1.3e+02;  
Matches 10; Conservative 8; Mismatches 12; Indels 0; Gaps 0;  
Db 5 QEQLEHRRSLQTLRDIQRLFPDEKEFTG 34  
590 ENQRSHQELISQLQSYMKLLPDPDEKEFHG 619  
RESULT 31  
ADQ17519  
ID ADQ17519 standard; protein; 1132 AA.  
XX AC ADQ17519;  
XX DT 26-AUG-2004 (first entry)  
XX DE Human soft tissue sarcoma-upregulated protein - SEQ ID 336.  
XX KW soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human.  
XX OS Homo sapiens.  
XX PN WO2004048938-A2.  
XX PD 10-JUN-2004.  
XX PF 26-NOV-2003; 2003WO-US038193.  
XX PR 26-NOV-2002; 2002US-0429739P.  
XX PA (PROT-) PROTEIN DESIGN LABS INC.  
XX PI Aziz N, Ginsburg WM, Zlotnik A;  
XX DR WPI, 2004-441208/41.  
XX PT Early detection of soft tissue sarcoma comprises determining expression  
XX PT of a gene in a first soft tissue sample and a normal soft tissue sample  
XX PT and comparing the gene expression, also useful in treating soft tissue  
XX PT sarcoma.  
XX

PS Example 2; SEQ ID NO 336; 210pp; English.  
 CC The invention relates to a novel method for detecting soft tissue sarcoma  
 CC which comprises obtaining a first soft tissue sample from an individual  
 CC and a normal soft tissue sample from the same or different individual,  
 CC determining the expression of a gene in both samples and comparing the  
 CC expression of the gene in both soft tissue samples, where a higher level  
 CC of protein expression in the first soft tissue sample indicates the  
 CC presence of soft tissue sarcoma. The method of the invention has  
 CC cytostatic applications and may be useful for detecting soft tissue  
 CC sarcoma, possibly via gene therapy or vaccine production. The nucleic  
 CC acid sequences may be useful in diagnostic and screening applications.  
 CC The current sequence is that of a human soft tissue sarcoma-upregulated  
 CC protein of the invention. The current sequence is not shown within the  
 CC specification per se but was submitted in CD format by the inventor.  
 XX  
 SQ Sequence 1132 AA;  
 Query Match 30.6%; Score 56; DB 8; Length 1132;  
 Best Local Similarity 33.3%; Pred. No. 1.3e+02;  
 Matches 10; Conservative 8; Mismatches 12; Indels 0; Gaps 0;  
 QY 5 QEQLEHRRERSLQTLRDIQRLFPDEKEFTG 34  
 Db 590 ENQRSHQELISQLQSYMKLLPDPDEKFG 619  
 RESULT 32  
 ABB63502  
 ID ABB63502 standard; protein; 1294 AA.  
 XX  
 AC ABB63502;  
 XX  
 DT 26-MAR-2002 (first entry)  
 XX  
 DE Drosophila melanogaster polypeptide SEQ ID NO 17298.  
 XX  
 KW Drosophila; developmental biology; cell signalling; insecticide;  
 KW pharmaceutical.  
 XX  
 OS Drosophila melanogaster.  
 XX  
 PN WO200171042-A2.  
 XX  
 PD 27-SEP-2001.  
 XX  
 PF 23-MAR-2001; 2001WO-US009231.  
 XX  
 PR 23-MAR-2000; 2000US-0191637P.  
 PR 11-JUL-2000; 2000US-00614150.  
 XX  
 PA (PEKE ) PE CORP NY.  
 XX  
 PI Venter JC, Adams M, Li PWD, Myers EW;  
 XX  
 DR WPI; 2001-656860/75.  
 DR N-PSDB; ABL07605.  
 XX  
 PT New isolated nucleic acid detection reagent for detecting 1000 or more  
 PT genes from Drosophila and for elucidating cell signaling and cell-cell  
 PT interactions.  
 XX  
 PS Disclosure; SEQ ID NO 17298; 21pp + Sequence Listing; English.  
 XX  
 CC The invention relates to an isolated nucleic acid detection reagent  
 CC capable of detecting 1000 or more genes from Drosophila. The invention is  
 CC useful in developmental biology and in elucidating cell signaling and  
 CC cell-cell interactions in higher eukaryotes for the development of  
 CC insecticides, therapeutics and pharmaceutical drugs. The invention  
 CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA  
 CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-  
 CC ABB72072). The sequence data for this patent did not form part of the  
 CC printed specification, but was obtained in electronic format directly

CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 1294 AA;  
 Query Match 30.6%; Score 56; DB 4; Length 1294;  
 Best Local Similarity 45.5%; Pred. No. 1.5e+02;  
 Matches 10; Conservative 6; Mismatches 6; Indels 0; Gaps 0;  
 QY 3 LSQEQLEHRRERSLQTLRDIQRM 24  
 Db 897 LQQQQAESQEQASTLRDLRL 918  
 RESULT 33  
 ABU17570  
 ID ABU17570 standard; protein; 757 AA.  
 XX  
 AC ABU17570;  
 XX  
 DT 19-JUN-2003 (first entry)  
 XX  
 DE Protein encoded by Prokaryotic essential gene #3097.  
 XX  
 KW Antisense; prokaryotic essential gene; cell proliferation; drug design.  
 XX  
 OS Bacillus anthracis.  
 XX  
 PN WO200277183-A2.  
 XX  
 PD 03-OCT-2002.  
 XX  
 PF 21-MAR-2002; 2002WO-US009107.  
 XX  
 PR 21-MAR-2001; 2001US-00815242.  
 PR 06-SEP-2001; 2001US-00948993.  
 PR 25-OCT-2001; 2001US-0342923P.  
 PR 08-FEB-2002; 2002US-00072851.  
 PR 06-MAR-2002; 2002US-0362699P.  
 XX  
 PA (ELIT-) ELITRA PHARM INC.  
 XX  
 PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;  
 PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH;  
 XX  
 DR WPI; 2003-029926/02.  
 DR N-PSDB; ACA21440.  
 XX  
 PT New antisense nucleic acids, useful for identifying proteins or screening  
 PT for homologous nucleic acids required for cellular proliferation to  
 PT isolate candidate molecules for rational drug discovery programs.  
 XX  
 PS Claim 25; SEQ ID NO 45494; 1766pp; English.  
 XX  
 CC The invention relates to an isolated nucleic acid comprising any one of  
 CC the 6213 antisense sequences given in the specification where expression  
 CC of the nucleic acid inhibits proliferation of a cell. Also included are:  
 CC (1) a vector comprising a promoter operably linked to the nucleic acid  
 CC encoding a polypeptide whose expression is inhibited by the antisense  
 CC nucleic acid; (2) a host cell containing the vector; (3) an isolated  
 CC polypeptide or its fragment whose expression is inhibited by the  
 CC antisense nucleic acid; (4) an antibody capable of specifically binding  
 CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular  
 CC proliferation or the activity of a gene in an operon required for  
 CC proliferation; (7) identifying a compound that influences the activity of  
 CC the gene product or that has an activity against a biological pathway  
 CC required for proliferation, or that inhibits cellular proliferation; (8)  
 CC identifying a gene required for cellular proliferation or the biological  
 CC pathway in which a proliferation-required gene or its gene product lies  
 CC or a gene on which the test compound that inhibits proliferation of an  
 CC organism acts; (9) manufacturing an antibiotic; (10) profiling a  
 CC compound's activity; (11) a culture comprising strains in which the gene  
 CC product is overexpressed or underexpressed; (12) determining the extent  
 CC to which each of the strains is present in a culture or collection of

CC strains; or (13) identifying the target of a compound that inhibits the  
CC proliferation of an organism. The antisense nucleic acids are useful for  
CC identifying proteins or screening for homologous nucleic acids required  
CC for cellular proliferation to isolate candidate molecules for rational  
CC drug discovery programs, or for screening homologous nucleic acids  
CC required for proliferation in cells other than *S. aureus*, *S. typhimurium*,  
CC *K. pneumoniae* or *P. aeruginosa*. The present sequence is encoded by one of  
CC the target prokaryotic essential genes. Note: The sequence data for this  
CC patent did not form part of the printed specification, but was obtained  
CC in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 757 AA;

Query Match 30.3%; Score 55.5; DB 6; Length 757;  
Best Local Similarity 38.7%; Pred. No. 98;  
Matches 12; Conservative 8; Mismatches 8; Indels 3; Gaps 1;

Oy 3 LSGEQLEHRRERSLQTLRDIQRLPDEKEFT 33  
::|||||::|::|::|::|  
Db 180 VAQEQLEHQE--ENIRQIQKQMLADEERNT 207

RESULT 34  
ADP56607  
ID ADP56607 standard; protein; 237 AA.  
XX  
AC ADP56607;

XX  
DT 09-SEP-2004 (first entry)

XX  
DE Human breast cancer-related protein - SEQ ID 141.

XX  
KW BSNA; BSP; cytostatic; breast cancer; vaccine; gene therapy; human;  
XX chromosome 22q13.31.

XX  
OS Homo sapiens.

XX  
PN WO2004053075-A2.

XX  
PD 24-JUN-2004.

XX  
PF 05-DEC-2003; 2003WO-US038739.

XX  
PR 05-DEC-2002; 2002US-0431097P.

XX  
PR 05-DEC-2002; 2002US-0431122P.

XX  
PA (DIAD-) DIADEXUS INC.

XX  
PI Macina RA, Turner LR, Sun Y;

XX  
DR WPI; 2004-468847/44.

XX  
DR N-PSDB; ADP56516.

XX  
PT New breast specific nucleic acid molecules and polypeptides useful for  
PT diagnosing, preventing or treating breast cancer, for producing  
PT transgenic animals or cells, or for research purposes.

XX  
PS Claim 12; SEQ ID NO 141; 387pp; English.

XX  
CC The invention relates to a novel isolated breast specific nucleic acid  
CC (BSNA) molecule which comprises a nucleic acid sequence encoding any of  
CC the 107 breast specific protein (BSP) amino acid sequences fully defined  
CC in the specification. The molecules of the invention demonstrate  
CC cytostatic activity and may be useful for diagnosing, preventing or  
CC treating breast cancer, possibly via vaccine production or gene therapy.  
CC The current sequence is that of a human breast cancer-related protein of  
CC the invention.

XX  
SQ Sequence 237 AA;

Query Match 30.1%; Score 55; DB 8; Length 237;  
Best Local Similarity 52.2%; Pred. No. 32;

Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;  
Oy 2 GLSQEQLEHRRERSLQTLRDIQRM 24  
::|||||::|::|::|::|  
Db 28 GLRTEGLFRRSASVQTVREIQRL 50

RESULT 35  
ADP56608  
ID ADP56608 standard; protein; 248 AA.  
XX  
AC ADP56608;

XX  
DT 09-SEP-2004 (first entry)

XX  
DE Human breast cancer-related protein - SEQ ID 142.

XX  
KW BSNA; BSP; cytostatic; breast cancer; vaccine; gene therapy; human;  
XX chromosome 22q13.31.

XX  
OS Homo sapiens.

XX  
PN WO2004053075-A2.

XX  
PD 24-JUN-2004.

XX  
PF 05-DEC-2003; 2003WO-US038739.

XX  
PR 05-DEC-2002; 2002US-0431097P.

XX  
PR 05-DEC-2002; 2002US-0431122P.

XX  
PA (DIAD-) DIADEXUS INC.

XX  
PI Macina RA, Turner LR, Sun Y;

XX  
DR WPI; 2004-468847/44.

XX  
DR N-PSDB; ADP56516.

XX  
PT New breast specific nucleic acid molecules and polypeptides useful for  
PT diagnosing, preventing or treating breast cancer, for producing  
PT transgenic animals or cells, or for research purposes.

XX  
PS Claim 12; SEQ ID NO 142; 387pp; English.

XX  
CC The invention relates to a novel isolated breast specific nucleic acid  
CC (BSNA) molecule which comprises a nucleic acid sequence encoding any of  
CC the 107 breast specific protein (BSP) amino acid sequences fully defined  
CC in the specification. The molecules of the invention demonstrate  
CC cytostatic activity and may be useful for diagnosing, preventing or  
CC treating breast cancer, possibly via vaccine production or gene therapy.  
CC The current sequence is that of a human breast cancer-related protein of  
CC the invention.

XX  
SQ Sequence 248 AA;

Query Match 30.1%; Score 55; DB 8; Length 248;  
Best Local Similarity 52.2%; Pred. No. 34;  
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Oy 2 GLSQEQLEHRRERSLQTLRDIQRM 24  
|||::|::|::|::|  
Db 39 GLRTEGLFRRSASVQTVREIQRL 61

RESULT 36

AAB95073  
ID AAB95073 standard; protein; 294 AA.  
XX

XX  
AC AAB95073;

XX  
DT 26-JUN-2001 (first entry)

XX  
DE Human protein sequence SEQ ID NO:16943.

XX	Human; primer; detection; diagnosis; antisense therapy; gene therapy.
KW	Homo sapiens.
OS	EP1074617-A2.
XX	07-FEB-2001.
PN	28-JUL-2000; 2000EP-00116126.
XX	29-JUL-1999; 99JP-00248036.
PR	27-AUG-1999; 99JP-00300253.
PR	11-JAN-2000; 2000JP-00118776.
PR	02-MAY-2000; 2000JP-00183767.
PR	09-JUN-2000; 2000JP-00241899.
PA	(HELI-) HELIX RES INST.
XX	Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI	Ishi S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX	WPI; 2001-318749/34.
DR	Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
PT	Claim 8; SEQ ID NO 16943; 2537bp + Sequence Listing; English.
PS	The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises:
CC	(a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the
CC	oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the
CC	oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesising polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention
CC	
CC	
SQ	Sequence 294 AA;
QY	Query Match 30.1%; Score 55; DB 4; Length 294; Best Local Similarity 52.2%; Pred. No. 41; Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;
Dn	2 GLSQEQLHRERSLQTLRDIGRM 24         :    :    : 224 GLRTEGLFRRSASVQTVEIRQL 246
RESULT 37	
ID	ABR82444 standard; protein; 294 AA.
AC	ABR82444;
XX	
DT	06-NOV-2003 (first entry)
XX	

```
DE Human ARPI3 polypeptide.
XX
KW ARP; prostate; neoplastic; androgen responsive prostate; ARPI5;
XX cytostatic; gene therapy; human; ARPI3.
OS Homo sapiens.
XX
PN WO2003060148-A2.
XX
PD 24-JUL-2003.
XX
PF 15-JAN-2003; 2003WO-US001457.
XX
PR 15-JAN-2002; 2002US-00053248.
XX
PA (SYST-) INST SYSTEMS BIOLOGY.
XX
PI Lin B;
XX
DR WPI; 2003-587287/55.
XX N-PSDB; ACF35892.
PT
PT Diagnosing or predicting susceptibility to a prostate neoplastic
PT condition by contacting a specimen from the individual with an ARPI5
PT binding agent that selectively binds an ARPI5 polypeptide.
XX
PS Claim 78; Page 195-197; 227pp; English.
XX
CC The invention relates to diagnosing or predicting susceptibility to a
CC prostate neoplastic condition. The method involves (a) contacting a
CC specimen from the individual with an androgen responsive prostate
CC specific (ARP)15 binding agent that selectively binds an ARPI5
CC polypeptide; (b) determining a test expression level of ARPI5 polypeptide
CC in the specimen; and (c) comparing the test expression level to a non-
CC neoplastic control expression level of ARPI5 polypeptide, where an
CC altered test expression level as compared to the control expression level
CC indicates the presence of a prostate neoplastic condition in the
CC individual. The method is useful for diagnosing or predicting
CC susceptibility to a prostate neoplastic condition or for treating or
CC reducing severity of a prostate neoplastic condition. The present
CC sequence represents a human ARPI3 polypeptide
XX
SQ Sequence 294 AA;

Query Match          30.1%; Score 55; DB 6; Length 294;
Best Local Similarity 52.2%; Pred. No. 41;
Matches 12; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY      2 GLSQEQLEHRRSLQTLRDIQRM 24
       ||||| | | :||:||||:
Db      224 GLRTGLFRRSASVQTVEIQRL 246

RESULT 38
ADQ74859
ID ADQ74859 standard; protein; 294 AA.
XX
AC ADQ74859;
DT 07-OCT-2004 (first entry)
XX
DE Human androgen responsive prostate specific (ARP) polypeptide #6.
XX
KW Human; androgen responsive prostate specific polypeptide; ARP;
KW prostate neoplastic condition; prostate cancer; cytostatic.
XX
OS Homo sapiens.
XX
PN US2004137440-A1.
XX
PD 15-JUL-2004.
XX
PF 15-JAN-2003; 2003US-00345837.
```

XX  
PR 15-JAN-2003; 2003US-00345837.  
XX (LINB/) LIN B.  
PA  
XX  
PI Lin B;  
XX  
DR WPI; 2004-517182/49.  
DR N-PSDB; ADQ74858.  
XX  
PT New substantially pure androgen responsive specific nucleic acid, useful  
PT for diagnosing and treating prostate cancer.  
XX  
PS Claim 89; SEQ ID NO 12; 102pp; English.  
XX  
CC The invention relates to human androgen responsive prostate specific  
CC (ARP) polynucleotides and the polypeptides they encode. The invention  
CC also relates to a method of diagnosing or predicting susceptibility to a  
CC prostate neoplastic condition in an individual and a method for treating  
CC or reducing the severity of a prostate neoplastic condition in an  
CC individual. The polynucleotides, polypeptides and methods of the  
CC invention are useful for diagnosing and treating prostate cancer. This  
CC sequence represents a human ARP polypeptide of the invention.  
XX  
SQ Sequence 294 AA;

Query Match	30.1%	Score 55;	DB 8;	Length 294;
Best Local Similarity	52.2%;	Pred. No. 41;		
Matches 12; Conservative	4;	Mismatches 7;	Indels 0;	Gaps 0;

```
QY      2 GLSQQLHRRSLQTLRDIRM 24
          ||| | :|:|:|:|:|:|:
Db      224 GLRTEGLFRRSASVQTVREIQL 246
```

RESULT 39  
ADM83551

ID ADM83551 standard; protein; 333 AA.

AC ADM83551;

DT 03-JUN-2004 (first entry)

DE Human Rho GTPase activating protein 8.

KW GTPase-activating protein; GTPAP; cell signalling;  
KW cell proliferative disorder; colon cancer; immune disorder; cytostatic;  
KW human; Rho GTPase activating protein 8.

Homo sapiens.

	Key	Location/Qualifiers
FH	Region	176. .189
FT		/note= "Proline-rich region"
FT		

PN US2003129655-A1.

PD 10-JUL-2003.

PF 29-OCT-2002; 2002US-00284753.

PR 18-FEB-2000; 2000US-00507765.

PA (INCY-) INCYTE GENOMICS INC.

PI Klinger TM, Stewart EA, Yue H, Baughn MR;

DR WPI; 2003-829559/77.

**PT** New GTPase-activating proteins designated GTPAP-1 and its variant GTPAP-2 are useful to diagnose, stage, treat and monitor cell signaling and cell proliferative disorders, particularly colon cancer.

PS Disclosure; SEQ ID NO 32; 64pp; English..

The present invention relates to novel GTPase-activating proteins  
 (collectively designated as GRAP), GTPAP-1 or its variant GTPAP-2 and  
 their encoding cDNAs. The protein is used to diagnose, stage, treat and  
 monitor cell signalling, immune and cell proliferative disorders,  
 particularly colon cancer. The present sequence is human Rho GTPase  
 activating protein 8 used in the invention.

SQ Sequence 333 AA;

Query Match	30.1%;	Score 55;	DB 7;	Length 333;
Best Local Similarity	52.2%;	Pred. No. 47;		
Matches 12; Conservative	4;	Mismatches 7;	Indels 0;	Gaps 0;

```

QY      2  GLSQEQLEHRRSLQTLRDIRM  24
        ||  ||  |  |  ||  ||  ||  ||
Db      124 GLRTEGLFRKSASVQTVREIQRL 146

```

RESULT 40  
ADP56606

ID ADP56606 standard; protein; 337 AA.

ADP56606;

DT 09-SEP-2004 (first entry)

DE Human breast cancer-related protein - SEQ ID 140.

BSNA; BSP; cytoskeletal; breast cancer; vaccine; gene therapy; human; chromosome 22q13.31.

PN WO2004053075-A2.

PD 24-JUN-2004.

PF 05-DEC-2003; 2003WO-US038739.

PR 05-DEC-2002; 2002US-0431097P.

PR 05-DEC-2002; 2002US-0431122P.

PA (DIAD-) DIADEXUS INC.

PI Macina RA, Turner LR, Sun Y;

DR WPI; 2004-468847/44.

PT New breast specific nucleic acid molecules and polypeptides useful for  
PT diagnosing, preventing or treating breast cancer, for producing  
PT transgenic animals or cells, or for research purposes.

Claim 12; SEQ ID NO 140; 387pp; English.

CC The invention relates to a novel isolated breast specific nucleic acid  
CC (BSNA) molecule which comprises a nucleic acid sequence encoding any of  
CC the 107 breast specific protein (BSP) amino acid sequences fully defined  
CC in the specification. The molecules of the invention demonstrate  
CC cytosratic activity and may be useful for diagnosing, preventing or  
CC treating breast cancer, possibly via vaccine production or gene therapy.  
CC The current sequence is that of a human breast cancer-related protein of  
CC the invention.

**SQ Sequence 337 AA;**

Query Match	30.1%;	Score 55;	DB 8;	Length 337;
Best Local Similarity	52.2%;	Pred. No. 47;		
Matches 12; Conservative	4;	Mismatches 7;	Indels 0;	Gaps 0;

2 GLSQEQLHRERSLQTLRDIQRM 24

Db 128 GLRTEGLFRRSASVQTVREIQL 150

Search completed: June 8, 2005, 03:17:49  
Job time : 135.875 secs

---



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 8, 2005, 02:59:37 ; Search time 104.125 Seconds  
(without alignments)  
104.003 Million cell updates/sec

Title: US-09-915-543-15\_COPY\_177\_204  
Perfect score: 136  
Sequence: 1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_16Dec04:\*

1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	136	100.0	28	ADJ71891	Adj71891 Human lgs
2	136	100.0	1394	ADJ18945	Adj18945 Human sof
3	136	100.0	1426	AAB71229	Aab71229 Human leg
4	136	100.0	1426	ABW01534	Abw01534 Human lgs
5	136	100.0	1426	ADJ70152	Adj70152 Human hea
6	136	100.0	1426	ADJ71903	Adj71903 Human lgs
7	136	100.0	1435	ABW11808	Abw11808 Human BCL
8	129	94.9	140	AAO05855	Aao05855 Human pol
9	98	72.1	28	ABW01528	Abw01528 Drosophila
10	98	72.1	28	ADJ71890	Adj71890 Fruit fly
11	98	72.1	1429	ABW58779	Abw58779 Drosophila
12	98	72.1	1464	AAB71228	Aab71228 D. melano
13	98	72.1	1464	ABW01527	Abw01527 Drosophila
14	98	72.1	1464	ADJ71911	Adj71911 Fruit fly
15	94	69.1	1494	AAU78460	Aau78460 Mouse bet
16	91	66.9	114	ABP06595	Abp06595 Human ORF
17	67	49.3	320	AAU78461	Aau78461 Mouse bet
18	65	47.8	113	AAO07544	Aao07544 Human pol
19	53	39.0	133	ADN48110	Adn48110 Thermococ
20	53	39.0	322	ABO66692	AbO66692 Klebsiella
21	52	38.2	360	AGG33446	Aag33446 Zea may
22	52	38.2	448	AGG33445	Aag33445 Zea may
23	52	38.2	509	AGG33444	Aag33444 Zea may
24	51	37.5	1049	ABB60387	Abb60387 Drosophila
25	50	36.8	130	ABB89793	Abb89793 Human pol

26	50	36.8	365	4	ABG15088	Abg15088 Novel hum
27	50	36.8	621	5	AAE15740	Aae15740 Human ami
28	50	36.8	631	3	AAB43285	Aab43285 Human ORF
29	50	36.8	694	8	ABM80775	Abm80775 Tumour-as
30	50	36.8	961	8	ADI16244	Adi16244 Human nuc
31	50	36.8	1063	5	ABB08919	Abb08919 Human ami
32	50	36.8	1063	7	ADJ70652	Adj70652 Human hea
33	50	36.8	1078	7	ADK40961	Adk40961 Novel hum
34	50	36.8	1078	8	ADR15680	Adr15680 Kinase 69
35	49	36.0	187	5	ABP66271	Abp66271 Bifidobac
36	49	36.0	265	7	ABO61084	AbO61084 Klebsiella
37	49	36.0	586	6	ABU49676	Abu49676 Protein e
38	49	36.0	984	6	ABJ25889	Abj25889 Aspergill
39	49	36.0	1058	6	ABJ26489	Abj26489 Aspergill
40	48	35.3	310	7	ADC50023	Adc50023 Gene repa
41	48	35.3	330	8	ADS28390	Ads28390 Bacterial
42	48	35.3	498	3	AGG49364	Aag49364 Arabidops
43	48	35.3	498	3	AGG17973	Aag17973 Arabidops
44	48	35.3	609	3	AGG49363	Aag49363 Arabidops
45	48	35.3	609	3	AGG17972	Aag17972 Arabidops

ALIGNMENTS

RESULT 1	
ADJ71891	
ID ADJ71891 standard; peptide; 28 AA.	
XX	
AC ADJ71891;	
XX	
DT 20-MAY-2004 (first entry)	
XX	
DE Human lgs/Bcl9 peptide fragment #1.	
XX	
KW Human; legless; lgs; cell differentiation disorder;	
KW cell proliferation disorder; cancer; Wnt pathway; medulloblastoma; colon;	
KW breast; head; neck; brain; thyroid; skin; blood disease;	
KW tissue regeneration; tissue repair; cytoskeletal; lgs/Bcl9.	
XX	
OS Homo sapiens.	
XX	
PN US2004038901-A1.	
XX	
PD 26-FEB-2004.	
XX	
PF 22-SEP-2003; 2003US-00664859.	
XX	
PR 28-JUL-2000; 2000US-0221502P.	
PR 27-JUL-2001; 2001US-00915543.	
XX	
PA (UYZU-) UNIV ZURICH.	
XX	
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;	
XX	
DR WPI; 2004-203288/19.	
XX	
PT Novel polypeptide sharing one or more homologue amino acid domains with	
PT legless protein being functional homologue of legless, useful for	
PT diagnosing disorders of cell fate.	
XX	
PS Disclosure; SEQ ID NO 3; 62pp; English.	
XX	
CC The invention relates to a polypeptide sharing one or more homologous	
CC amino acid domains with a legless (lgs) protein and is therefore a	
CC functional homologue of lgs. The invention also relates to a nucleotide	
CC sequence encoding a protein present in invertebrate and/or vertebrate	
CC organisms, the nucleotide sequence encoding a protein comprising a	
CC positive function in a regulatory pathway and the use of the polypeptide	
CC for the isolation of lgs-binding proteins by carrying out an assay chosen	
CC from an in vitro binding assay with such a peptide or a co-	
CC immunoprecipitation from vertebrate or invertebrate cell lysates or a	
CC mammalian or yeast two hybrid assay. The polypeptide and polynucleotide	

CC are useful for treating disorders of cell fate, which involves  
CC administering therapeutic compounds chosen from invertebrate and  
CC vertebrate Igs protein homologues or fragments, antibodies, antibody  
CC fragments, Igs antisense DNA, Igs antisense RNA, Igs double-stranded RNA,  
CC small peptides or chemical and natural compounds being capable of  
CC interfering with Igs function, synthesis and degradation. The disorders  
CC are related to cell differentiation or cell proliferation. The compound  
CC is administered to treat a cancerous condition by preventing progression  
CC from a pre-neoplastic or non-malignant condition to a neoplastic or  
CC malignant state. The cancerous condition is characterised by over-  
CC stimulation of the Wnt pathway and is medulloblastoma or cancer of the  
CC colon, breast, head and neck, brain, thyroid or skin. The therapeutic  
CC compound may also be administered to a blood disease to promote tissue  
CC regeneration and repair. This sequence represents a human Igs/Bc19  
CC peptide fragment of the invention.  
XX  
SQ Sequence 28 AA;  
  
Query Match 100.0%; Score 136; DB 8; Length 28;  
Best Local Similarity 100.0%; Pred. No. 5.2e-14;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28  
1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28  
Db 1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28  
  
RESULT 2  
ADQ18945  
ID ADQ18945 standard; protein; 1394 AA.  
XX  
AC ADQ18945;  
XX  
DT 26-AUG-2004 (first entry)  
XX  
DE Human soft tissue sarcoma-upregulated protein - SEQ ID 1764.  
XX  
KM soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2004048938-A2.  
XX  
PD 10-JUN-2004.  
XX  
PF 26-NOV-2003; 2003WO-US038193.  
XX  
PR 26-NOV-2002; 2002US-0429739P.  
XX  
PA (PROT-) PROTEIN DESIGN LABS INC.  
XX  
PI Aziz N, Ginsburg WM, Zlotnik A;  
XX  
DR WPI; 2004-441208/41.  
XX  
PT Early detection of soft tissue sarcoma comprises determining expression  
PT of a gene in a first soft tissue sample and a normal soft tissue sample  
PT and comparing the gene expression, also useful in treating soft tissue  
PT sarcoma.  
XX  
PS Example 2; SEQ ID NO 1764; 210pp; English.  
XX  
CC The invention relates to a novel method for detecting soft tissue sarcoma  
CC which comprises obtaining a first soft tissue sample from an individual  
CC and a normal soft tissue sample from the same or different individual,  
CC determining the expression of a gene in both samples and comparing the  
CC expression of the gene in both soft tissue samples, where a higher level  
CC of protein expression in the first soft tissue sample indicates the  
CC presence of soft tissue sarcoma. The method of the invention has  
CC cytostatic applications and may be useful for detecting soft tissue  
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic  
CC acid sequences may be useful in diagnostic and screening applications.  
CC The current sequence is that of a human soft tissue sarcoma-upregulated

CC protein of the invention. The current sequence is not shown within the  
CC specification per se but was submitted in CD format by the inventor.  
XX  
SQ Sequence 1394 AA;  
  
Query Match 100.0%; Score 136; DB 8; Length 1394;  
Best Local Similarity 100.0%; Pred. No. 5.5e-12;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 VYVFSTEMANKAAEAVLKQGVETIVSFH 28  
177 VYVFSTEMANKAAEAVLKQGVETIVSFH 204  
Db 177 VYVFSTEMANKAAEAVLKQGVETIVSFH 204  
  
RESULT 3  
AAB71229  
ID AAB71229 standard; protein; 1426 AA.  
XX  
AC AAB71229;  
XX  
DT 18-NOV-2002 (first entry)  
XX  
DE Human legless homologue Igs/bc19 protein.  
XX  
KM legless; human; Igs; Wnt/Wingless signaling pathway; Wnt; Wg;  
KM tissue proliferation; tumour; cytostatic; cellular disorder; colon;  
KM blood disorder; cancer; breast; head and neck cancer; brain; thyroid;  
KM medulloblastoma; skin cancer; tissue regeneration; tissue repair.  
XX  
OS Homo sapiens.  
XX  
PN US2002086986-A1.  
XX  
PD 04-JUL-2002.  
XX  
PF 27-JUL-2001; 2001US-00915543.  
XX  
PR 28-JUL-2000; 2000US-0221502P.  
XX  
PA (BASL/) BASLER K.  
PA (BRUN/) BRUNNER E.  
PA (FROE/) FROESCH B.  
PA (KRAM/) KRAMPS T.  
PA (PETE/) PETER O.  
XX  
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
XX  
DR WPI; 2002-635689/68.  
DR N-PSDB; AAF88467.  
XX  
PT Novel polypeptide useful in therapeutic method for treating disorders of  
PT cell fate such as cell differentiation or cell proliferation.  
XX  
PS Example II; Fig 8B; 41pp; English.  
XX  
CC This invention describes a novel polypeptide sharing one or more  
CC homologous amino acid domains with the legless (Igs) protein, a  
CC downstream component of the Wnt/Wingless (Wnt/Wg) signaling pathway  
CC involved in the formation and maintenance of spatial arrangements and  
CC proliferation of tissues during development, and in the formation and  
CC growth of many human tumours. The products of the invention have  
CC cytostatic activity and can be used to treat cellular disorders, blood  
CC disorders and cancers caused by over-stimulation of the Wnt pathway,  
CC where the cancerous condition is colon, breast, head and neck, brain,  
CC thyroid, medulloblastoma or skin cancer. The product could also be used  
CC to promote tissue regeneration and repair. This sequence represents the  
CC human legless (Igs) protein homologue Igs/bc19 described in the  
CC disclosure of the invention  
XX  
SQ Sequence 1426 AA;  
  
Query Match 100.0%; Score 136; DB 5; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 5.7e-12;

Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VYVFSTEMANKAAEAVLKGQVETIVSFH 28  
|||||  
DB 177 VYVFSTEMANKAAEAVLKGQVETIVSFH 204

RESULT 4  
ABW01534  
ID ABW01534 standard; protein; 1426 AA.

XX AC ABW01534;

XX DT 15-JAN-2004 (first entry)

XX DE Human lgs/bcl9 protein.

XX KW Legless protein; lgs; cell fate disorder; blood disease; gene therapy;  
cancer; tissue regeneration; tissue repair; cytostatic.

XX OS Homo sapiens.

XX PN US2003114413-A1.

XX PD 19-JUN-2003.

XX PF 19-DEC-2002; 2002US-00322579.

XX PR 28-JUL-2000; 2000US-0221502P.

XX PR 27-JUL-2001; 2001US-00915543.

XX PA (UYZU-) UNIV ZURICH.

XX PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;

XX DR WPI; 2003-829432/77.

XX DR N-PSDB; AAD62642.

XX PT Novel lgs polypeptide useful for isolation of lgs-binding proteins,  
diagnosing disorders of cell fate, treating diseases such as cancer.

XX PS Example 2; Fig 8B; 0pp; English.

XX CC The invention relates to novel legless (lgs) proteins and polynucleotides  
encoding such proteins. lgs sequences are useful for the treatment of  
disorders of cell fate such as differentiation or proliferation. The  
invention is used to treat blood disease or a cancerous condition  
characterised by over-stimulation of the Wnt pathway such as colon,  
breast, head and neck, brain, thyroid, medulloblastoma or skin cancer and  
is administered to prevent progression from a pre-neoplastic or non-  
malignant condition to a neoplastic or malignant state. It is  
administered to promote tissue regeneration and repair. The invention is  
also useful in the therapy of diseases cost by an over-activation of Wg  
pathway. It is useful for reducing lgs gene expression in an invertebrate  
or vertebrate organism or an invertebrate or vertebrate cell line. The  
invention is also useful in gene therapy. The present sequence is human  
lgs/bcl9 protein used in the invention

XX SQ Sequence 1426 AA;

Query Match 100.0%; Score 136; DB 7; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 5.7e-12;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VYVFSTEMANKAAEAVLKGQVETIVSFH 28  
|||||  
DB 177 VYVFSTEMANKAAEAVLKGQVETIVSFH 204

RESULT 5  
ADJ70152  
ID ADJ70152 standard; protein; 1426 AA.  
XX

AC ADJ70152;  
XX DT 06-MAY-2004 (first entry)  
XX DE Human heat mitochondrial protein as a therapeutic target SegID1958.

XX KW mitochondrial; human; screening assay; diabetes mellitus;  
Huntington's disease; osteoarthritis;  
Leber's hereditary optic neuropathy; LHON;  
mitochondrial encephalopathy lactic acidosis and stroke; MELAS;  
myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;  
neuroprotective; nootropic; antidiabetic; anticonvulsant; antiarthritic;  
osteopathic; ophthalmological; cytostatic.

XX OS Homo sapiens.

XX PN WO2003087768-A2.

XX PD 23-OCT-2003.

XX PF 04-APR-2003; 2003WO-US010870.

XX PR 12-APR-2002; 2002US-0372843P.

XX PR 17-JUN-2002; 2002US-0389987P.

XX PR 20-SEP-2002; 2002US-0412418P.

XX PA (MITO-) MITOKOR.  
(BUCK-) BUCK INST AGE RES.

XX PI Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;  
Warnock DE;

XX DR WPI; 2003-845369/78.

XX PT Identifying a mitochondrial target for drug screening assays and for  
treating diseases associated with altered mitochondrial function,  
comprises detecting a modified polypeptide in a sample and correlating  
with the disease.

XX PS Claim 1; SEQ ID NO 1958; 180pp; English.

XX CC This invention relates to novel mitochondrial targets that can be used  
for therapeutic intervention in treating a disease associated with  
altered mitochondrial function. Specifically, it refers to a method for  
identifying proteins of the human heart mitochondrial proteome that are  
useful for drug screening assays, as well as therapeutic targets. The  
present invention describes a method for identifying such proteins that  
can be used in the treatment of various diseases associated with altered  
mitochondrial function including diabetes mellitus, Huntington's disease,  
osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial  
encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy  
ragged red fibre syndrome (MERRF) or cancer. Accordingly, these  
compositions have neuroprotective, nootropic, antidiabetic,  
anticonvulsant, antiarthritic, osteopathic, ophthalmological and  
cytostatic activities. This polypeptide sequence is a human heart  
mitochondrial protein of the invention.

XX SQ Sequence 1426 AA;

Query Match 100.0%; Score 136; DB 7; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 5.7e-12;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VYVFSTEMANKAAEAVLKGQVETIVSFH 28  
|||||  
DB 177 VYVFSTEMANKAAEAVLKGQVETIVSFH 204

RESULT 6  
ADJ71903  
ID ADJ71903 standard; protein; 1426 AA.  
XX AC ADJ71903;

XX 20-MAY-2004 (first entry)  
DT  
XX  
DE Human Lgs/Bcl9 polypeptide.  
XX  
KW Human; legless; lgs; cell differentiation disorder;  
KW cell proliferation disorder; cancer; Wnt pathway; medulloblastoma; colon;  
KW breast; head; neck; brain; thyroid; skin; blood disease;  
KW tissue regeneration; tissue repair; cytosstatic; Lgs/Bcl9.  
OS Homo sapiens.  
XX  
PN US2004038901-A1.  
XX  
PD 26-FEB-2004.  
XX  
PF 22-SEP-2003; 2003US-00664859.  
XX  
PR 28-JUL-2000; 2000US-0221502P.  
PR 27-JUL-2001; 2001US-00915543.  
XX  
PA (UYZU-) UNIV ZURICH.  
XX  
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;  
XX  
DR WPI; 2004-203288/19.  
DR N-PSDB; ADJ71902.  
XX  
XX  
PT Novel polypeptide sharing one or more homologue amino acid domains with  
PT legless protein being functional homologue of Legless, useful for  
PT diagnosing disorders of cell fate.  
XX  
XX  
PS Example 2; SEQ ID NO 15; 62pp; English.  
XX  
XX The invention relates to a polypeptide sharing one or more homologous  
CC amino acid domains with a Legless (Lgs) protein and is therefore a  
CC functional homologue of Lgs. The invention also relates to a nucleotide  
CC sequence encoding a protein present in invertebrate and/or vertebrate  
CC organisms, the nucleotide sequence encoding a protein comprising a  
CC positive function in a regulatory pathway and the use of the polypeptide  
CC for the isolation of Lgs-binding proteins by carrying out an assay chosen  
CC from an in vitro binding assay with such a peptide or a co-  
CC immunoprecipitation from vertebrate or invertebrate cell lysates or a  
CC mammalian or yeast two hybrid assay. The polypeptide and polynucleotide  
CC are useful for treating disorders of cell fate, which involves  
CC administering therapeutic compounds chosen from invertebrate and  
CC vertebrate Lgs protein homologues or fragments, antibodies, antibody  
CC fragments, lgs antisense DNA, lgs antisense RNA, lgs double-stranded RNA,  
CC small peptides or chemical and natural compounds being capable of  
CC interfering with Lgs function, synthesis and degradation. The disorders  
CC are related to cell differentiation or cell proliferation. The compound  
CC is administered to treat a cancerous condition by preventing progression  
CC from a pre-neoplastic or non-malignant condition to a neoplastic or  
CC malignant state. The cancerous condition is characterised by over-  
CC stimulation of the Wnt pathway and is medulloblastoma or cancer of the  
CC colon, breast, head and neck, brain, thyroid or skin. The therapeutic  
CC compound may also be administered to a blood disease to promote tissue  
CC regeneration and repair. This sequence represents the human Lgs/Bcl9  
CC polypeptide of the invention.  
XX  
SQ Sequence 1426 AA;  
  
Query Match 100.0%; Score 136; DB 8; Length 1426;  
Best Local Similarity 100.0%; Pred. No. 5.7e-12;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVFSTEMANKAAEAVLKGQVETIVSFH 28  
Db 177 VYVFSTEMANKAAEAVLKGQVETIVSFH 204

RESULT 7  
ABBI1808

ID ABB11808 standard; peptide; 1435 AA.  
XX  
AC ABB11808;  
XX  
DT 11-JAN-2002 (first entry)  
DE  
XX Human BCL9 homologue, SEQ ID NO:2178.  
KW  
KW Human; cytokine; cell proliferation; cell differentiation; growth factor;  
KW haematopoiesis regulation; tissue growth; immunomodulator; activin;  
KW inhibit; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;  
KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;  
KW chronic inflammatory condition; proliferative retinopathy;  
KW atherosclerosis; coronary heart disease; arterial ischaemia;  
KW bone disorder; osteoporosis; vascular growth disorder;  
KW tissue regeneration; wound healing; infection; immune disorder;  
KW cell culture; drug screening; gene therapy; antiinflammatory;  
KW antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;  
KW cytosstatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
KW antifungal; vulnerrary; antilulcer.  
XX  
OS Homo sapiens.  
XX  
PN WO200157188-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 05-FEB-2001; 2001WO-US003800.  
XX  
PR 03-FEB-2000; 2000US-00496914.  
PR 27-APR-2000; 2000US-00560875.  
XX  
XX (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Drmanac RT;  
XX  
DR WPI; 2001-457740/49.  
DR N-PSDB; ABA09052.  
XX  
XX Human proteins and DNA encoding sequences useful for preventing, treating  
PT or ameliorating a medical condition in a mammalian subject e.g. arthritis  
PT and cancer.  
XX  
PS Claim 20; Page 256-257; 1963pp; English.  
XX  
XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
CC invention also relates to vectors and recombinant host cells comprising a  
CC nucleotide of the invention, methods of producing the novel polypeptides,  
CC antibodies against the polypeptides, methods of detecting the nucleotides  
CC or polypeptides in a sample, and methods of identifying compounds which  
CC bind to polypeptides of the invention. Although novel, many of the  
CC polypeptides of the invention have homology to known proteins, thereby  
CC giving an insight into their probable biological activities, and hence  
CC potential therapeutic applications. The polypeptides of the invention may  
CC have various activities, including cytokine, cell proliferation or cell  
CC differentiation activities; stem cell growth factor activity;  
CC haematopoiesis regulatory activity; tissue growth activity;  
CC immunomodulatory activity; activin- or inhibitin-related activities;  
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or  
CC thrombolytic activities; receptor or ligand activities; or may be  
CC involved in oncogenesis, cancer cell proliferation and metastasis.  
CC Depending on their biological activities, polypeptides and nucleotides of  
CC the invention are useful for preventing, treating or ameliorating medical  
CC conditions, e.g., by protein or gene therapy. Such conditions include  
CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),  
CC proliferative retinopathy, atherosclerosis, coronary heart disease,  
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
CC vascular growth. Polypeptides involved with tissue regeneration and  
CC repair (or nucleic acids encoding them) may be used to promote wound  
CC healing (e.g., of burns, incisions and ulcers), while those with

CC immunomodulatory activities may be used in the treatment of viral,  
CC bacterial and fungal infections in addition to immune disorders.  
CC Polypeptides with growth factor activity may be used in cell cultures to  
CC promote cell growth. For example, such polypeptides may be used to  
CC manipulate stem cells in culture to give rise to neuroepithelial cells  
CC that can be used to augment or replace cells damaged by illness,  
CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
CC may also be used in the diagnosis of the above conditions, and in drug  
CC screening techniques. The present sequence represents a novel human  
CC polypeptide of the invention  
XX  
SQ Sequence 1435 AA;

```

Query Match      100.0%; Score 136; DB 4; Length 1435;
Best Local Similarity 100.0%; Pred. No. 5.7e-12;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  VYVFSTEMANKAAEAVALKGOVETIVSFH 28
          |||||
Db       217 VYVFSTEMANKAAEAVALKGOVETIVSFH 244

```

RESULT 8  
AA005855  
ID AA005855 standard; protein; 140 AA.

AC AA005855;

DT 06-NOV-2001 (first entry)

Human polypeptide SEQ ID NO 19747.

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
KW nervous system disorders; arthritis; inflammation.

OS Homo sapiens.

PN WO200164835-A2.

PD 07-SEP-2001.

26-FEB-2001; 2001WO-US004927.

PR 28-FEB-2000; 2000US-00515126.

PR 18-MAY-2000; 2000US-00577409.

PA (HYSE-) HYSEQ INC.

Tang YT, Liu C, Drmanac RT;

DR WPI; 2001-514838/56.

DR N-PSDB; AA185786.

PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing and treating e.g. leukemia, inflammation and immune disorders.

PS Claim 20; SEQ ID NO 19747; 1399pp + Sequence Listing; English.

CC The invention relates to human polynucleotides (AA179941-AA193841) and  
CC the encoded proteins (AA000010-AA03910) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation. Note: The sequence data for this patent did not form part  
CC of the printed specification, but was obtained in electronic format  
CC directly from WIPO at [ftp.wipo.int/pub/published/pct](http://ftp.wipo.int/pub/published/pct) sequences

XX  
SQ Sequence 140 AA;

Query Match.	94.9%;	Score 129;	DB 4;	Length 140;
Best Local Similarity	92.9%;	Pred. No. 4.5e-12;		
Matches 26;	Conservative 2;	Mismatches 0;	Indels 0;	Gaps 0;

QY 1 YVVFSTEMANKAAEAVLKQGVETIVSFH 28  
|||:|||||:||||  
Db 59 YVVFSTEMANKAAKAVLKQGVETIVSFH 86

RESULT 9  
ABW01528

ID ABW01528 standard; peptide; 28 AA.

AC ABW01528;

DT 15-JAN-2004 (first entry)

DE Drosophila species legless (lgs) peptide #1.

Legless protein; lgs; cell fate disorder; blood disease; gene therapy;  
 cancer; tissue regeneration; tissue repair; cytostatic.  
 KW

**Drosophila** sp.

PN US2003114413-A1.

PD 19-JUN-2003.

19-DEC-2002; 2002US-00322579.

PR 28-JUL-2000; 2000US-0221502P.

PR 27-JUL-2001; 2001US-00915543.

PA (UYZU-) UNIV ZURICH.

PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;

DR WPI; 2003-829432/77.

Novel IgG polypeptide useful for isolation of IgG-binding proteins, PT diagnosing disorders of cell fate, treating diseases such as cancer.

PS Claim 28; Fig 7B; opp; English.

The invention relates to novel legless (lgs) proteins and polynucleotides encoding such proteins. Lgs sequences are useful for the treatment of disorders of cell fate such as differentiation or proliferation. The invention is used to treat blood disease or a cancerous condition characterised by over-stimulation of the Wnt pathway such as colon, breast, head and neck, brain, thyroid, medulloblastoma or skin cancer and is administered to prevent progression from a pre-neoplastic or non-malignant condition to a neoplastic or malignant state. It is administered to promote tissue regeneration and repair. The invention is also useful in the therapy of diseases cost by an over-activation of Wg pathway. It is useful for reducing lgs gene expression in an invertebrate or vertebrate organism or an invertebrate or vertebrate cell line. The invention is also useful in gene therapy. The present sequence is *Drosophila* species legless (lgs) peptide

**SQ Sequence 28 AA;**

Query Match	72.1%;	Score 98;	DB 7;	Length 28;
Best Local Similarity	57.1%;	Pred. No. 4.9e-08;		
Matches 16; Conservative	9;	Mismatches 3;	Indels 0;	Gaps 0;

```
Qy      1 VYVESTEMANKAAEAVALKGQVETIVSFH 28
        ::|||::||| ||| ||| ::|||::||
Db      1 IFVESTOLANKGAESVLSGFOQTIIAYH 28
```



```

RESULT 10
ID ADJ71890 standard; peptide; 28 AA.
XX AC ADJ71890;
XX DT 20-MAY-2004 (first entry)
XX DE Fruit fly legless (lgs) peptide fragment #1.
XX KW Fruit fly; legless; lgs; cell differentiation disorder;
XX KW cell proliferation disorder; cancer; Wnt pathway; medulloblastoma; colon;
XX KW breast; head; neck; brain; thyroid; skin; blood disease;
XX KW tissue regeneration; tissue repair; cytostatic.
XX OS Drosophila melanogaster.
XX PN US2004038901-A1.
XX PD 26-FEB-2004.
XX PF 22-SEP-2003; 2003US-00664859.
XX PR 28-JUL-2000; 2000US-0221502P.
XX PR 27-JUL-2001; 2001US-00915543.
XX PA (UYZU-) UNIV ZURICH.
XX PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;
XX DR WPI; 2004-203288/19.
XX PT Novel polypeptide sharing one or more homologue amino acid domains with
PT Legless protein being functional homologue of Legless, useful for
PT diagnosing disorders of cell fate.
XX PS Disclosure; SEQ ID NO 2; 62pp; English.
XX
CC The invention relates to a polypeptide sharing one or more homologous
CC amino acid domains with a Legless (lgs) protein and is therefore a
CC functional homologue of lgs. The invention also relates to a nucleotide
CC sequence encoding a protein present in invertebrate and/or vertebrate
CC organisms, the nucleotide sequence encoding a protein comprising a
CC positive function in a regulatory pathway and the use of the polypeptide
CC for the isolation of lgs-binding proteins by carrying out an assay chosen
CC from an in vitro binding assay with such a peptide or a co-
CC immunoprecipitation from vertebrate or invertebrate cell lysates or a
CC mammalian or yeast two hybrid assay. The polypeptide and polynucleotide
CC are useful for treating disorders of cell fate, which involves
CC administering therapeutic compounds chosen from invertebrate and
CC vertebrate lgs protein homologues or fragments, antibodies, antibody
CC fragments, lgs antisense DNA, lgs antisense RNA, lgs double-stranded RNA,
CC small peptides or chemical and natural compounds being capable of
CC interfering with lgs function, synthesis and degradation. The disorders
CC are related to cell differentiation or cell proliferation. The compound
CC is administered to treat a cancerous condition by preventing progression
CC from a pre-neoplastic or non-malignant condition to a neoplastic or
CC malignant state. The cancerous condition is characterised by over-
CC stimulation of the Wnt pathway and is medulloblastoma or cancer of the
CC colon, breast, head and neck, brain, thyroid or skin. The therapeutic
CC compound may also be administered to a blood disease to promote tissue
CC regeneration and repair. This sequence represents a Drosophila lgs
CC peptide fragment of the invention.
XX
SQ Sequence 28 AA;

Query Match 72.1%; Score 98; DB 8; Length 28;
Best Local Similarity 57.1%; Pred. No. 4.9e-08;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

1 VVVFSTEMANKAAEAVALKGOVETIVSFH 28
:::||||:|||||:|:|:|:|:|:|
1 IFVFSTOLANKGAESVLSGQFOTIIAYH 28

```

```

RESULT 11
ABB58779
ID ABB58779 standard; protein, 1429 AA.
XX
XX ABB58779;
AC
XX 26-MAR-2002 (first entry)
DT
XX Drosophila melanogaster polypeptide SEQ ID NO 3129.
DE
XX Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
XX Drosophila melanogaster.
OS
XX WO200171042-A2.
PN
XX 27-SEP-2001.
PD
XX
XX 23-MAR-2001; 2001WO-US009231.
PF
XX
XX 23-MAR-2000; 2000US-0191637P.
PR
XX 11-JUL-2000; 2000US-00614150.
PR
XX
XX (PEKE ) PE CORP NY.
PA
XX
XX Venter JC, Adams M, Li PWD, Myers EW;
PI
XX WPI; 2001-656860/75.
DR
XX N-PSDB; ABL02882.
DR
XX
XX New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signaling and cell-cell
PT interactions.
PT
XX
XX Disclosure; SEQ ID NO 3129; 21pp + Sequence listing; English.
XX
XX
XX The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABLI6176-ABLI30511), expressed DNA
CC sequences (ABLI01840-ABLI6175) and the encoded proteins (ABB57737-
CC ABB72072). The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 1429 AA;
SQ
Query Match 72.1%; Score 98; DB 4; length 1429;
Best Local Similarity 57.1%; Pred. NO. 5.4e-06;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;
QY 1 VYVFSTEMANKAAEAVLKGQVETIVSFH 28
::||||::||| ||| :||::|
Db 323 IFVFSTOLANKGAESVLSGQFQTIAYH 350
RESULT 12
ABB71228
ID AAB71228 standard; protein, 1464 AA.
XX
XX AAB71228;
AC
XX 18-NOV-2002 (first entry)
DT
XX D. melanogaster lgs protein.
DE
XX
XX Legless; fruitfly; lgs; Wnt/Wingless signaling pathway; Wnt; Wg;
KW tissue proliferation; tumour; cytosolic; cellular disorder; colon;
XX

```



KM	blood disorder; cancer; breast; head and neck cancer; brain; thyroid;
KW	medulloblastoma; skin cancer; tissue regeneration; tissue repair.
OS	Drosophila melanogaster.
PN	US2002086986-A1.
XX	
PD	04-JUL-2002.
XX	
Pf	27-JUL-2001; 2001US-00915543.
XX	
PR	28-JUL-2000; 2000US-0221502P.
XX	
PA	(BASL/) BASLER K.
PA	(BRUN/) BRUNNER E.
PA	(FROE/) FROESCH B.
PA	(KRAM/) KRAMPS T.
PA	(PETE/) PETER O.
XX	
PI	Basler K, Brunner E, Froesch B, Kramps T, Peter O;
XX	
DR	WPI; 2002-635689/68.
DR	N-PSDB; AAF88466.
XX	
PT	Novel polypeptide useful in therapeutic method for treating disorders of
PT	cell fate such as cell differentiation or cell proliferation.
XX	
PS	Example II; Fig 2; 41pp; English.
XX	
CC	This invention describes a novel polypeptide sharing one or more
CC	homologous amino acid domains with the legless (lgs) protein, a
CC	downstream component of the Wnt/Wingless (Wnt/Wg) signaling pathway
CC	involved in the formation and maintenance of spatial arrangements and
CC	proliferation of tissues during development, and in the formation and
CC	growth of many human tumours. The products of the invention have
CC	cytostatic activity and can be used to treat cellular disorders, blood
CC	disorders and cancers caused by over-stimulation of the Wnt pathway,
CC	where the cancerous condition is colon, breast, head and neck, brain,
CC	thyroid, medulloblastoma or skin cancer. This product could also be used
CC	to promote tissue regeneration and repair. This sequence represents the
CC	Drosophila melanogaster (fruitfly) legless (lgs) protein described in the
CC	disclosure of the invention
XX	
SQ	Sequence 1464 AA;
	Query Match                      72.1%; Score 98; DB 5; Length 1464;
	Best Local Similarity    57.1%; Pred. No. 5.5e-06;
	Matches    16; Conservative    9; Mismatches    3; Indels    0; Gaps    0;
OY	1 VYVFSTEMANKAAEAVALKGQVETIVSFH 28
	:::    ::   :   :: :: :
Db	318 IFVFSTQLANKGAESVLSGQFTIAYH 345
	RESULT 13
ID	ABW01527 standard; protein; 1464 AA.
XX	
AC	ABW01527;
XX	
DT	15-JAN-2004 (first entry)
XX	
DE	Drosophila species legless (lgs) protein.
XX	
KM	legless protein; lgs; cell fate disorder; blood disease; gene therapy;
KW	cancer; tissue regeneration; tissue repair; cytostatic.
OS	Drosophila sp.
XX	
PN	US2003114413-A1.
XX	
PD	19-JUN-2003.
XX	

```

PF 19-DEC-2002; 2002US-00322579.
XX
PR 28-JUL-2000; 2000US-0221502P.
PR 27-JUL-2001; 2001US-00915543.
XX
PA (UYZU-) UNIV ZURICH.
XX
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;
XX
DR WPI; 2003-829432/77.
DR N-PSDB; AAD62641.
XX
PT Novel Igs polypeptide useful for isolation of Igs-binding proteins,
PT diagnosing disorders of cell fate, treating diseases such as cancer.
XX
PS Claim 5; Fig 2; 0pp; English.
XX
XX The invention relates to novel legless (lgs) proteins and polynucleotides
CC encoding such proteins. Igs sequences are useful for the treatment of
CC disorders of cell fate such as differentiation or proliferation. The
CC invention is used to treat blood disease or a cancerous condition
CC characterised by over-stimulation of the Wnt pathway such as colon,
CC breast, head and neck, brain, thyroid, medulloblastoma or skin cancer and
CC is administered to prevent progression from a pre-neoplastic or non-
CC malignant condition to a neoplastic or malignant state. It is
CC administered to promote tissue regeneration and repair. The invention is
CC also useful in the therapy of diseases cost by an over-activation of Wg
CC pathway. It is useful for reducing lgs gene expression in an invertebrate
CC or vertebrate organism or an invertebrate or vertebrate cell line. The
CC invention is also useful in gene therapy. The present sequence is
CC Drosophila species legless (lgs) protein
CC
SQ Sequence 1464 AA;
QY
Query Match 72.1%; Score 98; DB 7; Length 1464;
Best Local Similarity 57.1%; Pred. No. 5.5e-06;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0
Db 1 VYVFSTEMANKAAEAVALKGQVETIVSFH 28
:::||||:|||||:|:|:|:|:|
318 IFVFSTQLANKGAESVLSGQFQRIIAYH 345

RESULT 14
ID ADJ71911 standard; protein; 1464 AA.
XX
AC ADJ71911;
XX
DT 20-MAY-2004 (first entry)
XX
DE Fruit fly legless (lgs) polypeptide.
XX
KW Fruit fly; legless; lgs; cell differentiation disorder;
KW cell proliferation disorder; cancer; Wnt pathway; medulloblastoma; colon;
KW breast; head; neck; brain; thyroid; skin; blood disease;
KW tissue regeneration; tissue repair; cyostatic.
XX
OS Drosophila melanogaster.
XX
PN US2004038901-A1.
XX
PD 26-FEB-2004.
XX
PF 22-SEP-2003; 2003US-00664859.
XX
PR 28-JUL-2000; 2000US-0221502P.
PR 27-JUL-2001; 2001US-00915543.
XX
PA (UYZU-) UNIV ZURICH.
XX
PI Basler K, Brunner E, Froesch B, Kramps T, Peter O;
XX

```







[illegible]

PR 28-SEP-1999; 99US-0156458P.  
PR 29-SEP-1999; 99US-0156596P.  
PR 04-OCT-1999; 99US-0157117P.  
PR 05-OCT-1999; 99US-0157753P.  
PR 06-OCT-1999; 99US-0157865P.  
PR 07-OCT-1999; 99US-0158029P.  
PR 08-OCT-1999; 99US-0158232P.  
PR 12-OCT-1999; 99US-0158369P.  
PR 13-OCT-1999; 99US-0159293P.  
PR 13-OCT-1999; 99US-0159294P.  
PR 13-OCT-1999; 99US-0159295P.  
PR 14-OCT-1999; 99US-0159329P.  
PR 14-OCT-1999; 99US-0159330P.  
PR 14-OCT-1999; 99US-0159331P.  
PR 14-OCT-1999; 99US-0159637P.  
PR 14-OCT-1999; 99US-0159638P.  
PR 18-OCT-1999; 99US-0159584P.  
PR 21-OCT-1999; 99US-0160741P.  
PR 21-OCT-1999; 99US-0160767P.  
PR 21-OCT-1999; 99US-0160768P.  
PR 21-OCT-1999; 99US-0160770P.  
PR 21-OCT-1999; 99US-0160814P.  
PR 21-OCT-1999; 99US-0160815P.  
PR 22-OCT-1999; 99US-0160980P.  
PR 22-OCT-1999; 99US-0160981P.  
PR 22-OCT-1999; 99US-0160989P.  
PR 25-OCT-1999; 99US-0161404P.  
PR 25-OCT-1999; 99US-0161405P.  
PR 25-OCT-1999; 99US-0161406P.  
PR 26-OCT-1999; 99US-0161359P.  
PR 26-OCT-1999; 99US-0161360P.  
PR 26-OCT-1999; 99US-0161361P.  
PR 28-OCT-1999; 99US-0161920P.  
PR 28-OCT-1999; 99US-0161992P.  
PR 28-OCT-1999; 99US-0161993P.  
PR 29-OCT-1999; 99US-0162142P.

Query Match 38.2%; Score 52; DB 3; Length 360;  
Best Local Similarity 50.0%; Pred. No. 18;  
Matches 12; Conservative 2; Mismatches 10; Indels 0; Gaps 0;

QY 4 FSTEMANKAAEVLKGQVETIVSF 27  
|||:|||||:|||||:  
DB 97 FSTRLANNLNENLVKEGPETIAAF 120

RESULT 22  
AAG33445  
ID AAG33445 standard; protein; 448 AA.

XX AAG33445;

DT 18-OCT-2000 (first entry)

DE Zea mays protein fragment SEQ ID NO: 40524.

XX Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence; corn.

XX Zea mays subsp. mays.

PN EP1033405-A2.

XX PD 06-SEP-2000.

XX PF 25-FEB-2000; 2000EP-00301439.

XX 25-FEB-1999; 99US-0121825P.  
PR 05-MAR-1999; 99US-0123180P.  
PR 09-MAR-1999; 99US-0123548P.  
PR 23-MAR-1999; 99US-0125788P.  
PR 25-MAR-1999; 99US-0126264P.

PR 29-MAR-1999; 99US-0126785P.  
PR 01-APR-1999; 99US-0127462P.  
PR 06-APR-1999; 99US-0128234P.  
PR 08-APR-1999; 99US-0128714P.  
PR 16-APR-1999; 99US-0129845P.  
PR 19-APR-1999; 99US-0130077P.  
PR 21-APR-1999; 99US-0130449P.  
PR 23-APR-1999; 99US-0130510P.  
PR 23-APR-1999; 99US-0130891P.  
PR 28-APR-1999; 99US-0131449P.  
PR 30-APR-1999; 99US-0132048P.  
PR 30-APR-1999; 99US-0132407P.  
PR 04-MAY-1999; 99US-0132484P.  
PR 05-MAY-1999; 99US-0132485P.  
PR 06-MAY-1999; 99US-0132486P.  
PR 06-MAY-1999; 99US-0132487P.  
PR 07-MAY-1999; 99US-0132863P.  
PR 11-MAY-1999; 99US-0134256P.  
PR 14-MAY-1999; 99US-0134218P.  
PR 14-MAY-1999; 99US-0134219P.  
PR 14-MAY-1999; 99US-0134221P.  
PR 14-MAY-1999; 99US-0134370P.  
PR 18-MAY-1999; 99US-0134768P.  
PR 19-MAY-1999; 99US-0134941P.  
PR 20-MAY-1999; 99US-0135124P.  
PR 21-MAY-1999; 99US-0135353P.  
PR 24-MAY-1999; 99US-0135629P.  
PR 25-MAY-1999; 99US-0136021P.  
PR 27-MAY-1999; 99US-0136392P.  
PR 28-MAY-1999; 99US-0136782P.  
PR 01-JUN-1999; 99US-0137222P.  
PR 03-JUN-1999; 99US-0137528P.  
PR 04-JUN-1999; 99US-0137502P.  
PR 07-JUN-1999; 99US-0137724P.  
PR 08-JUN-1999; 99US-0138094P.  
PR 10-JUN-1999; 99US-0138540P.  
PR 10-JUN-1999; 99US-0138847P.  
PR 14-JUN-1999; 99US-0139119P.  
PR 16-JUN-1999; 99US-0139452P.  
PR 16-JUN-1999; 99US-0139453P.  
PR 17-JUN-1999; 99US-0139492P.  
PR 18-JUN-1999; 99US-0139454P.  
PR 18-JUN-1999; 99US-0139455P.  
PR 18-JUN-1999; 99US-0139456P.  
PR 18-JUN-1999; 99US-0139457P.  
PR 18-JUN-1999; 99US-0139458P.  
PR 18-JUN-1999; 99US-0139459P.  
PR 18-JUN-1999; 99US-0139460P.  
PR 18-JUN-1999; 99US-0139461P.  
PR 18-JUN-1999; 99US-0139462P.  
PR 18-JUN-1999; 99US-0139463P.  
PR 18-JUN-1999; 99US-0139750P.  
PR 18-JUN-1999; 99US-0139763P.  
PR 21-JUN-1999; 99US-0139817P.  
PR 22-JUN-1999; 99US-0139899P.  
PR 23-JUN-1999; 99US-0140353P.  
PR 23-JUN-1999; 99US-0140354P.  
PR 24-JUN-1999; 99US-0140695P.  
PR 28-JUN-1999; 99US-0140823P.  
PR 29-JUN-1999; 99US-0140991P.  
PR 30-JUN-1999; 99US-0141287P.  
PR 01-JUL-1999; 99US-0141842P.  
PR 01-JUL-1999; 99US-0142154P.  
PR 02-JUL-1999; 99US-0142055P.  
PR 06-JUL-1999; 99US-0142390P.  
PR 08-JUL-1999; 99US-0142803P.  
PR 09-JUL-1999; 99US-0142920P.  
PR 12-JUL-1999; 99US-0142977P.  
PR 13-JUL-1999; 99US-0143542P.  
PR 14-JUL-1999; 99US-0143624P.  
PR 15-JUL-1999; 99US-0144005P.  
PR 16-JUL-1999; 99US-0144085P.  
PR 16-JUL-1999; 99US-0144086P.



PR 19-JUL-1999; 99US-0144325P.  
PR 19-JUL-1999; 99US-0144331P.  
PR 19-JUL-1999; 99US-0144332P.  
PR 19-JUL-1999; 99US-0144333P.  
PR 19-JUL-1999; 99US-0144334P.  
PR 19-JUL-1999; 99US-0144335P.  
PR 20-JUL-1999; 99US-0144352P.  
PR 20-JUL-1999; 99US-0144632P.  
PR 20-JUL-1999; 99US-0144884P.  
PR 21-JUL-1999; 99US-0144814P.  
PR 21-JUL-1999; 99US-0145086P.  
PR 21-JUL-1999; 99US-0145088P.  
PR 22-JUL-1999; 99US-0145085P.  
PR 22-JUL-1999; 99US-0145087P.  
PR 22-JUL-1999; 99US-0145089P.  
PR 22-JUL-1999; 99US-0145192P.  
PR 23-JUL-1999; 99US-0145145P.  
PR 23-JUL-1999; 99US-0145218P.  
PR 23-JUL-1999; 99US-0145224P.  
PR 26-JUL-1999; 99US-0145276P.  
PR 27-JUL-1999; 99US-0145913P.  
PR 27-JUL-1999; 99US-0145918P.  
PR 27-JUL-1999; 99US-0145919P.  
PR 28-JUL-1999; 99US-0145951P.  
PR 02-AUG-1999; 99US-0146386P.  
PR 02-AUG-1999; 99US-0146388P.  
PR 02-AUG-1999; 99US-0146389P.  
PR 03-AUG-1999; 99US-0147038P.  
PR 04-AUG-1999; 99US-0147204P.  
PR 04-AUG-1999; 99US-0147302P.  
PR 05-AUG-1999; 99US-0147192P.  
PR 05-AUG-1999; 99US-0147260P.  
PR 06-AUG-1999; 99US-0147303P.  
PR 06-AUG-1999; 99US-0147416P.  
PR 09-AUG-1999; 99US-0147493P.  
PR 09-AUG-1999; 99US-0147935P.  
PR 10-AUG-1999; 99US-0148171P.  
PR 11-AUG-1999; 99US-0148319P.  
PR 12-AUG-1999; 99US-0148341P.  
PR 13-AUG-1999; 99US-0148565P.  
PR 13-AUG-1999; 99US-0148684P.  
PR 16-AUG-1999; 99US-0149368P.  
PR 17-AUG-1999; 99US-0149175P.  
PR 18-AUG-1999; 99US-0149426P.  
PR 20-AUG-1999; 99US-0149722P.  
PR 20-AUG-1999; 99US-0149723P.  
PR 20-AUG-1999; 99US-0149929P.  
PR 23-AUG-1999; 99US-0149930P.  
PR 23-AUG-1999; 99US-0150566P.  
PR 25-AUG-1999; 99US-0150884P.  
PR 26-AUG-1999; 99US-0151065P.  
PR 27-AUG-1999; 99US-0151066P.  
PR 27-AUG-1999; 99US-0151080P.  
PR 30-AUG-1999; 99US-0151303P.  
PR 31-AUG-1999; 99US-0151438P.  
PR 01-SEP-1999; 99US-0151930P.  
PR 07-SEP-1999; 99US-0152363P.  
PR 10-SEP-1999; 99US-0153070P.  
PR 13-SEP-1999; 99US-0153758P.  
PR 15-SEP-1999; 99US-0154018P.  
PR 16-SEP-1999; 99US-0154039P.  
PR 20-SEP-1999; 99US-0154779P.  
PR 22-SEP-1999; 99US-0155139P.  
PR 23-SEP-1999; 99US-0155486P.  
PR 24-SEP-1999; 99US-0155659P.  
PR 28-SEP-1999; 99US-0156458P.  
PR 29-SEP-1999; 99US-0156596P.  
PR 04-OCT-1999; 99US-0157117P.  
PR 05-OCT-1999; 99US-0157753P.  
PR 06-OCT-1999; 99US-0157865P.  
PR 07-OCT-1999; 99US-0158029P.  
PR 08-OCT-1999; 99US-0158232P.

PR 12-OCT-1999; 99US-0158369P.  
PR 13-OCT-1999; 99US-0159293P.  
PR 13-OCT-1999; 99US-0159294P.  
PR 13-OCT-1999; 99US-0159295P.  
PR 14-OCT-1999; 99US-0159329P.  
PR 14-OCT-1999; 99US-0159330P.  
PR 14-OCT-1999; 99US-0159331P.  
PR 14-OCT-1999; 99US-0159637P.  
PR 14-OCT-1999; 99US-0159638P.  
PR 18-OCT-1999; 99US-0159584P.  
PR 21-OCT-1999; 99US-0160741P.  
PR 21-OCT-1999; 99US-0160767P.  
PR 21-OCT-1999; 99US-0160768P.  
PR 21-OCT-1999; 99US-0160770P.  
PR 21-OCT-1999; 99US-0160814P.  
PR 21-OCT-1999; 99US-0160815P.  
PR 22-OCT-1999; 99US-0160980P.  
PR 22-OCT-1999; 99US-0160981P.  
PR 22-OCT-1999; 99US-0160989P.  
PR 25-OCT-1999; 99US-0161404P.  
PR 25-OCT-1999; 99US-0161405P.  
PR 25-OCT-1999; 99US-0161406P.  
PR 26-OCT-1999; 99US-0161359P.  
PR 26-OCT-1999; 99US-0161360P.  
PR 26-OCT-1999; 99US-0161361P.  
PR 28-OCT-1999; 99US-0161920P.  
PR 28-OCT-1999; 99US-0161992P.  
PR 28-OCT-1999; 99US-0161993P.  
PR 29-OCT-1999; 99US-0162142P.

Query Match 38.2%; Score 52; DB 3; length 448;  
Best Local Similarity 50.0%; Pred. No. 23;  
Matches 12; Conservative 2; Mismatches 10; Indels 0; Gaps 0;

OY 4 FSTEMANKAAEAVLKGOETIVSF 27  
DB 185 FSTRLANLENVLKGEPTIAAF 208

RESULT 23  
AAG33444  
ID AAG33444 standard; protein; 509 AA.  
XX  
AC AAG33444;  
XX  
DT 18-OCT-2000 (first entry)  
XX  
DE Zea mays protein fragment SEQ ID NO: 40523.  
XX  
KW Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence; corn.  
XX  
OS Zea mays subsp. mays.  
XX  
PN EP1033405-A2.  
XX  
PD 06-SEP-2000.  
XX  
PF 25-FEB-2000; 2000EP-00301439.  
XX  
PR 25-FEB-1999; 99US-0121825P.  
PR 05-MAR-1999; 99US-0123180P.  
PR 09-MAR-1999; 99US-0123548P.  
PR 23-MAR-1999; 99US-0125788P.  
PR 25-MAR-1999; 99US-0126264P.  
PR 29-MAR-1999; 99US-0126785P.  
PR 01-APR-1999; 99US-0127462P.  
PR 06-APR-1999; 99US-0128234P.  
PR 08-APR-1999; 99US-0128714P.  
PR 16-APR-1999; 99US-0129845P.  
PR 19-APR-1999; 99US-0130077P.  
PR 21-APR-1999; 99US-0130449P.

PR 23-APR-1999; 99US-0130510P.  
PR 23-APR-1999; 99US-0130891P.  
PR 28-APR-1999; 99US-0131449P.  
PR 30-APR-1999; 99US-0132048P.  
PR 30-APR-1999; 99US-0132407P.  
PR 04-MAY-1999; 99US-0132484P.  
PR 05-MAY-1999; 99US-0132485P.  
PR 06-MAY-1999; 99US-0132486P.  
PR 06-MAY-1999; 99US-0132487P.  
PR 07-MAY-1999; 99US-0132863P.  
PR 11-MAY-1999; 99US-0134256P.  
PR 14-MAY-1999; 99US-0134218P.  
PR 14-MAY-1999; 99US-0134219P.  
PR 14-MAY-1999; 99US-0134221P.  
PR 18-MAY-1999; 99US-0134370P.  
PR 18-MAY-1999; 99US-0134768P.  
PR 19-MAY-1999; 99US-0134941P.  
PR 20-MAY-1999; 99US-0135124P.  
PR 21-MAY-1999; 99US-0135353P.  
PR 24-MAY-1999; 99US-0135629P.  
PR 25-MAY-1999; 99US-0136021P.  
PR 27-MAY-1999; 99US-0136392P.  
PR 28-MAY-1999; 99US-0136782P.  
PR 01-JUN-1999; 99US-0137222P.  
PR 03-JUN-1999; 99US-0137528P.  
PR 04-JUN-1999; 99US-0137502P.  
PR 07-JUN-1999; 99US-0137724P.  
PR 08-JUN-1999; 99US-0138094P.  
PR 10-JUN-1999; 99US-0138540P.  
PR 10-JUN-1999; 99US-0138847P.  
PR 14-JUN-1999; 99US-0139119P.  
PR 16-JUN-1999; 99US-0139452P.  
PR 16-JUN-1999; 99US-0139453P.  
PR 17-JUN-1999; 99US-0139492P.  
PR 18-JUN-1999; 99US-0139454P.  
PR 18-JUN-1999; 99US-0139455P.  
PR 18-JUN-1999; 99US-0139456P.  
PR 18-JUN-1999; 99US-0139457P.  
PR 18-JUN-1999; 99US-0139458P.  
PR 18-JUN-1999; 99US-0139459P.  
PR 18-JUN-1999; 99US-0139460P.  
PR 18-JUN-1999; 99US-0139461P.  
PR 18-JUN-1999; 99US-0139462P.  
PR 18-JUN-1999; 99US-0139463P.  
PR 18-JUN-1999; 99US-0139750P.  
PR 18-JUN-1999; 99US-0139763P.  
PR 21-JUN-1999; 99US-0139817P.  
PR 22-JUN-1999; 99US-0139899P.  
PR 23-JUN-1999; 99US-0140353P.  
PR 23-JUN-1999; 99US-0140354P.  
PR 24-JUN-1999; 99US-0140695P.  
PR 28-JUN-1999; 99US-0140823P.  
PR 29-JUN-1999; 99US-0140991P.  
PR 30-JUN-1999; 99US-0141287P.  
PR 01-JUL-1999; 99US-0141842P.  
PR 02-JUL-1999; 99US-0142055P.  
PR 06-JUL-1999; 99US-0142390P.  
PR 08-JUL-1999; 99US-0142803P.  
PR 09-JUL-1999; 99US-0142920P.  
PR 12-JUL-1999; 99US-0142977P.  
PR 13-JUL-1999; 99US-0143542P.  
PR 14-JUL-1999; 99US-0143624P.  
PR 15-JUL-1999; 99US-0144005P.  
PR 16-JUL-1999; 99US-0144085P.  
PR 16-JUL-1999; 99US-0144086P.  
PR 19-JUL-1999; 99US-0144325P.  
PR 19-JUL-1999; 99US-0144331P.  
PR 19-JUL-1999; 99US-0144332P.  
PR 19-JUL-1999; 99US-0144333P.  
PR 19-JUL-1999; 99US-0144334P.  
PR 19-JUL-1999; 99US-0144335P.  
PR 20-JUL-1999; 99US-0144352P.

PR 20-JUL-1999; 99US-0144632P.  
PR 20-JUL-1999; 99US-0144684P.  
PR 21-JUL-1999; 99US-0144814P.  
PR 21-JUL-1999; 99US-0145086P.  
PR 21-JUL-1999; 99US-0145088P.  
PR 22-JUL-1999; 99US-0145085P.  
PR 22-JUL-1999; 99US-0145087P.  
PR 22-JUL-1999; 99US-0145089P.  
PR 22-JUL-1999; 99US-0145192P.  
PR 23-JUL-1999; 99US-0145145P.  
PR 23-JUL-1999; 99US-0145218P.  
PR 23-JUL-1999; 99US-0145224P.  
PR 26-JUL-1999; 99US-0145276P.  
PR 27-JUL-1999; 99US-0145913P.  
PR 27-JUL-1999; 99US-0145918P.  
PR 27-JUL-1999; 99US-0145919P.  
PR 28-JUL-1999; 99US-0145951P.  
PR 02-AUG-1999; 99US-0146386P.  
PR 02-AUG-1999; 99US-0146388P.  
PR 03-AUG-1999; 99US-0147038P.  
PR 04-AUG-1999; 99US-0147204P.  
PR 04-AUG-1999; 99US-0147302P.  
PR 05-AUG-1999; 99US-0147192P.  
PR 05-AUG-1999; 99US-0147260P.  
PR 06-AUG-1999; 99US-0147303P.  
PR 06-AUG-1999; 99US-0147416P.  
PR 09-AUG-1999; 99US-0147493P.  
PR 09-AUG-1999; 99US-0147935P.  
PR 10-AUG-1999; 99US-0148171P.  
PR 11-AUG-1999; 99US-0148319P.  
PR 12-AUG-1999; 99US-0148341P.  
PR 13-AUG-1999; 99US-0148565P.  
PR 16-AUG-1999; 99US-0148684P.  
PR 17-AUG-1999; 99US-0149175P.  
PR 18-AUG-1999; 99US-0149426P.  
PR 20-AUG-1999; 99US-0149722P.  
PR 20-AUG-1999; 99US-0149723P.  
PR 20-AUG-1999; 99US-0149929P.  
PR 23-AUG-1999; 99US-0149930P.  
PR 25-AUG-1999; 99US-0150566P.  
PR 26-AUG-1999; 99US-0150884P.  
PR 27-AUG-1999; 99US-0151065P.  
PR 27-AUG-1999; 99US-0151066P.  
PR 27-AUG-1999; 99US-0151080P.  
PR 30-AUG-1999; 99US-0151303P.  
PR 31-AUG-1999; 99US-0151438P.  
PR 01-SEP-1999; 99US-0151930P.  
PR 07-SEP-1999; 99US-0152630P.  
PR 10-SEP-1999; 99US-0153070P.  
PR 13-SEP-1999; 99US-0153758P.  
PR 15-SEP-1999; 99US-0154018P.  
PR 16-SEP-1999; 99US-0154039P.  
PR 20-SEP-1999; 99US-0154779P.  
PR 22-SEP-1999; 99US-0155139P.  
PR 23-SEP-1999; 99US-0155486P.  
PR 24-SEP-1999; 99US-0155659P.  
PR 28-SEP-1999; 99US-0156458P.  
PR 29-SEP-1999; 99US-0156596P.  
PR 04-OCT-1999; 99US-0157117P.  
PR 05-OCT-1999; 99US-0157753P.  
PR 06-OCT-1999; 99US-0157865P.  
PR 07-OCT-1999; 99US-0158029P.  
PR 08-OCT-1999; 99US-0158232P.  
PR 12-OCT-1999; 99US-0158369P.  
PR 13-OCT-1999; 99US-0159293P.  
PR 13-OCT-1999; 99US-0159294P.  
PR 13-OCT-1999; 99US-0159295P.  
PR 14-OCT-1999; 99US-0159329P.  
PR 14-OCT-1999; 99US-0159330P.  
PR 14-OCT-1999; 99US-0159331P.

PR 14-OCT-1999; 99US-0159637P.  
PR 14-OCT-1999; 99US-0159638P.  
PR 18-OCT-1999; 99US-0159584P.  
PR 21-OCT-1999; 99US-0160741P.  
PR 21-OCT-1999; 99US-0160767P.  
PR 21-OCT-1999; 99US-0160768P.  
PR 21-OCT-1999; 99US-0160770P.  
PR 21-OCT-1999; 99US-0160814P.  
PR 21-OCT-1999; 99US-0160815P.  
PR 22-OCT-1999; 99US-0160980P.  
PR 22-OCT-1999; 99US-0160981P.  
PR 22-OCT-1999; 99US-0160989P.  
PR 25-OCT-1999; 99US-0161404P.  
PR 25-OCT-1999; 99US-0161405P.  
PR 25-OCT-1999; 99US-0161406P.  
PR 26-OCT-1999; 99US-0161359P.  
PR 26-OCT-1999; 99US-0161360P.  
PR 26-OCT-1999; 99US-0161361P.  
PR 28-OCT-1999; 99US-0161920P.  
PR 28-OCT-1999; 99US-0161992P.  
PR 28-OCT-1999; 99US-0161993P.  
PR 29-OCT-1999; 99US-0162142P.

Query Match 38.2%; Score 52; DB 3; length 509;  
Best Local Similarity 50.0%; Pred. No. 27;  
Matches 12; Conservative 2; Mismatches 10; Indels 0; Gaps 0;

OY 4 FSTEMANKAEAVLKQVETIVSF 27  
DB 246 FSTRLANLENLVLEKEPETIAAF 269

RESULT 24

ABB60387  
ID ABB60387 standard; protein; 1049 AA.  
XX  
AC ABB60387;  
XX  
DT 26-MAR-2002 (first entry)  
XX  
DE Drosophila melanogaster polypeptide SEQ ID NO 7953.  
XX  
KW Drosophila; developmental biology; cell signalling; insecticide;  
KW pharmaceutical.  
XX  
OS Drosophila melanogaster.  
XX  
PN WO200171042-A2.  
XX  
PD 27-SEP-2001.  
XX  
PF 23-MAR-2001; 2001WO-US009231.  
XX  
PR 23-MAR-2000; 2000US-0191637P.  
PR 11-JUL-2000; 2000US-00614150.  
XX  
PA (PEKE ) PE CORP NY.  
XX  
PI Venter JC, Adams M, Li PWD, Myers EW;  
XX  
DR WPI; 2001-656860/75.  
DR N-PSDB; ABL04490.  
XX  
PT New isolated nucleic acid detection reagent for detecting 1000 or more  
PT genes from Drosophila and for elucidating cell signaling and cell-cell  
PT interactions.  
XX  
PS Disclosure; SEQ ID NO 7953; 21pp + Sequence Listing; English.  
XX  
CC The invention relates to an isolated nucleic acid detection reagent  
CC capable of detecting 1000 or more genes from Drosophila. The invention is  
CC useful in developmental biology and in elucidating cell signalling and  
CC cell-cell interactions in higher eukaryotes for the development of

CC insecticides, therapeutics and pharmaceutical drugs. The invention  
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA  
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-  
CC ABB72072). The sequence data for this patent did not form part of the  
CC printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 1049 AA;

Query Match 37.5%; Score 51; DB 4; length 1049;  
Best Local Similarity 40.7%; Pred. No. 92;  
Matches 11; Conservative 5; Mismatches 11; Indels 0; Gaps 0;

OY 2 YFSTEMANKAEAVLKQVETIVSFH 28  
DB 471 YVSCSDMAASATEAVRSGELKTIPEHH 497

RESULT 25

ABB89793  
ID ABB89793 standard; protein; 130 AA.  
XX  
AC ABB89793;  
XX  
DT 24-MAY-2002 (first entry)  
XX  
DE Human polypeptide SEQ ID NO 2169.  
XX  
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;  
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;  
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;  
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;  
KW neurological disease; infection; human; secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO200190304-A2.  
XX  
PD 29-NOV-2001.  
XX  
PF 18-MAY-2001; 2001WO-US016450.  
XX  
PR 19-MAY-2000; 2000US-0205515P.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Birse CE, Rosen CA;  
XX  
DR WPI; 2002-122018/16.  
DR N-PSDB; ABL90202.  
XX  
PT Novel 1405 isolated polypeptides, useful for diagnosis, treatment and  
PT prevention of neural, immune system, muscular, reproductive,  
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative  
PT disorders.  
XX  
PS Claim 11; SEQ ID NO 2169; 2081pp + Sequence Listing; English.  
XX  
CC The invention relates to novel genes (ABL89449-ABL90853) and proteins  
CC (ABB89040-ABB90444) useful for preventing, treating or ameliorating  
CC medical conditions e.g. by protein or gene therapy. The genes are  
CC isolated from a range of human tissues disclosed in the specification.  
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in  
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and  
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,  
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune  
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic  
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,  
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)  
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing  
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)  
CC infectious diseases such as viral, bacterial, fungal and parasitic  
CC infections. Note: The sequence data for this patent did not form part of

CC the printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 130 AA;

Query Match 36.8%; Score 50; DB 5; Length 130;  
Best Local Similarity 44.4%; Pred. No. 11;  
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

DY 2 YVFSTEMANKAAEAVLKQVETIVSFH 28  
:|::||::|::|  
Db 67 FVRCEMGARAKAVESGALFLSPSFH 93

RESULT 26  
ABG15088  
ID ABG15088 standard; protein; 365 AA.  
XX  
AC ABG15088;  
XX  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #15079.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KM food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US008631.  
XX  
PR 31-MAR-2000; 2000US-00540217.  
PR 23-AUG-2000; 2000US-00649167.  
XX  
PA (HYSE-) HYSEQ INC.  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR WPI; 2001-639362/73.  
XX N-PSDB; AAS79275.

New isolated polynucleotide and encoded polypeptides, useful in  
diagnostics, forensics, gene mapping, identification of mutations  
responsible for genetic disorders or other traits and to assess  
biodiversity.

Claim 20; SEQ ID NO 45447; 103pp; English.

The invention relates to isolated polynucleotide (I) and polypeptide (II)  
sequences. (I) is useful as hybridisation probes, polymerase chain  
reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
and in recombinant production of (II). The polynucleotides are also used  
in diagnostics as expressed sequence tags for identifying expressed  
genes. (I) is useful in gene therapy techniques to restore normal  
activity of (II) or to treat disease states involving (II). (II) is  
useful for generating antibodies against it, detecting or quantitating a  
polypeptide in tissue, as molecular weight markers and as a food  
supplement. (II) and its binding partners are useful in medical imaging  
of sites expressing (II). (I) and (II) are useful for treating disorders  
involving aberrant protein expression or biological activity. The  
polypeptide and polynucleotide sequences have applications in  
diagnostics, forensics, gene mapping, identification of mutations  
responsible for genetic disorders or other traits to assess biodiversity  
and to produce other types of data and products dependent on DNA and  
amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
amino acid sequences of the invention. Note: The sequence data for this  
patent did not appear in the printed specification, but was obtained in  
electronic format directly from WIPO at  
ftp.wipo.int/pub/published\_pct\_sequences

XX	SO	Sequence	365 AA;
OY	Query Match	36.8%; Score 50; DB 4; Length 365;	
	Best Local Similarity	29.6%; Pred. No. 38;	
	Matches	8; Conservative	8; Mismatches 11; Indels 0; Gaps 0
Db		2 YVFESTEMANKAAEAVLKQGVETIVSFH 28    :: :: :: ::  67 YVFAYPVCNAsAKTIISGLTECLIHCH 93	
RESULT 27			
AAE15740			
ID	AAE15740	standard; protein; 621 AA.	
AC	AAE15740;		
DT	26-MAR-2002	(first entry)	
DE	Human aminoacyl-tRNA synthetase-3 (ATRS-3).		
KW	Human; aminoacyl-tRNA synthetase; ATRS; cell proliferative disorder; cancer; actinic keratosis; arteriosclerosis; atherosclerosis; bursitis; cirrhosis; immunostimulant; antithyroid; immunosuppressive; fungicide; hepatitis; psoriasis; autoimmune disorder; inflammatory disorder; acquired immune deficiency syndrome; AIDS; Addison's disease; allergy; adult respiratory distress syndrome; anaemia; autoimmune thyroiditis; osteoporosis; autoimmune haemolytic anaemia; hepatotropic; anthelmintic; Crohn's disease; atopic dermatitis; diabetic mellitus; Graves' disease; glomerulonephritis; rheumatoid arthritis; scleroderma; osteopathic; systemic lupus erythematosus; systemic sclerosis; ulcerative colitis; haemodialysis; uveitis; infection; single nucleotide polymorphism; gene therapy; cytostatic; dermatological; antiulcer; antibacterial; virucide; antiparasitic; protozoacide; tranquiliser; vulnerary; human immunodeficiency virus; antiinflammatory; nephrotropic; ophthalmological; anti-HIV; asthma.		
OS	Homo sapiens.		
PN	WO200190330-A2.		
PD	29-NOV-2001.		
Pf	22-MAY-2001; 2001WO-US016808.		
PR	25-MAY-2000; 2000US-0207248P. 01-JUN-2000; 2000US-0208791P. 08-JUN-2000; 2000US-0210585P.		
PA	(INCY-) INCYTE GENOMICS INC.		
PI	Yue H, Tang TY, Patterson C, Gandhi AR, Tribouley CM, Lee EA; Yao MG, Bandman O, Lu DAM;		
PT	Novel human aminoacyl-tRNA synthetase polypeptides and polynucleotides for diagnosing, preventing or treating Addison's disease, allergies, asthma, rheumatoid arthritis, scleroderma, systemic lupus erythematosus.		
PS	Claim 1; Page 98-99; 103pp; English.		

CC actinic keratosis, arteriosclerosis, atherosclerosis, bursitis,  
CC cirrhosis, hepatitis and psoriasis, autoimmune/inflammatory disorders  
CC such as acquired immune deficiency syndrome (AIDS), adult respiratory  
CC distress syndrome, Addison's disease, allergies, anaemia, asthma,  
CC osteoporosis, autoimmune haemolytic anaemia, autoimmune thyroiditis,  
CC Crohn's disease, atopic dermatitis, diabetic mellitus, Graves' disease,  
CC glomerulonephritis, rheumatoid arthritis, scleroderma, systemic lupus  
CC erythematosus, systemic sclerosis, ulcerative colitis, haemodialysis,  
CC uveitis, viral, bacterial, fungal, parasitic, protozoal, helminthic  
CC infections and trauma. ATRS DNA is also useful for generating  
CC hybridisation probes useful in mapping the naturally occurring genomic  
CC sequence and oligonucleotide primers derived from it are useful to detect  
CC single nucleotide polymorphisms. ATRS DNA is used in gene therapy. The  
CC present sequence is human ATRS-3 protein  
XX  
SQ Sequence 621 AA;  
  
Query Match 36.8%; Score 50; DB 5; Length 621;  
Best Local Similarity 44.4%; Pred. No. 71;  
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;  
  
QY 2 YVFSTEMANKAAEAVLKQVETIVSFH 28  
:| ||| :||:| | :| |||  
Db 39 FVRCQEMGARAARAKAVESGALIELSPSFH 65  
  
RESULT 28  
AAB43285  
ID AAB43285 standard; protein; 631 AA.  
XX  
AC AAB43285;  
XX  
DT 08-FEB-2001 (first entry)  
XX  
DE Human ORFX ORF3049 polypeptide sequence SEQ ID NO:6098.  
XX  
KW Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;  
KW vulnery; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;  
KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;  
KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;  
KW hypotensive; dermatological; immunosuppressive; antirheumatic;  
KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;  
KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;  
KW neurodegenerative disorder; osteoarthritis; graft vs host disease;  
KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;  
KW cholesterol ester storage; systemic lupus erythematosus; infection;  
KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;  
KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;  
KW bone damage; cartilage damage; antiinflammatory disease; coagulation;  
KW thrombosis; contraceptive.  
XX  
OS Homo sapiens.  
XX  
PN WO200058473-A2.  
XX  
PD 05-OCT-2000.  
XX  
PF 31-MAR-2000; 2000WO-US008621.  
XX  
PR 31-MAR-1999; 99US-0127607P.  
PR 02-APR-1999; 99US-0127636P.  
PR 05-APR-1999; 99US-0127728P.  
PR 30-MAR-2000; 2000US-00540763.  
XX  
PA (CURA-) CURAGEN CORP.  
XX  
PI Shimkets RA, Leach M;  
XX  
DR WPI; 2000-602362/57.  
DR N-PSDB; AAC77494.  
XX  
PT Novel nucleic acids and peptides derived from open reading frame X,  
PT useful for treating e.g. cancers, proliferative disorders,

PT neurodegenerative disorders and cardiovascular disease.  
XX  
PS Claim 11; Page 5281-5283; 5507pp; English.  
XX  
CC AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,  
CC which represent the human ORFX open reading frames 1 to 3161. The ORFX  
CC sequences have activities such as: cytostatic; hepatotropic; vulnery;  
CC antipsoriatic; antiparkinsonian; nootropic; neuroprotective; osteopathic;  
CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;  
CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;  
CC dermatological; immunosuppressive; antiinflammatory; antibacterial;  
CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The  
CC sequences can be used for determining the presence of or predisposition  
CC to, or preventing or treating pathological conditions associated with an  
CC ORFX-associated disorder. The nucleic acids can be used to express ORFX  
CC proteins in gene therapy vectors. The proteins and nucleic acids may be  
CC used to treat cancers, proliferative disorders, neurodegenerative  
CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,  
CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester  
CC storage, systemic lupus erythematosus, severe combined immunodeficiency  
CC (SCID), AIDS, viral, bacterial or fungal infection, malaria, autoimmune  
CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and  
CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to  
CC enhance coagulation; to inhibit thrombosis; and as a contraceptive  
XX  
SQ Sequence 631 AA;  
  
Query Match 36.8%; Score 50; DB 3; Length 631;  
Best Local Similarity 44.4%; Pred. No. 72;  
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;  
  
QY 2 YVFSTEMANKAAEAVLKQVETIVSFH 28  
:| ||| :||:| | :| |||  
Db 47 FVRCQEMGARAARAKAVESGALIELSPSFH 73  
  
RESULT 29  
ABM80775  
ID ABM80775 standard; protein; 694 AA.  
XX  
AC ABM80775;  
XX  
DT 18-NOV-2004 (first entry)  
XX  
DE Tumour-associated antigenic target (TAT) polypeptide PRO81404, SEQ:1996.  
XX  
KW Tumour-associated antigenic target; TAT; human; overexpression; cancer;  
KW tumour; diagnosis; cell proliferative disorder; breast cancer;  
KW colorectal cancer; lung cancer; ovarian cancer; liver cancer;  
KW central nervous system cancer; bladder cancer; pancreatic cancer;  
KW cervical cancer; melanoma; leukaemia; hybridisation probe;  
KW chromosome identification; chromosome mapping; gene mapping;  
KW gene therapy; cytostatic.  
XX  
OS Homo sapiens.  
XX  
PN WO2004030615-A2.  
XX  
PD 15-APR-2004.  
XX  
PF 29-SEP-2003; 2003WO-US028547.  
XX  
PR 02-OCT-2002; 2002US-0414971P.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Wu TD, Zhang Z, Zhou Y;  
XX  
DR WPI; 2004-347921/32.  
DR N-PSDB; ACN38464.  
XX  
PT New tumor-associated antigenic target polypeptides and nucleic acids,  
PT useful in preparing a medicament for treating or detecting a

PT proliferative disorder, e.g. breast, lung, colorectal, ovarian or  
PT prostate cancer or tumor.  
XX  
PS Claim 12; SEQ ID NO 1996; 7273pp; English.  
XX  
CC The invention relates to human tumour-associated antigenic target (TAT)  
CC polypeptides, and their related nucleic acids. The TAT polypeptides are  
CC overexpressed in cancer tissues compared to normal tissues, and may thus  
CC serve as effective targets for the diagnosis and treatment of cancer in  
CC mammals. The invention also relates to nucleic acid and polypeptide  
CC sequences at least 80% identical to the TAT nucleic acids and  
CC polypeptides; expression vectors and host cells comprising a TAT nucleic  
CC acid; an antibody specific for a TAT polypeptide; a peptide or organic  
CC molecule which binds to a TAT polypeptide; fusion proteins comprising a  
CC TAT polypeptide; and methods and compositions for the treatment or  
CC diagnosis of cancer in mammals. TAT polypeptides, nucleic acids,  
CC antibodies, antagonists, binding molecules and compositions are useful  
CC for diagnosing or treating a cell proliferative disorder associated with  
CC increased TAT expression, particularly cancers such as breast cancer,  
CC colorectal cancer, lung cancer, ovarian cancer, liver cancer, bladder  
CC cancer, pancreatic cancer, cervical cancer, cancers of the central  
CC nervous system, melanoma and leukaemia. TAT nucleic acids may further be  
CC used as hybridisation probes, in chromosome and gene mapping, in  
CC chromosome identification and in gene therapy. The present sequence  
CC represents a TAT polypeptide of the invention  
XX  
SQ Sequence 694 AA;  
  
Query Match 36.8%; Score 50; DB 8; Length 694;  
Best Local Similarity 44.4%; Pred. No. 81;  
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;  
  
QY 2 YVFSTEMANKAAEAVLKGOVETIVSFH 28  
:| || :||:| | :| |||  
Db 112 FVRCQEMGARAARAKAVESGALILSPSFH 138  
  
RESULT 30  
AD16244  
ID AD16244 standard; protein; 961 AA.  
XX  
AC AD16244;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human nucleic acid-associated protein (NAAP) #29.  
XX  
KW human; nucleic acid-associated protein; NAAP; autoimmune disorder;  
KW inflammatory disorder; AIDS; allergy; infection; metabolic disorder;  
KW obesity; reproductive disorder; infertility; neurological disorder;  
KW Parkinson's disease; Alzheimer's disease; cardiovascular disorder;  
KW myocardial infarction; hypertension; eye disorder;  
KW cell proliferative disease; cancer.  
XX  
OS Homo sapiens.  
XX  
PN WO2003094848-A2.  
XX  
PD 20-NOV-2003.  
XX  
PF 09-MAY-2003; 2003WO-US014450.  
XX  
PR 10-MAY-2002; 2002US-0379843P.  
PR 24-MAY-2002; 2002US-0383457P.  
PR 31-MAY-2002; 2002US-0384699P.  
PR 06-JUN-2002; 2002US-0387265P.  
XX  
PA (INCY-) INCYTE CORP.  
XX  
PI Kable AB, Eliott VS, Tran UK, Ramkumar J, Marquis JP, Chawla NK;  
PI Richardson TW, Bulloch SA, Khare R, Lee SY, Lai PG, Tang YT, Yue H;  
PI Swarnakar A, Becha SD, Hafalia AJA, Chang H, Baughn MR, Borowsky ML;  
PI Gietzen KJ, He A, Forsythe J, Sprague WW, Blake JJ, Warren BA;

PI Mason PM, Ison CH, Lindquist EA, Wilson AD, Jin P;  
XX  
XX WPI; 2004-011999/01.  
DR N-PSDB; AD16294.  
XX  
PT New human nucleic acid associated proteins and polynucleotides, useful  
PT for diagnosing, preventing or treating diseases or conditions associated  
PT with aberrant protein expression, e.g. cancer, AIDS, atherosclerosis or  
PT stroke.  
XX  
PS Claim 1; SEQ ID NO 29; 400pp; English.  
XX  
CC The invention comprises the amino acid and coding sequences of human  
CC nucleic acid-associated proteins (NAAP). The DNA and protein sequences of  
CC the invention are useful in diagnosing, preventing and treating  
CC diseases/conditions associated with altered expression of NAAP, such as:  
CC autoimmune/inflammatory disorders (e.g. AIDS and allergies), infections  
CC (e.g. bacterial and viral), metabolic disorders (e.g. obesity),  
CC reproductive disorders (e.g. infertility), neurological disorders (e.g.  
CC Parkinson's disease and Alzheimer's disease), cardiovascular disorders  
CC (e.g. myocardial infarction and hypertension), eye disorders, or cell  
CC proliferative diseases (e.g. cancer). The present amino acid sequence  
CC represents a human NAAP protein of the invention.  
XX  
SQ Sequence 961 AA;  
  
Query Match 36.8%; Score 50; DB 8; Length 961;  
Best Local Similarity 44.4%; Pred. No. 1.2e+02;  
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;  
  
QY 2 YVFSTEMANKAAEAVLKGOVETIVSFH 28  
:| || :||:| | :| |||  
Db 481 FVRCQEMGARAARAKAVESGALILSPSFH 507  
  
RESULT 31  
ABB08919  
ID ABB08919 standard; protein; 1063 AA.  
XX  
AC ABB08919;  
XX  
DT 21-OCT-2002 (first entry)  
XX  
DE Human aminoacyl tRNA synthetase (ATRS-1).  
XX  
KW Human; aminoacyl tRNA synthetase; ATRS-1; valyl-tRNA synthetase; Class I;  
KW Rossman fold; cell proliferative disorder; cancer; psoriasis;  
KW atherosclerosis; cirrhosis; hepatitis; autoimmune disorder;  
KW inflammatory disorder; allergy; acquired immunodeficiency syndrome; AIDS;  
KW anaemia; diabetes; dermatomyositis; polymyositis; rheumatoid arthritis;  
KW trauma; infection; immunomodulator; immunosuppressive; cytostatic;  
KW antiarthritic; gene therapy; enzyme.  
XX  
OS Homo sapiens.  
XX  
FH Key  
FH Region  
FT 1..612 Location/Qualifiers  
FT /note= "Cytosolic N-terminal region"  
FT 112..794  
FT /note= "Aminoacyl tRNA synthetase Class I (I, L, M and V)  
FT domain"  
FT 132..181  
FT /note= "Aminoacyl tRNA synthetase Class I signature  
FT motif"  
FT 139..150  
FT /note= "Valyl-tRNA synthetase signature motif"  
FT 146..157  
FT /note= "Aminoacyl tRNA synthetase Class I signature  
FT motif"  
FT 351..368  
FT /note= "Valyl-tRNA synthetase signature motif"  
FT 467..480  
FT /note= "Valyl-tRNA synthetase signature motif"



FT	Region	579. .600
FT		/note= "Valyl-tRNA synthetase signature motif"
FT	Region	610. .628
FT		/note= "Valyl-tRNA synthetase signature motif"
FT	Domain	613. .634
FT		/label= Transmembrane_domain
FT	Domain	841. .858
FT		/label= Transmembrane_domain
PN	WO200259323-A2.	
XX		
PD	01-AUG-2002.	
XX		
PF	13-DEC-2001; 2001WO-US048575.	
XX		
PR	15-DEC-2000; 2000US-0255963P.	
PA	(INCY-) INCYTE GENOMICS INC.	
XX		
PI	Lee EA, Baughn MR;	
XX		
DR	WPI; 2002-599795/64.	
DR	N-PSDB; ABA97729.	
PT	New aminoacyl tRNA synthetases, useful for diagnosing, treating or preventing autoimmune or inflammatory disorders (e.g. AIDS, allergies or anemia) or cell proliferative disorders (e.g. cancers, atherosclerosis or hepatitis).	
PT		
PS	Claim 1; Page 89-91; 92pp; English.	
XX		
CC	The invention relates to a novel human aminoacyl tRNA synthetase designated ATRS-1 (ABB08919) and cDNA encoding it (ABA97729). ATRS-1 is thought to be a valyl-tRNA synthetase, based on its 50% homology to mouse valyl-tRNA synthetase and the presence of a tRNA synthetase Class I (I, L, M and V) domain. Class I enzymes such as ATRS-1 contain a catalytic domain based on a nucleotide-binding motif known as the Rossman fold, and add amino acids to the 2' hydroxyl group at the 3' end of tRNAs. ATRS-1 nucleotides, polypeptides, agonists and antagonists may be used for diagnosing, treating or preventing disorders associated with aberrant expression of aminoacyl tRNA synthetases. Such disorders include cell proliferative disorders (e.g., cancers, psoriasis, atherosclerosis, cirrhosis and hepatitis); autoimmune or inflammatory disorders (e.g., allergies, AIDS (acquired immunodeficiency syndrome), anaemia, diabetes, dermatomyositis, polyomyositis and rheumatoid arthritis); trauma; and viral, bacterial, fungal, parasitic, protozoal or helminthic infections. They are also useful in screening for modulators of ATRS-1 expression or activity. The present sequence represents human aminoacyl tRNA synthetase ATRS-1	
CC		
XX		
SQ	Sequence 1063 AA;	
QY	Query Match	36.8%; Score 50; DB 5; Length 1063;
	Best Local Similarity	44.4%; Pred. No. 1.3e+02;
	Matches 12; Conservative	4; Mismatches 11; Indels 0; Gaps 0;
	2 YVFSTEMANKAAEAVLKQGVETIVSFH 28	
	: : : : : : :	
Db	481 FVRCQEMGARAKAVESGALIELSPSFH 507	
RESULT 32		
ADJ70652		
ID	ADJ70652 standard; protein; 1063 AA.	
XX		
AC	ADJ70652;	
XX		
DT	06-MAY-2004 (first entry)	
XX		
DE	Human heat mitochondrial protein as a therapeutic target SeqID2458.	
XX		
KM	mitochondrial; human; screening assay; diabetes mellitus; Huntington's disease; osteoarthritis;	
KM		

```

KW Leber's hereditary optic neuropathy; LHON;
KW mitochondrial encephalopathy lactic acidosis and stroke; MELAS;
KW myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;
KW neuroprotective; nootropic; antidiabetic; anticonvulsant; antiarthritic;
KW osteopathic; ophthalmological; cyostatic.
XX
XX Homo sapiens.
XX
XX WO2003087768-A2.
XX
XX PD 23-OCT-2003.
XX
XX PF 04-APR-2003; 2003WO-US010870.
XX
XX PR 12-APR-2002; 2002US-0372843P.
XX PR 17-JUN-2002; 2002US-0389987P.
XX PR 20-SEP-2002; 2002US-0412418P.
XX
PA (MITO-) MITOKOR.
PA (BUCK-) BUCK INST AGE RES.
PI Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;
PI Warnock DE;
XX DR WPI; 2003-845369/78.
XX
PT Identifying a mitochondrial target for drug screening assays and for
PT treating diseases associated with altered mitochondrial function,
PT comprises detecting a modified polypeptide in a sample and correlating
PT with the disease.
XX PS Claim 1; SEQ ID NO 2458; 180pp; English.
XX
CC This invention relates to novel mitochondrial targets that can be used
CC for therapeutic intervention in treating a disease associated with
CC altered mitochondrial function. Specifically, it refers to a method for
CC identifying proteins of the human heart mitochondrial proteome that are
CC useful for drug screening assays, as well as therapeutic targets. The
CC present invention describes a method for identifying such proteins that
CC can be used in the treatment of various diseases associated with altered
CC mitochondrial function including diabetes mellitus, Huntington's disease,
CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial
CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy
CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these
CC compositions have neuroprotective, nootropic, antidiabetic,
CC anticonvulsant, antiarthritic, osteopathic, ophthalmological and
CC cyostatic activities. This polypeptide sequence is a human heart
CC mitochondrial protein of the invention.
XX SQ Sequence 1063 AA;
XX
Query Match 36.8%; Score 50; DB 7; Length 1063;
Best Local Similarity 44.4%; Pred. No. 1.3e+02;
Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;
QY 2 YVFSTEMANKAAEAVLKGOVETIVSFH 28
:|::||::||::|
Db 481 FVRCEMGARAKAVESGALFLSPSFH 507

```

KW cancer; peripheral nervous system; central nervous system;  
 KW Alzheimer's disease; Parkinson's disease; multiple sclerosis;  
 KW amyotrophic lateral sclerosis; viral infection; prion infection;  
 KW ocular disease; migraine; pain; sexual dysfunction; mood disorder;  
 KW attention disorder; cognition disorder; hypotension; hypertension;  
 KW psychotic disorder; neurological disorder; dyskinesia;  
 KW metabolic disorder; organ transplant rejection; enzyme.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003057841-A2.  
 XX  
 PD 17-JUL-2003.  
 XX  
 PF 31-DEC-2002; 2002WO-US041687.  
 XX  
 PR 31-DEC-2001; 2001US-0343169P.  
 XX  
 PA (GRIG/) GRIGORIEV I V.  
 PA (SUDA/) SUDARSANAM S.  
 XX  
 PI Grigoriev IV, Sudarsanam S;  
 XX  
 DR WPI; 2003-587115/55.  
 XX  
 PT New isolated, enriched or purified nucleic acid molecule encoding a  
 PT kinase polypeptide, useful for treating cancer, immune-related diseases,  
 PT cardiovascular disease, brain or neuronal-associated diseases and  
 PT metabolic disorders.  
 XX  
 PS Claim 1; SEQ ID NO 68; 491pp; English.  
 XX  
 CC The invention relates to novel isolated, enriched or purified nucleic acid  
 CC molecules encoding a kinase polypeptide. The nucleic acid molecule  
 CC comprises a sequence that: (a) encodes a kinase polypeptide; (b) is a  
 CC complement of (a); (c) hybridizes under stringent conditions to (a) and  
 CC encodes a naturally occurring kinase polypeptide; (d) encodes the  
 CC polypeptide in (a), except that it lacks one or more, but not all, of an  
 CC N-terminal domain, C-terminal catalytic domain, a catalytic domain, a C-  
 CC terminal domain, a coiled-coil structure region, a spacer region and a C-  
 CC terminal tail; or (e) is a complement of (d). The nucleic acid molecules,  
 CC polypeptides, methods and substance are useful for treating cancers,  
 CC immune-related diseases or disorders, cardiovascular disease, brain or  
 CC neuronal-associated diseases, and metabolic disorders. The disorders are  
 CC preferably cancers of the tissues or of hematopoietic origin, diseases of  
 CC the central or peripheral nervous system, Alzheimer's disease,  
 CC Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis,  
 CC viral infections, infections caused by prions, infections caused by  
 CC bacteria, infections caused by fungi, ocular diseases, migraines, pain,  
 CC sexual dysfunction, mood disorders, attention disorders, cognition  
 CC disorders, hypotension, hypertension, psychotic disorders, neurological  
 CC disorders, dyskinesias, metabolic disorders and organ transplant  
 CC rejection. This sequence corresponds to one of the kinase polypeptides of  
 CC the invention.  
 XX  
 SQ Sequence 1078 AA;  
 XX  
 Query Match 36.8%; Score 50; DB 7; Length 1078;  
 Best Local Similarity 44.4%; Pred. No. 1.4e+02;  
 Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;  
 QY 2 YVFSTEMANKAAEAVLKGQVETIVSFH 28  
 :| | | :| | | :| | | |  
 Db 469 FVRCQEMGARAKAVESGALELSPSFH 495  
 RESULT 34  
 ID ADR15680 standard; protein, 1078 AA.  
 XX  
 AC ADR15680;  
 XX  
 DT 04-NOV-2004 (first entry)

XX  
 DE Kinase 698561 hCT1827780 1, SEQ ID 73.  
 XX  
 KW Cytostatic; Cardiovascular; Neuroprotective; Nootropic; Antiparkinsonian;  
 KW Virucide; Cerebroprotective; Antibacterial; Fungicide; Ophthalmological;  
 KW Antimigraine; Analgesic; Endocrine; Tranquillizer; Hypotensive;  
 KW Immunosuppressive; Gene Therapy; kinase; enzyme; cancer;  
 KW immune-related disease; cardiovascular disease;  
 KW neuronal-associated disease; metabolic disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004069154-A2.  
 XX  
 PD 19-AUG-2004.  
 XX  
 PF 28-JAN-2003; 2003WO-US002234.  
 XX  
 PR 28-JAN-2003; 2003WO-US002234.  
 XX  
 PA (GRIG/) GRIGORIEV I V.  
 PA (SUDA/) SUDARSANAM S.  
 XX  
 PI Grigoriev IV, Sudarsanam S;  
 XX  
 DR WPI; 2004-604329/58.  
 DR N-PSDB; ADR15757.  
 XX  
 PT New isolated, enriched, or purified kinase nucleic acids and  
 PT polypeptides, useful for diagnosing or treating kinase-related diseases  
 PT and conditions, e.g. cardiovascular disease, brain or neuronal-associated  
 PT diseases, or metabolic disorders.  
 XX  
 PS Claim 7; Fig 2; 496pp; English.  
 XX  
 CC The present invention relates to a method for detecting remote  
 CC polypeptide homologues, comprising analysis of conserved secondary  
 CC structure pattern in a protein family, and conserved active site amino  
 CC acid residues. The analyses are used to identify conserved residues  
 CC embedded into the secondary structure pattern (CRISSP), which are used to  
 CC detect remote homologues of the referent protein family, wherein said  
 CC referent protein family is the protein kinase family. The present  
 CC sequence is a kinase, used to illustrate the method of the invention. The  
 CC kinases are useful for diagnosing or treating various kinase-related  
 CC diseases and conditions. Diseases or disorders include cancers, immune-  
 CC related diseases and disorders, cardiovascular disease, brain or neuronal  
 CC -associated diseases, or metabolic disorders. Preferably, the diseases or  
 CC disorders are cancers of tissues, cancers of hematopoietic origin,  
 CC diseases of the central nervous system, diseases of the peripheral  
 CC nervous system, Alzheimer's disease, Parkinson's disease, multiple  
 CC sclerosis, amyotrophic lateral sclerosis, viral infections, infections  
 CC caused by prions, infections caused by bacteria, infections caused by  
 CC fungi, or ocular diseases. The disease or disorder is also migraines,  
 CC pain, sexual dysfunction, mood disorders, attention disorders, cognition  
 CC disorders, hypertension, psychotic disorders, neurological disorders,  
 CC dyskinesias, metabolic disorders, or organ transplant rejection.  
 XX  
 SQ Sequence 1078 AA;  
 XX  
 Query Match 36.8%; Score 50; DB 8; Length 1078;  
 Best Local Similarity 44.4%; Pred. No. 1.4e+02;  
 Matches 12; Conservative 4; Mismatches 11; Indels 0; Gaps 0;  
 QY 2 YVFSTEMANKAAEAVLKGQVETIVSFH 28  
 :| | | :| | | :| | | |  
 Db 469 FVRCQEMGARAKAVESGALELSPSFH 495  
 RESULT 35  
 ID ABP66271 standard; protein, 187 AA.  
 XX  
 AC ABP66271;  
 XX

XX 19-NOV-2002 (first entry)  
DT  
XX Bifidobacterium longum NCC2705 ORF amino acid sequence SEQ ID NO:1015.  
DE  
XX Bifidobacterium longum NCC2705; Bifidobacterium; bacterial;  
KW antidiarrheic; antibacterial; inhibitor of Salmonella; detection;  
KW identification; lactic acid bacterium; diarrhoea; pathogenic bacteria;  
KW rotavirus; food composition; pharmaceutical composition.  
XX  
OS Bifidobacterium longum.  
XX  
PN EP1227152-A1.  
XX  
PD 31-JUL-2002.  
XX  
PF 30-JAN-2001; 2001EP-00102050.  
XX  
PR 30-JAN-2001; 2001EP-00102050.  
XX  
PA (NEST ) SOC PROD NESTLE SA.  
XX  
DR WPI; 2002-668397/72.  
XX  
PT Novel polynucleotide comprising Bifidobacterium genome sequence useful as  
PT a probe or primer for detecting and/or identifying Bifidobacterium longum  
PT in a biological sample.  
XX  
PS Claim 3; SEQ ID NO 1015; 80pp; English.  
XX  
CC The present invention describes a polynucleotide (I) comprising a  
CC sequence of a Bifidobacterium genome selected from the nucleotide  
CC sequences given in ABQ81842 and ABQ81843, or a sequence exhibiting at  
CC least 90% identity or which hybridises with the sequences given in  
CC ABQ81842 and ABQ81843. Also described is a polynucleotide (II) encoding a  
CC fusion protein, comprising a sequence selected from 1097 sequences given  
CC in ABP63258 to ABP6354 ligated in frame to a polynucleotide encoding a  
CC heterologous polypeptide. (I) has antidiarrheic and antibacterial  
CC activities, and can be used as an inhibitor of Salmonella. (I) (which is  
CC a probe) is useful for the detection and/or identification of  
CC Bifidobacterium longum in a biological sample. A carrier containing the  
CC lactic acid bacterium Bifidobacterium longum NCC2705 (NCIM 1-2618) can be  
CC used for preventing and/or treating diarrhoea brought about by pathogenic  
CC bacteria and/or rotavirus. The carrier is a food composition selected  
CC from milk, yogurt, curd, cheese, fermented milks, milk based fermented  
CC products, ice-creams, fermented cereal based products, milk based  
CC powders, infant formula, pet food or a pharmaceutical composition.  
CC selected from tablets, liquid bacterial suspensions, dried oral  
CC supplement, wet oral supplement, dry tube feeding or wet tube feeding.  
CC (I) is useful in DNA arrays or chips to carry out analysis of the  
CC expression of the Bifidobacterium gene. ABQ81844 to ABQ81850 represent  
CC Bifidobacterium related nucleotide sequences given in the Sequence  
CC listing from the present invention but not mentioned further within the  
CC specification. N.B. The sequence data for this patent is not represented  
CC in the printed specification but is based on sequence information  
CC supplied by the European Patent Office  
XX  
SQ Sequence 187 AA;

Query Match 36.0%; Score 49; DB 5; Length 187;  
Best Local Similarity 45.2%; Pred. No. 24;  
Matches 14; Conservative 3; Mismatches 4; Indels 10; Gaps 1;

OY 7 EMANKAAE-----AVLKQVETIVSF 27  
||| | : | ||| | : | : |  
26 EMAALASEDYRDKNPPLVAVLKGA VNTLVAF 56

RESULT 36  
ABO61084  
ID ABO61084 standard; protein; 265 AA.  
XX  
AC ABO61084;

XX 29-JUL-2004 (first entry)  
DT  
XX Klebsiella pneumoniae polypeptide seqid 7601.  
DE  
XX Recombinant expression vector; transcription regulatory element;  
KW Klebsiella pneumoniae protein; antibacterial; Vaccine.  
XX  
OS Klebsiella pneumoniae.  
XX  
PN US6610836-B1.  
XX  
PD 26-AUG-2003.  
XX  
PF 27-JAN-2000; 2000US-00489039.  
XX  
PR 29-JAN-1999; 99US-0117747P.  
XX  
PA (GENO-) GENOME THERAPEUTICS CORP.  
XX  
PI Breton GL, Osborne M;  
XX  
DR WPI; 2003-895346/82.  
DR N-PSDB; ACH94635.  
XX  
XX New nucleic acid encoding a Klebsiella pneumoniae polypeptide, useful for  
PT preparing a vaccine composition against Klebsiella pneumoniae.  
XX  
PS Disclosure; SEQ ID NO 7601; 932pp; English.  
XX  
CC The invention describes a new isolated nucleic acid encoding a Klebsiella  
CC pneumoniae polypeptide. Also described are: a recombinant expression  
CC vector comprising the nucleic acid, operably linked to a transcription  
CC regulatory element; and a cell comprising the recombinant expression  
CC vector. The nucleic acid is useful for preparing a vaccine composition  
CC against Klebsiella pneumoniae. This is the amino acid sequence of a  
CC Klebsiella pneumoniae polypeptide of the invention  
XX  
SQ Sequence 265 AA;

Query Match 36.0%; Score 49; DB 7; Length 265;  
Best Local Similarity 45.0%; Pred. No. 37;  
Matches 9; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 8 MANKAAEAVLKQVETIVSF 27  
||| | : | ||| | : | : |  
Db 164 MANRAPYAIMKSAVETLTRY 183

RESULT 37  
ABU49676  
ID ABU49676 standard; protein; 586 AA.  
XX  
AC ABU49676;  
XX  
DT 19-JUN-2003 (first entry)  
XX  
DE Protein encoded by Prokaryotic essential gene #35203.  
XX  
KW Antisense; prokaryotic essential gene; cell proliferation; drug design.  
XX  
OS Vibrio cholerae.  
XX  
PN WO200277183-A2.  
XX  
PD 03-OCT-2002.  
XX  
PF 21-MAR-2002; 2002WO-US009107.  
XX  
PR 21-MAR-2001; 2001US-00815242.  
PR 06-SEP-2001; 2001US-00948993.  
PR 25-OCT-2001; 2001US-0342923P.  
PR 08-FEB-2002; 2002US-00072851.

PR 06-MAR-2002; 2002US-0362699P.  
XX  
XX  
PA (ELIT-) ELITRA PHARM INC.  
XX  
XX  
PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW,  
PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH,  
XX  
DR MPI; 2003-029926/02.  
DR N-PSDB; ACA53546.  
XX  
XX  
PT New antisense nucleic acids, useful for identifying proteins or screening  
PT for homologous nucleic acids required for cellular proliferation to  
PT isolate candidate molecules for rational drug discovery programs.  
XX  
XX  
PS Claim 25; SEQ ID NO 77600; 1766pp; English.  
XX  
XX  
CC The invention relates to an isolated nucleic acid comprising any one of  
CC the 6213 antisense sequences given in the specification where expression  
CC of the nucleic acid inhibits proliferation of a cell. Also included are:  
CC (1) a vector comprising a promoter operably linked to the nucleic acid  
CC encoding a polypeptide whose expression is inhibited by the antisense  
CC nucleic acid; (2) a host cell containing the vector; (3) an isolated  
CC polypeptide or its fragment whose expression is inhibited by the  
CC antisense nucleic acid; (4) an antibody capable of specifically binding  
CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular  
CC proliferation or the activity of a gene in an operon required for  
CC proliferation; (7) identifying a compound that influences the activity of  
CC the gene product or that has an activity against a biological pathway  
CC required for proliferation, or that inhibits cellular proliferation; (8)  
CC identifying a gene required for cellular proliferation or the biological  
CC pathway in which a proliferation-required gene or its gene product lies  
CC or a gene on which the test compound that inhibits proliferation of an  
CC organism acts; (9) manufacturing an antibiotic; (10) profiling a  
CC compound's activity; (11) a culture comprising strains in which the gene  
CC product is overexpressed or underexpressed; (12) determining the extent  
CC to which each of the strains is present in a culture or collection of  
CC strains; or (13) identifying the target of a compound that inhibits the  
CC proliferation of an organism. The antisense nucleic acids are useful for  
CC identifying proteins or screening for homologous nucleic acids required  
CC for cellular proliferation to isolate candidate molecules for rational  
CC drug discovery programs, or for screening homologous nucleic acids  
CC required for proliferation in cells other than *S. aureus*, *S. typhimurium*,  
CC *K. pneumoniae* or *P. aeruginosa*. The present sequence is encoded by one of  
CC the target prokaryotic essential genes. Note: The sequence data for this  
CC patent did not form part of the printed specification, but was obtained  
CC in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
XX  
SQ Sequence 586 AA;  
  
Query Match 36.0%; Score 49; DB 6; Length 586;  
Best Local Similarity 25.0%; Pred. No. 95;  
Matches 11; Conservative 8; Mismatches 7; Indels 18; Gaps 1;  
  
QY 2 YVFSTEMANKA-----AEAVLKQVETIVSF 27  
|:|:::| |::|:|:|:| |  
Db 9 YIFYSQWTKAPLLGLVTLIGYWLRLRDATTIIGSIKIVGF 52  
  
RESULT 38  
ABJ25889  
ID ABJ25889 standard; protein; 984 AA.  
XX  
XX  
AC ABJ25889;  
XX  
DT 16-APR-2003 (first entry)  
XX  
DE Aspergillus fumigatus essential gene protein #547.  
XX  
KW Fungicide; cytostatic; essential gene; Aspergillus fumigatus; infection;  
XX cancer; contamination; biofilm; antibody; immune response.  
OS Aspergillus fumigatus.

XX  
PN WO200286090-A2.  
XX  
XX  
PD 31-OCT-2002.  
XX  
XX  
PF 23-APR-2002; 2002WO-US013142.  
XX  
XX  
PR 23-APR-2001; 2001US-0285697P.  
PR 27-APR-2001; 2001US-0287066P.  
PR 05-JUN-2001; 2001US-0295890P.  
PR 09-JUL-2001; 2001US-0303899P.  
PR 31-AUG-2001; 2001US-0316362P.  
XX  
XX  
PA (ELIT-) ELITRA PHARM INC.  
XX  
XX  
PI Jiang B, Tishkoff D, Zamudio C, Eroshkin AM, Hu W, Lemieux SM;  
XX  
XX  
DR MPI; 2003-093124/08.  
XX  
XX  
PT New purified or isolated nucleic acids of essential genes of Aspergillus  
PT fumigatus, useful for treating or preventing infections by *A. fumigatus*,  
PT or for treating a non-infectious disease in a subject e.g. cancer.  
XX  
XX  
PS Disclosure; Page; 175pp; English.  
XX  
XX  
CC The invention relates to novel purified or isolated nucleic acids of  
CC essential genes of Aspergillus fumigatus. The isolated nucleic acids of  
CC the invention are used to treat or prevent infections by a pathogenic  
CC organism such as *A. fumigatus*, to treat a non-infectious disease in a  
CC subject (e.g. cancer), to prevent or contain contamination of an object  
CC by *A. fumigatus*, or to prevent or inhibit formation on a surface of a  
CC biofilm comprising *A. fumigatus*. The polynucleotides are useful for  
CC expressing recombinant protein for characterisation, screening or  
CC therapeutic use, as markers for host tissues in which the pathogenic  
CC organisms invade or reside, for comparing with the DNA sequence of *A.*  
CC fumigatus to identify duplicated genes or paralogues having the same or  
CC similar biochemical activity and/or function, for comparing with DNA  
CC sequences of other related or distant pathogenic organisms to identify  
CC potential orthologous essential or virulence genes, for selecting and  
CC making oligomers for attachment to a nucleic acid array for examination  
CC of expression patterns, for raising anti-protein antibodies, as an  
CC antigen to raise anti-DNA antibodies or to elicit another immune  
CC response, and for identifying polynucleotides encoding the other protein  
CC with which binding occurs or to identify inhibitors of the binding  
CC interaction. The polypeptides may be used to raise antibodies or to  
CC elicit immune response, as a reagent in assays designed to quantitatively  
CC determine levels of the protein in biological fluids, as a marker for  
CC host tissues in which pathogenic organism invade or reside, and to  
CC isolate correlative receptors or ligands in the case or virulence  
CC factors. This sequence represents a protein of one of the essential genes  
CC of Aspergillus fumigatus of the invention  
XX  
XX  
SQ Sequence 984 AA;  
  
Query Match 36.0%; Score 49; DB 6; Length 984;  
Best Local Similarity 52.6%; Pred. No. 1.8e+02;  
Matches 10; Conservative 4; Mismatches 5; Indels 0; Gaps 0;  
  
QY 3 VFSSTEMANKAAEAVLKQV 21  
|:|:::| |::|:|:|:| |  
Db 500 VYRANMANKSAAAVLKSKL 518  
  
RESULT 39  
ABJ26489  
ID ABJ26489 standard; protein; 1058 AA.  
XX  
XX  
AC ABJ26489;  
XX  
DT 16-APR-2003 (first entry)  
XX  
DE Aspergillus fumigatus essential gene protein #1147.  
XX

KW Fungicide; cytostatic; essential gene; Aspergillus fumigatus; infection;  
KW cancer; contamination; biofilm; antibody; immune response.  
XX  
OS Aspergillus fumigatus.  
XX  
PN WO200286090-A2.  
XX  
PD 31-OCT-2002.  
XX  
PF 23-APR-2002; 2002WO-US013142.  
XX  
PR 23-APR-2001; 2001US-0285697P.  
PR 27-APR-2001; 2001US-0287066P.  
PR 05-JUN-2001; 2001US-0295890P.  
PR 09-JUL-2001; 2001US-0303899P.  
PR 31-AUG-2001; 2001US-0316362P.  
XX  
PA (ELIT-) ELITRA PHARM INC.  
XX  
PI Jiang B, Tishkoff D, Zamudio C, Eroshkin AM, Hu W, Lemieux SM,  
XX  
DR WPI; 2003-093124/08.  
XX  
PT New purified or isolated nucleic acids of essential genes of Aspergillus  
PT fumigatus, useful for treating or preventing infections by A. fumigatus,  
PT or for treating a non-infectious disease in a subject e.g. cancer.  
XX  
PS Disclosure; Page; 175pp; English.  
XX  
CC The invention relates to novel purified or isolated nucleic acids of  
CC essential genes of Aspergillus fumigatus. The isolated nucleic acids of  
CC the invention are used to treat or prevent infections by a pathogenic  
CC organism such as A. fumigatus, to treat a non-infectious disease in a  
CC subject (e.g. cancer), to prevent or contain contamination of an object  
CC by A. fumigatus, or to prevent or inhibit formation on a surface of a  
CC biofilm comprising A. fumigatus. The polynucleotides are useful for  
CC expressing recombinant protein for characterisation, screening or  
CC therapeutic use, as markers for host tissues in which the pathogenic  
CC organisms invade or reside, for comparing with the DNA sequence of A.  
CC fumigatus to identify duplicated genes or paralogues having the same or  
CC similar biochemical activity and/or function, for comparing with DNA  
CC sequences of other related or distant pathogenic organisms to identify  
CC potential orthologous essential or virulence genes, for selecting and  
CC making oligomers for attachment to a nucleic acid array for examination  
CC of expression patterns, for raising anti-protein antibodies, as an  
CC antigen to raise anti-DNA antibodies or to elicit another immune  
CC response, and for identifying polynucleotides encoding the other protein  
CC with which binding occurs or to identify inhibitors of the binding  
CC interaction. The polypeptides may be used to raise antibodies or to  
CC elicit immune response, as a reagent in assays designed to quantitatively  
CC determine levels of the protein in biological fluids, as a marker for  
CC host tissues in which pathogenic organism invade or reside, and to  
CC isolate correlative receptors or ligands in the case of virulence  
CC factors. This sequence represents a protein of one of the essential genes  
CC of Aspergillus fumigatus of the invention  
XX  
SQ Sequence 1058 AA;  
  
Query Match 36.0%; Score 49; DB 6; Length 1058;  
Best Local Similarity 52.6%; Pred. No. 1.9e+02;  
Matches 10; Conservative 4; Mismatches 5; Indels 0; Gaps 0;  
  
QY 3 VFSTEMANKAAEAVLKGV 21  
|: ||||:| ||||:|  
Db 500 VYRANMANKSAAAVLKSKL 518  
  
RESULT 40  
ADC50023  
ID ADC50023 standard; protein; 310 AA.  
XX  
AC ADC50023;  
XX

DT 18-DEC-2003 (first entry)  
XX  
DE Gene repair function associated protein-34.1.  
XX  
KW Gene repair function associated protein-34.1; macroprotein-51.59;  
KW recombinant production; gene therapy; tumour; cancer; blood disease;  
KW HIV infection; human immunodeficiency virus; immune disorder; cytostatic;  
KW immunomodulator.  
XX  
OS Unidentified.  
XX  
PN CN1382717-A.  
XX  
PD 04-DEC-2002.  
XX  
PF 26-APR-2001; 2001CN-00112750.  
XX  
PR 26-APR-2001; 2001CN-00112750.  
XX  
PA (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.  
XX  
PI Mao Y, Xie Y;  
XX  
PI Mao Y, Xie Y;  
XX  
DR WPI; 2003-269479/27.  
DR N-PSDB; ADC50022.  
XX  
XX  
PT New gene repair function associated protein-34.1, encoding  
PT polynucleotide, antagonist, and recombinant production, useful for  
PT treating cancer, hemopathy, HIV and immune diseases.  
XX  
PS Claim 1; SEQ ID NO 2; 33pp; Chinese.  
XX  
XX  
CC The invention relates to gene repair function associated protein-34.1  
CC (ADC50023) and nucleic acids encoding it (ADC50022). The protein has a  
CC molecular weight of 34.1 kD, and has 34% identity and 47% homology over a  
CC 235 amino acid stretch with an Arabidopsis thaliana DNA repair protein-  
CC like protein (GenBank accession number AB016875). The invention also  
CC relates to a method for the recombinant production of the protein, an  
CC antagonist of the protein, and the use of the protein, gene and  
CC antagonist in therapeutic applications. Gene repair function associated  
CC protein-34.1 can be used in the treatment of a variety of diseases such  
CC as cancer, blood diseases, HIV (human immunodeficiency virus) infection  
CC and immune disorders. The present sequence represents gene repair  
CC function associated protein-34.1.  
XX  
SQ Sequence 310 AA;  
  
Query Match 35.3%; Score 48; DB 7; Length 310;  
Best Local Similarity 39.3%; Pred. No. 64;  
Matches 11; Conservative 7; Mismatches 6; Indels 4; Gaps 1;  
  
QY 2 YVFSTEMANKAAEAVLKGV---QVETIV 25  
|||:| ||: : ||: ||: |  
Db 116 YVFSTSEKANQEEDIPVKGSHSTKVEAVV 143

Search completed: June 8, 2005, 03:17:47  
Job time : 110.125 secs

***This Page Blank (uspto)***